

# **Document made available under the Patent Cooperation Treaty (PCT)**

International application number: PCT/US05/005596

International filing date: 24 February 2005 (24.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/547,512

Filing date: 26 February 2004 (26.02.2004)

Date of receipt at the International Bureau: 23 March 2005 (23.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1295793

UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 14, 2005*

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/547,512

FILING DATE: *February 26, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/05596



Certified by

A handwritten signature in black ink that reads "Don W. Duckas".

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

01619  
4099220  
U.S. PTOPage 1 of 1U.S. PATENT AND TRADEMARK OFFICE  
PROVISIONAL APPLICATION FOR PATENT COVER SHEETThis is a request for filing a PROVISIONAL APPLICATION FOR PATENT  
under 37 C.F.R. §1.53(b)(2)

Atty. Docket: KOPCHICK15

22582 U.S. PTO  
60/547512

022604

INVENTOR(S)/APPLICANT(S)			
LAST NAME	FIRST NAME	MI	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
KOPCHICK	John	J	Athens, OH
COSCHIGANO	Karen	T	The Plains, OH
BOYCE	Keith	S	Wexford, PA
KRIETE	Andres		Cherry Hill, NJ


Additional inventors are being named on separately numbered sheets attached hereto

TITLE OF THE INVENTION (280 characters max)			
DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON GENES DIFFERENTIALLY EXPRESSED IN MUSCLE CELLS			
CORRESPONDENCE ADDRESS			
Direct all correspondence to the address associated with Customer Number 001444, which is presently: BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W., Suite 300 Washington, D.C. 20001-5303			
ENCLOSED APPLICATION PARTS (check all that apply)			
<input checked="" type="checkbox"/> Specification	Number of Pages	261	<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 C.F.R. §1.27
<input type="checkbox"/> Drawing(s)	Number of Sheets		<input type="checkbox"/> Other (specify) _____
METHOD OF PAYMENT (check one)			
<input checked="" type="checkbox"/> Credit Card Payment Form PTO-2038 is enclosed to cover the Provisional filing fee of <input type="checkbox"/> \$160 large entity <input checked="" type="checkbox"/> \$80 small entity			
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number 02-4035			

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

 No [ ] Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
  
By: Iver P. Cooper  
Registration No.: 28,005

Date: February 26, 2004

IPC:gsk

DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND  
PROTECTION AGAINST SAME BASED ON GENES DIFFERENTIALLY  
EXPRESSED IN MUSCLE CELLS

*Cross-Reference to Related Applications*

5        In US Prov. Appl. 60/460,415, filed April 7, 2003  
(KOPCHICK6-USA), differential hybridization techniques were  
used to identify mouse genes that are differentially  
expressed in mouse liver, depending upon their development  
of hyperinsulinemia or type II diabetes.

10      In essence, complementary RNA derived from normal mice,  
or mouse models of hyperinsulinemia or type II diabetes, was  
screened for hybridization with oligonucleotide probes each  
specific to a particular mouse gene, each gene in turn  
representative of a particular mouse gene cluster (Unigene).

15      To obtain the mouse models, some mice were fed a high-  
fat diet, and then monitored for the development of  
hyperinsulinemia (elevated plasma insulin levels but normal  
fasting blood-glucose levels) or type II diabetes (both  
elevated plasma insulin and fasting blood glucose levels).  
20      Gene expression 2, 4, 8 and 16 weeks after commencement of  
the diet was analyzed.

The oligonucleotide probes were provided by the  
Codelink Uniset Mouse I Bioarray (Amersham, product code  
300013). Amine-terminated oligonucleotide probes are  
25      attached to a three-dimensional polyacrylamide gel matrix (a  
"gene chip"). There are 10,000 oligonucleotide probes,  
each specific to a well-characterized mouse gene. Each  
mouse gene is representative of a unique gene cluster from  
the fourth quarter 2001 Genbank Unigene build.

30      Mouse genes which were differentially expressed (normal  
vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or  
normal vs. diabetic), as measured by different levels of  
hybridization of the respective cRNA samples with the  
particular probe corresponding to that mouse gene) were  
35      identified. Related human genes and proteins were  
identified by sequence comparisons to the mouse gene or  
protein.

A later application added 6 month expression data, see

US Prov. Appl. 60/506,716, filed Sept. 30, 2003  
(Kopchick6.1-USA).

In a similar manner, in U.S. Provisional Appl. Ser. No. 5 60/517,376 filed November 6, 2003 (our docket Kopchick12-USA), we describe the identification of mouse genes differentially expressed (normal vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or normal vs. diabetic) in pancreas, and of cognate human genes and proteins.

10

In U.S. Provisional Appl. Ser. No. 60/458,398 (our docket Kelder1-USA), filed March 31, 2003, we describe the identification of genes differentially expressed in normal vs. hyperinsulinemic, hyperinsulinemic vs. type II diabetic, 15 or normal vs. type II diabetic mouse liver. Forward- and reverse-subtracted cDNA libraries were prepared, clones were isolated, and differentially expressed cDNA inserts were sequenced and compared with sequences in publicly available sequence databases. The corresponding mouse and 20 human genes and proteins were identified.

The use of differential hybridization to identify genes and proteins is also described in our Ser. No. PCT/US00/12145 (Kopchick 3A-PCT), Ser. No. PCT/US00/12366 (Kopchick4A-PCT), Ser. No. 60/400,052 (Kopchick5), and Ser. 25 No. 60/485,222 (Kopchick8).

None of the above applications examined muscle expression.

30 All of the above applications are incorporated by reference in their entirety.

#### **BACKGROUND OF THE INVENTION**

##### **Field of the Invention**

The invention relates to various nucleic acid molecules and proteins, and their use in (1) diagnosing hyperinsulinemia and type II diabetes, or conditions

associated with their development, and (2) protecting mammals (including humans) against them.

#### Description of the Background Art

5

##### **Diabetes**

A deficiency of insulin in the body results in diabetes mellitus, which affects about 18 million individuals in the United States. It is characterized by a high blood glucose (sugar) level and glucose spilling into the urine due to a deficiency of insulin. As more glucose concentrates in the urine, more water is excreted, resulting in extreme thirst, rapid weight loss, drowsiness, fatigue, and possibly dehydration. Because the cells of the diabetic cannot use glucose for fuel, the body uses stored protein and fat for energy, which leads to a buildup of acid (acidosis) in the blood. If this condition is prolonged, the person can fall into a diabetic coma, characterized by deep labored breathing and fruity-odored breath.

There are two types of diabetes mellitus, Type I and Type II. Type II diabetes is the predominant form found in the Western world; fewer than 8% of diabetic Americans have the type I disease.

25

Type I diabetes. In Type I diabetes, formerly called juvenile-onset or insulin-dependent diabetes mellitus, the pancreas cannot produce insulin. People with Type I diabetes must have daily insulin injections. But they need to avoid taking too much insulin because that can lead to insulin shock, which begins with a mild hunger. This is quickly followed by sweating, shallow breathing, dizziness, palpitations, trembling, and mental confusion. As the blood sugar falls, the body tries to compensate by breaking down fat and protein to make more sugar. Eventually, low blood sugar leads to a decrease in the sugar supply to the brain, resulting in a loss of consciousness. Eating a sugary food can prevent insulin shock until appropriate medical measures

can be taken.

Type I diabetics are often characterized by their low or absent levels of circulating endogenous insulin, i.e., hypoinsulinemia (1). Islet cell antibodies causing damage to the pancreas are frequently present at diagnosis. 5 Injection of exogenous insulin is required to prevent ketosis and sustain life.

Type II diabetes. Type II diabetes, formerly called adult-onset or non-insulin-dependent diabetes mellitus (NIDDM), can occur at any age. The pancreas can produce insulin, but the cells do not respond to it. 10

Type II diabetes is a metabolic disorder that affects approximately 17 million Americans. It is estimated that another 10 million individuals are "prone" to becoming diabetic. These vulnerable individuals can become resistant to insulin, a pancreatic hormone that signals glucose (blood sugar) uptake by fat and muscle. In order to maintain normal glucose levels, the islet cells of the pancreas produce more insulin, resulting in a condition called hyperinsulinemia. When the pancreas can no longer produce enough insulin to compensate for the insulin resistance, and thereby maintain normal glucose levels, hyperglycemia (elevated blood glucose) results, and type II diabetes is 15 diagnosed. 20 25

Early Type II diabetics are often characterized by hyperinsulinemia and resistance to insulin. Late Type II diabetics may be normoinsulinemic or hypoinsulinemic. Type II diabetics are usually not insulin dependent or prone to ketosis under normal circumstances. 30

Little is known about the disease progression from the normoinsulinemic state to the hyperinsulinemic state, and from the hyperinsulinemic state to the Type II diabetic state.

As stated above, type II diabetes is a metabolic disorder that is characterized by insulin resistance and impaired glucose-stimulated insulin secretion (2,3,4). However, Type II diabetes and atherosclerotic disease are 35

viewed as consequences of having the insulin resistance syndrome (IRS) for many years (5). The current theory of the pathogenesis of Type II diabetes is often referred to as the "insulin resistance/islet cell exhaustion" theory.

5 According to this theory, a condition causing insulin resistance compels the pancreatic islet cells to hypersecrete insulin in order to maintain glucose homeostasis. However, after many years of hypersecretion, the islet cells eventually fail and the symptoms of clinical diabetes are manifested. Therefore, this theory implies that, at some point, peripheral hyperinsulinemia will be an antecedent of Type II diabetes. Peripheral hyperinsulinemia can be viewed as the difference between what is produced by the  $\beta$  cell minus that which is taken up by the liver.

10 15 Therefore, peripheral hyperinsulinemia can be caused by increased  $\beta$  cell production, decreased hepatic uptake or some combination of both. It is also important to note that it is not possible to determine the origin of insulin resistance once it is established since the onset of peripheral hyperinsulinemia leads to a condition of global insulin resistance.

20 25 Multiple environmental and genetic factors are involved in the development of insulin resistance, hyperinsulinemia and type II diabetes. An important risk factor for the development of insulin resistance, hyperinsulinemia and type II diabetes is obesity, particularly visceral obesity (6,7,8). Type II diabetes exists world-wide, but in developed societies, the prevalence has risen as the average age of the population increases and the average individual becomes more obese.

30 35 *Obesity and Diabetes.* Obesity is a serious and growing problem in the United States. Obesity-related health risks include high blood pressure, hardening of the arteries, cardiovascular disease, and Type II diabetes (also known as non-insulin-dependent diabetes mellitus, Type II diabetes) (9,10,11). Recent studies show that 85% of the individuals with Type II diabetes are obese (12).

5           Treatment of Diabetes. For many years, treatment was insulin therapy for Type I and oral sulfonylureas and/or insulin therapy for Type II. Metformin (glucophage) was the  
10          first antidiabetic drug approved by FDA (May 1995) for the treatment of Type II diabetes since the oral sulfonylureas were introduced in 1984. Metformin promotes the use of insulin already in the blood. This May 1995 approval was followed by the September 1995 approval of another  
15          antidiabetic drug, Acarbose (precose). It slows down the digestion and absorption of complex sugars, which reduces blood sugar levels after meals.

15          Before 1982, insulin was purified from beef or pork pancreas. This was a problem for those diabetics allergic to animal insulin. Researchers produced a synthetic insulin called humulin. Approved by FDA in 1982, it was the first genetically engineered consumer health product manufactured for diabetics. Synthetic insulins can be produced in unlimited quantities.

20          Another possible treatment for diabetes includes surgically replacing the pancreas' endocrine tissues (islets of Langerhans) with healthy islet of Langerhans tissue grafts. Since 1988, 45 patients worldwide have undergone successful transplantation.

25          Complications. Complications of diabetes (end organ damage) include retinopathy, neuropathy, and nephropathy (traditionally designated as microvascular complications) as well as atherosclerosis (a macrovascular complication).  
30          Early stages of hyperglycemia can usually be controlled by an alteration in diet and increasing the amount of exercise, but drug treatment, including insulin, may be required. It has been shown that meticulous blood glucose control can often slow down or halt the progression of diabetic  
35          complications if caught early enough (1). However, tight metabolic control is extremely difficult to achieve.

**Animal Models**

Transgenic Mouse Models of Diabetes or Diabetes Resistance. McGrane, et al., J. Biol. Chem. 263:11443-51 (1988) and Chen, et al., J. Biol. Chem., 269:15892-7 (1994) describe the genetic engineering of mice to express bovine growth hormone (bGH) or human growth hormone (hGH), respectively. These mice exhibited an enhanced growth phenotype. They also developed kidney lesions similar to those seen in diabetic glomerulosclerosis, see Yang, et al., Lab. Invest., 68:62-70 (1993). Ogueta, et al., J. Endocrinol., 165: 321-8 (2000) reported that transgenic mice expressing bovine GH develop arthritic disorder and self-antibodies.

Growth hormone has many roles, ranging from regulation of protein, fat and carbohydrate metabolism to growth promotion. GH is produced in the somatotrophic cells of the anterior pituitary and exerts its effects either through the GH-induced action of IGF-I, in the case of growth promotion, or by direct interaction with the GHR on target cells including liver, muscle, adipose, and kidney cells. Hyposecretion of GH during development leads to dwarfism, and hypersecretion before puberty leads to gigantism. In adults, hypersecretion of GH results in acromegaly, a clinical condition characterized by enlarged facial bones, hands, feet, fatigue and an increase in weight. Of those individuals with acromegaly, 25% develop type II diabetes. This may be due to insulin resistance caused by the high circulating levels of GH leading to high circulating levels of insulin (Kopchick et al., Annual Rev. Nutrition 1999. 19:437-61).

A further mode of GH action may be through the transcriptional regulation of a number of genes contributing to the physiological effects of GH.

Growth hormone genes and the proteins encoded by them can be converted into growth hormone antagonists by mutation, see Kopchick USP 5,350,836. Transgenic mice have been made that express the GH antagonists bGH-G119R or hGH

G120R, and which exhibit a dwarf phenotype. Chen, et al., J. Biol. Chem., 263:15892-7 (1994); Chen, et al., Mol. Endocrinol., 5:1845-52 (1991); Chen, et al., Proc. Nat. Acad. Sci. USA 87:5061-5 (1990). These mice did not develop kidney lesions. See Yang (1993), supra.

Chen, et al., Endocrinol., 136:660-7 (1995) compared the effect of streptozotocin treatment in normal nontransgenic mice, and in mice transgenic for (1) a GH receptor antagonist, the G119R mutant of bovine growth hormone or (2) the E117L-mutant of bGH. (According to Chen's ref. 24, these large GH transgenic streptozotocin-treated mice constitute an animal model for diabetes.) Glomerulosclerosis was seen in diabetic (STZ-treated) nontransgenic mice and in diabetic bGH-E117L mice, but not in diabetic bGH-G119R (GH antagonist) mice.

Two of the proteins which mediate growth hormone activity are the growth hormone receptor and the growth hormone binding protein, encoded by the same gene in mice (GHR/BP). It is possible to genetically engineer mice so that the gene encoding these proteins is disrupted ("knocked-out"; inactivated), see Zhou, et al., Proc. Nat. Acad. Sci. (USA), 94:13215-20 (1997). Zhou, et al. inactivated the GHR/BP gene by replacing the 3' portion of exon 4 (which encodes a portion of the GH binding domains) and the 5' region of intron 4 with a neomycin gene cassette. The modified gene was introduced into the target mice by homologous recombination. Like mice expressing a GH antagonist, homozygous GHR/BP-KO mice exhibit a dwarf phenotype. GHR/BP-KO mice, made diabetic by streptozotocin treatment, are protected from the development of diabetes-associated nephropathy. Bellush, et al., Endocrinol., 141:163-8 (2000).

High-Fat Diets. High-fat diets have been shown to induce both obesity and Type II diabetes in laboratory animals (13). Surwit and colleagues demonstrated that male C57BL/6J mice are extremely sensitive to the diabetogenic effects of a high-fat diet when initiated at weaning. At

six months of age, high-fat fed animals had significantly elevated fasting blood-glucose and insulin levels and also demonstrated a decrease in insulin sensitivity (14). Ahren and colleagues (15) reported evidence of insulin resistance 5 as well as diminished glucose-stimulated insulin release, after feeding with a high-fat diet for 12 weeks. These mice also showed elevated levels of total cholesterol, triglycerides, and free fatty acids, another hallmark of Type II diabetes.

10

#### **Anatomy and Physiology of Muscle**

Muscle tissue constitutes about 40% of the body mass.

Muscles may be classified by location, i.e., skeletal if attached to bone, cardiac if forming the wall of the heart, and visceral if associated with another body organ. Muscles 15 may also be classified as voluntary or involuntary, depending on how their contractions and relaxations are controlled. Skeletal muscles are voluntary, while cardiac and visceral muscles are involuntary. It is also possible 20 to classify muscles morphologically; skeletal and cardiac muscle cells are striated, whereas visceral muscle cells are not.

25 Each skeletal muscle is composed of many individual muscle cells called muscle fibers. The fibers are held together by fibrous connective-tissue membranes called fascia. The fascium which envelops the entire muscle is the epimysium, and the fascia which penetrate the muscle, separating the 30 fibers into bundles (fasciculi) are called perimysium. Very thin fascia (endomysium) sheath each muscle fiber. Skeletal muscles are attached either directly to a bone, or indirectly through a tendon.

35 The individual muscle fibers (cells) comprise threadlike protein structures called myofibrils.

There are over 600 muscles in the human body. We will have

occasion later to refer to the gastrocnemius. It is a superficial muscle in the posterior compartment of the lower leg, which together with the underlying soleus forms the characteristic bulge of the calf.

5

#### **Role of Muscle in Development of Type II Diabetes**

Muscle, fat and liver tissues are the major contributors to the development of insulin resistance, hyperinsulinemia, and, ultimately, type II diabetes.

10 Muscle cells respond to insulin by increasing glucose uptake from the bloodstream. Muscle tissue can become resistant to insulin, causing the beta cells to initially increase insulin secretion. Eventually, though, the beta cells become unable to compensate for this increasing insulin resistance from muscle and other cells, and they fail to respond to elevated blood glucose levels. Thus, clinical type 2 diabetes results from the combination of insulin resistance and impaired beta cell function.

20 Defects in muscle glycogen synthesis are known to play a role in the development of insulin resistance. At least three steps-those mediated by glycogen synthase, hexokinase, and GLUT4-have been reported to be defective in patients with type 2 diabetes.

25 Fatty acids can induce insulin resistance, and it has been suggested that this was a consequence of altered insulin signaling through PI3-kinase. PKC-theata has also been implicated.

30 See generally Petersen, et al., "Pathogenesis of Skeletal muscle insulin resistance in type 2 diabetes mellitus", in "A Symposium: Evolution of type 2 diabetes mellitus management", at Amer. J. Cardiol., 90(5A) : 11G-18G, (Sept. 5, 2002).

#### **35 Adverse Effects of Type II Diabetes on Muscle**

"Myopathy is a general term used to describe any disease of muscles, such as the muscular dystrophies and myopathies associated with thyroid disease. It can be caused

by endocrine disorders, including diabetes, metabolic disorders, infection or inflammation of the muscle, certain drugs and mutations in genes. In diabetes, myopathy is thought to be caused by neuropathy, a complication of diabetes. General symptoms of myopathies include muscle weakness of limbs sometimes occurring during exercise although in some cases the symptoms diminish as exercise increases. Depending on the type of myopathy, one muscle group may be more affected than others." See "Joint and Muscle Problems Associated with Diabetes", [www.iddtinternational.org/jointandmuscleproblems.html](http://www.iddtinternational.org/jointandmuscleproblems.html) [Last modified June 12, 2003].

Diabetic muscle infarction can spontaneously affect patients with a long history of poorly controlled diabetes. "Most affected patients have multiple microvascular complications (neuropathy, nephropathy, and retinopathy). The clinical presentation is an acute onset of pain and swelling over days to weeks in the affected muscle groups (usually the thigh or calf), along with varying degrees of tenderness.... Therapy consists of rest and analgesia. Routine daily activities are not deleterious to the condition, but physical therapy may cause exacerbation. Spontaneous diabetic muscle infarction tends to resolve over a period of weeks to months in most cases." See "Musculoskeletal Complications of Diabetes - Part 2", [www.diabetic-lifestyle.com/articles/jan02\\_whats\\_1.htm](http://www.diabetic-lifestyle.com/articles/jan02_whats_1.htm) [last modified Feb. 9, 2004]. See also Trujillo-Santos, et al., "Diabetes muscle infarction: an underdiagnosed complication of long-standing diabetes," Diabetes Care, 26(1):211-5 (2003).

**Identification of genes involved in hyperinsulinemia and type II diabetes, generally**

5        Our attention recently has focused on the generation of muscle mRNA expression profiles and the identification of genes involved in the genesis of the obesity-induced hyperinsulinemia and type-II diabetes. To date, no one has attempted to study the actual progression from the normal 10 condition to that of hyperinsulinemia or from hyperinsulinemia to Type II diabetes in an attempt to identify genes that are up-regulated or down-regulated in muscle as the disease progresses.

15      In previous studies aimed at identifying genes involved in diabetes-induced glomerulosclerosis, differential display and traditional subtractive hybridization techniques were used (16-20). While effective for the identification of a few genes (e.g. hmunc13, PED/PEA-15, lactate dehydrogenase, amiloride sensitive sodium channel, ubiquitin-like protein, 20 mdr 1, and a-amylloid protein precursor as well as a few novel genes), these techniques can be quite labor intensive. The PCR-based method of subtractive hybridization requires less starting material, and allows the simultaneous isolation of all differentially expressed cDNAs into two 25 groups (up-regulated and down-regulated).

30      However, the PCR-based method of subtractive hybridization is also quite labor-intensive, produced large numbers of false positive candidates and ultimately resulted in the identification of a relatively limited number of differentially expressed genes. (see Kelder1-USA application).

35      In order to expand the number of genes that can be analyzed simultaneously, several groups have begun to utilize DNA microarray analysis to measure differences in gene expression between normal and diseased states. However, these experiments have been limited in regards to the number of experimental conditions analyzed. DNA microarray analysis has been performed on normal, obese and

diabetic mice (21). Also, the obesity and diabetes in the mouse models examined were caused by a specific endogenous genetic mutation (22). The differentially expressed genes in the above models may be very different from genes differentially expressed due to diet-induced obesity and Type-II diabetes.

The use of differential expression and related techniques to identify genes useful in the treatment of diabetes has been reviewed by Perfetti, et al., *Diabetes Technol. & Therapeut.*, 5(3) : 421-3 (2003). Bernal-Mizrachi, et al., *Diabetes Metab. Res. Rev.* 19: 32-42 (2003).

Other papers of interest include:

Wada, et al., "Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis", *Kidney Int.*, 59:1363-73 (2001);

Song, et al., "Cloning of a novel gene in the human kidney homologous to rat munc13S: its potential role in diabetic nephropathy", *Kidney Int.*, 53:1689-95 (1998);

Page, et al., "Isolation of diabetes-associated kidney genes using differential display", *Biochem. Biophys. Res. Comm.*, 232:49-53 (1997).

Peradi, "Subtractive hybridization claims: An efficient technique to detect overexpressed mRNAs in diabetic nephropathy," *Kidney Int.* 53:926-31 (1998).

Condorelli, *EMBO J.*, 17:3858-66 (1998).

### **Differential Expression in Muscle**

Sreekumar, et al., "Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment," *Diabetes* 51: 1913 (June 2002) surveyed 6,451 genes, and identified 85 genes for which there was an alteration in skeletal muscle transcription in diabetic patients after withdrawal of insulin treatment. Subsequent insulin treatment resulted in further changes in transcription of 74 of the 85 genes (15 increased, 59

decreased), and also resulted in alteration of 29 additional gene transcripts.

Mootha, et al., "PCG-1 $\alpha$  responsive genes involved in oxidative phosphorylation are coordinatively downregulated in human diabetes," *Nature Genetics* 34(3); 267 (July 2003), used DNA microarrays to detect changes in the expression of sets of related genes, rather than of individual genes. They classified over 22,000 genes into 149 data sets; some of these data sets overlapped. They looked for a statistical correlation between the overall rank order of the genes in differential expression, and the groups to which the genes belonged. Expression was compared pairwise among three groups: males with normal glucose tolerance; males with impaired glucose tolerance; and males with type 2 diabetes. The set with the highest enrichment score (the one whose members ranked highly most often relative to chance expectation) was an internally curated set of 106 genes involved in oxidative phosphorylation. While the average decrease for the individual genes was modest (~20%), it was also consistent, being observed in 89% (94/106) of the genes in question. This paper is reviewed by Toye and Gauguier, "Genetics and functional genomics of type 2 diabetes mellitus", *Genome Biology*, 4: 241 (2003).

Patti, et al., "Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1", Proc. Nat. Acad. Sci. (USA), 100(14): 8466 (July 8, 2003) used microarrays to analyze skeletal muscle expression of genes in nondiabetic insulin-resistant subjects at high risk for diabetes (based on family history of diabetes and Mexican-American ethnicity) and diabetic Mexican-American subjects. Of 7,129 sequences represented on the microarray, 187 were differentially expressed between control and diabetic subjects. However, no single gene remained significantly differentially expressed after controlling for multiple comparison false discovery by using the Benjamini-Hochberg

method, see Benjamini, et al., J. R. Stat. Soc. Sert. B. 57:289-300 (1995); Dudait, et al., Stat. Sin. 12: 111-139 (2002). Consequently, Patti et al. sought to identify groups of related genes with similar patterns of differential expression using MAPP FINDER and ONTOEXPRESS. According to MAPP FINDER, the top-ranked cellular component terms were mitochondrion, mitochondrial membrane, mitochondrial inner membrane, and ribosome, and the top-ranked process term was ATP biosynthesis. According to ONTOEXPRESS, the over-represented groups were energy generation, protein biosynthesis/ribosomal proteins, RNA binding, ribosomal structural protein, and ATP synthase complex.

Huang, Xudong, "Identification of abnormally expressed genes in skeletal muscle contributing to insulin resistance and type 2 diabetes", Thesis, document id: 9576 Lunds University 2002, reported differential expression of the mitochondrially-encoded ND1 gene in human diabetic patients and of the nuclear-encoded cathepsin L gene in mice.

Standaert, et al., "Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota" Diabetes 51: 2936 (Oct. 2002). The authors concluded that defective activation of atypical PKCs played an important role in the pathogenesis of peripheral insulin resistance in both obese prediabetic and diabetic monkeys. They attributed this linkage to the apparent requirement for aPKCs during insulin-stimulated glucose transport.

Srommer, et al., Am. J. Physiol., "Skeletal muscle insulin resistance after trauma: insulin signaling and glucose transport", 275(2 Pt. 1): E3518 (Aug. 1998) concluded that insulin resistance in skeletal muscle after surgical trauma is associated with reduced glucose transport but not with impaired glucose signaling to PI 3-kinase or its downstream target, Akt.

**SUMMARY OF THE INVENTION**

Differential hybridization techniques have been used to identify mouse genes that are differentially expressed in mice, depending upon their development of hyperinsulinemia or type II diabetes.

In essence, complementary RNA derived from normal mice, or mouse models of hyperinsulinemia or type II diabetes, was screened for hybridization with oligonucleotide probes each specific to a particular mouse gene, each gene in turn representative of a particular mouse gene cluster (Unigene). Mouse genes which were differentially expressed (normal vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or normal vs. diabetic), as measured by different levels of hybridization of the respective cRNA samples with the particular probe corresponding to that mouse gene) were identified. Related human genes and proteins were identified by sequence comparisons to the mouse gene or protein.

After identifying related human genes and proteins, one may formulate agents useful in screening humans at risk for progression toward hyperinsulinemia or toward type II diabetes.

Since the progression is from normal to hyperinsulinemic, and thence from hyperinsulinemic to type II diabetic, one may define mammalian subjects as being more favored or less favored, with normal subjects being more favored than hyperinsulinemic subjects, and hyperinsulinemic subjects being more favored than type II diabetic subjects. The subjects' state may then be correlated with their gene expression activity.

Thus, "favorable" human genes/proteins are defined as those corresponding to mouse genes which were less strongly expressed in mouse hyperinsulinemic muscle than in control muscle, or less strongly expressed in mouse type II diabetic muscle than in hyperinsulinemic muscle. (The control muscle is the muscle of a mouse which is normal vis-a-vis fasting insulin and fasting glucose levels . The term "normal", as

used herein, means normal relative to those parameters, and does not necessitate that the mouse be normal in every respect.) Likewise, one may define "unfavorable" human genes/proteins as those corresponding to mouse genes which were more strongly expressed in mouse hyperinsulinemic muscle than in control muscle, or more strongly expressed in mouse type II diabetic muscle than in hyperinsulinemic muscle.

As used herein, the term "corresponding" does not mean identical, but rather implies the existence of a statistically significant sequence similarity, such as one sufficient to qualify the human protein or gene as a homologous protein or DNA as defined below. The greater the degree of relationship as thus defined (i.e., by the statistical significance of each alignment used to connect the mouse cDNA to the human protein or gene, measured by an E value), the more close the correspondence. The connection may be direct (mouse gene to human protein) or indirect (e.g., mouse gene to human gene, human gene to human protein). By "mouse gene", we mean the mouse gene from which the gene chip DNA in question was derived.

In general, the human genes/proteins which most closely correspond, directly or indirectly, to the mouse genes are preferred, such as the one(s) with the highest, top two highest, top three highest, top four highest, top five highest, and top ten highest E values for the final alignment in the connection process. The human genes/proteins deemed to correspond to our mouse cDNA clones are identified in the Master Tables.

A human gene/protein corresponding to a mouse cDNA which was more strongly expressed in hyperinsulinemic muscle than in either normal or type II diabetic muscle (i.e., C<HI, HI>D) will be deemed both "unfavorable", by virtue of the control:hyperinsulinemic comparison, and "favorable", by virtue of the hyperinsulinemic:diabetic comparison. This is one of several possible "mixed" expression patterns.

Thus, we can subdivide the "favorables" into wholly and partially favorables. Likewise, we can subdivide the

unfavorables into wholly and partially unfavorables. The genes/proteins with "mixed" expression patterns are, by definition, both partially favorable and partially unfavorable. In general, use of the wholly favorable or wholly unfavorable genes/proteins is preferred to use of the partially favorable or partially unfavorable ones.

Agents which bind the "favorable" and "unfavorable" nucleic acids (e.g., the agent is a substantially complementary nucleic acid hybridization probe), or the corresponding proteins (e.g., an antibody vs. the protein) may be used to evaluate whether a human subject is at increased or decreased risk for progression toward type II diabetes. A subject with one or more elevated "unfavorable" and/or one or more depressed "favorable" genes/proteins is at increased risk, and one with one or more elevated "favorable" and/or one or more depressed "unfavorable" genes/proteins is at decreased risk. One may further take into account whether the subject is normoinsulinemic or hyperinsulinemic at the time of the assay. If the subject is non-diabetic and normoinsulinemic, we are especially interested in the "favorable" and "unfavorable" genes/proteins corresponding to mouse genes differentially expressed in hyperinsulinemic vs. normal muscle. If the subject is already hyperinsulinemic, yet non-diabetic, we are especially interested in the "favorable" and "unfavorable" genes/proteins corresponding to mouse genes differentially expressed in type II diabetic vs. hyperinsulinemic muscle.

The assay may be used as a preliminary screening assay to select subjects for further analysis, or as a formal diagnostic assay.

35

The identification of the related genes and proteins may also be useful in protecting humans against these disorders.

Thus, Applicants contemplate:

- (1) use of the "favorable" mouse DNAs of the Master Tables (below) to isolate or identify related human DNAs;
- 5 (2) use of human DNAs, related to favorable mouse DNAs, to express the corresponding human proteins;
- (3) use of the corresponding human proteins (and mouse proteins, if biologically active in humans), to protect against the disorder(s);
- 10 (4) use of the corresponding mouse or human proteins, or nucleic acid probes derived from the mouse or human genes, in diagnostic agents, in assays to measure progression toward hyperinsulinemia or type II diabetes, or protection against the disorder(s), or to estimate related end organ damage such as kidney damage; and
- 15 (5) use of the corresponding human or mouse genes therapeutically in gene therapy, to protect against the disorder(s).

Moreover Applicants contemplate:

- (1) use of the "unfavorable" mouse DNAs of the Master Tables to isolate or identify related human DNAs;
- 20 (2) use of the complement to the "unfavorable" mouse DNAs or related human DNAs, as antisense molecules to inhibit expression of the related human DNAs;
- (3) use of the mouse or human DNAs to express the corresponding mouse or human proteins;
- 25 (4) use of the corresponding mouse or human proteins, in diagnostic agents, to measure progression toward hyperinsulinemia or type II diabetes, or protection against the disorder(s), or to estimate related end organ damage such as kidney damage;
- 30 (5) use of the corresponding mouse or human proteins in assays to determine whether a substance binds to (and hence may neutralize) the protein; and
- (6) use of the neutralizing substance to protect against the disorder(s).

The related human DNAs may be identified by comparing the mouse sequence (or its AA translation product) to known human DNAs (and their AA translation products). If this is

unsuccessful, human cDNA or genomic DNA libraries may be screened using the mouse DNA as a probe.

Our animal models of hyperinsulinemia and diabetes are also  
5 obese. It is possible that the genes found to be favorable act indirectly by inhibiting obesity. Likewise, it is possible that the genes found to be unfavorable act indirectly by accentuating obesity. Consequently, it is  
10 within the compass of the present invention to use the favorable genes and proteins, or to use antagonists of the unfavorable genes and proteins, to protect against obesity, as well as against sequelae of obesity such as hyperinsulinemia and diabetes.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE  
INVENTION

**Subjects**

5       A mouse is considered to be a diabetic subject if, regardless of its fasting plasma insulin level, it has a fasting plasma glucose level of at least 190 mg/dL. A mouse is considered to be a hyperinsulinemic subject if its fasting plasma insulin level is at least 0.67 ng/mL and it  
10      does not qualify as a diabetic subject. A mouse is considered to be "normal" if it is neither diabetic nor hyperinsulinemic. Thus, normality is defined in a very limited manner.

15      A mouse is considered "obese" if its weight is at least 15% in excess of the mean weight for mice of its age and sex. A mouse which does not satisfy this standard may be characterized as "non-obese", the term "normal" being reserved for use in reference to glucose and insulin levels as previously described.

20      A human is considered a diabetic subject if, regardless of his or her fasting plasma insulin level, the fasting plasma glucose level is at least 126 mg/dL. A human is considered a hyperinsulinemic subject if the fasting plasma insulin level is more than 26 micro International Units/mL (it is believed that this is equivalent to 1.08 ng/mL), and does not qualify as a diabetic subject. A human is considered to be "normal" if it is neither diabetic nor hyperinsulinemic. Thus, normality is defined in a very limited manner.

25      A human is considered "obese" if the body mass index (BMI) (weight divided by height squared) is at least 30 kg/m<sup>2</sup>. A human who does not satisfy this standard may be characterized as "non-obese", the term "normal" being reserved for use in reference to glucose and insulin levels as previously described.

30      A human is considered overweight if the BMI is at least 25 kg/m<sup>2</sup>. Thus, we define overweight to include obese

individuals, consistent with the recommendations of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A human who does not satisfy this standard may be characterized as "non-overweight."

5

According to the Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20: 1183-97 (1997), the following are risk factors for diabetes type II:

10

older (e.g., at least 45; see below)

excessive weight (see below)

15

first-degree relative with diabetes mellitus

member of high risk ethnic group (black, Hispanic, Native American, Asian)

20

history of gestational diabetes mellitus or delivering a baby weighing more than 9 pounds (4.032 kg)

hypertensive (>140/90 mm Hg)

25

HDL cholesterol level >35 mg/dL (0.90 mmol/L)

triglyceride level >=250 mg/dL (2.83 mmol/L)

30

Hence, in a preferred embodiment, the diagnostic and protective methods of the present invention are applied to human subjects exhibiting one or more of the aforementioned risk factors. Likewise, in a preferred embodiment, they are applied to human subjects who, while not diabetic, exhibit impaired glucose homeostasis (110 to <126 mg/dL).

35

The risk of diabetes increases with age. Hence, in successive preferred embodiments, the age of the subjects is

at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, and at least 75.

With regard to excessive weight, NIDDK says that "The relative risk of diabetes increases by approximately 25 percent for each additional unit of BMI over 22." Hence, in successive preferred embodiments, the BMIs of the human subjects is at least 23, at least 24, at least 25 (i.e., overweight by our criterion), at least 26, at least 27, at least 28, at least 29, at least 30 (i.e., obese), at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, or over 40.

#### 15      **Genes/Proteins of Interest**

Favorable genes/proteins are those corresponding to genes less strongly expressed in hyperinsulinemic muscle than in normal muscle, or in type II diabetic muscle as compared to hyperinsulinemic muscle. Unfavorable genes/proteins are those corresponding to genes more strongly expressed in hyperinsulinemic muscle than in normal muscle, or in type II diabetic muscle as compared to hyperinsulinemic muscle.

Mixed genes/proteins are those exhibiting a combination of favorable and unfavorable behavior. A mixed gene/protein can be used as would a favorable gene/protein if its favorable behavior outweighs the unfavorable. It can be used as would an unfavorable gene/protein if its unfavorable behavior outweighs the favorable. Preferably, they are used in conjunction with other agents that affect their balance of favorable and unfavorable behavior. Use of mixed genes/proteins is, in general, less desirable than use of purely favorable or purely unfavorable genes/proteins.

35      For each of the differentially expressed genes, corresponding mouse and human proteins have been identified, as set forth in the Master Tables.

**Direct and Indirect Utility of Identified Nucleic Acid Sequences and Related Molecules**

The mouse or human genes (or fragments thereof) may be used directly. For diagnostic or screening purposes, they (or specific binding fragments thereof) may be labeled and used as hybridization probes. For therapeutic purposes, they (or specific binding fragments thereof) may be used as antisense reagents to inhibit the expression of the corresponding gene, or of a sufficiently homologous gene of another species..

Since each of the probes is representative of a full-length mouse gene, that is, it encodes an entire, functional protein, then it may be used in the expression of that protein. Likewise, if the corresponding human gene is known in full-length, it may be used to express the human protein. Such expression may be in cell culture, with the protein subsequently isolated and administered exogenously to subjects who would benefit therefrom, or *in vivo*, i.e., administration by gene therapy. Naturally, any DNA encoding the same protein, or a fragment or a mutant protein which retains the desired activity, may be used for the same purpose. The encoded protein of course has utility therapeutically and, in labeled or immobilized form, diagnostically.

The genes may also be used indirectly, that is, to identify other useful DNAs, proteins, or other molecules.

There thus are several ways that a human protein homologue of interest can be identified by database searching, including:

- 1) a DNA->DNA (BlastN) search for database DNAs closely related to the mouse gene identifies a known human gene, and the sequence of the human protein is deduced by the Genetic Code;

- 2) a DNA->Protein (BlastX) search for database proteins closely related to the translated DNA of the mouse gene identifies a known human protein; and
- 5       3) the sequence of the mouse protein is known or is deduced by the Genetic Code, and a Protein->Protein (BlastP) search for closely related database proteins identifies a known human protein.
- 10      Once a known human gene is identified, it may be used in further BlastN or BlastX searches to identify other human genes or proteins. Once a known human protein is identified, it may be used in further BlastP searches to identify other human proteins.
- 15      Searches may also take cognizance, intermediately, of known genes and proteins other than mouse or human ones, e.g., use the mouse sequence to identify a known rat sequence and then the rat sequence to identify a human one.
- 20      Thus, if we have identified a mouse gene, and it encodes a mouse protein which appears similar to a human protein, then that human protein may be used (especially in humans) for purposes analogous to the proposed use of the mouse protein in mice. Moreover, a specific binding fragment of an appropriate strand of the corresponding human gene or cDNA could be labeled and used as a hybridization probe (especially against samples of human mRNA or cDNA).
- 25      In determining whether the disclosed genes have significant similarities to known DNAs (and their translated AA sequences to known proteins), one would generally use the disclosed gene as a query sequence in a search of a sequence database. The results of several such searches are set forth in the Examples. Such results are dependent, to some degree, on the search parameters. Preferred parameters are set forth in Example 1. The results are also dependent on the content of the database. While the raw similarity score of a particular target (database) sequence will not vary

with content (as long as it remains in the database), its informational value (in bits), expected value, and relative ranking can change. Generally speaking, the changes are small.

5

It will be appreciated that the nucleic acid and protein databases keep growing. Hence a later search may identify high scoring target sequences which were not 10 uncovered by an earlier search because the target sequences were not previously part of a database.

Hence, in a preferred embodiment, the cognate DNAs and proteins include not only those set forth in the examples, but those which would have been highly ranked (top ten, more 15 preferably top three, even more preferably top two, most preferably the top one) in a search run with the same parameters on the date of filing of this application.

If the known human DNA is appears to be a partial DNA, 20 it may be used as a hybridization probe to isolate the full-length DNA. If the partial DNA encodes a biologically functional fragment of the cognate protein, it may be used in a manner similar to the full length DNA, i.e., to produce the functional fragment.

25

If we have indicated that an antagonist of a protein or other molecule is useful, then such an antagonist may be obtained by preparing a combinatorial library, as described below, of potential antagonists, and screening the library members for binding to the protein or other molecule in question. The binding members may then be further screened for the ability to antagonize the biological activity of the target. The antagonists may be used therapeutically, or, in suitably labeled or immobilized form, diagnostically.

35

If the identified DNA is related to a known protein, then substances known to interact with that protein (e.g., agonists, antagonists, substrates, receptors, second messengers, regulators, and so forth), and binding molecules

which bind them, are also of utility. Such binding molecules can likewise be identified by screening a combinatorial library.

5       **Isolation of Full Length cDNAs Using Partial cDNAs as probes**

If it is determined that a DNA of the present invention is a partial DNA, and the cognate full length DNA is not listed in a sequence database, the available DNA may be used as a hybridization probe to isolate the full-length cDNA

10       from a suitable cDNA library.

Stringent hybridization conditions are appropriate, that is, conditions in which the hybridization temperature is 5-10 deg. C. below the T<sub>m</sub> of the cDNA as a perfect duplex.

15

**Identification and Isolation of Homologous Genes/cDNAs Using a cDNA Probe**

It may be that the sequence databases available do not include the sequence of any homologous gene, or at least of the homologous gene for a species of interest. However, given the cDNAs set forth above, one may readily obtain the homologous gene.

20       The possession of one DNA (the "starting DNA") greatly facilitates the isolation of homologous genes/cDNAs. If only a partial DNA is known, this partial DNA may first be used as a probe to isolate the corresponding full length DNA for the same species, and that the latter may be used as the starting DNA in the search for homologous genes.

25       The starting DNA, or a fragment thereof, is used as a hybridization probe to screen a cDNA or genomic DNA library for clones containing inserts which encode either the entire homologous protein, or a recognizable fragment thereof. The minimum length of the hybridization probe is dictated by the need for specificity. If the size of the library in bases is L, and the GC content is 50%, then the probe should have a length of at least l, where L = 4<sup>l</sup>. This will yield, on average, a single perfect match in random DNA of L bases.

The human cDNA library is about  $10^8$  bases and the human genomic DNA library is about  $10^{10}$  bases.

The library is preferably derived from an organism which is known, on biochemical evidence, to produce a homologous protein, and more preferably from the genomic DNA or mRNA of cells of that organism which are likely to be relatively high producers of that protein. A cDNA library (which is derived from an mRNA library) is especially preferred.

If the organism in question is known to have substantially different codon preferences from that of the organism whose relevant cDNA or genomic DNA is known, a synthetic hybridization probe may be used which encodes the same amino acid sequence but whose codon utilization is more similar to that of the DNA of the target organism. Alternatively, the synthetic probe may employ inosine as a substitute for those bases which are most likely to be divergent, or the probe may be a mixed probe which mixes the codons for the source DNA with the preferred codons (encoding the same amino acid) for the target organism.

By routine methods, the  $T_m$  of a perfect duplex of starting DNA is determined. One may then select a hybridization temperature which is sufficiently lower than the perfect duplex  $T_m$  to allow hybridization of the starting DNA (or other probe) to a target DNA which is divergent from the starting DNA. A 1% sequence divergence typically lowers the  $T_m$  of a duplex by 1-2°C, and the DNAs encoding homologous proteins of different species typically have sequence identities of around 50-80%. Preferably, the library is screened under conditions where the temperature is at least 20°C., more preferably at least 50°C., below the perfect duplex  $T_m$ . Since salt reduces the  $T_m$ , one ordinarily would carry out the search for DNAs encoding highly homologous proteins under relatively low salt hybridization conditions, e.g., <1M NaCl. The higher the salt concentration, and/or the lower the temperature, the greater the sequence divergence which is tolerated.

For the use of probes to identify homologous genes in other species, see, e.g., Schwinn, et al., J. Biol. Chem., 265:8183-89 (1990) (hamster 67-bp cDNA probe vs. human leukocyte genomic library; human 0.32kb DNA probe vs. bovine brain cDNA library, both with hybridization at 42°C in 6xSSC); Jenkins et al., J. Biol. Chem., 265:19624-31 (1990) (Chicken 770-bp cDNA probe vs. human genomic libraries; hybridization at 40°C in 50% formamide and 5xSSC); Murata et al., J. Exp. Med., 175:341-51 (1992) (1.2-kb mouse cDNA probe v. human eosinophil cDNA library; hybridization at 65°C in 6xSSC); Guyer et al., J. Biol. Chem., 265:17307-17 (1990) (2.95-kb human genomic DNA probe vs. porcine genomic DNA library; hybridization at 42°C in 5xSSC). The conditions set forth in these articles may each be considered suitable for the purpose of isolating homologous genes.

#### **Homologous Proteins and DNAs**

A human protein can be said to be identifiable as homologous to a mouse gene (and hence to "correspond" to such gene) if

(1) its sequence can be aligned to the mouse gene, using BlastX with the default parameters set forth below, and the expected value (E) of the alignment (the probability that such an alignment would have occurred by chance alone) is less than e-10,

(2) its sequence can be aligned to a human gene, using BlastX with the default parameters set forth below, and the cDNA of said human gene can be aligned to the mouse gene, using BlastN with the default parameters set forth below, and the E value for both alignments is less than e-10,

(3) its sequence can be aligned to a mouse protein, using BlastP with the default parameters set forth below, and that mouse protein can be aligned to the mouse gene, using BlastX

with the default parameters set forth below, and in both alignments the E value of the alignment is less than e-10.

5 Naturally, if the human protein is encoded by the human gene of (2), or the mouse protein is encoded by the mouse gene of (3), the BlastX alignment will be satisfied.

Desirably, two or all three of these conditions (1) - (3) are satisfied.

10 Preferably, for any of the alignments noted above, and more preferably for all of them, the E value is less than e-15, more preferably less than e-20, still more preferably less than e-40, even more preferably less than e-60, 15 considerably more preferably less than e-80, and most preferably less than e-100. More preferably, for those conditions in which the mouse cDNA clone is indirectly connected to the human protein by virtue of two or more successive alignments, the E value is so limited for all of 20 said alignments in the connecting chain.

BlastN and BlastX report very low expected values as "0.0". This does not truly mean that the expected value is exactly zero (since any alignment could occur by chance), 25 but merely that it is so infinitesimal that it is not reported. The documentation does not state the cutoff value, alignments with explicit E values as low as e-178 (624 bits) have been reported as such, while a score of 636 bits was reported as "0.0".

30 Functionally homologous human proteins are also of interest. A human protein may be said to be functionally homologous to the mouse gene if (1) it can be aligned to the mouse gene, using BlastX with the default parameters set 35 forth below, and the E value of the alignment is less than e-50, and (2) the human protein has at least one biological activity in common with the mouse protein.

The human proteins of interest also include those that are substantially and/or conservatively identical (as defined below) to the homologous and/or functionally homologous human proteins defined above.

5

#### Relevance of Favorable and Unfavorable Genes

10

If a gene is down-regulated in more favored mammals, or up-regulated in less favored mammals, (i.e., an "unfavorable gene") then several utilities are apparent.

15

First, the complementary strand of the gene, or a portion thereof, may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Elevated levels are indicative of progression, or propensity to progression, to a less favored state, and 20 clinicians may take appropriate preventative, curative or ameliorative action.

25

Secondly, the messenger RNA product (or equivalent cDNA), the protein product, or a binding molecule specific for that product (e.g., an antibody which binds the product), or a downstream product which mediates the activity (e.g., a signaling intermediate) or a binding molecule (e.g., an antibody) therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said nucleic acid product, protein product, or downstream product (e.g., a signaling intermediate). Again, elevated levels are indicative of a present or future problem.

30

35

Thirdly, an agent which down-regulates expression of the gene may be used to reduce levels of the corresponding protein and thereby inhibit further damage. This agent could inhibit transcription of the gene in the subject, or translation of the corresponding messenger RNA. Possible inhibitors of transcription and translation include

antisense molecules and repressor molecules. The agent could also inhibit a post-translational modification (e.g., glycosylation, phosphorylation, cleavage, GPI attachment) required for activity, or post-translationally modify the protein so as to inactivate it. Or it could be an agent which down- or up-regulated a positive or negative regulatory gene, respectively.

Fourthly, an agent which is an antagonist of the messenger RNA product or protein product of the gene, or of a downstream product through which its activity is manifested (e.g., a signaling intermediate), may be used to inhibit its activity.

This antagonist could be an antibody, a peptide, a peptoid, a nucleic acid, a peptide nucleic acid (PNA) oligomer, a small organic molecule of a kind for which a combinatorial library exists (e.g., a benzodiazepine), etc. An antagonist is simply a binding molecule which, by binding, reduces or abolishes the undesired activity of its target. The antagonist, if not an oligomeric molecule, is preferably less than 500 daltons.

Fifthly, an agent which degrades, or abets the degradation of, that messenger RNA, its protein product or a downstream product which mediates its activity (e.g., a signaling intermediate), may be used to curb the effective period of activity of the protein.

If a gene is up-regulated in more favored mammals, or down-regulated in less favored animals then the utilities are converse to those stated above.

First, the complementary strand of the gene, or a portion thereof, may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Depressed levels are indicative of damage, or possibly of a propensity to damage, and clinicians may take appropriate preventative, curative or ameliorative action.

Secondly, the messenger RNA product, the equivalent cDNA, protein product, or a binding molecule specific for those products, or a downstream product, or a signaling

intermediate, or a binding molecule therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said protein product or downstream product. Again, depressed levels are indicative of a present or future problem.

5 Thirdly, an agent which up-regulates expression of the gene may be used to increase levels of the corresponding protein and thereby inhibit further progression to a less favored state. By way of example, it could be a vector 10 which carries a copy of the gene, but which expresses the gene at higher levels than does the endogenous expression system. Or it could be an agent which up- or down-regulates a positive or negative regulatory gene.

15 Fourthly, an agent which is an agonist of the protein product of the gene, or of a downstream product through which its activity (of inhibition of progression to a less favored state) is manifested, or of a signaling intermediate may be used to foster its activity.

20 Fifthly, an agent which inhibits the degradation of that protein product or of a downstream product or of a signaling intermediate may be used to increase the effective period of activity of the protein.

25 **Mutant Proteins**

The present invention also contemplates mutant proteins (peptides) which are substantially identical (as defined below) to the parental protein (peptide). In general, the fewer the mutations, the more likely the mutant protein is 30 to retain the activity of the parental protein. The effect of mutations is usually (but not always) additive. Certain individual mutations are more likely to be tolerated than others.

A protein is more likely to tolerate a mutation which  
35           (a) is a substitution rather than an insertion or deletion;  
           (b) is an insertion or deletion at the terminus, rather than internally, or, if internal, is at a

domain boundary, or a loop or turn, rather than in an alpha helix or beta strand;

(c) affects a surface residue rather than an interior residue;

5 (d) affects a part of the molecule distal to the binding site;

(e) is a substitution of one amino acid for another of similar size, charge, and/or hydrophobicity, and does not destroy a disulfide bond or other crosslink; and

10 (f) is at a site which is subject to substantial variation among a family of homologous proteins to which the protein of interest belongs.

These considerations can be used to design functional

15 mutants.

#### *Surface vs. Interior Residues*

Charged residues almost always lie on the surface of the protein. For uncharged residues, there is less certainty, but in general, hydrophilic residues are partitioned to the surface and hydrophobic residues to the interior. Of course, for a membrane protein, the membrane-spanning segments are likely to be rich in hydrophobic residues.

25 Surface residues may be identified experimentally by various labeling techniques, or by 3-D structure mapping techniques like X-ray diffraction and NMR. A 3-D model of a homologous protein can be helpful.

#### *Binding Site Residues*

Residues forming the binding site may be identified by (1) comparing the effects of labeling the surface residues before and after complexing the protein to its target, (2) labeling the binding site directly with affinity ligands, (3) fragmenting the protein and testing the fragments for binding activity, and (4) systematic mutagenesis (e.g., alanine-scanning mutagenesis) to determine which mutants destroy binding. If the binding site of a homologous

protein is known, the binding site may be postulated by analogy.

Protein libraries may be constructed and screened that a large family (e.g.,  $10^8$ ) of related mutants may be evaluated simultaneously.

Hence, the mutations are preferably conservative modifications as defined below.

"Substantially Identical"

A mutant protein (peptide) is substantially identical to a reference protein (peptide) if (a) it has at least 10% of a specific binding activity or a non-nutritional biological activity of the reference protein, and (b) is at least 50% identical in amino acid sequence to the reference protein (peptide). It is "substantially structurally identical" if condition (b) applies, regardless of (a).

Percentage amino acid identity is determined by aligning the mutant and reference sequences according to a rigorous dynamic programming algorithm which globally aligns their sequences to maximize their similarity, the similarity being scored as the sum of scores for each aligned pair according to an unbiased PAM250 matrix, and a penalty for each internal gap of -12 for the first null of the gap and -4 for each additional null of the same gap. The percentage identity is the number of matches expressed as a percentage of the adjusted (i.e., counting inserted nulls) length of the reference sequence.

A mutant DNA sequence is substantially identical to a reference DNA sequence if they are structural sequences, and encoding mutant and reference proteins which are substantially identical as described above.

If instead they are regulatory sequences, they are substantially identical if the mutant sequence has at least 10% of the regulatory activity of the reference sequence, and is at least 50% identical in nucleotide sequence to the reference sequence. Percentage identity is determined as for proteins except that matches are scored +5, mismatches -

4, the gap open penalty is -12, and the gap extension penalty (per additional null) is -4.

Preferably, sequence which are substantially identical exceed the minimum identity of 50% e.g., are 51%, 66%, 75%, 80%, 85%, 90%, 95% or 99% identical in sequence.

DNA sequences may also be considered "substantially identical" if they hybridize to each other under stringent conditions, i.e., conditions at which the Tm of the heteroduplex of the one strand of the mutant DNA and the more complementary strand of the reference DNA is not in excess of 10°C. less than the Tm of the reference DNA homoduplex. Typically this will correspond to a percentage identity of 85-90%.

15 "Conservative Modifications"

"Conservative modifications" are defined as

- (a) conservative substitutions of amino acids as hereafter defined; or
- (b) single or multiple insertions (extension) or deletions (truncation) of amino acids at the termini.

Conservative modifications are preferred to other modifications. Conservative substitutions are preferred to other conservative modifications.

25 "Semi-Conservative Modifications" are modifications which are not conservative, but which are (a) semi-conservative substitutions as hereafter defined; or (b) single or multiple insertions or deletions internally, but at interdomain boundaries, in loops or in other segments of relatively high mobility. Semi-conservative modifications are preferred to nonconservative modifications. Semi-conservative substitutions are preferred to other semi-conservative modifications.

35 Non-conservative substitutions are preferred to other non-conservative modifications.

The term "conservative" is used here in an a priori sense, i.e., modifications which would be expected to preserve 3D structure and activity, based on analysis of the

naturally occurring families of homologous proteins and of past experience with the effects of deliberate mutagenesis, rather than post facto, a modification already known to conserve activity. Of course, a modification which is 5 conservative a priori may, and usually is, also conservative post facto.

Preferably, except at the termini, no more than about five amino acids are inserted or deleted at a particular locus, and the modifications are outside regions known to 10 contain binding sites important to activity.

Preferably, insertions or deletions are limited to the termini.

A conservative substitution is a substitution of one amino acid for another of the same exchange group, the 15 exchange groups being defined as follows

- I Gly, Pro, Ser, Ala (Cys) (and any nonbiogenic, neutral amino acid with a hydrophobicity not exceeding that of the aforementioned a.a.'s)
- II Arg, Lys, His (and any nonbiogenic, positively-charged amino acids)
- III Asp, Glu, Asn, Gln (and any nonbiogenic negatively-charged amino acids)
- IV Leu, Ile, Met, Val (Cys) (and any nonbiogenic, aliphatic, neutral amino acid with a hydrophobicity too high for I above)
- V Phe, Trp, Tyr (and any nonbiogenic, aromatic neutral amino acid with a hydrophobicity too high for I above).

Note that Cys belongs to both I and IV.

Residues Pro, Gly and Cys have special conformational roles. Cys participates in formation of disulfide bonds. Gly imparts flexibility to the chain. Pro imparts rigidity to the chain and disrupts  $\alpha$  helices. These residues may be essential in certain regions of the polypeptide, but 35 substitutable elsewhere.

One, two or three conservative substitutions are more likely to be tolerated than a larger number.

5 "Semi-conservative substitutions" are defined herein as being substitutions within supergroup I/II/III or within supergroup IV/V, but not within a single one of groups I-V. They also include replacement of any other amino acid with alanine. If a substitution is not conservative, it preferably is semi-conservative.

"Non-conservative substitutions" are substitutions which are not "conservative" or "semi-conservative".

10 "Highly conservative substitutions" are a subset of conservative substitutions, and are exchanges of amino acids within the groups Phe/Tyr/Trp, Met/Leu/Ile/Val, His/Arg/Lys, Asp/Glu and Ser/Thr/Ala. They are more likely to be tolerated than other conservative substitutions. Again, the 15 smaller the number of substitutions, the more likely they are to be tolerated.

#### "Conservatively Identical"

20 A protein (peptide) is conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by conservative modifications, the protein (peptide) remaining at least seven amino acids long if the reference protein (peptide) was at least seven amino acids long.

25 A protein is at least semi-conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by semi-conservative or conservative modifications.

30 A protein (peptide) is nearly conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by one or more conservative modifications and/or a single nonconservative substitution.

35 It is highly conservatively identical if it differs, if at all, solely by highly conservative substitutions. Highly conservatively identical proteins are preferred to those merely conservatively identical. An absolutely identical protein is even more preferred.

5       The core sequence of a reference protein (peptide) is the largest single fragment which retains at least 10% of a particular specific binding activity, if one is specified, or otherwise of at least one specific binding activity of the referent. If the referent has more than one specific binding activity, it may have more than one core sequence, and these may overlap or not.

10      If it is taught that a peptide of the present invention may have a particular similarity relationship (e.g., markedly identical) to a reference protein (peptide), preferred peptides are those which comprise a sequence having that relationship to a core sequence of the reference protein (peptide), but with internal insertions or deletions in either sequence excluded. Even more preferred peptides 15 are those whose entire sequence has that relationship, with the same exclusion, to a core sequence of that reference protein (peptide).

20      **Library**

The term "library" generally refers to a collection of chemical or biological entities which are related in origin, structure, and/or function, and which can be screened simultaneously for a property of interest.

25      Libraries may be classified by how they are constructed (natural vs. artificial diversity; combinatorial vs. noncombinatorial), how they are screened (hybridization, expression, display), or by the nature of the screened library members (peptides, nucleic acids, etc.).

30      In a "natural diversity" library, essentially all of the diversity arose without human intervention. This would be true, for example, of messenger RNA extracted from a non-engineered cell.

35      In a "synthetic diversity" library, essentially all of the diversity arose deliberately as a result of human intervention. This would be true for example of a combinatorial library; note that a small level of natural diversity could still arise as a result of spontaneous

mutation. It would also be true of a noncombinatorial library of compounds collected from diverse sources, even if they were all natural products.

5 In a "non-natural diversity" library, at least some of the diversity arose deliberately through human intervention.

In a "controlled origin" library, the source of the diversity is limited in some way. A limitation might be to 10 cells of a particular individual, to a particular species, or to a particular genus, or, more complexly, to individuals of a particular species who are of a particular age, sex, physical condition, geographical location, occupation and/or 15 familial relationship. Alternatively or additionally, it might be to cells of a particular tissue or organ. Or it could be cells exposed to particular pharmacological, environmental, or pathogenic conditions. Or the library 20 could be of chemicals, or a particular class of chemicals, produced by such cells.

In a "controlled structure" library, the library members are deliberately limited by the production 25 conditions to particular chemical structures. For example, if they are oligomers, they may be limited in length and monomer composition, e.g. hexapeptides composed of the twenty genetically encoded amino acids.

#### 25 Hybridization Library

In a hybridization library, the library members are nucleic acids, and are screened using a nucleic acid hybridization probe. Bound nucleic acids may then be amplified, cloned, and/or sequenced.

30

#### Expression Library

In an expression library, the screened library members are gene expression products, but one may also speak of an underlying library of genes encoding those products. The 35 library is made by subcloning DNA encoding the library members (or portions thereof) into expression vectors (or into cloning vectors which subsequently are used to construct expression vectors), each vector comprising an

expressible gene encoding a particular library member, introducing the expression vectors into suitable cells, and expressing the genes so the expression products are produced.

5 In one embodiment, the expression products are secreted, so the library can be screened using an affinity reagent, such as an antibody or receptor. The bound expression products may be sequenced directly, or their sequences inferred by, e.g., sequencing at least the  
10 variable portion of the encoding DNA.

In a second embodiment, the cells are lysed, thereby exposing the expression products, and the latter are screened with the affinity reagent.

15 In a third embodiment, the cells express the library members in such a manner that they are displayed on the surface of the cells, or on the surface of viral particles produced by the cells. (See display libraries, below).

20 In a fourth embodiment, the screening is not for the ability of the expression product to bind to an affinity reagent, but rather for its ability to alter the phenotype of the host cell in a particular detectable manner. Here, the screened library members are transformed cells, but there is a first underlying library of expression products which mediate the behavior of the cells, and a second  
25 underlying library of genes which encode those products.

#### Display Library

30 In a display library, the library members are each conjugated to, and displayed upon, a support of some kind. The support may be living (a cell or virus), or nonliving (e.g., a bead or plate).

35 If the support is a cell or virus, display will normally be effectuated by expressing a fusion protein which comprises the library member, a carrier moiety allowing integration of the fusion protein into the surface of the cell or virus, and optionally a lining moiety. In a variation on this theme, the cell coexpresses a first fusion comprising the library member and a linking moiety L1, and a

second fusion comprising a linking moiety L2 and the carrier moiety. L1 and L2 interact to associate the first fusion with the second fusion and hence, indirectly, the library member with the surface of the cell or virus.

5

#### Soluble Library

In a soluble library, the library members are free in solution. A soluble library may be produced directly, or one may first make a display library and then release the library members from their supports.

10

#### Encapsulated Library

In an encapsulated library, the library members are inside cells or liposomes. Generally speaking, encapsulated libraries are used to store the library members for future use; the members are extracted in some way for screening purposes. However, if they differentially affect the phenotype of the cells, they may be screened indirectly by screening the cells.

20

#### cDNA Library

A cDNA library is usually prepared by extracting RNA from cells of particular origin, fractionating the RNA to isolate the messenger RNA (mRNA has a poly(A) tail, so this is usually done by oligo-dT affinity chromatography), synthesizing complementary DNA (cDNA) using reverse transcriptase, DNA polymerase, and other enzymes, subcloning the cDNA into vectors, and introducing the vectors into cells. Often, only mRNAs or cDNAs of particular sizes will be used, to make it more likely that the cDNA encodes a functional polypeptide.

A cDNA library explores the natural diversity of the transcribed DNAs of cells from a particular source. It is not a combinatorial library.

35

A cDNA library may be used to make a hybridization library, or it may be used as an (or to make) expression library.

Genomic DNA Library

A genomic DNA library is made by extracting DNA from a particular source, fragmenting the DNA, isolating fragments of a particular size range, subcloning the DNA fragments into vectors, and introducing the vectors into cells.

Like a cDNA library, a genomic DNA library is a natural diversity library, and not a combinatorial library. A genomic DNA library may be used the same way as a cDNA library.

Synthetic DNA library

A synthetic DNA library may be screened directly (as a hybridization library), or used in the creation of an expression or display library of peptides/proteins.

Combinatorial Libraries

The term "combinatorial library" refers to a library in which the individual members are either systematic or random combinations of a limited set of basic elements, the properties of each member being dependent on the choice and location of the elements incorporated into it. Typically, the members of the library are at least capable of being screened simultaneously. Randomization may be complete or partial; some positions may be randomized and others predetermined, and at random positions, the choices may be limited in a predetermined manner. The members of a combinatorial library may be oligomers or polymers of some kind, in which the variation occurs through the choice of monomeric building block at one or more positions of the oligomer or polymer, and possibly in terms of the connecting linkage, or the length of the oligomer or polymer, too. Or the members may be nonoligomeric molecules with a standard core structure, like the 1,4-benzodiazepine structure, with the variation being introduced by the choice of substituents at particular variable sites on the core structure. Or the members may be nonoligomeric molecules assembled like a jigsaw puzzle, but wherein each piece has both one or more variable moieties (contributing to library diversity) and

one or more constant moieties (providing the functionalities for coupling the piece in question to other pieces).

Thus, in a typical combinatorial library, chemical building blocks are at least partially randomly combined into a large number (as high as  $10^{15}$ ) of different compounds, which are then simultaneously screened for binding (or other) activity against one or more targets.

In a "simple combinatorial library", all of the members belong to the same class of compounds (e.g., peptides) and can be synthesized simultaneously. A "composite combinatorial library" is a mixture of two or more simple libraries, e.g., DNAs and peptides, or peptides, peptoids, and PNAs, or benzodiazepines and carbamates. The number of component simple libraries in a composite library will, of course, normally be smaller than the average number of members in each simple library, as otherwise the advantage of a library over individual synthesis is small.

Libraries of thousands, even millions, of random oligopeptides have been prepared by chemical synthesis (Houghten et al., *Nature*, 354:84-6(1991)), or gene expression (Marks et al., *J Mol Biol*, 222:581-97(1991)), displayed on chromatographic supports (Lam et al., *Nature*, 354:82-4(1991)), inside bacterial cells (Colas et al., *Nature*, 380:548-550(1996)), on bacterial pili (Lu, Bio/Technology, 13:366-372(1990)), or phage (Smith, *Science*, 228:1315-7(1985)), and screened for binding to a variety of targets including antibodies (Valadon et al., *J Mol Biol*, 261:11-22(1996)), cellular proteins (Schmitz et al., *J Mol Biol*, 260:664-677(1996)), viral proteins (Hong and Boulanger, *Embo J*, 14:4714-4727(1995)), bacterial proteins (Jacobsson and Frykberg, *Biotechniques*, 18:878-885(1995)), nucleic acids (Cheng et al., *Gene*, 171:1-8(1996)), and plastic (Siani et al., *J Chem Inf Comput Sci*, 34:588-593(1994)).

Libraries of proteins (Ladner, USP 4,664,989), peptoids (Simon et al., *Proc Natl Acad Sci U S A*, 89:9367-71(1992)), nucleic acids (Ellington and Szostak, *Nature*, 246:818(1990)), carbohydrates, and small organic molecules

(Eichler et al., Med Res Rev, 15:481-96(1995)) have also been prepared or suggested for drug screening purposes.

The first combinatorial libraries were composed of peptides or proteins, in which all or selected amino acid positions were randomized. Peptides and proteins can exhibit high and specific binding activity, and can act as catalysts. In consequence, they are of great importance in biological systems.

Nucleic acids have also been used in combinatorial libraries. Their great advantage is the ease with which a nucleic acid with appropriate binding activity can be amplified. As a result, combinatorial libraries composed of nucleic acids can be of low redundancy and hence, of high diversity.

There has also been much interest in combinatorial libraries based on small molecules, which are more suited to pharmaceutical use, especially those which, like benzodiazepines, belong to a chemical class which has already yielded useful pharmacological agents. The techniques of combinatorial chemistry have been recognized as the most efficient means for finding small molecules that act on these targets. At present, small molecule combinatorial chemistry involves the synthesis of either pooled or discrete molecules that present varying arrays of functionality on a common scaffold. These compounds are grouped in libraries that are then screened against the target of interest either for binding or for inhibition of biological activity.

The size of a library is the number of molecules in it. The simple diversity of a library is the number of unique structures in it. There is no formal minimum or maximum diversity. If the library has a very low diversity, the library has little advantage over just synthesizing and screening the members individually. If the library is of very high diversity, it may be inconvenient to handle, at least without automatizing the process. The simple diversity of a library is preferably at least 10, 10E2, 10E3, 10E4, 10E6, 10E7, 10E8 or 10E9, the higher the better

under most circumstances. The simple diversity is usually not more than  $10E15$ , and more usually not more than  $10E10$ .

The average sampling level is the size divided by the simple diversity. The expected average sampling level must be high enough to provide a reasonable assurance that, if a given structure were expected, as a consequence of the library design, to be present, that the actual average sampling level will be high enough so that the structure, if satisfying the screening criteria, will yield a positive result when the library is screened. Thus, the preferred average sampling level is a function of the detection limit, which in turn is a function of the strength of the signal to be screened.

There are more complex measures of diversity than simple diversity. These attempt to take into account the degree of structural difference between the various unique sequences. These more complex measures are usually used in the context of small organic compound libraries, see below.

The library members may be presented as solutes in solution, or immobilized on some form of support. In the latter case, the support may be living (cell, virus) or nonliving (bead, plate, etc.). The supports may be separable (cells, virus particles, beads) so that binding and nonbinding members can be separated, or nonseparable (plate). In the latter case, the members will normally be placed on addressable positions on the support. The advantage of a soluble library is that there is no carrier moiety that could interfere with the binding of the members to the support. The advantage of an immobilized library is that it is easier to identify the structure of the members which were positive.

When screening a soluble library, or one with a separable support, the target is usually immobilized. When screening a library on a nonseparable support, the target will usually be labeled.

#### Oligonucleotide Libraries

An oligonucleotide library is a combinatorial library, at least some of whose members are single-stranded oligonucleotides having three or more nucleotides connected by phosphodiester or analogous bonds. The oligonucleotides 5 may be linear, cyclic or branched, and may include non-nucleic acid moieties. The nucleotides are not limited to the nucleotides normally found in DNA or RNA. For examples of nucleotides modified to increase nuclease resistance and chemical stability of aptamers, see Chart 1 in Osborne and 10 Ellington, Chem. Rev., 97: 349-70 (1997). For screening of RNA, see Ellington and Szostak, Nature, 346: 818-22 (1990).

There is no formal minimum or maximum size for these 15 oligonucleotides. However, the number of conformations which an oligonucleotide can assume increases exponentially with its length in bases. Hence, a longer oligonucleotide is more likely to be able to fold to adapt itself to a protein surface. On the other hand, while very long molecules can be synthesized and screened, unless they provide a much 20 superior affinity to that of shorter molecules, they are not likely to be found in the selected population, for the reasons explained by Osborne and Ellington (1997). Hence, the libraries of the present invention are preferably composed of oligonucleotides having a length of 3 to 100 25 bases, more preferably 15 to 35 bases. The oligonucleotides in a given library may be of the same or of different lengths.

Oligonucleotide libraries have the advantage that 30 libraries of very high diversity (e.g.,  $10^{15}$ ) are feasible, and binding molecules are readily amplified in vitro by polymerase chain reaction (PCR). Moreover, nucleic acid molecules can have very high specificity and affinity to targets.

In a preferred embodiment, this invention prepares and screens oligonucleotide libraries by the SELEX method, as 35 described in King and Famulok, Molec. Biol. Repts., 20: 97-107 (1994); L. Gold, C. Tuerk. Methods of producing nucleic acid ligands, US#5595877; Oliphant et al. Gene 44:177 (1986).

The term "aptamer" is conferred on those oligonucleotides which bind the target protein. Such aptamers may be used to characterize the target protein, both directly (through identification of the aptamer and the points of contact between the aptamer and the protein) and indirectly (by use of the aptamer as a ligand to modify the chemical reactivity of the protein).

In a classic oligonucleotide, each nucleotide (monomeric unit) is composed of a phosphate group, a sugar moiety, and either a purine or a pyrimidine base. In DNA, the sugar is deoxyribose and in RNA it is ribose. The nucleotides are linked by 5'-3' phosphodiester bonds.

The deoxyribose phosphate backbone of DNA can be modified to increase resistance to nuclease and to increase penetration of cell membranes. Derivatives such as mono- or dithiophosphates, methyl phosphonates, boranophosphates, formacetals, carbamates, siloxanes, and dimethylenethio-sulfoxido- and sulfo- linked species are known in the art.

20

#### Peptide Library

A peptide is composed of a plurality of amino acid residues joined together by peptidyl (-NHCO-) bonds. A biogenic peptide is a peptide in which the residues are all genetically encoded amino acid residues; it is not necessary that the biogenic peptide actually be produced by gene expression.

Amino acids are the basic building blocks with which peptides and proteins are constructed. Amino acids possess both an amino group (-NH<sub>2</sub>) and a carboxylic acid group (-COOH). Many amino acids, but not all, have the alpha amino acid structure NH<sub>2</sub>-CHR-COOH, where R is hydrogen, or any of a variety of functional groups.

Twenty amino acids are genetically encoded: Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Glutamic Acid, Glutamine, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, and Valine. Of these, all

save Glycine are optically isomeric, however, only the L-form is found in humans. Nevertheless, the D-forms of these amino acids do have biological significance; D-Phe, for example, is a known analgesic.

5 Many other amino acids are also known, including: 2-Aminoadipic acid; 3-Aminoadipic acid; beta-Aminopropionic acid; 2-Aminobutyric acid; 4-Aminobutyric acid (Piperidinic acid); 6-Aminocaproic acid; 2-Aminoheptanoic acid; 2-Aminoisobutyric acid, 3-Aminoisobutyric acid; 2-Aminopimelic acid; 2,4-Diaminobutyric acid; Desmosine; 2,2'-Diaminopimelic acid; 2,3-Diaminopropionic acid; N-Ethylglycine; N-Ethylasparagine; Hydroxylysine; allo-Hydroxylysine; 3-Hydroxyproline; 4-Hydroxyproline; Isodesmosine; allo-Isoleucine; N-Methylglycine (Sarcosine); N-Methylisoleucine; N-Methylvaline; Norvaline; Norleucine; and Ornithine.

20 Peptides are constructed by condensation of amino acids and/or smaller peptides. The amino group of one amino acid (or peptide) reacts with the carboxylic acid group of a second amino acid (or peptide) to form a peptide (-NHCO-) bond, releasing one molecule of water. Therefore, when an amino acid is incorporated into a peptide, it should, technically speaking, be referred to as an amino acid residue. The core of that residue is the moiety which 25 excludes the -NH and -CO linking functionalities which connect it to other residues. This moiety consists of one or more main chain atoms (see below) and the attached side chains.

30 The main chain moiety of each amino acid consists of the -NH and -CO linking functionalities and a core main chain moiety. Usually the latter is a single carbon atom. However, the core main chain moiety may include additional carbon atoms, and may also include nitrogen, oxygen or sulfur atoms, which together form a single chain. In a 35 preferred embodiment, the core main chain atoms consist solely of carbon atoms.

The side chains are attached to the core main chain atoms. For alpha amino acids, in which the side chain is

attached to the alpha carbon, the C-1, C-2 and N-2 of each residue form the repeating unit of the main chain, and the word "side chain" refers to the C-3 and higher numbered carbon atoms and their substituents. It also includes H atoms attached to the main chain atoms.

Amino acids may be classified according to the number of carbon atoms which appear in the main chain between the carbonyl carbon and amino nitrogen atoms which participate in the peptide bonds. Among the 150 or so amino acids which occur in nature, alpha, beta, gamma and delta amino acids are known. These have 1-4 intermediary carbons. Only alpha amino acids occur in proteins. Proline is a special case of an alpha amino acid; its side chain also binds to the peptide bond nitrogen.

For beta and higher order amino acids, there is a choice as to which main chain core carbon a side chain other than H is attached to. The preferred attachment site is the C-2 (alpha) carbon, i.e., the one adjacent to the carboxyl carbon of the -CO linking functionality. It is also possible for more than one main chain atom to carry a side chain other than H. However, in a preferred embodiment, only one main chain core atom carries a side chain other than H.

A main chain carbon atom may carry either one or two side chains; one is more common. A side chain may be attached to a main chain carbon atom by a single or a double bond; the former is more common.

A simple combinatorial peptide library is one whose members are peptides having three or more amino acids connected via peptide bonds.

The peptides may be linear, branched, or cyclic, and may covalently or noncovalently include nonpeptidyl moieties. The amino acids are not limited to the naturally occurring or to the genetically encoded amino acids.

A biased peptide library is one in which one or more (but not all) residues of the peptides are constant residues.

### Cyclic Peptides

Many naturally occurring peptides are cyclic. Cyclization is a common mechanism for stabilization of peptide conformation thereby achieving improved association of the peptide with its ligand and hence improved biological activity. Cyclization is usually achieved by intra-chain cystine formation, by formation of peptide bond between side chains or between N- and C- terminals. Cyclization was usually achieved by peptides in solution, but several publications have appeared that describe cyclization of peptides on beads.

A peptide library may be an oligopeptide library or a protein library.

#### *Oligopeptides*

Preferably, the oligopeptides are at least five, six, seven or eight amino acids in length. Preferably, they are composed of less than 50, more preferably less than 20 amino acids.

In the case of an oligopeptide library, all or just some of the residues may be variable. The oligopeptide may be unconstrained, or constrained to a particular conformation by, e.g., the participation of constant cysteine residues in the formation of a constraining disulfide bond.

25

#### *Proteins*

Proteins, like oligopeptides, are composed of a plurality of amino acids, but the term protein is usually reserved for longer peptides, which are able to fold into a stable conformation. A protein may be composed of two or more polypeptide chains, held together by covalent or noncovalent crosslinks. These may occur in a homooligomeric or a heterooligomeric state.

A peptide is considered a protein if it (1) is at least 35 50 amino acids long, or (2) has at least two stabilizing covalent crosslinks (e.g., disulfide bonds). Thus, conotoxins are considered proteins.

Usually, the proteins of a protein library will be characterizable as having both constant residues (the same for all proteins in the library) and variable residues (which vary from member to member). This is simply because, 5 for a given range of variation at each position, the sequence space (simple diversity) grows exponentially with the number of residue positions, so at some point it becomes inconvenient for all residues of a peptide to be variable positions. Since proteins are usually larger than 10 oligopeptides, it is more common for protein libraries than oligopeptide libraries to feature variable positions.

In the case of a protein library, it is desirable to focus the mutations at those sites which are tolerant of mutation. These may be determined by alanine scanning 15 mutagenesis or by comparison of the protein sequence to that of homologous proteins of similar activity. It is also more likely that mutation of surface residues will directly affect binding. Surface residues may be determined by inspecting a 3D structure of the protein, or by labeling the 20 surface and then ascertaining which residues have received labels. They may also be inferred by identifying regions of high hydrophilicity within the protein.

Because proteins are often altered at some sites but not others, protein libraries can be considered a special 25 case of the biased peptide library.

There are several reasons that one might screen a protein library instead of an oligopeptide library, including (1) a particular protein, mutated in the library, has the desired activity to some degree already, and (2) the 30 oligopeptides are not expected to have a sufficiently high affinity or specificity since they do not have a stable conformation.

When the protein library is based on a parental protein which does not have the desired activity, the parental 35 protein will usually be one which is of high stability (melting point  $\geq$  50 deg. C.) and/or possessed of hypervariable regions.

The variable domains of an antibody possess hypervariable regions and hence, in some embodiments, the protein library comprises members which comprise a mutant of VH or VL chain, or a mutant of an antigen-specific binding fragment of such a chain. VH and VL chains are usually each about 110 amino acid residues, and are held in proximity by a disulfide bond between the adjoining CL and CH1 regions to form a variable domain. Together, the VH, VL, CL and CH1 form an Fab fragment.

In human heavy chains, the hypervariable regions are at 31-35, 49-65, 98-111 and 84-88, but only the first three are involved in antigen binding. There is variation among VH and VL chains at residues outside the hypervariable regions, but to a much lesser degree.

A sequence is considered a mutant of a VH or VL chain if it is at least 80% identical to a naturally occurring VH or VL chain at all residues outside the hypervariable region.

In a preferred embodiment, such antibody library members comprise both at least one VH chain and at least one VL chain, at least one of which is a mutant chain, and which chains may be derived from the same or different antibodies. The VH and VL chains may be covalently joined by a suitable linker moiety, as in a "single chain antibody", or they may be noncovalently joined, as in a naturally occurring variable domain.

If the joining is noncovalent, and the library is displayed on cells or virus, then either the VH or the VL chain may be fused to the carrier surface/coat protein. The complementary chain may be co-expressed, or added exogenously to the library.

The members may further comprise some or all of an antibody constant heavy and/or constant light chain, or a mutant thereof.

35

#### Peptoid Library

A peptoid is an analogue of a peptide in which one or more of the peptide bonds (-NH-CO-) are replaced by

pseudopeptide bonds, which may be the same or different. It is not necessary that all of the peptide bonds be replaced, i.e., a peptoid may include one or more conventional amino acid residues, e.g., proline.

5       A peptide bond has two small divalent linker elements, -NH- and -CO-. Thus, a preferred class of pseudopeptide bonds are those which consist of two small divalent linker elements. Each may be chosen independently from the group consisting of amine (-NH-), substituted amine (-NR-), carbonyl (-CO-), thiocarbonyl (-CS-), methylene (-CH<sub>2</sub>-), monosubstituted methylene (-CHR-), disubstituted methylene (-CR<sub>1</sub>R<sub>2</sub>-), ether (-O-) and thioether (-S-). The more 10 preferred pseudopeptide bonds include:

15       N-modified -NRCO-  
           Carba  $\Psi$  -CH<sub>2</sub>-CH<sub>2</sub>-  
           Depsi  $\Psi$  -CO-O-  
           Hydroxyethylene  $\Psi$  -CHOH-CH<sub>2</sub>-  
           Ketomethylene  $\Psi$  -CO-CH<sub>2</sub>-  
           Methylene-Oxy -CH<sub>2</sub>-O-  
 20       Reduced -CH<sub>2</sub>-NH-  
           Thiomethylene -CH<sub>2</sub>-S-  
           Thiopeptide -CS-NH-  
           Retro-Inverso -CO-NH-

25       A single peptoid molecule may include more than one kind of pseudopeptide bond.

For the purposes of introducing diversity into a peptoid library, one may vary (1) the side chains attached to the core main chain atoms of the monomers linked by the 30 pseudopeptide bonds, and/or (2) the side chains (e.g., the R of an -NRCO-) of the pseudopeptide bonds. Thus, in one embodiment, the monomeric units which are not amino acid residues are of the structure -NR<sub>1</sub>-CR<sub>2</sub>-CO-, where at least one of R<sub>1</sub> and R<sub>2</sub> are not hydrogen. If there is variability 35 in the pseudopeptide bond, this is most conveniently done by using an -NRCO- or other pseudopeptide bond with an R group, and varying the R group. In this event, the R group will

usually be any of the side chains characterizing the amino acids of peptides, as previously discussed.

If the R group of the pseudopeptide bond is not variable, it will usually be small, e.g., not more than 10 atoms (e.g., hydroxyl, amino, carboxyl, methyl, ethyl, propyl).

If the conjugation chemistries are compatible, a simple combinatorial library may include both peptides and peptoids.

10

#### Peptide Nucleic Acid Library

A PNA oligomer is here defined as one comprising a plurality of units, at least one of which is a PNA monomer which comprises a side chain comprising a nucleobase. For nucleobases, see USP 6,077,835.

The classic PNA oligomer is composed of (2-aminoethyl)glycine units, with nucleobases attached by methylene carbonyl linkers. That is, it has the structure

20



where the outer parenthesized substructure is the PNA monomer.

25

In this structure, the nucleobase B is separated from the backbone N by three bonds, and the points of attachment of the side chains are separated by six bonds. The nucleobase may be any of the bases included in the nucleotides discussed in connection with oligonucleotide libraries. The bases of nucleotides A, G, T, C and U are preferred.

A PNA oligomer may further comprise one or more amino acid residues, especially glycine and proline.

35

One can readily envision related molecules in which (1) the -COCH<sub>2</sub>- linker is replaced by another linker, especially one composed of two small divalent linkers as defined previously, (2) a side chain is attached to one of the three main chain carbons not participating in the peptide bond

(either instead or in addition to the side chain attached to the N of the classic PNA); and/or (3) the peptide bonds are replaced by pseudopeptide bonds as disclosed previously in the context of peptoids.

5 PNA oligomer libraries have been made; see e.g. Cook, 6,204,326.

#### Small Organic Compound Library

10 The small organic compound library ("compound library", for short) is a combinatorial library whose members are suitable for use as drugs if, indeed, they have the ability to mediate a biological activity of the target protein.

15 Peptides have certain disadvantages as drugs. These include susceptibility to degradation by serum proteases, and difficulty in penetrating cell membranes. Preferably, all or most of the compounds of the compound library avoid, or at least do not suffer to the same degree, one or more of the pharmaceutical disadvantages of peptides.

20 In designing a compound library, it is helpful to bear in mind the methods of molecular modification typically used to obtain new drugs. Three basic kinds of modification may be identified: disjunction, in which a lead drug is simplified to identify its component pharmacophoric moieties; conjunction, in which two or more known 25 pharmacophoric moieties, which may be the same or different, are associated, covalently or noncovalently, to form a new drug; and alteration, in which one moiety is replaced by another which may be similar or different, but which is not in effect a disjunction or conjunction. The use of the 30 terms "disjunction", "conjunction" and "alteration" is intended only to connote the structural relationship of the end product to the original leads, and not how the new drugs are actually synthesized, although it is possible that the two are the same.

35 The process of disjunction is illustrated by the evolution of neostigmine (1931) and edrophonium (1952) from physostigmine (1925). Subsequent conjunction is illustrated by demecarium (1956) and ambenonium (1956).

Alterations may modify the size, polarity, or electron distribution of an original moiety. Alterations include ring closing or opening, formation of lower or higher homologues, introduction or saturation of double bonds, 5 introduction of optically active centers, introduction, removal or replacement of bulky groups, isosteric or bioisosteric substitution, changes in the position or orientation of a group, introduction of alkylating groups, and introduction, removal or replacement of groups with a 10 view toward inhibiting or promoting inductive (electrostatic) or conjugative (resonance) effects.

Thus, the substituents may include electron acceptors and/or electron donors. Typical electron donors (+I) include -CH<sub>3</sub>, -CH<sub>2</sub>R, -CHR<sub>2</sub>, -CR<sub>3</sub>, and -COO<sup>-</sup>. Typical electron 15 acceptors (-I) include -NH<sub>3</sub><sup>+</sup>, -NR<sub>3</sub><sup>+</sup>, -NO<sub>2</sub>, -CN, -COOH, -COOR, -CHO, -COR, -COR, -F, -Cl, -Br, -OH, -OR, -SH, -SR, -CH=CH<sub>2</sub>, -CR=CR<sub>2</sub>, and -C=CH.

The substituents may also include those which increase or decrease electronic density in conjugated systems. The 20 former (+R) groups include -CH<sub>3</sub>, -CR<sub>3</sub>, -F, -Cl, -Br, -I, -OH, -OR, -OCOR, -SH, -SR, -NH<sub>2</sub>, -NR<sub>2</sub>, and -NHCOR. The later (-R) groups include -NO<sub>2</sub>, -CN, -CHC, -COR, -COOH, -COOR, -CONH<sub>2</sub>, -SO<sub>2</sub>R and -CF<sub>3</sub>.

Synthetically speaking, the modifications may be 25 achieved by a variety of unit processes, including nucleophilic and electrophilic substitution, reduction and oxidation, addition elimination, double bond cleavage, and cyclization.

For the purpose of constructing a library, a compound, 30 or a family of compounds, having one or more pharmacological activities (which need not be related to the known or suspected activities of the target protein), may be disjoined into two or more known or potential pharmacophoric moieties. Analogues of each of these moieties may be 35 identified, and mixtures of these analogues reacted so as to reassemble compounds which have some similarity to the original lead compound. It is not necessary that all

members of the library possess moieties analogous to all of the moieties of the lead compound.

The design of a library may be illustrated by the example of the benzodiazepines. Several benzodiazepine drugs, including chlordiazepoxide, diazepam and oxazepam, have been used as anti-anxiety drugs. Derivatives of benzodiazepines have widespread biological activities; derivatives have been reported to act not only as anxiolytics, but also as anticonvulsants; cholecystokinin (CCK) receptor subtype A or B, kappa opioid receptor, platelet activating factor, and HIV transactivator Tat antagonists, and GPIIbIIa, reverse transcriptase and ras farnesyltransferase inhibitors.

The benzodiazepine structure has been disjoined into a 2-aminobenzophenone, an amino acid, and an alkylating agent. See Bunin, et al., Proc. Nat. Acad. Sci. USA, 91:4708 (1994). Since only a few 2-aminobenzophenone derivatives are commercially available, it was later disjoined into 2-aminoarylstannane, an acid chloride, an amino acid, and an alkylating agent. Bunin, et al., Meth. Enzymol., 267:448 (1996). The arylstannane may be considered the core structure upon which the other moieties are substituted, or all four may be considered equals which are conjoined to make each library member.

A basic library synthesis plan and member structure is shown in Figure 1 of Fowlkes, et al., U.S. Serial No. 08/740,671, incorporated by reference in its entirety. The acid chloride building block introduces variability at the R<sup>1</sup> site. The R<sup>2</sup> site is introduced by the amino acid, and the R<sup>3</sup> site by the alkylating agent. The R<sup>4</sup> site is inherent in the arylstannane. Bunin, et al. generated a 1, 4-benzodiazepine library of 11,200 different derivatives prepared from 20 acid chlorides, 35 amino acids, and 16 alkylating agents. (No diversity was introduced at R<sup>4</sup>; this group was used to couple the molecule to a solid phase.) According to the Available Chemicals Directory (HDL Information Systems, San Leandro CA), over 300 acid chlorides, 80 Fmoc-protected amino acids and 800 alkylating

agents were available for purchase (and more, of course, could be synthesized). The particular moieties used were chosen to maximize structural dispersion, while limiting the numbers to those conveniently synthesized in the wells of a microtiter plate. In choosing between structurally similar compounds, preference was given to the least substituted compound.

The variable elements included both aliphatic and aromatic groups. Among the aliphatic groups, both acyclic and cyclic (mono- or poly-) structures, substituted or not, were tested. (While all of the acyclic groups were linear, it would have been feasible to introduce a branched aliphatic). The aromatic groups featured either single and multiple rings, fused or not, substituted or not, and with heteroatoms or not. The secondary substitutents included -NH<sub>2</sub>, -OH, -OMe, -CN, -Cl, -F, and -COOH. While not used, spacer moieties, such as -O-, -S-, -OO-, -CS-, -NH-, and -NR-, could have been incorporated.

Bunin et al. suggest that instead of using a 1, 4-benzodiazepine as a core structure, one may instead use a 1, 4-benzodiazepine-2, 5-dione structure.

As noted by Bunin et al., it is advantageous, although not necessary, to use a linkage strategy which leaves no trace of the linking functionality, as this permits construction of a more diverse library.

Other combinatorial nonoligomeric compound libraries known or suggested in the art have been based on carbamates, mercaptoacylated pyrrolidines, phenolic agents, aminimides, N-acylamino ethers (made from amino alcohols, aromatic hydroxy acids, and carboxylic acids), N-alkylamino ethers (made from aromatic hydroxy acids, amino alcohols and aldehydes) 1, 4-piperazines, and 1, 4-piperazine-6-ones.

DeWitt, et al., Proc. Nat. Acad. Sci. (USA), 90:6909-13 (1993) describe the simultaneous but separate, synthesis of 40 discrete hydantoins and 40 discrete benzodiazepines. They carry out their synthesis on a solid support (inside a gas dispersion tube), in an array format, as opposed to other conventional simultaneous synthesis techniques (e.g.,

in a well, or on a pin). The hydantoins were synthesized by first simultaneously deprotecting and then treating each of five amino acid resins with each of eight isocyanates. The benzodiazepines were synthesized by treating each of five deprotected amino acid resins with each of eight 2-amino benzophenone imines.

Chen, et al., J. Am. Chem. Soc., 116:2661-62 (1994) described the preparation of a pilot (9 member) combinatorial library of formate esters. A polymer bead-bound aldehyde preparation was "split" into three aliquots, each reacted with one of three different ylide reagents. The reaction products were combined, and then divided into three new aliquots, each of which was reacted with a different Michael donor. Compound identity was found to be determinable on a single bead basis by gas chromatography/mass spectroscopy analysis.

Holmes, USP 5,549,974 (1996) sets forth methodologies for the combinatorial synthesis of libraries of thiazolidinones and metathiazanones. These libraries are made by combination of amines, carbonyl compounds, and thiols under cyclization conditions.

Ellman, USP 5,545,568 (1996) describes combinatorial synthesis of benzodiazepines, prostaglandins, beta-turn mimetics, and glycerol-based compounds. See also Ellman, USP 5,288,514.

Summerton, USP 5,506,337 (1996) discloses methods of preparing a combinatorial library formed predominantly of morpholino subunit structures.

Heterocyclic combinatorial libraries are reviewed generally in Nefzi, et al., Chem. Rev., 97:449-472 (1997).

For pharmacological classes, see, e.g., Goth, Medical Pharmacology: Principles and Concepts (C.V. Mosby Co.: 8th ed. 1976); Korolkovas and Burckhalter, Essentials of Medicinal Chemistry (John Wiley & Sons, Inc.: 1976). For synthetic methods, see, e.g., Warren, Organic Synthesis: The Disconnection Approach (John Wiley & Sons, Ltd.: 1982); Fuson, Reactions of Organic Compounds (John Wiley & Sons:

1966); Payne and Payne, How to do an Organic Synthesis (Allyn and Bacon, Inc.: 1969); Greene, Protective Groups in Organic Synthesis (Wiley-Interscience). For selection of substituents, see e.g., Hansch and Leo, Substituent Constants for Correlation Analysis in Chemistry and Biology (John Wiley & Sons: 1979).

The library is preferably synthesized so that the individual members remain identifiable so that, if a member is shown to be active, it is not necessary to analyze it.

Several methods of identification have been proposed, including:

- (1) encoding, i.e., the attachment to each member of an identifier moiety which is more readily identified than the member proper. This has the disadvantage that the tag may itself influence the activity of the conjugate.
- (2) spatial addressing, e.g., each member is synthesized only at a particular coordinate on or in a matrix, or in a particular chamber. This might be, for example, the location of a particular pin, or a particular well on a microtiter plate, or inside a "tea bag".

The present invention is not limited to any particular form of identification.

However, it is possible to simply characterize those members of the library which are found to be active, based on the characteristic spectroscopic indicia of the various building blocks.

Solid phase synthesis permits greater control over which derivatives are formed. However, the solid phase could interfere with activity. To overcome this problem, some or all of the molecules of each member could be liberated, after synthesis but before screening.

Examples of candidate simple libraries which might be evaluated include derivatives of the following:

Cyclic Compounds Containing One Hetero Atom  
Heteronitrogen  
pyrroles

	pentasubstituted pyrroles
	pyrrolidines
	pyrrolines
	prolines
5	indoles
	beta-carbolines
	pyridines
	dihydropyridines
	1,4-dihydropyridines
10	pyrido[2,3-d]pyrimidines
	tetrahydro-3H-imidazo[4,5-c] pyridines
	Isoquinolines
	tetrahydroisoquinolines
	quinolones
15	beta-lactams
	azabicyclo[4.3.0]nonen-8-one amino acid
	Heterooxygen
	furans
	tetrahydrofurans
20	2,5-disubstituted tetrahydrofurans
	pyrans
	hydroxypyranones
	tetrahydroxypyranones
	gamma-butyrolactones
25	Heterosulfur
	sulfolenes
	Cyclic Compounds with Two or More Hetero atoms
	Multiple heteronitrogens
	imidazoles
30	pyrazoles
	piperazines
	diketopiperazines
	arylpiperazines
	benzylpiperazines
35	benzodiazepines
	1,4-benzodiazepine-2,5-diones
	hydantoins
	5-alkoxyhydantoins

## dihydropyrimidines

1,3-disubstituted-5,6-dihydropyrimidine-2,4-diones

5 cyclic ureas

cyclic thioureas

quinazolines

chiral 3-substituted-quinazoline-2,4-

diones

10 triazoles

1,2,3-triazoles

purines

Heteronitrogen and Heterooxygen

dikelomorpholines

15 isoxazoles

isoxazolines

Heteronitrogen and Heterosulfur

thiazolidines

N-axylthiazolidines

20 dihydrothiazoles

2-methylene-2,3-dihydrothiazates

2-aminothiazoles

thiophenes

3-amino thiophenes

25 4-thiazolidinones

4-melathiazanones

benzisothiazolones

For details on synthesis of libraries, see Nefzi, et al., Chem. Rev., 97:449-72 (1997), and references cited therein.

**Pharmaceutical Methods and Preparations**

The preferred animal subject of the present invention is a mammal. By the term "mammal" is meant an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects, although it is intended for veterinary and nutritional uses as well. Preferred nonhuman subjects are of the orders

Primata (e.g., apes and monkeys), Artiodactyla or Perissodactyla (e.g., cows, pigs, sheep, horses, goats), Carnivora (e.g., cats, dogs), Rodenta (e.g., rats, mice, guinea pigs, hamsters), Lagomorpha (e.g., rabbits) or other pet, farm or laboratory mammals.

The term "protection", as used herein, is intended to include "prevention," "suppression" and "treatment." "Prevention", strictly speaking, involves administration of the pharmaceutical prior to the induction of the disease (or other adverse clinical condition). "Suppression" involves administration of the composition prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after the appearance of the disease.

It will be understood that in human and veterinary medicine, it is not always possible to distinguish between "preventing" and "suppressing" since the ultimate inductive event or events may be unknown, latent, or the patient is not ascertained until well after the occurrence of the event or events. Therefore, unless qualified, the term "prevention" will be understood to refer to both prevention in the strict sense, and to suppression.

The preventative or prophylactic use of a pharmaceutical involves identifying subjects who are at higher risk than the general population of contracting the disease, and administering the pharmaceutical to them in advance of the clinical appearance of the disease. The effectiveness of such use is measured by comparing the subsequent incidence or severity of the disease, or of particular symptoms of the disease, in the treated subjects against that in untreated subjects of the same high risk group.

While high risk factors vary from disease to disease, in general, these include (1) prior occurrence of the disease in one or more members of the same family, or, in the case of a contagious disease, in individuals with whom the subject has come into potentially contagious contact at a time when the earlier victim was likely to be contagious,

(2) a prior occurrence of the disease in the subject, (3) prior occurrence of a related disease, or a condition known to increase the likelihood of the disease, in the subject; (4) appearance of a suspicious level of a marker of the disease, or a related disease or condition; (5) a subject who is immunologically compromised, e.g., by radiation treatment, HIV infection, drug use,, etc., or (6) membership in a particular group (e.g., a particular age, sex, race, ethnic group, etc.) which has been epidemiologically associated with that disease.

A prophylaxis or treatment may be curative, that is, directed at the underlying cause of a disease, or ameliorative, that is, directed at the symptoms of the disease, especially those which reduce the quality of life.

It should also be understood that to be useful, the protection provided need not be absolute, provided that it is sufficient to carry clinical value. An agent which provides protection to a lesser degree than do competitive agents may still be of value if the other agents are ineffective for a particular individual, if it can be used in combination with other agents to enhance the level of protection, or if it is safer than competitive agents. It is desirable that there be a statistically significant ( $p=0.05$  or less) improvement in the treated subject relative to an appropriate untreated control, and it is desirable that this improvement be at least 10%, more preferably at least 25%, still more preferably at least 50%, even more preferably at least 100%, in some indicia of the incidence or severity of the disease or of at least one symptom of the disease.

At least one of the drugs of the present invention may be administered, by any means that achieve their intended purpose, to protect a subject against a disease or other adverse condition. The form of administration may be systemic or topical. For example, administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the

oral route. Parenteral administration can be by bolus injection or by gradual perfusion over time.

A typical regimen comprises administration of an effective amount of the drug, administered over a period ranging from a single dose, to dosing over a period of hours, days, weeks, months, or years.

It is understood that the suitable dosage of a drug of the present invention will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. However, the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation. This will typically involve adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight.

Prior to use in humans, a drug will first be evaluated for safety and efficacy in laboratory animals. In human clinical studies, one would begin with a dose expected to be safe in humans, based on the preclinical data for the drug in question, and on customary doses for analogous drugs (if any). If this dose is effective, the dosage may be decreased, to determine the minimum effective dose, if desired. If this dose is ineffective, it will be cautiously increased, with the patients monitored for signs of side effects. See, e.g., Berkow et al, eds., *The Merck Manual*, 15th edition, Merck and Co., Rahway, N.J., 1987; Goodman et al., eds., *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 8th edition, Pergamon Press, Inc., Elmsford, N.Y., (1990); *Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics*, 3rd edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, MD. (1987), Ebadi, *Pharmacology*, Little, Brown and Co., Boston, (1985), which references and references cited therein, are entirely incorporated herein by reference.

The total dose required for each treatment may be administered by multiple doses or in a single dose. The protein may be administered alone or in conjunction with

other therapeutics directed to the disease or directed to other symptoms thereof.

Typical pharmaceutical doses, for adult humans, are in the range of 1 ng to 10g per day, more often 1 mg to 1g per day.

The appropriate dosage form will depend on the disease, the pharmaceutical, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, solutions, ointments and parenteral depots. See, e.g., Berker, *supra*, Goodman, *supra*, Avery, *supra* and Ebadi, *supra*, which are entirely incorporated herein by reference, including all references cited therein.

In the case of peptide drugs, the drug may be administered in the form of an expression vector comprising a nucleic acid encoding the peptide; such a vector, after incorporation into the genetic complement of a cell of the patient, directs synthesis of the peptide. Suitable vectors include genetically engineered poxviruses (vaccinia), adenoviruses, adeno-associated viruses, herpesviruses and lentiviruses which are or have been rendered nonpathogenic.

In addition to at least one drug as described herein, a pharmaceutical composition may contain suitable pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. See, e.g., Berker, *supra*, Goodman, *supra*, Avery, *supra* and Ebadi, *supra*, which are entirely incorporated herein by reference, included all references cited therein.

#### **Assay Compositions and Methods**

##### Target Organism

The invention contemplates that it may be appropriate to ascertain or to mediate the biological activity of a substance of this invention in a target organism.

The target organism may be a plant, animal, or microorganism.

In the case of a plant, it may be an economic plant, in which case the drug may be intended to increase the disease, weather or pest resistance, alter the growth characteristics, or otherwise improve the useful  
5 characteristics or mute undesirable characteristics of the plant. Or it may be a weed, in which case the drug may be intended to kill or otherwise inhibit the growth of the plant, or to alter its characteristics to convert it from a weed to an economic plant. The plant may be a tree, shrub,  
10 crop, grass, etc. The plant may be an algae (which are in some cases also microorganisms), or a vascular plant, especially gymnosperms (particularly conifers) and angiosperms. Angiosperms may be monocots or dicots. The plants of greatest interest are rice, wheat, corn, alfalfa,  
15 soybeans, potatoes, peanuts, tomatoes, melons, apples, pears, plums, pineapples, fir, spruce, pine, cedar, and oak.

If the target organism is a microorganism, it may be algae, bacteria, fungi, or a virus (although the biological activity of a virus must be determined in a virus-infected cell). The microorganism may be human or other animal or plant pathogen, or it may be nonpathogenic. It may be a soil or water organism, or one which normally lives inside other living things.

If the target organism is an animal, it may be a vertebrate or a nonvertebrate animal. Nonvertebrate animals are chiefly of interest when they act as pathogens or parasites, and the drugs are intended to act as biocidic or biostatic agents. Nonvertebrate animals of interest include worms, mollusks, and arthropods.

The target organism may also be a vertebrate animal, i.e., a mammal, bird, reptile, fish or amphibian. Among mammals, the target animal preferably belongs to the order Primata (humans, apes and monkeys), Artiodactyla (e.g., cows, pigs, sheep, goats, horses), Rodenta (e.g., mice, rats) Lagomorpha (e.g., rabbits, hares), or Carnivora (e.g., cats, dogs). Among birds, the target animals are preferably of the orders Anseriformes (e.g., ducks, geese, swans) or Galliformes (e.g., quails, grouse, pheasants, turkeys and

chickens). Among fish, the target animal is preferably of the order Clupeiformes (e.g., sardines, shad, anchovies, whitefish, salmon).

5      Target Tissues

The term "target tissue" refers to any whole animal, physiological system, whole organ, part of organ, miscellaneous tissue, cell, or cell component (e.g., the cell membrane) of a target animal in which biological activity may be measured.

Routinely in mammals one would choose to compare and contrast the biological impact on virtually any and all tissues which express the subject receptor protein. The main tissues to use are: brain, heart, lung, kidney, liver, pancreas, skin, intestines, adipose, stomach, skeletal muscle, adrenal glands, breast, prostate, vasculature, retina, cornea, thyroid gland, parathyroid glands, thymus, bone marrow, bone, etc.

Another classification would be by cell type: B cells, T cells, macrophages, neutrophils, eosinophils, mast cells, platelets, megakaryocytes, erythrocytes, bone marrow stromal cells, fibroblasts, neurons, astrocytes, neuroglia, microglia, epithelial cells (from any organ, e.g. skin, breast, prostate, lung, intestines etc), cardiac muscle cells, smooth muscle cells, striated muscle cells, osteoblasts, osteocytes, chondroblasts, chondrocytes, keratinocytes, melanocytes, etc.

Of course, in the case of a unicellular organism, there is no distinction between the "target organism" and the "target tissue".

Screening Assays

Assays intended to determine the binding or the biological activity of a substance are called preliminary screening assays.

Screening assays will typically be either *in vitro* (cell-free) assays (for binding to an immobilized receptor) or cell-based assays (for alterations in the phenotype of

the cell). They will not involve screening of whole multicellular organisms, or isolated organs. The comments on diagnostic biological assays apply mutatis mutandis to screening cell-based assays.

5

#### In Vitro vs. In Vivo Assays

The term *in vivo* is descriptive of an event, such as binding or enzymatic action, which occurs within a living organism. The organism in question may, however, be genetically modified. The term *in vitro* refers to an event which occurs outside a living organism. Parts of an organism (e.g., a membrane, or an isolated biochemical) are used, together with artificial substrates and/or conditions. For the purpose of the present invention, the term *in vitro* excludes events occurring inside or on an intact cell, whether of a unicellular or multicellular organism.

*In vivo* assays include both cell-based assays, and organismic assays. The cell-based assays include both assays on unicellular organisms, and assays on isolated cells or cell cultures derived from multicellular organisms. The cell cultures may be mixed, provided that they are not organized into tissues or organs. The term organismic assay refers to assays on whole multicellular organisms, and assays on isolated organs or tissues of such organisms.

25

#### In vitro Diagnostic Methods and Reagents

The *in vitro* assays of the present invention may be applied to any suitable analyte-containing sample, and may be qualitative or quantitative in nature.

##### *Sample*

The sample will normally be a biological fluid, such as blood, urine, lymph, semen, milk, or cerebrospinal fluid, or a fraction or derivative thereof, or a biological tissue, in the form of, e.g., a tissue section or homogenate. However, the sample conceivably could be (or derived from) a food or beverage, a pharmaceutical or diagnostic composition, soil,

30

35

or surface or ground water. If a biological fluid or tissue, it may be taken from a human or other mammal, vertebrate or animal, or from a plant. The preferred sample is blood, or a fraction or derivative thereof.

5

#### *Binding and Reaction Assays*

The assay may be a binding assay, in which one step involves the binding of a diagnostic reagent to the analyte, or a reaction assay, which involves the reaction of a reagent with the analyte. The reagents used in a binding assay may be classified as to the nature of their interaction with analyte: (1) analyte analogues, or (2) analyte binding molecules (ABM). They may be labeled or insolubilized.

In a reaction assay, the assay may look for a direct reaction between the analyte and a reagent which is reactive with the analyte, or if the analyte is an enzyme or enzyme inhibitor, for a reaction catalyzed or inhibited by the analyte. The reagent may be a reactant, a catalyst, or an inhibitor for the reaction.

An assay may involve a cascade of steps in which the product of one step acts as the target for the next step. These steps may be binding steps, reaction steps, or a combination thereof.

25

#### *Signal Producing System (SPS)*

In order to detect the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system (SPS) in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent (or, in a quantitative assay, on the amount of the analyte). The detectable signal may be one which is visually detectable, or one detectable only with instruments. Possible signals include production of colored or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or emission of radiation by an assay component or product, and

precipitation or agglutination of a component or product. The term "signal" is intended to include the discontinuance of an existing signal, or a change in the rate of change of an observable parameter, rather than a change in its absolute value. The signal may be monitored manually or automatically.

In a reaction assay, the signal is often a product of the reaction. In a binding assay, it is normally provided by a label borne by a labeled reagent.

10

#### Labels

The component of the signal producing system which is most intimately associated with the diagnostic reagent is called the "label". A label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, an agglutinable particle.

The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful for the purpose of the present invention include  $^3\text{H}$ ,  $^{125}\text{I}$ ,

15  $^{131}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$  and  $^{33}\text{P}$ .  $^{125}\text{I}$  is preferred for antibody labeling.

The label may also be a fluorophore. When the fluorescently labeled reagent is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin,  $\alpha$ -phthaldehyde and fluorescamine.

30 Alternatively, fluorescence-emitting metals such as  $^{125}\text{Eu}$ , or others of the lanthanide series, may be incorporated into a diagnostic reagent using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediamine-tetraacetic acid (EDTA).

35 The label may also be a chemiluminescent compound. The presence of the chemiluminescently labeled reagent is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples

of particularly useful chemiluminescent labeling compounds are luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used for labeling. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Enzyme labels, such as horseradish peroxidase and alkaline phosphatase, are preferred. When an enzyme label is used, the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears.

An enzyme analyte may act as its own label if an enzyme inhibitor is used as a diagnostic reagent.

20

#### *Binding Assay Formats*

Binding assays may be divided into two basic types, heterogeneous and homogeneous. In heterogeneous assays, the interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free label. In homogeneous assays, the interaction does affect the activity of the label, and therefore analyte levels can be deduced without the need for a separation step.

In one embodiment, the ABM is insolubilized by coupling it to a macromolecular support, and analyte in the sample is allowed to compete with a known quantity of a labeled or specifically labelable analyte analogue. The "analyte analogue" is a molecule capable of competing with analyte for binding to the ABM, and the term is intended to include analyte itself. It may be labeled already, or it may be labeled subsequently by specifically binding the label to a moiety differentiating the analyte analogue from analyte.

The solid and liquid phases are separated, and the labeled analyte analogue in one phase is quantified. The higher the level of analyte analogue in the solid phase, i.e., sticking to the ABM, the lower the level of analyte in the sample.

In a "sandwich assay", both an insolubilized ABM, and a labeled ABM are employed. The analyte is captured by the insolubilized ABM and is tagged by the labeled ABM, forming a ternary complex. The reagents may be added to the sample in either order, or simultaneously. The ABMs may be the same or different. The amount of labeled ABM in the ternary complex is directly proportional to the amount of analyte in the sample.

The two embodiments described above are both heterogeneous assays. However, homogeneous assays are conceivable. The key is that the label be affected by whether or not the complex is formed.

#### Conjugation Methods

A label may be conjugated, directly or indirectly (e.g., through a labeled anti-ABM antibody), covalently (e.g., with SPDP) or noncovalently, to the ABM, to produce a diagnostic reagent. Similarly, the ABM may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent.

Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.

The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target. Thus the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc.

Biological Assays

A biological assay measures or detects a biological response of a biological entity to a substance.

The biological entity may be a whole organism, an isolated organ or tissue, freshly isolated cells, an immortalized cell line, or a subcellular component (such as a membrane; this term should not be construed as including an isolated receptor). The entity may be, or may be derived from, an organism which occurs in nature, or which is modified in some way. Modifications may be genetic (including radiation and chemical mutants, and genetic engineering) or somatic (e.g., surgical, chemical, etc.). In the case of a multicellular entity, the modifications may affect some or all cells. The entity need not be the target organism, or a derivative thereof, if there is a reasonable correlation between bioassay activity in the assay entity and biological activity in the target organism.

The entity is placed in a particular environment, which may be more or less natural. For example, a culture medium may, but need not, contain serum or serum substitutes, and it may, but need not, include a support matrix of some kind, it may be still, or agitated. It may contain particular biological or chemical agents, or have particular physical parameters (e.g., temperature), that are intended to nourish or challenge the biological entity.

There must also be a detectable biological marker for the response. At the cellular level, the most common markers are cell survival and proliferation, cell behavior (clustering, motility), cell morphology (shape, color), and biochemical activity (overall DNA synthesis, overall protein synthesis, and specific metabolic activities, such as utilization of particular nutrients, e.g., consumption of oxygen, production of CO<sub>2</sub>, production of organic acids, uptake or discharge of ions).

The direct signal produced by the biological marker may be transformed by a signal producing system into a different signal which is more observable, for example, a fluorescent or colorimetric signal.

The entity, environment, marker and signal producing system are chosen to achieve a clinically acceptable level of sensitivity, specificity and accuracy.

In some cases, the goal will be to identify substances which mediate the biological activity of a natural biological entity, and the assay is carried out directly with that entity. In other cases, the biological entity is used simply as a model of some more complex (or otherwise inconvenient to work with) biological entity. In that event, the model biological entity is used because activity in the model system is considered more predictive of activity in the ultimate natural biological entity than is simple binding activity in an in vitro system. The model entity is used instead of the ultimate entity because the former is more expensive or slower to work with, or because ethical considerations forbid working with the ultimate entity yet.

The model entity may be naturally occurring, if the model entity usefully models the ultimate entity under some conditions. Or it may be non-naturally occurring, with modifications that increase its resemblance to the ultimate entity.

Transgenic animals, such as transgenic mice, rats, and rabbits, have been found useful as model systems.

In cell-based model assays, where the biological activity is mediated by binding to a receptor (target protein), the receptor may be functionally connected to a signal (biological marker) producing system, which may be endogenous or exogenous to the cell.

There are a number of techniques of doing this.

#### "Zero-Hybrid" Systems

In these systems, the binding of a peptide to the target protein results in a screenable or selectable phenotypic change, without resort to fusing the target protein (or a ligand binding moiety thereof) to an endogenous protein. It may be that the target protein is endogenous to the host cell, or is substantially identical

to an endogenous receptor so that it can take advantage of the latter's native signal transduction pathway. Or sufficient elements of the signal transduction pathway normally associated with the target protein may be  
5 engineered into the cell so that the cell signals binding to the target protein.

#### "One-Hybrid" Systems

In these systems, a chimera receptor, a hybrid of the target protein and an endogenous receptor, is used. The chimeric receptor has the ligand binding characteristics of the target protein and the signal transduction characteristics of the endogenous receptor. Thus, the normal signal transduction pathway of the endogenous  
10 receptor is subverted.  
15

Preferably, the endogenous receptor is inactivated, or the conditions of the assay avoid activation of the endogenous receptor, to improve the signal-to-noise ratio.

See Fowlkes USP 5,789,184 for a yeast system.

Another type of "one-hybrid" system combines a peptide: DNA-binding domain fusion with an unfused target receptor that possesses an activation domain.

#### "Two-Hybrid" System

In a preferred embodiment, the cell-based assay is a two hybrid system. This term implies that the ligand is incorporated into a first hybrid protein, and the receptor into a second hybrid protein. The first hybrid also comprises component A of a signal generating system, and the  
25 second hybrid comprises component B of that system.  
30 Components A and B, by themselves, are insufficient to generate a signal. However, if the ligand binds the receptor, components A and B are brought into sufficiently close proximity so that they can cooperate to generate a  
35 signal.

Components A and B may naturally occur, or be substantially identical to moieties which naturally occur, as components of a single naturally occurring biomolecule,

or they may naturally occur, or be substantially identical to moieties which naturally occur, as separate naturally occurring biomolecules which interact in nature.

5 Two-Hybrid System: Transcription Factor Type

In a preferred "two-hybrid" embodiment, one member of a peptide ligand:receptor binding pair is expressed as a fusion to a DNA-binding domain (DBD) from a transcription factor (this fusion protein is called the "bait"), and the other is expressed as a fusion to a transactivation domain (TAD) (this fusion protein is called the "fish", the "prey", or the "catch"). The transactivation domain should be complementary to the DNA-binding domain, i.e., it should interact with the latter so as to activate transcription of a specially designed reporter gene that carries a binding site for the DNA-binding domain. Naturally, the two fusion proteins must likewise be complementary.

This complementarity may be achieved by use of the complementary and separable DNA-binding and transcriptional activator domains of a single transcriptional activator protein, or one may use complementary domains derived from different proteins. The domains may be identical to the native domains, or mutants thereof. The assay members may be fused directly to the DBD or TAD, or fused through an intermediated linker.

The target DNA operator may be the native operator sequence, or a mutant operator. Mutations in the operator may be coordinated with mutations in the DBD and the TAD. An example of a suitable transcription activation system is one comprising the DNA-binding domain from the bacterial repressor LexA and the activation domain from the yeast transcription factor Gal4, with the reporter gene operably linked to the LexA operator.

It is not necessary to employ the intact target receptor; just the ligand-binding moiety is sufficient.

The two fusion proteins may be expressed from the same or different vectors. Likewise, the activatable reporter

gene may be expressed from the same vector as either fusion protein (or both proteins), or from a third vector.

Potential DNA-binding domains include Gal4, LexA, and mutant domains substantially identical to the above.

5 Potential activation domains include E. coli B42, Gal4 activation domain II, and HSV VP16, and mutant domains substantially identical to the above.

10 Potential operators include the native operators for the desired activation domain, and mutant domains substantially identical to the native operator.

The fusion proteins may comprise nuclear localization signals.

15 The assay system will include a signal producing system, too. The first element of this system is a reporter gene operably linked to an operator responsive to the DBD and TAD of choice. The expression of this reporter gene will result, directly or indirectly, in a selectable or screenable phenotype (the signal). The signal producing system may include, besides the reporter gene, additional 20 genetic or biochemical elements which cooperate in the production of the signal. Such an element could be, for example, a selective agent in the cell growth medium. There may be more than one signal producing system, and the system may include more than one reporter gene.

25 The sensitivity of the system may be adjusted by, e.g., use of competitive inhibitors of any step in the activation or signal production process, increasing or decreasing the number of operators, using a stronger or weaker DBD or TAD, etc.

30 When the signal is the death or survival of the cell in question, or proliferation or nonproliferation of the cell in question, the assay is said to be a selection. When the signal merely results in a detectable phenotype by which the signaling cell may be differentiated from the same cell in a 35 nonsignaling state (either way being a living cell), the assay is a screen. However, the term "screening assay" may be used in a broader sense to include a selection. When the

narrower sense is intended, we will use the term "nonselective screen".

Various screening and selection systems are discussed in Ladner, USP 5,198,346.

5 Screening and selection may be for or against the peptide: target protein or compound:target protein interaction.

10 Preferred assay cells are microbial (bacterial, yeast, algal, protozoal), invertebrate, vertebrate (esp. mammalian, particularly human). The best developed two-hybrid assays are yeast and mammalian systems.

15 Normally, two hybrid assays are used to determine whether a protein X and a protein Y interact, by virtue of their ability to reconstitute the interaction of the DBD and the TAD. However, augmented two-hybrid assays have been used to detect interactions that depend on a third, non-protein ligand.

20 For more guidance on two-hybrid assays, see Brent and Finley, Jr., Ann. Rev. Genet., 31:663-704 (1997); Fremont-Racine, et al., Nature Genetics, 277-281 (16 July 1997); Allen, et al., TIBS, 511-16 (Dec. 1995); LeCrenier, et al., BioEssays, 20:1-6 (1998); Xu, et al., Proc. Nat. Acad. sci. (USA), 94:12473-8 (Nov. 1992); Esotak, et al., Mol. Cell. Biol., 15:5820-9 (1995); Yang, et al., Nucleic Acids Res., 23:1152-6 (1995); Bendixen, et al., Nucleic Acids Res., 22:1778-9 (1994); Fuller, et al., BioTechniques, 25:85-92 (July 1998); Cohen, et al., PNAS (USA) 95:14272-7 (1998); Kolonin and Finley, Jr., PNAS (USA) 95:14266-71 (1998). See also Vasavada, et al., PNAS (USA), 88:10686-90 (1991) 25 (contingent replication assay), and Rehrauer, et al., J. Biol. Chem., 271:23865-73 91996) (LexA repressor cleavage assay).

30 Two-Hybrid Systems: reporter Enzyme type

35 In another embodiment, the components A and B reconstitute an enzyme which is not a transcription factor.

As in the last example, the effect of the reconstitution of the enzyme is a phenotypic change which may be a screenable change, a selectable change, or both.

5      In vivo Diagnostic Uses

Radio-labeled ABM may be administered to the human or animal subject. Administration is typically by injection, e.g., intravenous or arterial or other means of administration in a quantity sufficient to permit subsequent dynamic and/or static imaging using suitable radio-detecting devices. The dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radio-imaging agents as a guide.

15     Typically, the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study. The amount of radio-labeled ABM accumulated at a given point in time in relevant target organs can then be quantified.

20     A particularly suitable radio-detecting device is a scintillation camera, such as a gamma camera. A scintillation camera is a stationary device that can be used to image distribution of radio-labeled ABM. The detection device in the camera senses the radioactive decay, the distribution of which can be recorded. Data produced by the imaging system can be digitized. The digitized information can be analyzed over time discontinuously or continuously. The digitized data can be processed to produce images, called frames, of the pattern of uptake of the radio-labeled ABM in the target organ at a discrete point in time. In most continuous (dynamic) studies, quantitative data is obtained by observing changes in distributions of radioactive decay in target organs over time. In other words, a time-activity analysis of the data will illustrate uptake through clearance of the radio-labeled binding protein by the target organs with time.

30     Various factors should be taken into consideration in selecting an appropriate radioisotope. The radioisotope

must be selected with a view to obtaining good quality resolution upon imaging, should be safe for diagnostic use in humans and animals, and should preferably have a short physical half-life so as to decrease the amount of radiation received by the body. The radioisotope used should preferably be pharmacologically inert, and, in the quantities administered, should not have any substantial physiological effect.

The ABM may be radio-labeled with different isotopes of iodine, for example  $^{123}\text{I}$ ,  $^{125}\text{I}$ , or  $^{131}\text{I}$  (see for example, U.S. Patent 4,609,725). The extent of radio-labeling must, however be monitored, since it will affect the calculations made based on the imaging results (i.e. a diiodinated ABM will result in twice the radiation count of a similar monoiiodinated ABM over the same time frame).

In applications to human subjects, it may be desirable to use radioisotopes other than  $^{125}\text{I}$  for labeling in order to decrease the total dosimetry exposure of the human body and to optimize the detectability of the labeled molecule (though this radioisotope can be used if circumstances require). Ready availability for clinical use is also a factor. Accordingly, for human applications, preferred radio-labels are for example,  $^{99\text{m}}\text{Tc}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{90}\text{Y}$ ,  $^{111}\text{In}$ ,  $^{113\text{m}}\text{In}$ ,  $^{123}\text{I}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$  or  $^{211}\text{At}$ .

The radio-labeled ABM may be prepared by various methods. These include radio-halogenation by the chloramine - T method or the lactoperoxidase method and subsequent purification by HPLC (high pressure liquid chromatography), for example as described by J. Gutkowska et al in "Endocrinology and Metabolism Clinics of America: (1987) 16 (1):183. Other known methods of radio-labeling can be used, such as IODOBEADS™.

There are a number of different methods of delivering the radio-labeled ABM to the end-user. It may be administered by any means that enables the active agent to reach the agent's site of action in the body of a mammal. Because proteins are subject to being digested when administered orally, parenteral administration, i.e.,

intravenous, subcutaneous, intramuscular, would ordinarily be used to optimize absorption of an ABM, such as an antibody, which is a protein.

5

### **EXAMPLES**

#### **Animal Models.**

Obesity and subsequent hyperinsulinemia and hyperglycemia were induced by feeding a group of 3 week old mice (50 C57BL/6 males) a high-fat diet (Bio-Serve, Frenchtown, NJ, #F1850 High Carbohydrate-High Fat). Another group of 3 week old mice (20 C57B1/6 males) were fed the normal control diet (PMI Nutrition International Inc., Brentwood, MO, Prolab RMH3000). The mice were placed onto the respective diets immediately following weaning. Animal weights were determined weekly. Fasting blood-glucose and plasma insulin measurements were determined after 2, 4, 8 and 16 weeks on the respective diets.

Normal weight, normal fasting blood glucose and normal fasting plasma insulin levels are defined as the respective mean values of the animals fed the control diet.

Two of the "most typical" animals were selected for each group (Control, hyperinsulinemic and Diabetic) at each time point ( 2,4, 8, and 16 weeks after commencement of diet) for sacrifice. The selected mice were sacrificed and muscle tissue obtained and immediately processed for RNA isolation.

#### **Fasting Blood Glucose Levels.**

Blood glucose levels was measured from a drop of blood taken from the tip of the tail of fasted (8 hr) mice using a Lifescan Genuine One Touch glucometer. All measurements occurred between 2:00 pm and 5:00 pm.

#### **35 Plasma insulin measurements.**

Blood was collected from the tail of fasted (8 hr) mice into a heparinized capillary tube and stored on ice. All collections occurred between 2:00 pm and 5:00 pm. Plasma

was separated from red blood cells by centrifugation for 10 minutes at 8000 x g and then stored at -20°C. Insulin concentrations were determined using the Rat Insulin ELISA kit and rat insulin standards (ALPCO) essentially as instructed by the manufacturer. Values were adjusted by a factor of 1.23 as determined by the manufacturer to correct for the species difference in cross-reactivity with the antibody.

10 **RNA isolation.**

Total RNA was isolated from muscle (skeletal muscle, specifically, gastrocnemius) using the RNA STAT-60 Total RNA/mRNA Isolation Reagent according to the manufacturer's instructions (Tel-Test, Friendswood, TX).

15

**Sample Quantification and Quality Assessment**

Total RNA was quantified and assessed for quality on a Bioanalyzer RNA 6000 Nano chip (Agilent). Each chip contained an interconnected set of gel-filled channels that allowed for molecular sieving of nucleic acids. Pin-electrodes in the chip were used to create electrokinetic forces capable of driving molecules through these micro-channels to perform electrophoretic separations. Ribosomal peaks were measured by fluorescence signal and displayed in an electropherogram. A successful total RNA sample featured 2 distinct ribosomal peaks (18S and 28S rRNA).

30 **Biotinylated cRNA Hybridization Target.**

Total RNA was prepared for use as a hybridization target as described in the manufacturer's instructions for CodeLink Expression Bioarrays(TM) (Amersham Biosciences). The CodeLink Expression Bioarrays utilize nucleic acid hybridization of a biotin-labeled complementary RNA(cRNA) target with DNA oligonucleotide probes attached to a gel matrix.

The biotin-labeled cRNA target is prepared by a linear amplification method. Poly (A) + RNA (within the total RNA

population) is primed for reverse transcription by a DNA oligonucleotide containing a T7 RNA polymerase promoter 5' to a (dT) 24 sequence. After second-strand cDNA synthesis, the cDNA serves as the template in an *in vitro* transcription (IVT) reaction to produce the target cRNA. The IVT is performed in the presence of biotinylated nucleotides to label the target cRNA. This procedure results in a 50-200 fold linear amplification of the input poly (A) + RNA.

10 **Hybridization Probes.**

The oligonucleotide probes were provided by the Codelink Uniset Mouse I Bioarray (Amersham, product code 300013). Amine-terminated oligonucleotide probes are attached to a three-dimensional polyacrylamide gel matrix. There are 10,000 oligonucleotide probes, each specific to a well-characterized mouse gene. Each mouse gene is representative of a unique gene cluster from the fourth quarter 2001 Genbank Unigene build. There are also 500 control probes.

20 The sequences of the probes is proprietary to Amersham. However, for each probe, Amersham identifies the corresponding mouse gene by NCBI accession number, OGS, LocusLink, Unigene Cluster ID, and description (name).

25 This information should be available from Amersham. In the case of the differentially expressed probes, this information is duplicated in master table 1. For the complete list, see

[http://www4.amershambiosciences.com/aptrix/upp01077.nsf/Content/codelink\\_literature](http://www4.amershambiosciences.com/aptrix/upp01077.nsf/Content/codelink_literature)

30 Under "Gene Lists", select "Uniset Human I", and a gene list, in Excel format, can be downloaded.

**Hybridization**

35 Using the cRNA target, the hybridization reaction mixture is prepared and loaded until array chambers for bioarray processing as set forth in the manufacturer's instructions for CodeLink Gene Expression Bioarrays™

(Amerhsam Biosciences). Each sample is hybridized to an individual microarray. Hybridization is at 37°C. The hybridization buffer is prepared as set forth in the Motorola instructions. Hybridization to the microarray is detected with an avidinated fluorescent reagent, Streptavidin-Alexa Fluor® 647 (Amersham).

#### Mouse Gene Expression Analysis

Processed arrays were scanned using a GenePix 4000B Microarray Scanner (Axon Instruments, Inc.); array images were acquired using the Amersham CodeLink™ Analysis Software (Release 2.2). The Amersham CodeLink™ Analysis Software gives an integrated optical density (IOD) value for every spot; a unique background value for that spot is subtracted, resulting in "raw" data points. Individual chips are then normalized by the Amersham Codelink™ software according to the median raw intensity for all 10,000 genes. A negative control threshold is also calculated according to the control probes. A significant difference in expression between samples was defined as a minimum of 2-fold change in expression values. Genes with expression values below the negative control threshold were eliminated from the analysis and then the expression data was analyzed to identify genes whose expression levels changed significantly with respect to:

Normal mice compared to hyperinsulinemic mice at 2, 4, 8 and 16 weeks on normal vs. high-fat diet.

Normal mice compared to hyperinsulinemic/hyperglycemic mice at 2, 4, 8 and 16 weeks on normal vs. high-fat diet.

Hyperinsulinemic compared to hyperinsulinemic/hyperglycemic mice at 2, 4, 8 and 16 weeks on high-fat diets.

**Database Searches** Nucleotide sequences and predicted amino acid sequences were compared to public domain databases using the Blast 2.0 program (National Center for Biotechnology Information, National Institutes of Health).

5 Nucleotide sequences were displayed using ABI prism Edit View 1.0.1 (PE Applied Biosystems, Foster City, CA).

Nucleotide database searches were conducted with the then current version of BLASTN 2.0.12, see Altschul, et al., "Gapped BLAST and PSI-BLAST: a new generation of protein 10 database search programs", Nucleic Acids Res., 25:3389-3402 (1997). Searches employed the default parameters, unless otherwise stated.

For blastN searches, the default was the blastN matrix (1, -3), with gap penalties of 5 for existence and 2 for 15 extension.

Protein database searches were conducted with the then-current version of BLAST X, see Altschul et al. (1997), supra. Searches employed the default parameters, unless 20 otherwise stated. The scoring matrix was BLOSUM62, with gap costs of 11 for existence and 1 for extension. The standard low complexity filter was used.

"ref" indicates that NCBI's RefSeq is the source database. The identifier that follows is a RefSeq accession number, not a GenBank accession number. "RefSeq sequences 25 are derived from GenBank and provide non-redundant curated data representing our current knowledge of known genes. Some records include additional sequence information that was never submitted to an archival database but is available in the literature. A small number of sequences are provided 30 through collaboration; the underlying primary sequence data is available in GenBank, but may not be available in any one GenBank record. RefSeq sequences are not submitted primary sequences. RefSeq records are owned by NCBI and therefore can be updated as needed to maintain current annotation or 35 to incorporate additional sequence information." See also <http://www.ncbi.nlm.nih.gov/LocusLink/refseq.html>

It will be appreciated by those in the art that the exact results of a database search will change from day to

day, as new sequences are added. Also, if you query with a longer version of the original sequence, the results will change. The results given here were obtained at one time and no guarantee is made that the exact same hits would be obtained in a search on the filing date. However, if an alignment between a particular query sequence and a particular database sequence is discussed, that alignment should not change (if the parameters and sequences remain unchanged).

10

#### **Northern Analysis.**

Northern analysis may be used to confirm the results. Favorable and unfavorable genes, identified as described above, or fragments thereof, will be used as probes in Northern hybridization analyses to confirm their differential expression. Total RNA isolated from Control, Hyperinsulinemic and Type-II Diabetic mice will be resolved by agarose gel electrophoresis through a 1% agarose, 1 % formaldehyde denaturing gel, transferred to positively charged nylon membrane, and hybridized to a probe labeled with [<sup>32</sup>P] dCTP that was generated from the aforementioned gene or fragment using the Random Primed DNA Labeling Kit (Roche, Palo Alto, CA) or to a probe labeled with digoxigenin (Roche Molecular Biochemicals, Indianapolis, IN) that was generated from the aforementioned gene or fragment using asymmetric PCR.

#### **Real-Time RNA Analysis.**

Real-time RNA analysis may also be used for confirmation. For "real-time" RNA analysis, RNA will be converted to cDNA and then probed with gene-specific primers made for each clone. "Real-time" incorporation of fluorescent dye will be measured to determine the amount of specific transcript present in each sample. Sample differences (control vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or control vs. diabetic) of 2-fold or greater (in either direction) will be considered differentially

30

35

expressed. Confirmation using several independent animals is desirable.

#### **In situ Hybridization**

Another form of confirmation may be provided by nonisotopic *in situ* hybridizations (NISH) on selected human (obtained by Tissue Informatics) and mouse tissues using cRNA probes generated from mouse genes found to be up- or down-regulated during the disease progression. Nonisotopic *in situ* hybridizations may also be performed on mouse tissues using cRNA probes generated from all "novel" cDNA's identified through PCR subtractive hybridizations. These cRNA's will hybridize to their corresponding messenger RNA's present in cells and will provide information regarding the particular cell types within a tissue that is expressing the particular gene as well as the relative level of gene expression. The cRNA probes may be generated by *in vitro* transcription of template cDNA by Sp6 or T7 RNA polymerase in the presence of digoxigenin-11-UTP (Roche Molecular Biochemicals, Indianapolis IN; Pardue, M.L. 1985. In: *In situ hybridization, Nucleic acid hybridization, a practical approach*: IRL Press, Oxford, 179-202).

#### **Transgenic Animals.**

Transgenic expression may be used to confirm the results. In one embodiment, a mouse is engineered to overexpress the favorable or unfavorable mouse gene in question. In another embodiment, a mouse is engineered to express the corresponding favorable or unfavorable human gene. In a third embodiment, a nonhuman animal other than a mouse, such as a rat, rabbit, goat, sheep or pig, is engineered to express the favorable or unfavorable mouse or human gene.

#### **Hyperquantitative Tissue Analysis**

In addition to gene expression analysis the muscle sections can also be analyzed using TissueInformatics, Inc.'s TissueAnalytics™ software. A single representative section may be cut from each muscle block, placed on a

slide, and stained with H&E. Digital images of each slide may be acquired using an research microscope and digital camera (Olympus E600 microscope and Sony DKC-ST5). These images were acquired at 20x magnification with a resolution of 0.64 mm/pixel. A hyperquantitative analysis may be performed on the resulting images: First a digital image analysis can identify and annotate structural objects in a tissue using machine vision. These objects, which are constituents of the tissue, can be annotated because they are visually identifiable and have a biological meaning. Subsequently a quantification of these structures regarding their geometric properties like area or stain intensities and their relationship to the field of view or per unit area in terms of a % coverage may be performed. Features or parameters for hyper-quantification are specific for each tissue, and may also include relations between features, measures of overall heterogeneity, including orientation, relative locations, and textures.

20      **Correlation Analysis**

Mathematical statistics provides a rich set of additional tools to analyze time resolved data sets of hyper-quantitative and gene expression profiles for similarities, including rank correlation, the calculation of regression and correlations coefficients, and clustering. Continuous functions may also be fitted through the data points of individual gene and tissue feature data. Relation between gene expression and hyper-quantitative tissue data may be linear or non-linear, in synchronous or asynchronous arrangements.

A Spearman rank correlation analysis using was done on the 2 classes of measurements (Genes and Tissues Features) to help identify other significant genes. A small number of genes that did not meet the 2-Fold difference for significance were added to the list of genes based on their correlation with tissue features or consistent differential expression in multiple samples.



Citation of documents herein is not intended as an admission that any of the documents cited herein is pertinent prior art, or an admission that the cited documents is considered material to the patentability of any of the claims of the present application. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicant and does not constitute any admission as to the correctness of the dates or contents of these documents.

The appended claims are to be treated as a non-limiting recitation of preferred embodiments.

In addition to those set forth elsewhere, the following references are hereby incorporated by reference, in their most recent editions as of the time of filing of this application: Kay, *Phage Display of Peptides and Proteins: A Laboratory Manual*; the John Wiley and Sons Current Protocols series, including Ausubel, *Current Protocols in Molecular Biology*; Coligan, *Current Protocols in Protein Science*; Coligan, *Current Protocols in Immunology*; *Current Protocols in Human Genetics*; *Current Protocols in Cytometry*; *Current Protocols in Pharmacology*; *Current Protocols in Neuroscience*; *Current Protocols in Cell Biology*; *Current Protocols in Toxicology*; *Current Protocols in Field Analytical Chemistry*; *Current Protocols in Nucleic Acid Chemistry*; and *Current Protocols in Human Genetics*; and the following Cold Spring Harbor Laboratory publications: Sambrook, *Molecular Cloning: A Laboratory Manual*; Harlow, *Antibodies: A Laboratory Manual*; *Manipulating the Mouse Embryo: A Laboratory Manual*; *Methods in Yeast Genetics: A Cold Spring Harbor Laboratory Course Manual*; *Drosophila Protocols*; *Imaging Neurons: A Laboratory Manual*; *Early Development of Xenopus laevis: A Laboratory Manual*; *Using Antibodies: A Laboratory Manual*; *At the Bench: A Laboratory Navigator*; *Cells: A Laboratory Manual*; *Methods in Yeast Genetics: A Laboratory Course Manual*; *Discovering Neurons: The Experimental Basis of Neuroscience*; *Genome Analysis: A Laboratory Manual Series*; *Laboratory DNA Science*; *Strategies for Protein Purification and Characterization: A*

5       *Laboratory Course Manual; Genetic Analysis of Pathogenic Bacteria: A Laboratory Manual; PCR Primer: A Laboratory Manual; Methods in Plant Molecular Biology: A Laboratory Course Manual ; Manipulating the Mouse Embryo: A Laboratory Manual; Molecular Probes of the Nervous System; Experiments with Fission Yeast: A Laboratory Course Manual; A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria; DNA Science: A First Course in Recombinant DNA Technology; Methods in Yeast Genetics: A Laboratory Course Manual; Molecular Biology of Plants: A Laboratory Course Manual.*

10

15

20

All references cited herein, including journal articles or abstracts, published, corresponding, prior or otherwise related U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

25       Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

30       The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology

35

or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

5 Any description of a class or range as being useful or preferred in the practice of the invention shall be deemed a description of any subclass (e.g., a disclosed class with one or more disclosed members omitted) or subrange contained therein, as well as a separate description of each  
10 individual member or value in said class or range.

The description of preferred embodiments individually shall be deemed a description of any possible combination of such preferred embodiments, except for combinations which are impossible (e.g., mutually exclusive choices for an  
15 element of the invention) or which are expressly excluded by this specification.

If an embodiment of this invention is disclosed in the prior art, the description of the invention shall be deemed to include the invention as herein disclosed with such  
20 embodiment excised.

## Introduction to Master Tables

The master tables reflect applicants' analysis of the gene chip data.

5

For each probe corresponding to a differentially expressed mouse gene, Master Table 1 identifies

10 Col. 1: The mouse gene (upper) and mouse protein (lower) database accession #s.

Col. 2: The corresponding mouse Unigene Cluster, as of the 4<sup>th</sup> Quarter 2001 build.

15 Col. 3: The behavior (differential expression) observed for the mouse gene. This column identifies the gene as favorable(F) or unfavorable (U) on the basis of its differential behavior. There are three possible comparisons, HI-D, C-HI, and C-D, where C=control (normal), 20 HI=hyperinsulinemic, and D=diabetic.

If the level of the gene in the former state is at least two-fold that in the latter state, it is considered unfavorable. If the level of the gene in the former state is not more than half (i.e., not more than negative two fold) that in the latter state, it is considered favorable.

25 Col. 4: A related human protein, identified by its database accession number. Usually, several such proteins are identified relative to each mouse gene. These proteins have been identified by BLAST searches, as explained in cols. 6-30 8.

Col. 5: The name of the related human protein.

35 Col. 6: The score (in bits) for the alignment performed by the BLAST program.

Col. 7: The E-value for the alignment performed by the BLAST program. It is worth noting that Unigene considers a Blastx E Value of less than 1e-6 to be a "match" to the reference sequence of a cluster.

5

Master Table 1 is divided into three subtables on the basis of the Behavior" in col. 3. If a gene has at least one favorable behavior, and no unfavorable ones, it is put into Subtable 1A. In the opposite case, it is put into Subtable 1B. If its behavior is mixed, i.e., at least one favorable and at least one unfavorable, it is put into Subtable 1C.

10

The corresponding human gene clusters are also of interest.  
15 These may be obtained in a number of ways. First, one may search on Unigene

(<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene>) for the identified human protein. Review the "hits" (each of which is a Unigene record) for those prefixed by "Hs."  
20 Secondly, one may access the Unigene record for the mouse gene cluster (which is given in Master Table 1), and then click on "Homologene". This will bring up a new page which includes the section "Possible Homologous Genes". One of the entries should be a Homo sapiens gene (considered by  
25 Unigene to be the most related human gene); click on its Unigene record link.

Additional information of interest may be accessed by searching with the mouse gene accession # in the Mouse Gene Informatics database, at <http://www.informatics.jax.org/>.

**Master Table 1**  
**Subtable 1A: Favorable Genes and Proteins**

Mouse Gene Protein	Unigene	Behavior	Human Proteins	Human Protein Name	Score (bits)	E-value
X82786 CAA58026.1	Mm_4078 NP_038816.1	F:(IR-D) -3.33	NP_002408.2	antigen identified by monoclonal antibody Ki-67; Proliferation-related Ki-67 antigen	1711	0
			P46013	KI67 HUMAN Antigen KI-67	1711	0
			A48666	cell proliferation antigen Ki-67, long form	1711	0
			CAA46519.1	antigen of the monoclonal antibody Ki-67	1711	0
			CAA46520.1	antigen of the monoclonal antibody Ki-67	1315	0
			B48666	cell proliferation antigen Ki-67, short form	1276	0
NM_013788	Mm_90135 NP_038816.1	F:(IR-D) -2.74	BAB86352.1	GSK-3beta binding protein FRAT1	205	8.00E-54
			AAH34476.1	frequently rearranged in advanced T-cell lymphomas	204	1.00E-53
			NP_005470.1	frequently rearranged in advanced T-cell lymphomas	204	2.00E-53
			Q92837	FRT1_HUMAN Proto-oncogene FRAT1 (Frequently rearranged in advanced T-cell lymphomas)	204	2.00E-53
			AAB97096.2	proto-oncogene	204	2.00E-53
NM_019641	Mm_28479 NP_062615.1	F:(IR-D) -2.54	NP_005554.1	stathmin 1; metablastin; prosolin; oncprotein 18; phosphoprotein 19; stathmin; leukemia-associated phosphoprotein p18	286	8.00E-78
			P16949	STN1_HUMAN Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18) (Leukemia-associated phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Pr22) protein	286	8.00E-78
			A40936	stathmin	286	8.00E-78
			CAA77660.1	Pr22 protein	286	8.00E-78
			CAA37391.1	stathmin	286	8.00E-78
			AAA59971.1	oncoprotein 18	286	8.00E-78
			AAA59980.1	protein p18	286	8.00E-78
			CAA64398.1	Pr22	286	8.00E-78
			CAC16020.1	dJ12513.1 (leukemia-associated phosphoprotein p18 (stathmin))	286	8.00E-78
			AAAH14353.1	AAAH14353 Similar to stathmin 1/oncoprotein 18	285	2.00E-77
			Q9H169	STN4_HUMAN Stathmin 4 (Stathmin-like protein B3) (RB3)	194	4.00E-50
			CAC22254.1	RB3 protein	194	4.00E-50

		CAB66503.1	hypothetical protein	194	4.00E-50
		NP_110422.2	stathmin-like-protein RB3	194	4.00E-50
		AAH11520.1	AAH11520 Similar to stathmin-like-protein RB3	194	4.00E-50
NM_011623	Mm.4237	F:(R-D) -2.33	NP_001058.2 DNA topoisomerase II, alpha isozyme; topoisomerase (DNA) II alpha (170kD); DNA topoisomerase II, 170 kD	2463	0
NP_035753.1					
		P11388	TP2A_HUMAN DNA topoisomerase II, alpha isozyme	2463	0
		AAC77388.1	topoisomerase II alpha	2463	0
		AAA61209.1	DNA topoisomerase II (EC 5.99.1.3)	2462	0
		CAA09762.1	DNA topoisomerase (ATP-hydrolysing); topoisomerase II alpha	2454	0
		A40493	DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) alpha	2441	0
		Q02880	TP2B_HUMAN DNA topoisomerase II, beta isozyme	1923	0
		A39242	DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) beta; splice form 2	1923	0
		NP_001059.2	DNA topoisomerase II, beta isozyme; topo II beta; DNA topoisomerase II, 180 kD; topoisomerase (DNA) II beta (180kD)	1923	0
		CAA48197.1	DNA topoisomerase II	1923	0
		AACT77432.1	DNA topoisomerase II beta	1918	0
		AAA61210.1	topoisomerase II	1494	0
AK007688	Mm.41925	F:(R-D) -2.27	NP_076947.1 hypothetical protein MGCG2601	457	e-128
AAH37181.1					
		CAB56188.1	c380A1.2.1 (novel protein (isoform 1))	457	e-128
		AAH00662.1	Unknown (protein for MGCG2601)	457	e-128
		AAK61247.1	AE006464_15 unknown	457	e-128
NM_011593	Mm.8245	F:(R-D) -2.18	CAB56189.1 c380A1.2.2 (novel protein (isoform 2))	300	3E-81
NP_035723.1			CAA26443.1 EPA glycoprotein	270	1.00E-72
		NP_003245.1	tissue inhibitor of metalloproteinase 1 precursor; Erythroid-potentiating activity (tissue inhibitor of metalloproteinases); erythroid potentiating activity	270	1.00E-72
		P01033	TIM1_HUMAN Metalloproteinase inhibitor 1 precursor (TIMP-1) (Erythroid potentiating activity) (EPA) (Tissue inhibitor of metalloproteinases) (Fibroblast	270	1.00E-72

			collagenase inhibitor) (Collagenase inhibitor)		
	ZYHUEP		metalloproteinase tissue inhibitor 1 precursor [validated]		270 1.00E-72
CAA26902.1	precursor				270 1.00E-72
AAA52436.1	prefibroblast collagenase inhibitor				270 1.00E-72
AAA62234.1	collagenase inhibitor				270 1.00E-72
AAD14009.1	S68252_1 metalloproteinase inhibitor				270 1.00E-72
AAH00866.1	AAH00866 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)				270 1.00E-72
1107278A	erythroid potentiating activity				270 1.00E-72
1308125A	metalloproteinase inhibitor				270 1.00E-72
IUEA	B Chain B, Mmp-3TIMP-1 Complex				264 8.00E-71
IUEA	D Chain D, Mmp-3TIMP-1 Complex				264 8.00E-71
BAA01913.1	tissue inhibitor of metalloproteinases				236 1.00E-62
AAH07097.1	AAH07097 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)				221 6.00E-58
NM_016785	Mm_10169 F:(IR-D) NP_058065.1	NP_000358.1	thiopurine S-methyltransferase	376 e-104	
	-2.18				
P51580	TPMT HUMAN Thiopurine S-methyltransferase (Thiopurine methyltransferase)				376 e-104
I57946	thiopurine methyltransferase				376 e-104
AAB27277.1	thiopurine methyltransferase; TPMT				376 e-104
AAC50130.1	thiopurine methyltransferase				376 e-104
AAC50368.1	thiopurine methyltransferase				376 e-104
AAC51865.1	thiopurine S-methyltransferase				376 e-104
BAA97037.1	thiopurine S-methyltransferase				376 e-104
AAH09596.1	AAH09596 thiopurine S-methyltransferase				376 e-104
AAB71630.1	thiopurine methyltransferase				375 e-104
AAB71626.1	thiopurine methyltransferase				375 e-104
AAB80746.1	thiopurine S-methyltransferase				374 e-103
AAB71629.1	thiopurine methyltransferase				374 e-103
AAB71627.1	thiopurine methyltransferase				373 e-103
AAH05339.1	AAH05339 thiopurine S-methyltransferase				372 e-103
AAB71625.1	thiopurine methyltransferase				371 e-103

		AAB80747.1	thiopurine S-methyltransferase	371 e-130
		AAC50129.1	thiopurine methyltransferase	265 9.00E-84
		XP_031946.2	similar to thiopurine methyltransferase	265 6.00E-83
U08020	Mm.22621 F:(IR-D) -2.16	P02452	CA11_HUMAN Collagen alpha 1(I) chain precursor	486 e-136
AAA88912.1		AAB94054.2	pro alpha 1(I) collagen	486 e-136
		NP_000079.1	alpha 1 type I collagen preprotein; Collagen I, alpha-1 polypeptide; osteogenesis imperfecta type IV; collagen of skin, tendon and bone, alpha-1 chain	484 e-136
		CAA98968.1	prepro-alpha1(I) collagen	484 e-136
		CGHU1S	collagen alpha 1(I) chain precursor	483 e-136
		AAA51995.1	alpha 1 (I) chain propeptide	482 e-135
		AAH36531.1	Unknown (protein for MGC:33668)	480 e-135
		AAB27856.1	type I collagen pro alpha 1(I) chain propeptide	469 e-131
		CAA29605.1	C-terminal propeptide domain	435 e-121
		CAA29604.1	pro-alpha 1 (II) collagen (313 AA; AA 975-271c)	372 e-102
		NP_001835.2	alpha 1 type II collagen isoform 1; collagen II, alpha-1 polypeptide; cartilage collagen; chondrocalcin, included; COL11A3, formerly	372 e-102
		AAC41772.1	alpha-1 type II collagen	372 e-102
NM_023043	Mm.18075 F:(IR-D) -2.14	NP_036541.1	prion gene complex, downstream	283 1.00E-75
NP_075530.1				
		Q9UKY0	PRND_HUMAN Prion-like protein doppel precursor (PrP <sup>L</sup> ) (Prion protein 2)	283 1.00E-75
		AAF02424.1	AF106918_1 prion-like protein	283 1.00E-75
		CAB75502.1	dJ1068H6.4 (prion protein like protein doppel)	282 2.00E-75
		AAAG43449.1	prion-like protein	281 3.00E-75
		AAAG43448.1	AF187843_1 doppel protein	246 2.00E-64
NM_009464	Mm.6254 F:(IR-D) -2.07	NP_003347.1	uncoupling protein 3, isoform UCP3L	531 e-151
NP_033490.1		P55916	UCP3_HUMAN Mitochondrial uncoupling protein 3 (UCP3)	531 e-151
		JC5522	uncoupling protein UCP3, mitochondrial	531 e-151

	AAC51367.1	UCP3		531 e-151
	AAC51369.1	uncoupling protein 3		531 e-151
	AAC51767.1	uncoupling protein-3		531 e-151
	AAG02284.1	AF050113_1 uncoupling protein-3		531 e-151
	AAC18822.1	uncoupling protein 3		525 e-149
	AAC51785.1	uncoupling protein 3		510 e-144
	NP_073714.1	uncoupling protein 3, isoform UCP3S		464 e-131
	AAC51356.1	UCP3S		464 e-131
	AAB48411.1	uncoupling protein-2		457 e-129
	NP_003346.2	uncoupling protein 2		456 e-128
	P55851	UCP2_HUMAN Mitochondrial uncoupling protein 2 (UCP 2) (UCPH)		456 e-128
	AAC51336.1	UCP2		456 e-128
	AAC39690.1	uncoupling protein 2		456 e-128
	AAD21151.1	uncoupling protein-2		456 e-128
	AAH11737.1	AAH11737 uncoupling protein 2 (mitochondrial, proton carrier)		456 e-128
	AAB52091.1	uncoupling protein homolog		456 e-128
	CAA11402.1	uncoupling protein 2		456 e-128
	NP_068605.1	uncoupling protein 1; mitochondrial brown fat uncoupling protein		345 7E-95
	G01858	uncoupling protein 1, mitochondrial		345 7E-95
	AAA82271.1	uncoupling protein		345 7E-95
	P25874	UCP1_HUMAN Mitochondrial brown fat uncoupling protein 1 (UCP 1) (Thermogenin)		342 6E-94
	CAA36214.1	uncoupling protein		342 6E-94
	AAH08392.1	AAH08392 Similar to uncoupling protein 3 (mitochondrial, proton carrier)		214 2E-55
AK014626	Mm.10557 F.(R-D) 1	dJ137F1.2 (novel member of the potassium channel subfamily K)		309 9E-84
	XP_138942.1	NP_115491.1 potassium channel, subfamily K, member 16, pancreatic 2P domain potassium channel TALK-1		
		Q96T55 C1WYG_HUMAN Potassium channel subfamily K member 16 (TWIK-related alkaline pH activated K+ channel 1) (2P domain potassium channel Talk-1)		285 2E-76

NM_010514 NP_034644.1	Mm.3862 NP_036130.1	F:(R-D) -2.06	AAK40532.1 NP_000603.1	AF358909 1 2P domain potassium channel Talk-1 insulin-like growth factor 2 (somatomedin A); somatomedin A	285 2E-76 255 5.00E-67
		P01344	IGF2_HUMAN Insulin-like growth factor II precursor (IGF-II) (Somatomedin A)	255 5.00E-67	
			IGHU2 insulin-like growth factor II precursor [validated]	255 5.00E-67	
			CAA25426.1 IGF-II precursor	255 5.00E-67	
			CAA29516.1 precursor polypeptide (AA -24 to 156)	255 5.00E-67	
			AAA52442.1 preproinsulin-like growth factor II, domains A-E	255 5.00E-67	
			AAA52535.1 insulin-like growth factor	255 5.00E-67	
			AAA52545.1 insulin-like growth factor II precursor	255 5.00E-67	
			AAA60088.1 insulin-like growth factor II	255 5.00E-67	
			AAB34155.1 insulin-like growth factor II; IGF-II	255 5.00E-67	
			AAG17220.1 AF217977 1 unknown	255 5.00E-67	
			AAH00531.1 AAH00531 insulin-like growth factor 2 (somatomedin A)	255 5.00E-67	
			AAM51825.1 AF517226 1 insulin-like growth factor 2 (somatomedin A)	255 5.00E-67	
			1009249A insulin-like growth factor II precursor	255 5.00E-67	
			I203258B insulin-like growth factor II	255 5.00E-67	
			AAA52544.1 insulin-like growth factor II precursor	254 1.00E-66	
			I67610 insulin-like growth factor II, domains A-E	250 2.00E-65	
			AAA52443.1 preproinsulin-like growth factor II, domains A-E	250 2.00E-65	
			S02423 insulin-like growth factor II precursor, splice form II	249 3.00E-65	
			CAA27249.1 put. IGF-II	249 3.00E-65	
			CAA29517.1 precursor polypeptide (AA -24 to 140)	223 2.00E-57	
NM_012000 NP_036130.1	Mm.21578 NP_036130.1	F:(R-D) -2.09	AAH07725.1	AAH07725 ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation)	448 e-125
			NP_061764.1 ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation)	446 e-125	
			Q9UBY8 CLN8 HUMAN CLN8 protein	446 e-125	
			AAF13115.1 AF123757 1 putative transmembrane protein	446 e-125	
			AAF13116.1 AF123758 1 putative transmembrane protein	446 e-125	
			AAF13117.1 AF123759 1 putative transmembrane protein	446 e-125	

		AAF13118.1	AF123760_1 putative transmembrane protein	446 e-125
		AAF13119.1	AF123761_1 putative transmembrane protein	446 e-125
NM_025285	Mm.29580 F:(C-IR)-4.72	XP_170521.1	similar to data source:MGD, source key:MGI:98241, evidence:ISS~putative~superiorcervical ganglia, neural specific 10	345 2.00E-94
NP_079561.1		AAH06302.1	AAH06302 Similar to superiorcervical ganglia, neural specific 10	345 2.00E-94
		NP_008960.1	superiorcervical ganglia, neural specific 10; neuronal growth-associated protein (silencer element); superior cervical ganglia, neural specific 10	342 1.00E-93
		AAB36428.1	SCG10	342 1.00E-93
		Q93045	STN2_HUMAN Stathmin 2 (SCG10 protein) (Superior cervical ganglion-10 protein)	342 1.00E-93
		BAA23326.1	silencer element	342 1.00E-93
		NP_056978.2	SCG10-like-protein	249 1.00E-65
		Q9NZ72	STN3_HUMAN Stathmin 3 (SCG10-like protein)	249 1.00E-65
		AAF35245.1	SCG10-like-protein	249 1.00E-65
		CAC16222.1	bK3184A7.2 (SCG10-like protein (SCLIP) (ortholog of rabbit neuroplastin-2 (NPC2)))	249 1.00E-65
		AAH09381.1	AAH09381 Unknown (protein for MIGC:16668)	249 1.00E-65
		AAD12730.1	SCG10-like-protein	248 2.00E-65
		BAC11252.1	unnamed protein product	245 2.00E-65
		Q9H169	STN4_HUMAN Stathmin 4 (Stathmin-like protein B3) (RB3)	217 5.00E-56
		CAC22254.1	RB3 protein	217 5.00E-56
		CAB66503.1	hypothetical protein	217 5.00E-56
		NP_110422.2	stathmin-like-protein RB3	206 7.00E-53
		AAH11520.1	AAH11520 Similar to stathmin-like-protein RB3	206 7.00E-53
NM_008687	Mm.4025 F:(C-IR)-2.69	AAH01283.1	Similar to nuclear factor I/B	808 0
NP_032713.1		NP_005587.1	nuclear factor I/B	807 0
		O00712	NFIB_HUMAN Nuclear factor 1 B-type (Nuclear factor I/B) (NF1-B) (NF-I/B) (CCAAT-box binding transcription factor) (CTF) (TGGCA-binding protein)	807 0
		AAB41899.1	nuclear factor I-B2	807 0

		AAA93125.1	nuclear factor 1 B-type	507 e-143
		NP_005588.1	nuclear factor I/C (CCAAT-binding transcription factor)	499 e-140
		CAA63440.1	NFI/CAAT-binding transcription factor 5 (CTF5)	499 e-140
		AAH12120.1	nuclear factor I/C (CCAAT-binding transcription factor)	499 e-140
		P08651	NFIC_HUMAN Nuclear factor 1 C-type (Nuclear factor 1/C) (NF1-C) (CCAAT-box binding transcription factor) (CTF) (TGCGCA-binding protein)	487 e-137
		B33416	nuclear factor I	484 e-136
		BAA92677.1	KIAA1439 protein	484 e-136
		Q12857	NFIA_HUMAN Nuclear factor 1 A-type (Nuclear factor 1/A) (NF1-A) (NF1/A) (CCAAT-box binding transcription factor) (CTF) (TGCGCA-binding protein)	483 e-136
		XP_046827.7	similar to transcription factor NF1	483 e-136
		AAH22264.1	Nuclear Factor IA	483 e-136
AK013022	Mm.28026 F:(C-IR) Q9NZJ3 -2.41	Q9NZJ3	SELT_HUMAN Selenoprotein T	334 2E-91
		NP_057359.1	selenoprotein T	326 4E-89
		AAF13696.1	selenoprotein T	326 4E-89
		XP_088553.	similar to Selenoprotein T	317 2E-86
		AAD20063.1	Unknown	284 2E-76
		AAH36738.1	Unknown (protein for MGC:45090)	284 2E-76
NM_019643	Mm.18637 F:(C-IR) NP_062617.1 -2.4	NP_067061.1	TERA protein	402 e-111
		T46918	hypothetical protein DKFZp762L137.1	402 e-111
		CAB75656.1	hypothetical protein	402 e-111
		AAF87322.1	AF212220_1_TERA	402 e-111
		BAB15592.1	unnamed protein product	402 e-111
		AAH00024.1	AAH00024_TERA_protein	402 e-111
NM_022314	Mm.17306 F:(C-IR) NP_071709.1 -2.32	P06753	TPM3_HUMAN Tropomyosin alpha 3 chain (Tropomyosin 3) (Tropomyosin gamma)	365 e-101

		XP_036829.5	similar to tropomyosin, fibroblast	365 e-101
		A24199	tropomyosin NM, skeletal muscle	365 e-101
		CAA27798.1	skeletal muscle tropomyosin (AA 1-285)	365 e-101
		AAH08407.1	AAH08407 Unknown (protein for MGC:14532)	365 e-101
		AAH08425.1	AAH08425 Unknown (protein for MGC:14582)	365 e-101
		I209280A	tropomyosin	365 e-101
		P09493	TPM1 HUMAN Tropomyosin 1 alpha chain (Alpha-tropomyosin)	345 8.00E-95
		A25825	tropomyosin alpha chain, cardiac and skeletal muscle	345 8.00E-95
		AAA61225.1	skeletal muscle tropomyosin	345 8.00E-95
		P07951	TPM2 HUMAN Tropomyosin beta chain (Tropomyosin 2) (Beta-tropomyosin)	326 3.00E-89
		S00922	tropomyosin beta, skeletal muscle	326 3.00E-89
		CAA29971.1	beta-tropomyosin (AA 1-284)	326 3.00E-89
		AAH07433.1	AAH07433 Similar to tropomyosin 1 (alpha)	325 7.00E-89
		NP_689476.1	tropomyosin 3	315 9.00E-86
		BAC03946.1	unnamed protein product	315 9.00E-86
		AAA61226.1	skeletal muscle tropomyosin	310 2.00E-84
		BAB14554.1	unnamed protein product	300 2.00E-81
		NP_000357.2	tropomyosin 1 (alpha)	281 1.00E-75
		A27674	tropomyosin 3, fibroblast	281 1.00E-75
		AAA36771.1	tropomyosin	281 1.00E-75
		T08796	tropomyosin	278 1.00E-74
		CAB43309.1	hypothetical protein	278 1.00E-74
NM_011825	Mm.25760 F:(C-IR) NP_035955.1	NP_071914.1 -2.24	hypothetical protein FLJ21195 similar to protein related to DAC	308 5.00E-83
			BAB15026.1	unnamed protein product
				308 5.00E-83
NM_009831	Mm.2103 F:(C-IR) NP_033961.1	NP_004051.1 -2.2	cyclin G1	543 e-154
		P51959	CGG1_HUMAN Cyclin G1 (Cyclin G)	543 e-154
		G02401	cyclin G1	543 e-154

	AAC41977.1	cyclin G1	543 e-154
	AAC50688.1	cyclin G1	543 e-154
	BAA11353.1	cyclin G	543 e-154
	AAH00196.1	cyclin G1	543 e-154
	22 0321A	cyclin G1	543 e-154
	AAH07093.	cyclin G1	541 e-154
	BAA13007.1	cyclin G	514 e-146
	CAA54821.1	cyclin G1	462 e-130
	G02523	cyclin G	421 e-117
	AAB03903.1	cyclin G	421 e-117
	AAH32518.1	Similar to cyclin G2	292 8E-79
	NP_004345.1	cyclin G2	292 8E-79
	Q16589	CGG2_HUMAN Cyclin G2	292 8E-79
	AAC41978.1	cyclin G2	292 8E-79
	AAC50689.1	cyclin G2	292 8E-79
	AAN40704.1	cyclin G2	292 8E-79
	22 0321B	cyclin G2	292 8E-79
NM_021282 NP_067257.1	Mm.21758 F:(C-IR) -2.19 F:(C-D) - 2.5	NP_000764.1 cytochrome P450, subfamily IIE, polypeptide 1; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase; cytochrome P450, subfamily IIE (ethanol-inducible)	792 0
	P05181	CPE1_HUMAN Cytochrome P450 2E1 (CYP2E1) (P450-J)	792 0
	A31949	cytochrome P450 2E	792 0
	AAA52155.1	cytochrome P450IE1	792 0
	AAA35743.1	cytochrome P450j	792 0
	AAF13601.1	AF182276_1 cytochrome P450-2E1	790 0
	AADI1753.1	cytochrome P450 2E1	751 0
	NP_000760.1	cytochrome P450, subfamily IIC (mephentytoin 4-hydroxylase), polypeptide 19; mephentytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; <b>flavoprotein-linked monooxygenase</b>	557 e-158
	P33261	CPCJ_HUMAN Cytochrome P450 2C19 (CYP2C19) (P450-11A) (Mephentytoin 4-hydroxylase) (CYP2C17) (P450-254C)	557 e-158

	AAB59426.1	cytochrome		557 e-158
	NP_000763.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase	556 e-158	
	AAB59356.1	cytochrome		556 e-158
	P33260	CPC1_HUMAN Cytochrome P450 2C18 (CYP2C18) (P450-6B/29C)	553 e-157	
	A61269	cytochrome P450 2C18	553 e-157	
	AAA02630.1	cytochrome P4502C18	553 e-157	
	BAA00123.1	cytochrome P450	550 e-156	
	NP_000762.2	cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	550 e-156	
	P11712	CPC9_HUMAN Cytochrome P450 2C9 (CYP2C9) (P450 PB-1) (P450 MP-4) (S-mephenytoin 4-hydroxylase) (P-450MP)	550 e-156	
	B38462	S-mephenytoin 4-hydroxylase (EC 1.14.14.-) cytochrome P450 2C9	550 e-156	
	1313295A	cytochrome P450	550 e-156	
	F38462	S-mephenytoin 4-hydroxylase (EC 1.14.14.-) cytochrome P450 2C19	550 e-156	
	AAB23864.2	cytochrome P450	545 e-155	
AK019452	Mm.29952 F(C-IR)-2.19	hypothetical protein FLJ22940	258 9E-69	
	BAB31728.1			
	AAH01381.1	polymerase (RNA) III (DNA directed) polypeptide K (12.3 kDa)	258 9E-69	
	AAAH09179.1	hypothetical protein FLJ22940	258 9E-69	
	AAK61211.1	AE006462_3 Minus_99_protein	258 9E-69	
	BAB15505.1	unnamed protein product	256 4E-68	
NM_008832	Mm.42254 F(C-IR)-2.18	phosphorylase kinase, alpha 1 (muscle); phosphorylase kinase, alpha 1 (muscle), muscle glycogenesis; phosphorylase kinase, muscle, alpha polypeptide	2244 0	
NP_032858.1				
	P46020	KPB1_HUMAN Phosphorylase B kinase alpha regulatory chain, skeletal muscle isoform (Phosphorylase kinase alpha M subunit)	2244 0	
	I38111	phosphorylase kinase (EC 2.7.1.38) alpha-1 chain	2244 0	

		CAA52083.1	phosphorylase kinase	2244	0
		NP_000283.1	phosphorylase kinase, alpha 2 (liver); Phosphorylase kinase deficiency, liver (glycogen storage disease; phosphorylase kinase, alpha 2 (liver), glycogen storage disease IX	1628	0
	P46019	KPB2_HUMAN	Phosphorylase B kinase alpha regulatory chain, liver isoform (Phosphorylase kinase alpha L subunit)	1628	0
	CAA56662.1	phosphorylase kinase		1628	0
	BAA07606.1	phosphorylase kinase alpha subunit		1628	0
	AAD32846.1	phosphorylase kinase alpha subunit		1628	0
	AAH14036.1	AAH14036 Similar to phosphorylase kinase, alpha 2 (liver)		1624	0
	CAB86408.1	dj499B10.2 (phosphorylase kinase, alpha 2 (liver) (PYK))		631	e-180
	AAB27307.1	phosphorylase kinase alpha subunit liver isoform, PHKA2 {EC 2.7.1.38} [human, hepatoma, Peptide Partial, 377 aa]		473	e-132
	S74251	phosphorylase kinase (EC 2.7.1.38) beta chain		461	e-129
	AAH33657.1	Similar to phosphorylase kinase, beta		461	e-129
NM_023831	Mm.30006 F:(C-IR) NP_076320.1 -2.16	CAB96537.1 hypothetical protein		465	e-131
		CAB66868.1 hypothetical protein		465	e-131
		AAH11647.1 AAH11647 Similar to hypothetical protein		465	e-131
		AAH12802.1 AAH12802 Similar to hypothetical protein		465	e-131
		AAH22856.1 hypothetical protein		465	e-131
		NP_064538.2 hypothetical protein FLJ21827		465	e-131
		BAB15146.1 unnamed protein product		465	e-131
AK004839	Mm.2605 F:(C-IR) NP_006735.1 -2.15	retinol-binding protein 4, plasma precursor		343	2E-94
XP_129259.1					
		pir VAHU plasma retinol-binding protein precursor		343	2E-94
		CAA24959.1 precursor RBP		343	2E-94
	P02753	Plasma retinol-binding protein precursor (PRBP) (RBP) (PRO2222)		341	1E-93
		AAH20633.1 Similar to retinol binding protein 4, plasma		341	1E-93
		XP_005907.5 similar to Plasma retinol-binding protein precursor (PRBP) (RBP) (PRO2222)		341	1E-93

		IRBP	Retinol Binding Protein	340	2E-93
		IRBP	Retinol Binding Protein (Holo Form)	340	2E-93
		IBRQ	Retinol Binding Protein (Apo Form)	340	2E-93
	1401251A	retinol binding protein		340	2E-93
	1QAB	E Chain E, The Structure Of Human Retinol Binding Protein With Its Carrier Protein Transthyretin Reveals Interaction With The Carboxy Terminus Of Rbp		328	9E-90
	1QAB	F Chain F, The Structure Of Human Retinol Binding Protein With Its Carrier Protein Transthyretin Reveals Interaction With The Carboxy Terminus Of Rbp		328	9E-90
	AAF69622.1	AF119917_30 PRO2222		288	6E-78
	CAA26553.1	RBP		199	5E-51
NM_011823	Mm.89979 F:(C-IR)-2.12	AAD50531.1	AF039686_1 G-protein coupled receptor GPR34	698	0
		NP_005291.1	G protein-coupled receptor 34	697	0
		Q9UPC5	GPR34 HUMAN Probable G protein-coupled receptor GPR34	697	0
		AAD17248.1	orphan G protein-coupled receptor	697	0
		BAB553362.1	unnamed protein product	697	0
		AAH20678.1	AAH20678 G protein-coupled receptor 34	697	0
NM_025950	Mm.78875 F:(C-IR)-2.08	CAC12705.1	bA6J24.4 (A novel protein similar to cell division cycle control protein 37(CDC37))	514	e-145
NP_080226.1		AAH14133.1	AAH14133 Unknown (protein for MGC:20783)		
		NP_060383.1	Hsp90-associating relative of Cdc37; hypothetical protein FLJ20639	513	e-145
		BAA91304.1	unnamed protein product	513	e-145
		BAA91206.1	unnamed protein product	303	1.00E-81
		NP_008996.1	CDC37 homolog; CDC37 (cell division cycle 37, <i>S. cerevisiae</i> , homolog); CDC37 ( <i>S. cerevisiae</i> ) homolog	210	9.00E-54
		Q16543	CC37_HUMAN Hsp90 co-chaperone Cdc37 (Hsp90 chaperone protein kinase-targeting subunit) (p50Cdc37)	210	9.00E-54
		G02313	CDC37 homolog	210	9.00E-54

		AAB63979.1	CDC37 homolog	210 9.00E-54
		AAB04798.1	CDC37 homolog	210 9.00E-54
		AAH00083.1	AAH00083 CDC37 (cell division cycle 37, S. cerevisiae, homolog)	210 9.00E-54
		AAH08793.1	AAH08793 CDC37 (cell division cycle 37, S. cerevisiae, homolog)	210 9.00E-54
NM_008452	Mm.26938 F;(C-IR) -2.05	AAD55891.1	AF134053_1 Kruppel-like factor LKLF	431 e-120
NP_032478.1		AAD25076.1	AF123344_1 Kruppel-like zinc finger transcription factor	429 e-120
		NP_057354.1	Kruppel-like factor	429 e-120
		Q9Y5W3	KLF2 HUMAN Kruppel-like factor 2 (Lung kruppel-like factor)	429 e-120
		AAF13295.1	AF205849_1 Kruppel-like factor	429 e-120
		AAC02462.1	EZF	213 5E-55
		O43474	KLF4 HUMAN Kruppel-like factor 4 (Epithelial zinc-finger protein EZF) (Gut-enriched Kruppel-like factor)	213 5E-55
		AAD42165.1	AF05036_1 zinc finger transcription factor GKLF	213 5E-55
		AAH29923.1	Kruppel-like factor 4 (gut)	213 5E-55
		NP_004226.1	Kruppel-like factor 4 (gut); endothelial Kruppel-like zinc finger protein	213 5E-55
		AAB48399.1	hEZF	213 5E-55
		AAH30811.1	Similar to Kruppel-like factor 4 (gut)	213 5E-55
		AAH35342.1	Similar to Kruppel-like factor 2 (lung)	211 3E-54
NM_020007	Mm.14199 F;(C-IR) 3	AAK94915.1	AF401998_1 muscleblind 41kD isoform	569 e-166
NP_064391.1	-2.04			
		NP_066368.1	muscleblind ( <i>Drosophila</i> )-like	546 e-160
		BAA24858.1	KIAA0428	546 e-160
		Q9NR56	MBNL_HUMAN Muscleblind-like protein (Triplet-expansion RNA-binding protein)	537 e-157
		CAA74155.1	MBNL protein	537 e-157
		NP_659002.1	muscleblind-like protein MBLL39 isoform 1	449 e-125
		AAM09798.1	AF491866_1 muscleblind-like protein MLP1	449 e-125
		AAM50085.1	muscleblind-like protein MBLL39	427 e-119
		NP_060858.2	CHCR isoform G	387 e-106

		Q9NUK0	MBXL_HUMAN Muscleblind-like X-linked protein (Cys3His CCG1-required protein) (HCHCR protein)	387 e-106
	AAL65661.1	CHCR isoform G		387 e-106
	BAB83648.1	hCHCR-G		387 e-106
	CAD20869.1	CHCR protein		387 e-106
	AAM09533.1	AF491305_1 MBLX39		387 e-106
	NP_005748.1	muscleblind-like protein MBLL39 isoform 2		377 e-103
	AAC67242.1	zinc finger protein		377 e-103
	BAB85649.1	hCHCR-R		343 1.00E-93
	CAD20870.1	CHCR protein		343 1.00E-93
	AAL87670.1	AF467070_1 Cys3His CCG1-required protein isoform R		343 1.00E-93
	AAK82889.1	AF395876_1 36 kDa muscleblind protein EXP36		286 7.00E-82
NM_009883	Mm.4863	F:(C-IR)-2.03	CAC14276.1 bA112L6.1 (CCAAT/enhancer binding protein (C/EBP), beta)	271 2E-72
	NP_034013.1			
		AAH07538.1	Unknown (protein for MGC:15409)	271 2E-72
		AAL55792.1	AF289608_1 unknown	271 2E-72
		AAH21931.1	Unknown (protein for MGC:32080)	271 2E-72
		AAN86350.1	CCAAT/enhancer binding protein (C/EBP), beta	271 2E-72
		NP_005185.1	CCAAT/enhancer binding protein (C/EBP), beta; CCAAT/enhancer-binding protein (C/EBP), beta (transcription factor-5)	271 2E-72
		P17676	CEBB_HUMAN CCAAT/enhancer binding protein beta (C/EBP beta) (Nuclear factor NF-IL6) (Transcription factor 5)	271 2E-72
		S12788	transcription factor NF-IL6	271 2E-72
		CAA36794.1	nuclear factor NF-IL6 (AA 1-345)	271 2E-72
AK004002	Mm.19844	F:(C-IR)-2.02	CAA36441.1 five-lipoxygenase activating protein (FLAP)	282 4E-76
BAB23117.1		NP_001620.2	arachidonate 5-lipoxygenase-activating protein; five-lipoxygenase activating protein; MK-886-binding protein	282 4E-76
		P20292	FLAP_HUMAN 5-lipoxygenase activating protein (FLAP) (MK-886-binding protein)	282 4E-76

		A39824	5-lipoxygenase-activating protein	282	4E-76
		AAA35845.1	5-lipoxygenase activating protein	282	4E-76
		1603359A	lipoxygenase activating protein	279	3E-75
NM_009776	Mm.38888 F:(C-IR) NP_033906.1	AAH11171.1 -2.02	serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor),member 1	634	0
		P05155	IC1_HUMAN Plasma protease C1 inhibitor precursor (C1 Inh) (C1Inh)	633	0
		ITIHUC1	complement C1 inhibitor precursor [validated]	633	0
		CAA39358.1	C1 inhibitor	633	0
		CAA30314.1	C1 inhibitor	633	0
		AAM21515.1	AF435921_1 C1 esterase inhibitor	633	0
		NP_000053.1	complement component 1 inhibitor precursor; serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1	632	0
		AAB55387.1	plasma protease (C1) inhibitor precursor	632	0
		AAA35613.1	plasma protease (C1) inhibitor precursor	632	0
		CAA30469.1	C1 inhibitor (AA 155-478 ) (1 is 2nd base in codon)	517	e-146
		AAA51848.1	C1-inhibitor	454	e-127
		AAA51849.1	C1 inhibitor	307	3E-83
NM_011082	Mm.4317 F:(C-IR) NP_035212.1	XP_052013.1 -2.02	similar to polymeric immunoglobulin receptor	930	0
		AAN65630.1	hepatocellular carcinoma associated protein TB6	930	0
		NP_002635.1	polymeric immunoglobulin Receptor	927	0
		P01833	PIGR_HUMAN Polymeric-immunoglobulin receptor precursor (Poly-Ig receptor) (PIGR) [Contains: Secretory component] (QRHUGS)	927	0
			secretory component precursor [validated]	927	0
		AAB20203.1	transmembrane secretory component; poly-Ig receptor; SC	927	0
		AAB22176.1	transmembrane secretory component; SC; poly-Ig receptor	927	0
		CAA51532.1	Polymeric immunoglobulin receptor	927	0
		AAA36102.1	poly-Ig receptor	817	0
NM_010274	Mm.3711 F:(C-IR) NP_034404.1	G02093 -2.01	glycerol-3-phosphate dehydrogenase (EC 1.1.99.5), mitochondrial precursor	1268	0

		AAB60403.1	glycerol-3-phosphate dehydrogenase	1268 0
		AAC50556.1	glycerol-3-phosphate dehydrogenase	1268 0
	NP_000399.1	glycerol-3-phosphate dehydrogenase 2 (mitochondrial)		1266 0
P43304	GPDM_HUMAN	Glycerol-3-phosphate dehydrogenase, mitochondrial precursor (GPDH-M) (GPDH-M)		1266 0
AAA65701.1	mitochondrial	glycerol-3-phosphate dehydrogenase		1266 0
AAG33851.1	AF311325	1 glycerol-3-phosphate dehydrogenase 3		1071 0
AAB50200.1	glycerol-3-phosphate dehydrogenase			684 0
AAH19874.1	AAH19874	Similar to glycerol-3-phosphate dehydrogenase 2 (mitochondrial)		624 e-178
XP_092005.2	similar to Glycerol-3-phosphate dehydrogenase, mitochondrial precursor (GPDH-M) (GPDH-M)			320 8.00E-87
NM_010801	Mm.10414	F:(C-IR) -2.01	NP_071888.1 myeloid leukemia factor 1	435 e-122
NP_034931.1				
		P58340	MLF1_HUMAN Myeloid leukemia factor 1 (Myelodysplasia-myeloid leukemia factor 1)	435 e-122
		AAA99997.1	t(3;5)(q25.1;p34) fusion gene	435 e-122
		AAH07045.1	AAH07045 myeloid leukemia factor 1	435 e-122
		BAC04885.1	unnamed protein product	396 e-110
		BAB71320.1	unnamed protein product	383 e-106
NM_028784	Mm.17403	F:(C-IR) -2.01	CAC36886.1 bA525O21.1 (coagulation factor XIII, A1 polypeptide)	482 e-135
NP_083060.1				
		IFI3	A Chain A, Recombinant Human Cellular Coagulation Factor XIII	482 e-135
		IFI3	B Chain B, Recombinant Human Cellular Coagulation Factor XIII	482 e-135
		IGGT	A Chain A, Coagulation Factor XIII (A-Subunit Zymogen) (E.C.2.3.2.13) (Protein- Glutamine Gamma-Glutamyltransferase A Chain)	482 e-135
		IGGT	B Chain B, Coagulation Factor XIII (A-Subunit Zymogen) (E.C.2.3.2.13) (Protein- Glutamine Gamma-Glutamyltransferase A Chain)	482 e-135
		IGGU	B Chain B, Human Factor XIII With Calcium Bound In The Ion Site	482 e-135
		IGGY	B Chain B, Human Factor XIII With Ytterbium Bound In The Ion Site	482 e-135
		IQRK	B Chain B, Human Factor XIII With Strontium Bound In The Ion Site	482 e-135

	IGGY	A Chain A, Human Factor XIII With Ytterbium Bound In The Ion Site	482 e-135
	IGGU	A Chain A, Human Factor XIII With Calcium Bound In The Ion Site	482 e-135
IQRK		A Chain A, Human Factor XIII With Strontium Bound In The Ion Site	482 e-135
XP_165833.1	similar to coagulation factor XIII, A1 polypeptide		482 e-135
AAL12161.1	AF418272_1 coagulation factor XIII, A1 polypeptide		482 e-135
AAA52415.1	factor XIII a subunit		481 e-135
IEVU	A Chain A, Human Factor XIII With Calcium Bound In The Ion Site		481 e-135
IEVU	B Chain B, Human Factor XIII With Calcium Bound In The Ion Site		481 e-135
NP_000120.1	coagulation factor XIII A1 subunit precursor; Coagulation factor XIII, A polypeptide; Tgase		481 e-135
AAA52488.1	clotting factor XIIIa precursor (EC 2.3.2.13)		481 e-135
P00488	F13A_HUMAN Coagulation factor XIII A chain precursor (Protein-glutamine gamma-glutamyltransferase A chain) (Transglutaminase A chain)		481 e-135
EKHUX	protein-glutamine gamma-glutamyltransferase (EC 2.3.2.13), plasma		481 e-135
IFIE	B Chain B, Recombinant Human Coagulation Factor XIII		481 e-135
IFIE	A Chain A, Recombinant Human Coagulation Factor XIII		481 e-135
AAA52489.1	factor XIII precursor		481 e-135
AAH27963.1	coagulation factor XIII, A1 polypeptide		480 e-135
Mm_010439	NP_0021119.1	high-mobility group box 1; high-mobility group box 1; high-mobility group (nonhistone chromosomal) protein 1	324 3.00E-88
NP_034569.1	-2		
	P09429	HMG1_HUMAN High mobility group protein 1 (HMG-1)	324 3.00E-88
	S02826	nonhistone chromosomal protein HMG-1	324 3.00E-88
	CAA31110.1	HMG-1 protein (AA 1-215)	324 3.00E-88
	AAB08987.1	on-histone chromatin protein HMG1	324 3.00E-88
	AAH03378.1	AAH03378 high-mobility group (nonhistone chromosomal) protein 1	324 3.00E-88
	AAH30981.1	high-mobility group (nonhistone chromosomal) protein 1	324 3.00E-88
	BAA09924.1	HMG-1	321 3.00E-87
	S29857	nonhistone chromosomal protein HMG-1	318 2.00E-86
CAB92731.1	dJ579F20.1 (high-mobility group (nonhistone chromosomal) protein 1-like 1)	310 7.00E-84	
Q9UGV6	HM1X_HUMAN High mobility group protein 1-like 10 (HMG-1L10)	301 2.00E-81	
CAB62951.1	bK445C9.3 (high-mobility group (nonhistone chromosomal) protein 1-like 10)	301 2.00E-81	

		AAF19244.1	AC007277_1 similar to nonhistone chromosomal protein HMG-1 [Homo sapiens]; probable pseudogene; similar to P09429 (PID:g123369)	285 2.00E-76
		AAH00903.2	AAH00903 high-mobility group (nonhistone chromosomal) protein 2	283 1.00E-75
		NP_002120.1	high-mobility group box 2; high-mobility group (nonhistone chromosomal) protein 2	283 1.00E-75
		P26583	HMG2_HUMAN High mobility group protein 2 (HMG-2)	283 1.00E-75
		NSHUH2	nonhistone chromosomal protein HMG-2	283 1.00E-75
		CAA44395.1	HMG-2	283 1.00E-75
		AAA58659.1	high mobility group 2 protein	283 1.00E-75
		AAH01063.1	AAH01063 high-mobility group (nonhistone chromosomal) protein 2	283 1.00E-75
		2001363A	high mobility group protein 2	283 1.00E-75
		XP_086648.2	similar to dJ579P20.1 (high-mobility group (nonhistone chromosomal) protein 1-like 1)	250 7.00E-66
		NP_0053333.1	high-mobility group box 3; high-mobility group (nonhistone chromosomal) protein 4	244 4.00E-64
		O15347	HMG4_HUMAN High mobility group protein 4 (HMG-4) (High mobility group protein 2a) (HMG-2a)	244 4.00E-64
		CAA71143.1	high mobility group protein 2a	244 4.00E-64
		P00746	CFAD_HUMAN Complement factor D precursor (C3 convertase activator) (Properdin factor D) (Adipsin)	370 e-102
NM_013459	Mm.4407	F(C-IR)-2.13	CAC48304.1 adipsin/complement factor D precursor	358 4.00E-99
NP_038487.1			DBHU complement factor D (EC 3.4.21.46) precursor [validated]	352 5.00E-97
		1FDP	A Chain A, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	340 1.00E-93
		1FDP	B Chain B, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	340 1.00E-93
		1FDP	D Chain D, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	340 1.00E-93
		1FDP	C Chain C, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	340 1.00E-93
		AAH34529.1	Unknown (protein for IMAGE:4780594)	340 1.00E-93
		1DST	Mutant Of Factor D With Enhanced Catalytic Activity	330 1.00E-90

		IBIO	Human Complement Factor D In Complex With Isatoic Anhydride Inhibitor	329 4.00E-90
	IDIC	A Chain A, Structure Of 3,4-Dichloroisocoumarin-Inhibited Factor D		329 4.00E-90
	IDSU	A Chain A, Human Factor D, Complement Activating Enzyme		329 4.00E-90
	IHFID	Human Complement Factor D In A P21 Crystal Form		329 4.00E-90
	IDFP	A Chain A, Factor D Inhibited By Diisopropyl Fluorophosphate		329 4.00E-90
	IDFP	B Chain B, Factor D Inhibited By Diisopropyl Fluorophosphate		329 4.00E-90
	IDSU	B Chain B, Human Factor D, Complement Activating Enzyme		329 4.00E-90
	XP_084037.1	similar to Complement factor D precursor (C3 convertase activator) (Properdin factor D) (Adipsin)		328 8.00E-90
	NP_001919.1	adipsin/complement factor D precursor		324 1.00E-88
	AAA35527.1	adipsin/complement factor D		324 1.00E-88
AK017926	Mm.21697 F:(C-D) - 2.38	NP_061931.1 RTP801		372 e-103
BAB31006.1				
		BAA91214.1 unnamed protein product		372 e-103
		AAH07714.1 hypothetical protein		372 e-103
		AAH15236.1 hypothetical protein		372 e-103
		AAL38424.1 RTP801		372 e-103
		AAM10442.1 REDD-1		372 e-103
		CAB66603.1 hypothetical protein		370 e-102
NM_007706	Mm.4132 F:(C-D) - 2.03	NP_003868.1 suppressor of cytokine signaling-2; STAT induced STAT inhibitor-2; cytokine-inducible SH2 protein 2		364 e-100
NP_031732.1		XP_170547.1 similar to Suppressor of cytokine signaling 2 (SOCS-2) (Cytokine-inducible SH2 protein 2) (CIS-2) (STAT induced STAT inhibitor 2) (SSI-2)		364 e-100
	O14508	SOC2_HUMAN Suppressor of cytokine signaling 2 (SOCS-2) (Cytokine-inducible SH2 protein 2) (CIS-2) (STAT induced STAT inhibitor 2) (SSI-2)		364 e-100
	BAA22429.1	STAT induced STAT inhibitor-2		364 e-100
	AAC34745.1	STAT-induced STAT inhibitor-2		364 e-100
	AAH10399.1	STAT induced STAT inhibitor-2		364 e-100
	JC5626	STAT induced STAT inhibitor 2		361 e-100
	JCS760	cytokine-inducible SH2 protein 2		360 3E-99
	BAA22536.1	CIS2		359 4E-99

AK017895	Mm.56539	F;(C-D) - 2.02	AAC98896.1	suppressor of cytokine signalling-2; HSSOCS-2; unknown	350	3E-96
XP_132692.1					317	e-136
			XP_057054.6	similar to SET domain and mariner transposase fusion gene	317	e-136
			AAH11635.1	Similar to SET domain and mariner transposase fusion gene	317	e-136
			NP_006506.1	SET domain and mariner transposase fusion gene	313	e-135
			AAC52012.1	orf; encodes putative chimeric protein with SET domain in N-terminus with similarity to several other human, Drosophila, nematode and yeast proteins	313	e-135
NM_011638	Mm.26069	F;(C-D) - 2.02	NP_003225.1	transferrin receptor (p90, CD71); Transferrin receptor	1196	0
NP_035768.1			P02786	TFR1_HUMAN Transferrin receptor protein 1 (TFR1) (TR) (TFR) (Trf) (CD71 antigen) (T9) (p90)	1196	0
			JXHU	transferrin receptor	1196	0
			CAA2527.1	put. transferrin receptor (aa 1-760)	1196	0
			AAA61153.1	transferrin receptor	1196	0
			1011297A	transferrin receptor	1196	0
			AAF04564.1	AF187320_1 transferrin receptor	1195	0
			AAH01188.1	AAH01188 transferrin receptor (p90, CD71)	1195	0
			1DE4	C Chain C, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor	1023	0
			1DE4	F Chain F, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor	1023	0
			1DE4	I Chain I, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor	1023	0
			1CX8	A Chain A, Crystal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
			1CX8	B Chain B, Crystal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
			1CX8	C Chain C, Crystal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
			1CX8	D Chain D, Crystal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
			1CX8	E Chain E, Crystal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
			1CX8	F Chain F, Crystal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
			1CX8	G Chain G, Crystal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
			1CX8	H Chain H, Crystal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0

		Q9UP52	TFR2 HUMAN Transferrin receptor protein 2 (TFR2)	545 e-154
	AAD45561.1	AF067864_1 transferrin receptor 2 alpha		545 e-154
NP_003218.1	transferrin receptor 2			498 e-140
AAC78796.1	transferrin-receptor2			498 e-140
BAA91153.1	unnamed protein product			315 2.00E-85
AAC83972.1	prostate-specific membrane antigen			228 2.00E-59
NP_004467.1	folate hydrolase (prostate-specific membrane antigen) 1; folate hydrolase 1 (prostate-specific membrane antigen)			228 3.00E-59
Q04609	FOH1_HUMAN Glutamate carboxypeptidase II (Membrane glutamate carboxypeptidase) (mGCP) (N-acetylated-alpha-linked acidic dipeptidase 1) (NAALADase 1) (Pteroylpoly-gamma-glutamate carboxypeptidase) (Folypoly-gamma-glutamate carboxypeptidase) (FGCP) (Folate hydrolase 1) (Prostate-specific membrane antigen) (PSMA) (PSM)			228 3.00E-59
A56881	prostate-specific membrane antigen			228 3.00E-59
AAA60209.1	prostate-specific membrane antigen			228 3.00E-59
AAD51121.1	AF176574_1 folypoly-gamma-glutamate carboxypeptidase			228 3.00E-59
AAM34479.1	prostate-specific membrane antigen			228 3.00E-59
XP_165392.1	similar to folate hydrolase (prostate-specific membrane antigen) 1; folate hydrolase 1 (prostate-specific membrane antigen)			224 6.00E-58

**Subtable 1B: Unfavorable Genes and Proteins**

Mouse Gene Protein	Unigene	Behavior	Human Proteins	Human Protein Name	Score (bits)	E-value
NM_007588						
NP_031614.1	Mn.4642	U;(IR-D) 3.8	AAC50300.1	calcitonin receptor	758	0
			BAA86929.1	calcitonin receptor	758	0
			BAA86928.1	calcitonin receptor	758	0
			NP_001733.1	calcitonin receptor	754	0
			I37217	calcitonin receptor	754	0
			CAA49541.1	human calcitonin receptor	754	0
			CAA57849.1	truncated isomer of calcitonin receptor	754	0
			AAB82945.1	Calcitonin Receptor, alternatively spliced form	754	0
			P30988	CALR_HUMAN Calcitonin receptor precursor (CT-R)	748	0
			S34486	calcitonin receptor	748	0
			AAA35640.1	calcitonin receptor	748	0
			AAB83944.1	Calcitonin Receptor, alternatively spliced form	744	0
			AAC50301.1	calcitonin receptor isoform	731	0
			NP_005786.1	calcitonin receptor-like	511	e-144
			Q16602	CGRR_HUMAN Calcitonin gene-related peptide type 1 receptor precursor (CGRP type 1 receptor)	511	e-144
			JC2477	calcitonin receptor-like protein	511	e-144
			AAA62158.1	calcitonin-like receptor	511	e-144
			AAC41994.1	CGRP type 1 receptor	511	e-144
			NP_000307.1	parathyroid hormone receptor 1	237	1.00e-61
			Q03431	PTPR_HUMAN Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTTH/PTHr receptor)	237	1.00e-61

	A49191	parathyroid hormone/PTH-related peptide receptor	237	1.00e-61	
	AAA36525.1	parathyroid hormone receptor	237	1.00e-61	
	CAA48589.1	parathyroid hormone receptor	237	1.00e-61	
	AAA56774.1	parathyroid hormone/parathyroid hormone related peptide receptor	237	1.00e-61	
	AAB60657.1	parathyroid hormone/PTH-related peptide receptor	237	1.00e-61	
	21119172A	parathyryin receptor	237	1.00e-61	
		CRF2_HUMAN Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (Q133324)	221	6.00e-57	
		(CRF2) (Corticotropin-releasing hormone receptor 2) (CRH-R 2)	221	6.00e-57	
	AAC71653.1	corticotropin-releasing factor receptor	221	6.00e-57	
	BAC05922.1	seven transmembrane helix receptor	221	6.00e-57	
	AAB94503.1	corticotropin releasing hormone receptor type 2 beta isoform	221	8.00e-57	
		corticotropin releasing hormone receptor type 2 gamma isoform; CRH type 2 gamma receptor	220	1.00e-56	
		AAC71654.1 (PID:g2738889)	corticotropin releasing hormone receptor type 2 gamma isoform; match to AF019381	220	1.00e-56
AK007657	U:(IR-D) 3.55				
BAB25167.1	Mm.45138	NP_115744.2	leucine zipper and CTNNBIP1 domain containing	305	9.00e-83
		BAB72100.1	Leucine zipper & ICAT homologous protein LZIC	305	9.00e-83
AK007999					
BAB25399.1	Mm.35718	U:(IR-D) 3.3			
AF282730	AAF97239.1	U:(IR-D) 2.78	XP_114275.1 similar to RIKEN cDNA 2010001C09	244	1.00e-64
			TIM4_HUMAN Metalloproteinase inhibitor 4 precursor (TIMP-4) (Tissue inhibitor of metalloproteinases-4) (Q99727)	409	e-114
			AAB40391.1 tissue inhibitor of metalloproteinase 4	409	e-114
			AAC34422.1 tissue inhibitor of metalloproteinase 4	409	e-114
			AAH10553 AAH10553 tissue inhibitor of metalloproteinase 4	409	e-114

		NP_003246.1	tissue inhibitor of metalloproteinase 2 precursor	216	3.00e-56
	P16035	TIM2_HUMAN Metalloproteinase inhibitor 2 precursor (TIMP-2) (Tissue inhibitor of metalloproteinases-2) (CSC-21K)		216	3.00e-56
	A37128	metalloproteinase inhibitor 2 precursor		216	3.00e-56
	AAB19474.1	tissue inhibitor of metalloproteinase 2; TIMP-2		216	3.00e-56
	AAA5581.1	metalloproteinase inhibitor precursor		216	3.00e-56
	AAA61186.1	metalloproteinase-2 inhibitor precursor		216	3.00e-56
	AAC50729.1	tissue inhibitor of metalloproteinases-2		216	3.00e-56
	1GXD	C Chain C, Prommp-2/TIMP-2 Complex		214	1.00e-55
	1GXD	D Chain D, Prommp-2/TIMP-2 Complex		214	1.00e-55
	1BR9	Human Tissue Inhibitor Of Metalloproteinase-2		214	1.00e-55
	AAB24785.1	TIMP-2, CSC-21K=tissue inhibitor of metalloproteinase		211	9.00e-55
	AAA21815.1	metalloproteinase-3 tissue inhibitor		200	3.00e-51
	NP_000353.1	tissue inhibitor of metalloproteinase 3; Tissue inhibitor of metalloproteinase-3; K2222 expressed in degenerative retinas		199	4.00e-51
	P35625	TIM3_HUMAN Metalloproteinase inhibitor 3 precursor (TIMP-3) (Tissue inhibitor of metalloproteinases-3) (MIG-5 protein)		199	4.00e-51
	S45317	metalloproteinase inhibitor 3 precursor		199	4.00e-51
	AAA17672.1	tissue inhibitor of metalloproteinase-3 precursor		199	4.00e-51
	CAA53813.1	tissue inhibitor of metalloproteinases-3		199	4.00e-51
	AAB60373.1	tissue inhibitor of metalloproteinases-3		199	4.00e-51
	AAB34532.1	TIMP-3		199	4.00e-51
	AAC50393.1	tissue inhibitor of metalloproteinases-3		199	4.00e-51
	AAB07547.1	tissue inhibitor of metalloproteinase-3		199	4.00e-51
	AAH14277.1	AAH14277 Similar to tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory)		199	4.00e-51
	CAA38400.1	Tissue inhibitor of metalloproteinases, Type-2		199	6.00e-51

NM_008302		U:(IR-D)		heat shock 90kDa protein 1, beta; heat shock 90kD protein 1, beta; Heat-shock 90kD protein-1, beta	1202	0
NP_032328.1	Mm.2180	2.71	NP_031381.2	HS9B HUMAN Heat shock protein HSP 90-beta (HSP 84) (HSP 90)	1202	0
		P08238			1202	0
		AAA36026.1	90 kD heat shock protein		1202	0
		AAH04928.1	AAH04928 Unknown (protein for MGC:10493)		1202	0
		AAH12807.1	AAH12807 Unknown (protein for MGC:3483)		1202	0
		AAH14485.1	AAH14485 Unknown (protein for MGC:23206)		1202	0
		AAH16753.1	AAH16753 Unknown (protein for MGC:1138)		1202	0
		HHHU84	heat shock protein 90-beta [validated]		1197	0
		AAA36025.1	90kDa heat shock protein		1197	0
		1307197A	heat shock protein 90k		1197	0
		T46243	hypothetical protein DKFZp761K0511.1		1170	0
		CAB66478.1	hypothetical protein		1170	0
		NP_005339.1	heat shock 90kDa protein 1, alpha; heat shock 90kD protein 1, alpha		1099	0
		HHHU86	heat shock protein 90-alpha		1099	0
		AAA63194.1	heat shock protein		1099	0
		AAF82792.1	AF275719_1 chaperone protein HSP90 beta		1052	0
		AAH09206.1	AAH09206 heat shock 90kD protein 1, beta		1052	0
		AAH23006.1	Unknown (protein for MGC:30059)		961	0
		AAH09987.1	AAH09987 Unknown (protein for IMAGE:3446372)		800	0
		AAC25497.1	Hsp89-alpha-delta-N		750	0
		AAH07989.1	AAH07989 Similar to heat shock 90kD protein 1, alpha		696	0
NM_009056		U:(IR-D)		regulatory factor X2, isoform b; trans-acting regulatory factor 2; DNA binding protein RFX2	1166	0
NP_033082.1	Mm.102	2.63	NP_602309.1	RFX2; HLA class II regulatory factor RFX2	1153	0
			P483378	RFX2 HUMAN DNA-binding protein RFX2	1153	0
			B55926	DNA binding protein RFX2	1153	0

		CAA53705.1	DNA binding protein RFX2		1153	0
		NP_000626.2	regulatory factor X2, isoform a; trans-acting regulatory factor 2; DNA binding protein RFX2; HLA class II regulatory factor RFX2		1152	0
		AAH28579.1	regulatory factor X, 2 (influences HLA class II expression)		1151	0
		NP_602304.1	regulatory factor X3 isoform b; DNA binding protein RFX3		773	0
		AAH22191.1	AAH22191 Unknown (protein for MGC:3664)		773	0
		NP_002910.1	regulatory factor X3 isoform a; DNA binding protein RFX3		751	0
	P48380	RFX3_HUMAN	DNA-binding protein RFX3		751	0
	D55926		DNA binding protein RFX3		751	0
	CAA53706.1		DNA binding protein RFX3		751	0
	P22670		RFX1_HUMAN MHC class II regulatory factor RFX1 (RFX) (Enhancer factor C) (EF-C)		686	0
	A35913		regulatory factor X		686	0
	CAA41730.1		MHC class II regulatory factor RFX		686	0
	NP_002909.2		regulatory factor X1; trans-acting regulatory factor 1; enhancer factor C; MHC class II regulatory factor RFX		686	0
	CAC88163.1		bA32F11.1.2 (regulatory factor X, 3 (influences HLA class II expression), putative isoform 2)		507	e-143
	CAC88164.1		bA32F11.1.1 (regulatory factor X, 3 (influences HLA class II expression), isoform 1)		486	e-136
NM_026346	Mm.4046	U:(IR-D)	NP_478136.1	F-box only protein 32 isoform 1; muscle atrophy F-box protein; atrogin-1	710	0
NP_080622.1	6	2.28	Q969P5	FX32_HUMAN F-box only protein 32 (Muscle atrophy F-box protein) (MAFBx)	710	0
			AAL16407.1	muscle atrophy F-box protein (Atrogin-1)	710	0
			BAB71333.1	unnamed protein product	710	0
			CAD12251.1	F-box only 32	710	0
			BAB85128.1	F-box domain Fbx25-containing protein	446	e-124
			NP_680482.1	F-box only protein 32 isoform 2; muscle atrophy F-box protein; atrogin-1	422	e-117

		AAH24030.1	similar to RIKEN cDNA 4833442G10 gene	417	e-116
		AAF04526.1	AF174605_1 F-box protein Fbx25	354	4.00e-97
		NP_036305.1	F-box only protein 25; F-box protein Fbx25	353	6.00e-97
NM_009244	Mm.19341 NP_033270.1	U:(IR-D) 2.26	AAA51547.1 alpha-1-antitrypsin precursor	508	e-144
			AAH15642.1 Antiproteinase, antitrypsin, member 1	508	e-144
			1012287A antitrypsin alpha1 mutant	507	e-143
			A1AT_HUMAN Alpha-1-antitrypsin precursor (Alpha-1 protease inhibitor) (Alpha-1-antiproteinase) (PRO0684/PRO2209)	507	e-143
		P01069		507	e-143
		ITHU	alpha-1-antitrypsin precursor [validated]	507	e-143
		CAA25838.1	alpha 1-antitrypsin	507	e-143
		AAB53375.1	alpha-1-antitrypsin	507	e-143
		AAG35496.1	AF130117_27 PRO2209	507	e-143
		NP_000286.2	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1; Protease inhibitor (alpha-1-antitrypsin); protease inhibitor 1 (anti-elastase), alpha-1-antitrypsin	506	e-143
			AAH11991 Similar to serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1	506	e-143
		AAH11991.1		506	e-143
		AAF29581.1	AF113676_1 PRO0684	504	e-142
		AAB59495.1	alpha-1-antitrypsin	504	e-142
		AAA51546.1	alpha-1-antitrypsin	501	e-141
		1HP7	Chain A, A 2.1 Angstrom Structure Of An Uncleaved Alpha-1- Antitrypsin Shows Variability Of The Reactive Center And Other Loops	499	e-141
		1KCT	Alpha 1-Antitrypsin	498	e-141
NM_009194	U:(IR-D) 2.16	NP_001037.1	solute carrier family 12 (sodium/potassium/chloride transporters), member 2; Solute carrier family 12 (sodium/potassium/chloride transporters),	1978	0
NP_033220.1	Mm.4168				

	P55011	S122_HUMAN Solute carrier family 12 member 2 (Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1) (Basolateral Na-K-Cl symporter)	1978	0	
A57187		bumetanide-sensitive Na-K-Cl cotransporter	1978	0	
AAC 0561.1		bumetanide-sensitive Na-K-Cl cotransporter	1978	0	
AAH33003.1	2	Similar to solute carrier family 12 (sodium/potassium/chloride transporters), member 12	1851	0	
NP_ 000329.1		sodium potassium chloride cotransporter 2; Solute carrier family 12 (sodium/potassium/chloride transporters),	1294	0	
Q13621		S121_HUMAN Solute carrier family 12 member 1 (Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2) (Kidney-specific Na-K-Cl symporter)	1294	0	
AAB07364.1		bumetanide-sensitive Na-K-2Cl cotransporter	1294	0	
NP_ 000330.1		solute carrier family 12 (sodium/chloride transporters), member 3; Solute carrier family 12 (sodium/potassium/chloride transporters)	1028	0	
AAC50355.1		thiazide-sensitive Na-Cl	1028	0	
P55017		S123_HUMAN Solute carrier family 12 member 3 (Thiazide-sensitive sodium-chloride cotransporter) (Na-Cl symporter)	1024	0	
G01202		NaCl electroneutral Thiazide-sensitive cotransporter	1021	0	
CAA62613.1		NaCl electroneutral Thiazide-sensitive cotransporter	1021	0	
AAI32454.1	AF439152.1	sodium-potassium-chloride cotransporter	598	e-170	
PC4180		thiazide-sensitive sodium-chloride cotransporter	413	e-114	
AAH40138.1		Similar to solute carrier family 12 (sodium/potassium/chloride	403	e-111	
AAK21008.1		cation-chloride cotransporter-interacting protein 1	261	1.00e-68	
NM_ 009254	U(IR-D)	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6; protease inhibitor 6 (placental thrombin inhibitor)			
NP_ 033280.1	Mm2623	NP_ 004559.2	549	e-156	
		P35237	PT16_HUMAN Placental thrombin inhibitor (Cytoplasmic antiprotease) (CAP)(Protease inhibitor 6) (PI-6)	549	e-156
		AAB30320.1	cytoplasmic antiprotease; CAP	549	e-156

		AAH01394.1	AAH01394 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6	549	e-156
	A48681	placental thrombin inhibitor		548	e-156
	CAA80373.1	thrombin inhibitor		548	e-156
		serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8; protease inhibitor 8 (ovalbumin type)		459	e-129
NP_002631.1				459	e-129
P50452		SPB8_HUMAN Cytoplasmic antiproteinase 2 (CAP2) (CAP-2) (Protease inhibitor 8)(Serpin B8)		459	e-129
A59273		proteinase inhibitor 8		459	e-129
AAC41939.1		cytoplasmic antiproteinase 2		459	e-129
		serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; protease inhibitor 9 (ovalbumin type)		445	e-125
NP_004146.1				445	e-125
P50453		SPB9_HUMAN Cytoplasmic antiproteinase 3 (CAP3) (CAP-3) (Protease inhibitor 9)(Serpin B9)		445	e-125
B59273		proteinase inhibitor 9		445	e-125
AAC41940.1		cytoplasmic antiproteinase 3		445	e-125
AAC50793.1		serine proteinase inhibitor		445	e-125
AAH02538.1		AAH02538 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9		445	e-125
BAB91078.1		serine protease inhibitor 9		445	e-125
		serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1; protease inhibitor 2 (anti-elastase), monocyte/neutrophil; protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived		330	3.00e-90
NP_109591.1				330	3.00e-90
P30740		IL6U_HUMAN Leukocyte elastase inhibitor (LEI) (Monocyte/neutrophil elastase inhibitor) (M/NEI) (EI)		330	3.00e-90
S27383		elastase inhibitor		330	3.00e-90
AAC31394.1		monocyte/neutrophil elastase inhibitor		330	3.00e-90
AAH09015.1		AAH09015 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1		330	3.00e-90
XP_036951.4		similar to Squamous cell carcinoma antigen 2 (SCCA-2) (Leupin)		327	2.00e-89
P48594		SCC2_HUMAN Squamous cell carcinoma antigen 2 (SCCA-2) (Leupin)		327	2.00e-89

		CAA61420.1	leupin			327	2.00e-89
		AAA97553.1	squamous cell carcinoma antigen 2			327	2.00e-89
		AAA92602.1	squamous cell carcinoma antigen			327	2.00e-89
		BAB21525.1	squamous cell carcinoma antigen 2			327	2.00e-89
		AAH17401.1	AAH17401 Unknown (protein for MGC:27150)			327	2.00e-89
	I38202		leupin precursor			327	2.00e-89
	I38201		squamous cell carcinoma antigen 1			325	7.00e-89
		NP_008850.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3; squamous cell carcinoma antigen 1			325	9.00e-89
	P29508		SCC1_HUMAN Squamous cell carcinoma antigen 1 (SCCA-1) (Protein T4-A)			325	9.00e-89
		AAA86317.1	squamous cell carcinoma antigen			325	9.00e-89
		AAA97552.1	squamous cell carcinoma antigen 1			325	9.00e-89
		AAH05224.1	AAH05224 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3			325	9.00e-89
	AAB20405.1		squamous cell carcinoma antigen; SCC antigen			325	9.00e-89
NM_019431 NP_062304.1	Mm.1037 24	U:(IR-D) 2.09	NP_055220.1	voltage-dependent calcium channel gamma-4 subunit; neuronal voltage-gated calcium channel gamma-4 subunit		540	e-153
			Q9UBN1	CCG4_HUMAN Voltage-dependent calcium channel gamma-4 subunit (Neuronal voltage-gated calcium channel gamma-4 subunit)		540	e-153
			AAF03090.1	calcium channel gamma 4 subunit		540	e-153
			AAF14538.1	AF162692_1 putative voltage-gated calcium channel gamma-4 subunit		540	e-153
			AAH34532.1	calcium channel, voltage-dependent, gamma subunit 4		540	e-153
			NP_006069.1	voltage-dependent calcium channel gamma-2 subunit; stargazin; neuronal voltage-gated calcium channel gamma-2 subunit		303	2.00e-82
			Q9Y698	CCG2_HUMAN Voltage-dependent calcium channel gamma-2 subunit (Neuronal voltage-gated calcium channel gamma-2 subunit)		303	2.00e-82
			AAD22738.1	AF096322_1 neuronal voltage-gated calcium channel gamma-2 subunit		303	2.00e-82
			AAL50049.1	AF361354_1 voltage-dependent calcium channel gamma-8 subunit		302	4.00e-82

		NP_114101.4	voltage-dependent calcium channel gamma-8 subunit; neuronal voltage-gated calcium channel gamma-8 subunit	300	2.00e-81
	Q8WX55	CCG8_HUMAN	Voltage-dependent calcium channel gamma-8 subunit (Neuronal voltage-gated calcium channel gamma-8 subunit)	300	2.00e-81
	AAK20031.1	AF288388_1	calcium channel gamma subunit 8	300	2.00e-81
	NP_006530.1	CCG3_HUMAN	voltage-dependent calcium channel gamma-3 subunit; neuronal voltage-gated calcium channel gamma-3 subunit	298	8.00e-81
	O60359	CCG3_HUMAN	Voltage-dependent calcium channel gamma-3 subunit (Neuronal voltage-gated calcium channel gamma-3 subunit)	298	8.00e-81
	AAC15246.1	Unknown gene product		298	8.00e-81
	AAD22739.1	AF100346_1	neuronal voltage gated calcium channel gamma-3 subunit	298	8.00e-81
	AAF42975.1	AF134640_1	calcium channel gamma subunit 3	298	8.00e-81
	AAH40005.1	calcium channel, voltage-dependent, gamma subunit 3		298	8.00e-81
	XP_050231.1	similar to calcium channel gamma subunit 8		270	2.00e-72
	AAK15019.1	AF234892_1	putative voltage gated calcium channel gamma-8 subunit CACNG8		
NM_019999 NP_064383.1	Mm.1772_U(IR-D) 2.05	NP_072094.1	KIAA1184 protein	659	0
		AAH02937.1	AAH02937 Similar to hypothetical protein MNcb-5687	659	0
		BAA86498.1	KIAA1184 protein	579	e-165
		AAH36457.1	Unknown (protein for MGC:33461)	579	e-165
AK002297	Mm.18130_2	U:(C-IR) 6.3			
BAB21996.1		NP_060464.1	hypothetical protein FLJ10099		
		BAA91444.1	unnamed protein product	620	e-177
		AAH08675.1	hypothetical protein FLJ10099	620	e-177

			AAH12562.1	Similar to hypothetical protein FLJ10099	620	e-177
			AAH10519.1	Similar to hypothetical protein FLJ10099	385	e-106
NM_013744 NP_038772.1	Mm.7467 U:(C-IR) 6.11 U:(R-D) 2.04	NP_478137.1	zinc finger protein 354B		1031	0
			BAB71556.1	unnamed protein product	1031	0
			AAD05335.1	zinc finger protein EZNF	958	0
			NP_005640.1	transcription factor 17	957	0
			O60765	TC17_HUMAN Transcription factor 17 (Zinc finger protein eZNF)	957	0
			BAA25182.1	HKL1	957	0
			NP_009080.1	zinc finger protein 184 (Kruppel-like)	567	e-161
			AAH22992.1	Unknown (protein for MGC:29879)	567	e-161
			AAC51180.1	Kruppel-related zinc finger protein	567	e-161
			XP_166367.1	similar to Zinc finger protein 184	566	e-161
			Q99676	Z184_HUMAN Zinc finger protein 184	566	e-161
			CAA17278.1	b3418.1 (zinc finger protein 184 (Kruppel-like))	566	e-161
			XP_032054.2	similar to EZF1T-related protein 1	536	e-152
			AAK30252.1	AF352026_1 EZF1T-related protein 1	536	e-152
			CAD38551.1	hypothetical protein	536	e-152
			XP_091988.1	similar to zinc finger protein 91 (HPF7, HTE10)	533	e-151
			AAH36110.1	Similar to zinc finger protein 208	531	e-150
NM_018764 NP_061234.1	Mm.1196 4.56	NP_002580.2	protocadherin 7, isoform a precursor; BH-pcdh; BH-protocadherin (brain-heart); brain-heart protocadherin		1856	0
		O60245	PCH7_HUMAN Protocadherin 7 precursor (Brain-heart protocadherin) (BH-Pcdh)		1855	0
		BAA25194.1	PCDH7 (BH-Pcdh)a		1855	0
		NP_115832.1	protocadherin 7, isoform b precursor; BH-pcdh; brain-heart protocadherin; BH-protocadherin (brain-heart)		1838	0

	T00041	BH-protocadherin PCDH7 (clone BH-Pcdh-b)	1837	0
	BAA25195.1	PCDH7 (BH-Pcdh)b	1837	0
	NP_115833.1	protocadherin 7, isoform c precursor; BH-pcdh; brain-heart protocadherin; BH-protocadherin (brain-heart)	1691	0
	T00042	BH-protocadherin PCDH7 (clone BH-Pcdh-c)	1690	0
	BAA25196.1	PCDH7 (BH-Pcdh)c	1690	0
	NP_115796.1	protocadherin 1, isoform 2 precursor; protocadherin 42; cadherin-like protein 1	817	0
	AAH35812.1	Similar to protocadherin 1 (cadherin-like 1)	816	0
	NP_002578.1	protocadherin 1, isoform 1 precursor; protocadherin 42; cadherin-like protein 1	816	0
	Q08174	PCH1_HUMAN Protocadherin 1 precursor (Protocadherin 42) (PC42) (Cadherin-like protein 1)	816	0
	AAA36419.1	protocadherin 42	816	0
	NP_065136.1	protocadherin 9 precursor; cadherin superfamily protein VR4-11	575	e-163
	AAF89689.2	AF169692_1 protocadherin-9	575	e-163
U:(C-IR) 4.51	Mm.19038 U:(C-D) 2.06	gap junction protein, alpha 5, 40kDa (connexin 40); gap junction protein, alpha 5, 40kD (connexin 40)	580	e-165
NM_008121 NP_032147.1 6	P36382	CXA5_HUMAN Gap junction alpha-5 protein (Connexin 40) (Cx40)	580	e-165
	AAA91833.1	connexin 40	580	e-165
	AAD37801.1	AF151979_1 connexin 40	580	e-165
	AAA60457.2	connexin40	580	e-165
	AAH13313.1	gap junction protein, alpha 5, 40kD (connexin 40)	580	e-165
	I38429	connexin40	575	e-164
	NP_068773.2	gap junction protein, alpha 3, 46kDa (connexin 46); gap junction protein, alpha 3, 46kD (connexin 46)	301	1.00e-81
	CAC16957.1	bA26414.3 (novel connexin (gap junction protein)	301	1.00e-81
	Q9Y6H8	CXA3_HUMAN Gap junction alpha-3 protein (Connexin 46) (Cx46)	301	1.00e-81

		AAD42925.1	gap-junction protein alpha 3		301	1.00e-81
		NP_005258.1	gap junction protein, alpha 8, 50kDa (connexin 50); gap junction membrane channel protein alpha-8 (connexin 50); gap junction protein, alpha 8, 50kD (connexin 50)		299	4.00e-81
	139176		intrinsic membrane protein MP70		299	4.00e-81
		AAA77062.1	gap junction membrane channel protein alpha-8		299	4.00e-81
		P48165	CXA8_HUMAN Gap junction alpha-8 protein (Connexin 50) (Cx50) (Lens fiber protein MP70)		296	3.00e-80
		AAF32309.1	AF217524_1 gap junction protein alpha 8		296	3.00e-80
		AAK55516.1	AF271261_1 connexin 58		282	5.00e-76
		NP_110399.1	connexin 59; gap junction alpha 10		282	5.00e-76
		P57773	CXAA_HUMAN Gap junction alpha-10 protein (Connexin 59) (Cx59)		282	5.00e-76
		AAG0406.1	AF179597_1 connexin 59		282	5.00e-76
		AAD56533.1	AF180815_1 truncated connexin 37 polymorph		270	2.00e-72
		NP_115991.1	connexin 62		267	2.00e-71
		AAK51676.1	AF296766_1 connexin 62		267	2.00e-71
		CAC93847.1	connexin62		267	2.00e-71
		NM_008314	U:(C-IR) 4.49 U:(C-D)			
	NP_032340.1	Mm.4835	I37107	5-HT5A serotonin receptor	584	e-166
				CAA57168.1	5-HT5A serotonin receptor	
				AAM21132.1	5-hydroxytryptamine receptor 5A	
				BAA94458.1	5-hydroxytryptamine (serotonin) receptor 1E	
				NP_000856.1	5-hydroxytryptamine (serotonin) receptor 1E	
				P28566	5H1E_HUMAN 5-hydroxytryptamine 1E receptor (5-HT-1E) (Serotonin receptor) (5-HT1E) (S31)	
				A45260	serotonin receptor 1E	

	CAA77558.1	serotonin receptor		212	2.00e-54
	AAA58353.1	serotonin receptor		212	2.00e-54
	AAA58355.1	serotonin receptor		212	2.00e-54
	CAC10582.1	bA76H14.2 (5-hydroxytryptamine (serotonin) receptor 1E)		212	2.00e-54
	AAM21127.1	AF498980_1 5-hydroxytryptamine receptor 1E		212	2.00e-54
	NP_000857.1	5-hydroxytryptamine (serotonin) receptor 1F; 5-hydroxytryptamine receptor 1F		209	1.00e-53
	P30939	5H1F_HUMAN 5-hydroxytryptamine 1F receptor (5-HT-1F) (Serotonin receptor)		209	1.00e-53
	A47321	serotonin receptor 1F		209	1.00e-53
	AAA36605.1	serotonin receptor		209	1.00e-53
	AAA36646.1	serotonin receptor		209	1.00e-53
	AAM21128.1	AF498981_1 5-hydroxytryptamine receptor 1F		209	1.00e-53
	BAA90453.1	5-hydroxytryptamine (serotonin) receptor 1F		209	1.00e-53
		similar to 5-hydroxytryptamine 1A receptor (5-HT-1A) (Serotonin receptor)			
	XP_003692.2	5H1A_HUMAN 5-hydroxytryptamine 1A receptor (5-HT-1A) (Serotonin receptor) (5-HT1A)(G-21)		205	1.00e-52
	P08908	5H1A_HUMAN 5-hydroxytryptamine 1A receptor (5-HT-1A) (Serotonin receptor) (5-HT1A)(G-21)		205	1.00e-52
	I38209	serotonin receptor 1A		205	1.00e-52
	CAA40962.1	serotonin 5-HT1a receptor		205	1.00e-52
	AAA66493.1	serotonin receptor		205	1.00e-52
	BAA94488.1	serotonin receptor 1A		205	1.00e-52
	AAM21125.1	AF498978_1 5-hydroxytryptamine receptor 1A		205	1.00e-52
	XP_092299.1	similar to KIAA0622 protein - human (fragment)		205	1.00e-52
	NP_000854.1	5-hydroxytryptamine (serotonin) receptor 1B; 5-HT1B; 5-HT1DB		204	2.00e-52
		5H1B_HUMAN 5-hydroxytryptamine 1B receptor (5-HT-1B) (Serotonin receptor)(5-HT-1D-beta) (Serotonin 1D beta receptor) (S12)		204	2.00e-52
	JN0268	serotonin receptor 1B		204	2.00e-52
	AAA58675.1	serotonin 1Db receptor		204	2.00e-52

		AAA36029.1	serotonin receptor		204	2.00e-52
		AAA36030.1	5-hydroxytryptamine 1D receptor		204	2.00e-52
		BAA01763.1	serotonin 1B receptor		204	2.00e-52
		AAA60316.1	serotonin 1D receptor		204	2.00e-52
		CAB51537.1	dJ501M23.1 (5-hydroxytryptamine (serotonin) receptor 1B)		204	2.00e-52
		BAA94455.1	5-hydroxytryptamine (serotonin) receptor 1B		204	2.00e-52
		2209242B	serotonin receptor;ISOTYPE=1D-beta		204	2.00e-52
		NP_000515.1	5-Hydroxytryptamine (serotonin) receptor 1A		202	2.00e-51
		CAA31908.1	receptor protein (AA 1 - 421)		202	2.00e-51
		AAA36440.1	guanine nucleotide-binding regulatory protein-coupled receptor		202	2.00e-51
		1311340A	G protein coupled receptor		202	2.00e-51
NM_009183	U:(C-IR) 4.19					
NP_033209.1	U:(C-D) 2.35	Mm.10701	NP_005659.1	sialyltransferase 8D (alpha-2, 8-polysialyltransferase); Polysialyltransferase; sialyltransferase 8 (alpha-2, 8-polysialyltransferase) D	714	0
			Q92187	S18D_HUMAN CMP N-acetylneuraminate-poly-alpha-2,8-sialyl transferase (Alpha-2,8-sialyltransferase 8D) (ST8Sia IV) (Polysialyltransferase-1)	714	0
			159403	alpha-2,8-polysialyltransferase	714	0
			AAC41775.1	alpha-2,8-polysialyltransferase	714	0
			2116443A	polysialyltransferase	714	0
			NP_006002.1	sialyltransferase 8B (alpha-2, 8-sialyltransferase); Sialyltransferase X; sialyltransferase 8 (alpha-2, 8-sialyltransferase) B	429	e-119
			Q92186	S18B_HUMAN Alpha-2,8-sialyltransferase 8B (ST8Sia II) (Sialyltransferase X)(STX)	429	e-119
			139169	sialyltransferase	429	e-119
			AAC24458.1	sialyltransferase	429	e-119
			AAB51242.1	sialyltransferase X	429	e-119
			2123358A	sialyltransferase STX	429	e-119
			B54898	STX protein	330	2.00e-89

		AAA36613.1	sialyltransferase	330	2.00e-89
		AAH27866.1	Similar to sialyltransferase 8D (alpha-2, 8-polysialyltransferase)	320	1.00e-86
		AAC15901.1	alpha-2,8-sialyltransferase III	219	3.00e-56
			sialyltransferase 8C (alpha2,3Galbeta1,4GlcNAcalpha 2,8-sialyltransferase); alpha-2,8-sialyltransferase III	215	8.00e-55
		NP_056963.1		215	8.00e-55
	O43173	S18C_HUMAN Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R-alpha 2,8-sialyltransferase (Alpha-2,8-sialyltransferase 8C) (ST8Sia III)		215	8.00e-55
	AAB87642.1	Sia alpha2,3Galbeta1,4GlcNAcalpha 2,8-sialyltransferase		215	8.00e-55
NM_009520	U:(C-IR) 4.15 U:(C-D) 3.21		wingless-type MMTV integration site family, member 2B, isoform WNT-2B; wingless-type MMTV integration site family, member 13; XWNT2, Xenopus, homolog of	726	0
NP_033546.1	Mm.10740	NP_078613.1		726	0
		Q93097	WN2B_HUMAN WNT-2B protein precursor (WNT-13)	726	0
		BAB11985.1	WNT-2B Isoform 2	726	0
			wingless-type MMTV integration site family, member 2B, isoform WNT-2B1; wingless-type MMTV integration site family, member 13; XWNT2, Xenopus, homolog of	702	0
		NP_004176.2		702	0
		BAB11984.1	WNT-2B Isoform 1	702	0
		T09612	secreted glycoprotein Wnt-13	696	0
		CAA96283.1	Wnt-13	696	0
		NP_0033382.1	wingless-type MMTV integration site family member 2 precursor; int-1 related protein; oncogene INT1-like 1; secreted growth factor	535	e-152
		P09544	WNT2_HUMAN WNT-2 protein precursor (Int-1 related protein)	535	e-152
		S00834	int-1-like protein 1 precursor	535	e-152
		CAA30725.1	Irp protein (AA 1-360)	535	e-152
		AAH29854.1	wingless-type MMTV integration site family member 2	535	e-152
		AAB67043.1	secreted growth factor	404	e-112
		NP_0033383.1	wingless-type MMTV integration site family, member 5A precursor; proto-oncogene Wnt-5A precursor; WNT-5A protein precursor	360	2.00e-99

	P41221	WNT5A_HUMAN WNT-5A protein precursor	360	2.00e-99
	A48914	proto-oncogene Wnt-5A precursor	360	2.00e-99
	AAA16842.1	hWNT5A	360	2.00e-99
		wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein precursor	358	1.00e-98
NP_116031.1			358	1.00e-98
NP_110402.2		wingless-type MMTV integration site family, member 5B precursor;	358	1.00e-98
		WNT-5B protein precursor	358	1.00e-98
	Q9H1J7	WNT5B_HUMAN WNT-5B protein precursor	358	1.00e-98
	AAH01749.1	AAH01749 Similar to wingless-related MMTV integration site 5B	358	1.00e-98
	BAB62039.1	WNT5B	358	1.00e-98
	NP_478679.1	wingless-type MMTV integration site family, member 7B precursor	355	1.00e-97
	P56706	WNT7B_HUMAN WNT-7B protein precursor	355	1.00e-97
	BAB68399.1	WNT7B	355	1.00e-97
	AAH34923.1	wingless-type MMTV integration site family, member 7B	355	1.00e-97
	AAN32640.1	AF416743_1 WNT7B	355	1.00e-97
	NP_004616.2	wingless-type MMTV integration site family, member 7A precursor; proto-oncogene Wnt7a protein	348	1.00e-95
	AAH08811.1	Unknown (protein for MGC:10346)	348	1.00e-95
	AAG38659.1	WNT5b precursor	348	2.00e-95
	U:(C-IR) 3.61			
	U:(C-D) 2.66			
	U:(IR-D) 2.42			
AK011231	Mm_22533	NP_055330.1		
BAB27481.1		AAF29827.1	AF180473_1 Not2p	877 0
		AAH02597.1	CCR4-NOT transcription complex, subunit 2; NOT2 (negative regulator of transcription 2, yeast) homolog	877 0
				877 0

		AAH11826.1	Similar to CCR4-NOT transcription complex, subunit 2	877	0
		BAA91313.1	unnamed protein product	751	0
		AAF29095.1	AF161480_1 HS PC131	729	0
		AAG32297.1	AF113226_1 MSTP046	728	0
		T46494	hypothetical protein DKFZp434M0572.1	326	8.00e-89
		CAB70869.1	hypothetical protein	326	8.00e-89
NM_009613	U:(C-IR) 3.6				
NP_0333743.1	Mm 89854 U:(C-D) 2.86	NP_002381.2	a disintegrin and metalloprotease domain 11, isoform 1 preprotein; metalloproteinase-like, disintegrin-like, cysteine-rich protein	1454	0
		BAA32352.1	MD/C/ADAM11	1454	0
		O75078	AD11_HUMAN ADAM 11 precursor (A disintegrin and metalloproteinase domain 11) (Metalloproteinase-like, disintegrin-like, and cysteine-rich protein) (MD/C)	1451	0
		I65967	disintegrin-like metalloproteinase (EC 3.4.24.-), splice form 2	1345	0
		BAA06670.1	metalloprotease/disintegrin-like protein	1340	0
		NP_067625.1	a disintegrin and metalloprotease domain 11, isoform 2 preprotein; metalloproteinase-like, disintegrin-like, cysteine-rich protein	1011	0
		S38539	disintegrin-like metalloproteinase (EC 3.4.24.-), splice form 1	1011	0
		AAB29191.1	MDC=metalloprotease/disintegrin-like cysteine-rich protein [human, cerebellum, Peptide, 524 aa]	1011	0
		BAA04213.1	MDC protein	1011	0
		BAA06671.1	metalloprotease/disintegrin-like protein	1008	0
		NP_068367.1	a disintegrin and metalloproteinase domain 22 isoform 5 preprotein; MD/C2 delta	825	0
		BAA32350.1	MD/C2 beta	825	0
		AAF22476.2	AF073291_1 MD/C2	825	0
		NP_057435.2	a disintegrin and metalloproteinase domain 22 isoform 3 preprotein; MD/C2 delta	825	0
		NP_068368.2	a disintegrin and metalloproteinase domain 22 isoform 2 preprotein; MD/C2 delta	825	0

AK_002979	Mm.19588	U:(C-IRR) 3.58					
BAB22492.1	1	U:(C-D) 2.07	NP_056537.1	calcyon		336	5.00e-92
			Q9NYX4	D1IP_HUMAN D1 dopamine receptor-interacting protein calcyon		336	5.00e-92
			AAF34714.1	AF225903_1 D1 dopamine receptor interacting protein calcyon		336	5.00e-92
			AAH38978.1	Similar to calcyon; D1 dopamine receptor-interacting protein		336	5.00e-92
NM_008714		U:(C-IRR) 3.55					
NP_032740.1	Mm.31255	U:(C-D) 2.19	P46531	NTC1_HUMAN Neurogenic locus notch homolog protein 1 precursor (Notch 1) (hN1) (Translocation-associated notch protein TAN-1)	4646	0	
			AAG33848.1	AF308602_1 NOTCH 1	4646	0	
			A40043	notch protein homolog TAN-1 precursor	4528	0	
			AAA60614.1	TAN1	4482	0	
			NP_077719.2	notch 2 preproprotein	2628	0	
			AAG37073.1	AF315356_1 NOTCH2 protein	2627	0	
			Q04721	NTC2_HUMAN Neurogenic locus notch homolog protein 2 precursor (Notch 2) (hN2)	2627	0	
			AAA36377.2	NOTCH 2	2627	0	
			AAC14346.1	Notch3	2065	0	
			NP_000426.1	Notch homolog 3	2065	0	
			Q9UM47	NTC3_HUMAN Neurogenic locus notch homolog protein 3 precursor (Notch 3)	2065	0	
			S78549	notch3 protein	2065	0	
			AAB91371.1	Notch3	2065	0	
			AAC15789.1	Notch 3	2065	0	
			NP_004548.1	Notch homolog 4 (Drosophila); Notch, drosophila, homolog of, 4; Notch (Drosophila) homolog 4	1023	0	
			Q99466	NTC4_HUMAN Neurogenic locus notch homolog protein 4 precursor (Notch 4) (hNotch4)	1023	0	

			AAC32288.1	Notch4		1023	0
AK012553		U:(C-IR) 3.54 U:(C-D) 2.46					
BAB28313.1	Mm.45628	NP_001575.1	chromosome 11 open reading frame 8; 239FB			627	e-180
		Q15777	239F_HUMAN Fetal brain protein 239			627	e-180
		AAC50564.1	239FB gene product			627	e-180
		AAH31582.1	chromosome 11 open reading frame 8			627	e-180
		2122285A	239FB gene			627	e-180
		NP_001576.2	chromosome 22 open reading frame 1; 239AB			518	e-147
		O15442	239A_HUMAN Adult brain protein 239			518	e-147
		AAC51673.2	239AB			518	e-147
		AAH28035.1	Unknown (protein for MGC:40027)			518	e-147
		CAC48257.1	dJ873F21.1 (brain protein 239)			284	2.00e-76
		CAC10467.1	dJ710M3.1 (chromosome 11 open reading frame 8(Fetal brain protein 239))			253	5.00e-67
NM_007412		U:(C-IR) 3.52 U:(C-D) 3.08		adenomedullin receptor; G-protein-coupled receptor similar to the adenomedullin receptor		563	e-160
NP_031438.1	Mm.2857	NP_009195.1				563	e-160
		O15218	ADM_R_HUMAN Adrenomedullin receptor (AM-R)			563	e-160
		JC5784	adenomedullin receptor			563	e-160
		CAA73910.1	G-protein coupled receptor			563	e-160
		AAH34761.1	adenomedullin receptor			563	e-160
		P25106	RDC1_HUMAN G protein-coupled receptor RDC1 homolog			197	5.00e-50
		A39714	G protein-coupled receptor RDC1			197	5.00e-50
		AAA62370.1	orphan receptor			197	5.00e-50
		XP_051522.2	similar to G protein-coupled receptor RDC1 homolog			197	5.00e-50
		AAH36661.1	Unknown (protein for MGC:33224)			196	6.00e-50

NM_007488		U:(C-IR)							
NP_031514.1	Mm.4813	3.41	Q9HBZ2	ARN2_HUMAN	Aryl hydrocarbon receptor nuclear translocator 2 (ARNT protein 2)	1192	0		
			AAG15310.1	AFI185610_1	Aryl-hydrocarbon receptor nuclear translocator 2	1192	0		
			NP_055677.1		aryl-hydrocarbon receptor nuclear translocator 2; KIAA0307 gene product; aryl	1191	0		
			BAA20766.1	KIAA0307		1191	0		
			AAH36099.1	Unknown (protein for MGC:33872)		1165	0		
			NP_001659.1	aryl hydrocarbon receptor nuclear translocator		728	0		
				ARNT_HUMAN	Aryl hydrocarbon receptor nuclear translocator (ARNT protein)	728	0		
				(Dioxin receptor; nuclear translocator) (Hypoxia-inducible factor 1 beta) (HIF-1 beta)		728	0		
			P27540			728	0		
			I59550	aryl hydrocarbon receptor nuclear translocator Arnt [imported]		728	0		
			AAA51777.1	Arnt		728	0		
			CAC21446.1	aryl hydrocarbon receptor nuclear translocator, ARNT		728	0		
			CAD38953.1	hypothetical protein		714	0		
			AAC03365.1	aryl hydrocarbon receptor nuclear translocator; Arnt		412	e-115		
			O00327	BMAL_HUMAN BMAL1 protein (Brain and muscle ARNT-like 1) (Member of PAS protein 3) (Basic-helix-loop-helix-PAS orphan MOP3) (BHLH-PAS protein JAP3)		301	2.00e-81		
			BAA19968.1	BMAL1a		301	2.00e-81		
			NP_001169.2	aryl hydrocarbon receptor nuclear translocator-like		301	2.00e-81		
			AAB37248.1	bHLH-PAS protein JAP3		301	2.00e-81		
			AAC24353.1	basic-helix-loop-helix-PAS orphan MOP3		301	2.00e-81		
			AAC51213.1	PAS protein 3		301	3.00e-81		
			JC5405	brain and muscle Ah receptor nuclear translocator-like protein, BMAL1b		300	5.00e-81		
			BAA19935.1	BMAL1b		300	5.00e-81		
			U:(C-IR)						
		3.26							
		NP_033030.1	Mm.19663	U:(C-D)					
		8	2.41	NP_005724.1	RAB6 interacting, kinesin-like (rabkinesin6)				
						1345	0		



## 14.1

		AAH14640.1	Unknown (protein for MGC:15451)	461	e-129
		A35175	mucin 1 precursor, repetitive splice form A [validated]	370	e-102
NM_013605 NP_038633.1	Mm.1619 3.17	U:(C-IR) 3.17			
		NP_002447.2	mucin 1, transmembrane; peanut-reactive urinary mucin; epistatin; polymorphic epithelial mucin; epithelial membrane antigen; DF3 antigen; H23 antigen	368	e-101
		P15941	MUC1_HUMAN Mucin 1 precursor (MUC-1) (Polymorphic epithelial mucin) (PEM) (PEMT) (Epistatin) (Tumor-associated mucin) (Carcinoma-associated mucin) (Tumor-associated epithelial membrane antigen) (EMA) (H23AG) (Peanut-reactive urinary mucin) (PUM) (Breast carcinoma-associated antigen DF3) (CD227 antigen)	368	e-101
		AAA60019.1	mucin	368	e-101
		CAA36478.1	precursor polypeptide (AA -21 to 494)	325	2.00e-88
		AAA59876.1	polymorphic epithelial mucin	317	4.00e-86
		AAB53150.1	polymorphic epithelial mucin	317	4.00e-86
		XP_053256.8	similar to polymorphic epithelial mucin	317	4.00e-86
		AAA35805.1	epistatin variant A precursor	298	2.00e-80
		AAA35807.1	epistatin variant B precursor	298	2.00e-80
		AAD10858.1	MUC-1/Z mucin short variant	274	5.00e-73
		S48146	mucin 1 precursor, non-repetitive splice form Y [validated]	272	1.00e-72
		CAA56734.1	MUC1	272	1.00e-72
		AAD10857.1	MUC-1/Y mucin short variant	272	1.00e-72
		AAD27842.1	AF125525_1 MUC1/Y mucin precursor	271	3.00e-72
		AAD10856.1	MUC-1/X mucin short variant	214	4.00e-56
		U:(C-IR) 3.11			
NM_008652 NP_032678.1	Mm.4594 2	U:(C-D) 2	v-myb myeloblastosis viral oncogene homolog (avian)-like 2; B-MYB; v-myb avian myeloblastosis viral oncogene homolog-like 2	1123	0
		P10244	MYBB_HUMAN Myb-related protein B (B-Myb)	1123	0

	S01991	transforming protein B-myb	11123	0
	CAA31655.1	B-myb protein (AA 1-700)	11123	0
	CAC08392.1	dJ1028D 5.3 (v-myb avian myeloblastosis viral oncogene homolog-like 2)	11123	0
	AAH07585.1	v-myb avian myeloblastosis viral oncogene homolog-like 2	11123	0
P10243	MYBA_HUMAN	Myb-related protein A (A-Myb)	280	1.00e-74
S03423		transforming protein A-myb	280	1.00e-74
E.	CAA31656.1	A-myb N-terminal region)2341 is 2nd base in codon)	280	1.00e-74
	AAB49038.1	alternatively spliced product using exon 9A	276	1.00e-73
	CAA36371.1	MYB protein (AA 1-637)	276	1.00e-73
		v-myb myeloblastosis viral oncogene homolog (avian); v-myb avian myeloblastosis viral oncogene homolog; Avian myeloblastosis viral (v-myb) oncogene homolog;	276	1.00e-73
	NP_005366.1	c-rnyb	276	1.00e-73
	AAA52032.1	c-rnyb	276	1.00e-73
	XP_004256.3	similar to Myb proto-oncogene protein (C-myb)	276	1.00e-73
P10242	MYB_HUMAN	Myb proto-oncogene protein (C-myb)	276	1.00e-73
	AAB49039.1	c-rnyb gene product	276	1.00e-73
	AAC96326.1	MYB proto-oncogene protein	276	1.00e-73
	TVHUMB	transforming protein myb, splice form containing exon 9A	276	1.00e-73
	AAB49035.1	alternatively spliced product using exon 9B	276	1.00e-73
	AAB49036.1	alternatively spliced product using exon 8A	276	1.00e-73
	U:(C-IR) 2.99 U:(C-D) 2.57 U:(IR-D) 2.41			
NM_008168				
NP_032194.1	Mm.2879	GLK5_HUMAN Glutamate receptor, ionotropic kainate 5 precursor (Glutamate receptor KA-2) (KA2) (Excitatory amino acid receptor 2) (EAA2)	1757	0
		glutamate receptor subunit	1757	0
	I57936			
	AAB22591.1	glutamate receptor subunit; EAA2; excitatory amino acid receptor 2	1757	0

		NP_002079.2	glutamate receptor, ionotropic, kainate 5	1625	0
		CAC80547.1	kainate receptor subunit KA2a	1625	0
		NP_055434.1	glutamate receptor, ionotropic, kainate 4; excitatory amino acid receptor 1	1254	0
		Q16099	GIK4_HUMAN Glutamate receptor, ionotropic kainate 4 precursor (Glutamate receptor KA-1) (KA1) (Excitatory amino acid receptor 1)(EAA1)	1254	0
		JH0826	glutamate ionotropic receptor EAA1 chain precursor	1254	0
		AAB29311.1	excitatory amino acid receptor 1; kainate receptor subunit EAA1	1254	0
		A54260	glutamate receptor 6 kainate-prefering precursor	704	0
		AAB31362.1	GluR6 kainate receptor=ionotropic-type glutamate receptor	704	0
		NP_068775.1	glutamate receptor, ionotropic, kainate 2	704	0
		Q13002	GIK2_HUMAN Glutamate receptor, ionotropic kainate 2 precursor (Glutamate receptor 6) (GluR-6) (GluR6) (Excitatory amino acid receptor 4) (EAA4)	704	0
		AAC50420.1	EAA4	704	0
		CAC67487.1	GluR6 kainate receptor	689	0
		CAC81020.1	kainate receptor subunit	687	0
		Q13003	GIK3_HUMAN Glutamate receptor, ionotropic kainate 3 precursor (Glutamate receptor 7) (GluR-7) (GluR7) (Excitatory amino acid receptor 5) (EAA5)	687	0
		NP_000822.1	glutamate receptor, ionotropic, kainate 3	687	0
		AAB60407.1	EAA5	687	0
		AAA95961.1	EAA3	685	0
		NM_007765	U:(C-IR)		
		2.93			
		U:(C-D)			
	Mm.22695	2.6	collapsin response mediator protein 1; collapsin response mediator protein 1 (dihydropyrimidinase-like 1)	1036	0
NP_031791.1			DPY1_HUMAN Dihydropyrimidinase related protein-1 (DRP-1) (Collapsin response mediator protein 1) (CRMP-1)	1036	0
			JCS316	1036	0
			dihydropyrimidinase related protein 1	1036	0
			BAA11190.1	1036	0
			dihydropyrimidinase related protein-1		

		AAH00252.1	collapsin response mediator protein 1		1036	0
		AAH07613.1	collapsin response mediator protein 1		1036	0
		AAK55500.1	collapsin response mediator protein 1		963	0
		AAA93201.1	hCRMP-1		919	0
		NP_001377.1	dihydropyrimidinase-like 2; collapsin response mediator protein hCRMP-2		847	0
		DPY2_HUMAN	Dihydropyrimidinase related protein-2 (DRP-2) (Collapsin response mediator protein 2) (CRMP-2) (N2A3)		847	0
	Q165555	JC5317	dihydropyrimidinase-related protein 2		847	0
		AAA92202.1	hCRMP-2		847	0
		BAA11191.1	dihydropyrimidinase related protein-2		847	0
		AAC05793.1	N2A3		847	0
		BAA86991.1	dihydropyrimidinase related protein 2		847	0
		NP_001378.1	dihydropyrimidinase-like 3		813	0
	Q14195	DPY3_HUMAN	Dihydropyrimidinase related protein-3 (DRP-3) (Unc-33-like phosphoprotein) (ULIP protein) (Collapsin response mediator protein 4) (CRMP-4)		813	0
		JC5318	dihydropyrimidinase related protein 3		813	0
		BAA11192.1	dihydropyrimidinase related protein-3		813	0
		AAH39006.1	dihydropyrimidinase-like 3		813	0
		CAA69153.1	ULIP		810	0
		NP_006417.1	dihydropyrimidinase-like 4		781	0
	O14531	DPY4_HUMAN	Dihydropyrimidinase related protein-4 (DRP-4) (ULIP4 protein)		781	0
		BAA21886.1	dihydropyrimidinase related protein 4		781	0
		CAA71872.1	cytosolic phosphoprotein		749	0
		AAH07898.1	Similar to collapsin response mediator protein 1		712	0
NM_009872	U:(C-IR) 2.86 Mn.15383 3					
NP_034002.1	U:(C-D) 2.61	NP_003927.1	cyclin-dependent kinase 5, regulatory subunit 2; cyclin-dependent kinase 5 activator isoform		483	e-136

		Q13319	CDK5_HUMAN Cyclin-dependent kinase 5 activator 2 precursor (CDK5 activator 2)	483	e-136
	I39172	cyclin-dependent kinase 5 activator isoform p39i		483	e-136
	AAC50278.1	cyclin-dependent kinase 5 activator isoform p39i		483	e-136
	2202258A	cyclin-dependent kinase 5		483	e-136
		cyclin-dependent kinase 5, regulatory subunit 1; regulatory partner for cdk5 kinase;			
	NP_003876.1	TPKII regulatory subunit		228	1.00e-59
		CD5R_HUMAN Cyclin-dependent kinase 5 activator 1 precursor (CDK5 activator 1)			
		(Cyclin-dependent kinase 5 regulatory subunit 1) (Tau protein kinase II 23 kDa subunit) (TPKII regulatory subunit) (P23) (P25) (P35)		228	1.00e-59
	Q15078	cyclin-dependent kinase 5 regulatory chain p35		228	1.00e-59
	S50861	cyclin-dependent kinase 5 regulatory chain p35		228	1.00e-59
	CAA56587.1	regulatory partner for cdk5 kinase		228	1.00e-59
	AAH20580.1	AAH20580 cyclin-dependent kinase 5, regulatory subunit 1 (p35)		228	1.00e-59
	2019431A	cyclin-dependent kinase 5;SUBUNIT=>p35		228	1.00e-59
	AAH26347.1	cyclin-dependent kinase 5, regulatory subunit 1 (p35)		226	4.00e-59
	AAH30792.1	cyclin-dependent kinase 5, regulatory subunit 1 (p35)		226	4.00e-59
	1H4L	D Chain D, Structure And Regulation Of The Cdk5-P25(Nck5a) Complex		217	2.00e-56
	1H4L	E Chain E, Structure And Regulation Of The Cdk5-P25(Nck5a) Complex		217	2.00e-56
	U;(C-IR) 2.84	XP_093388.1 similar to DnaJ homolog subfamily B member 8 (mDJ6)		336	4.00e-92
NM_019964	Mm.2039				
NP_064348.1	NP_064348.1	U;(C-D) 3.13			
		NP_699161.1 hypothetical protein MGCG33884		336	4.00e-92
		AAH29521.1 Similar to DnaJ (Hsp40) homolog, subfamily B, member 8		336	4.00e-92
		NP_005485.1 DnaJ (Hsp40) homolog, subfamily B, member 6 isoform b; Heat shock protein J2		258	7.00e-69
		BAA32209.1 MRJ		258	7.00e-69
		AAD43194.1 AF075601_1 heat shock J2 protein		258	7.00e-69
		AAF21257.1 AF060703_1 DNAj homolog		258	7.00e-69

		BAA88770.1	DnaJ homolog		258	7.00e-69
		CAB6642.1	hypothetical protein		258	7.00e-69
		AAH00177.1	AAH00177 Similar to DnaJ (Hsp40) homolog, subfamily B, member 6		258	7.00e-69
		XP_052862.4	similar to DnaJ homolog		256	3.00e-68
		NP_490647.1	DnaJ (Hsp40) homolog, subfamily B, member 6 isoform a; Heat shock protein J2		249	6.00e-66
O75190		DBB6_HUMAN	DnaJ homolog subfamily B member 6 (Heat shock protein J2) (HSJ-2) (MSJ-1) (HHDJ1) (MRJ)		249	6.00e-66
		BAA88769.1	DnaJ homolog		249	6.00e-66
		AAH02446.1	AAH02446 MRJ gene for a member of the DNAJ protein family		249	6.00e-66
NM_008417	U:(C-IR) 2.82					
NP_032443.1	Mm.56930 U:(C-D) 2.47	NP_004965.1	potassium voltage-gated channel, shaker-related subfamily, member 2; voltage-gated potassium channel protein Kv1.2; potassium channel	880	0	
		P16389	CIK2_HUMAN Potassium voltage-gated channel subfamily A member 2 (Potassium channel Kv1.2) (RBK2) (HBK2) (NGK1) (MK2) (HUKIV)	880	0	
		I77466	potassium channel	880	0	
		AAA36141.1	potassium channel	880	0	
		NP_000208.1	potassium voltage-gated channel, shaker-related subfamily, member 1	662	0	
		Q09470	CIK1_HUMAN Potassium voltage-gated channel subfamily A member 1 (Potassium channel Kv1.1) (HUK1) (HBK1)	662	0	
		I57680	potassium channel KCNA1	662	0	
		AAA36139.1	potassium channel	662	0	
		NP_002223.2	potassium voltage-gated channel, shaker-related subfamily, member 3; potassium channel Kv1.3; type n potassium channel	600	e-171	
		P22001	CIK3_HUMAN Potassium voltage-gated channel subfamily A member 3 (Potassium channel Kv1.3) (HPCN3) (HGK5) (HUKIII) (HLK3)	600	e-171	
		AAB88073.1	voltage-gated potassium channel	600	e-171	
		AAH33059.1	potassium voltage-gated channel, shaker-related subfamily, member 3	600	e-171	

	A38101	potassium channel KCNA3	599	e-171
	AAA59457.1	potassium channel protein	599	e-171
	AAC31761.1	potassium channel	598	e-171
	AAA36425.1	potassium channel protein	595	e-170
		potassium voltage-gated channel, shaker-related subfamily, member 4; potassium voltage-gated channel, shaker-related subfamily, member 4-like; potassium channel KCNA4; shaker-related potassium channel Kv1.4; voltage-gated potassium channel; potassium channel protein; type A potassium channel; rapidly inactivating potassium channel; fetal skeletal muscle potassium channel; cardiac potassium channel; potassium channel 2; voltage-gated potassium channel protein Kv1.4	543	e-154
	NP_002224.1		543	e-154
	A39922	potassium channel KCNA4	543	e-154
	AAA36140.1	potassium channel	543	e-154
	AAA61275.1	voltage-gated potassium channel	543	e-154
P22459		CK4_HUMAN Potassium voltage-gated channel subfamily A member 4 (Potassium channel Kv1.4) (HK1) (HPCN2) (HBK4) (HUKII)	541	e-153
	AAA60034.1	potassium channel protein	541	e-153
		potassium voltage-gated channel, shaker-related subfamily, member 6; voltage-gated potassium channel protein Kv1.6; human brain potassium channel-2	519	e-147
	NP_002226.1		519	e-147
	P17658	CK4_HUMAN Potassium voltage-gated channel subfamily A member 6 (Potassium channel Kv1.6) (HBK2)	519	e-147
	CAA35623.1	put. HBK2 protein (AA 1-529)	519	e-147
	S12787	potassium channel KCNA2	517	e-146
	U:(C-IR) NP_000757.2	cytochrome P450, subfamily II A (phenobarbital-inducible), polypeptide 13	563	e-160
NM_013809	Mm.1023			
NP_038837.1	2.79 12 U:(C-D) 2.22			
		AAG35775.1 cytochrome P450 2A13	563	e-160
		Q16696 CPAD_HUMAN Cytochrome P450 2A13 (CYP2A13)	558	e-158
		AAB40519.1 cytochrome P450	558	e-158

	O4HUA6	coumarin 7-hydroxylase (EC 1.14.14.-) cytochrome P450 2A6	555	e-158
	AAA52067.1	cytochrome P450IIA3	555	e-158
	NP_000753.2	cytochrome P450, subfamily II A (phenobarbital-inducible), polypeptide 6; coumarin 7-hydroxylase; cytochrome P450, subfamily II A (phenobarbital-inducible), polypeptide 3; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	553	e-157
	P11509	CPA6 HUMAN Cytochrome P450 2A6 (CYP1A6) (Coumarin 7-hydroxylase) (IIA3) (CYP2A3) (P450(I))	552	e-157
	CAA32118.1	P-450 IIA4 protein (AA 1-494)	552	e-157
	AAF13600.1	AF182275_1 cytochrome P450-2A6	551	e-157
	1609083A	cytochrome P450IIA	551	e-156
	CAA32097.1	cytochrome P-450IIA (AA 1 - 489)	551	e-156
	P20833	CPA7 HUMAN Cytochrome P450 2A7 (CYP1A7) (P450-IIA4)	543	e-154
	AAA52138.1	cytochrome P450IIA4	543	e-154
	C34271	cytochrome P450 2A4	543	e-154
U:(C-IR) 2.74 U:(C-D) 2.8	NP_003890.1	Rho guanine nucleotide exchange factor 7 isoform a; SH3 domain-containing proline-rich protein; PAK-interacting exchange factor beta	1135	0
NM_017402 NP_059098.1	Q14155	PIXB HUMAN Rho guanine nucleotide exchange factor 7 (PAK-interacting exchange factor beta) (Beta-Pix) (COOL-1) (p85)	1135	0
	BAA09763.1	The KIAA0142 gene is related to human KIAA0006 gene.	1135	0
	CAD38906.1	hypothetical protein	1014	0
	NP_663778.1	Rho guanine nucleotide exchange factor 7 isoform b; SH3 domain-containing proline-rich protein; PAK-interacting exchange factor beta	1014	0
	BAA04985.1	this sequence overlaps D13631, it covers 954..4359 of this sequence.	751	0
	XP_042963.2	similar to Rho guanine nucleotide exchange factor 6 (PAK-interacting exchange factor alpha) (Alpha_Pix) (COOL-2)	751	0

		NP_004831.1	Rac/Cdc42 guanine nucleotide exchange factor 6; PAK-interacting exchange factor, alpha; Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6; rho guanine nucleotide exchange factor 6	751	0
		Q15052	ARH6_HUMAN Rho guanine nucleotide exchange factor 6 (PAK-interacting exchange factor alpha) (Alpha-Pix) (COOL-2)	751	0
		AAH39856.1	Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6	751	0
		BAA02796.1	KIAA0006	504	e-142
		1BY1	A Chain A, Dbl Homology Domain From Beta-Pix	385	e-106
		AAH33768.1	Similar to Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6	301	4.00e-81
NM_009819 NP_033949.1	U:(C-IR) 2.7 U:(C-D) 2.71	NP_004380.1	catenin (cadherin-associated protein), alpha 2; Catenin, alpha-2(cadherin-associated protein, related)	1684	0
Mm.34637		P26232	CTN2_HUMAN Alpha-2 catenin (Alpha-catenin related protein) (Alpha N-catenin)	1684	0
		AAA58407.2	catenin-associated protein-related	1684	0
		A45011	alpha-catenin 2	1317	0
		XP_038221.1	similar to Alpha-1 catenin (Cadherin-associated protein) (Alpha E-catenin)	1317	0
		P35221	CTN1_HUMAN Alpha-1 catenin (Cadherin-associated protein) (Alpha E-catenin)	1317	0
		N0607	alpha-catenin 1	1317	0
		BAA02979.1	alpha-catenin	1317	0
		AAC99459.1	alphaE-catenin	1317	0
		AAH00385.1	Unknown (protein for MGC:8429)	1317	0
		BAA03530.1	'human alpha-catenin'	1313	0
		2023176A	alpha catenin	1313	0
		JC2542	alpha-2(E)-catenin	1290	0
		AAA18949.1	alpha2(E)-catenin	1290	0
		NP_001894.1	catenin (cadherin-associated protein), alpha 1, 102kDa; catenin (cadherin-associated protein), alpha 1 (102kD); catenin (cadherin-associated protein), alpha 1 (102kDa	1286	0

		AAA86430.1	alpha1(E)-catenin	1286	0
		NP_037398.1	alpha-catenin-like protein	974	0
		AAF21801.1	AF091606_1 alpha T-catenin	974	0
		AAH31262.1	Similar to catenin (cadherin-associated protein), alpha 2	841	0
		IH6G	A Chain A, Alpha-Catenin M-Domain	389	e-107
		IH6G	B Chain B, Alpha-Catenin M-Domain	389	e-107
		XP_068797.2	similar to alpha(E)-catenin	380	e-105
NM_010437 NP_034567.1	Mm.4215 NP_034567.1	NP_006725.2	human immunodeficiency virus type I enhancer binding protein 2; human immunodeficiency virus type I enhancer-binding protein 2	3799	0
		WMHUE2	HIV-EP2 enhancer-binding protein	3799	0
		CAA46596.1	MBP-2 (MHC Binding Protein-2)	3799	0
		AAF81365.1	human immunodeficiency virus type I enhancer-binding protein 2	3797	0
		P31629	ZEP2_HUMAN HUMAN IMMUNODEFICIENCY VIRUS TYPE I ENHANCER-BINDING PROTEIN 2 (HIV-EP2)	2698	0
		AAB88218.1	HIV-EP2/Schurri-2	2698	0
		NP_078779.1	human immunodeficiency virus type I enhancer-binding protein 3	786	0
		AAK01082.1	AF2278765_1 kappa B and V(D)J recombination signal sequences binding protein	786	0
		BAB13381.1	KIAA1555 protein	486	e-136
		NP_002105.1	human immunodeficiency virus type I enhancer binding protein 1; human immunodeficiency virus type I enhancer-binding protein 1	257	2.00e-67
		P15822	ZEP1_HUMAN Zinc finger protein 40 (Human immunodeficiency virus type I enhancer-binding protein 1) (HIV-EP1) (Major histocompatibility complex binding protein 1) (MBP-1) (Positive regulatory domain II binding factor 1) (PRDI-BF1)	257	2.00e-67
		A34203	DNA-binding protein PRDI-BF1	257	2.00e-67
		CAA35798.1	PRDI-BF1 protein (AA 1-2717)	257	2.00e-67
		AAA17534.1	DNA-binding protein	250	2.00e-65



			AAA79212.1	ORF		1022	0
			AAA16173.1	Wilson disease-associated protein		608	e-173
		U:(C-IR) 2.61					
		U:(C-D) 2.38					
NM_008356	Mm20855		NP_000631.1	interleukin 13 receptor, alpha 2 precursor; interleukin 13 binding protein; interleukin 13 receptor alpha 2 chain; IL-13 receptor		431	e-120
NM_032382.1	Mm20855		Q14627	IL13_HUMAN Interleukin-13 receptor alpha-2 chain precursor (Interleukin-13 binding protein)		431	e-120
			CAA64617.1	interleukin 13 receptor		431	e-120
			AAB17170.1	interleukin-13 receptor		431	e-120
			CAA70021.1	IL-13 receptor		431	e-120
			CAD18962.1	dA204F4.1 (interleukin 13 receptor, alpha 2)		431	e-120
			AAH20739.1	interleukin 13 receptor, alpha 2		431	e-120
			AAH33705.1	interleukin 13 receptor, alpha 2		431	e-120
		U:(C-IR) 2.59	AAGI17965.1	AF089087_1 G protein-coupled receptor		411	e-114
		U:(C-D) 3.35					
		U:(IR-D) 2.3					
NM_022320	Mm.1527		NP_005292.1	G protein-coupled receptor 35		409	e-113
NP_071715.1	80		Q9HC97	GP35_HUMAN Probable G protein-coupled receptor GPR35		409	e-113
			AAC52028.1	G protein-coupled receptor		409	e-113
NM_010174	Mm.2222	U:(C-IR) 2.54	CAA71305.1	mammary-derived growth inhibitor		241	5.00e-64
NP_034304.1	0		NP_004093.1	fatty acid binding protein 3		240	1.00e-63
			XP_049316.1	similar to Fatty acid-binding protein, heart (H-FABP) (Muscle fatty acid-binding protein) (M-FABP) (Mammary-derived growth inhibitor) (MDGI)		240	1.00e-63

	P05413	FABH_HUMAN Fatty acid-binding protein, heart (H-FABP) (Muscle fatty acid-binding protein) (M-FABP) (Mammary-derived growth inhibitor) (MDGI)	240	1.00e-63
	FZHUC	fatty acid-binding protein, cardiac and skeletal muscle - human	240	1.00e-63
	CAA39889.1	muscle fatty-acid-binding protein (FABP)	240	1.00e-63
	AAB02555.1	fatty acid binding protein FABP	240	1.00e-63
	AAC99800.1	fatty acid binding protein	240	1.00e-63
	AAH07021.1	AAH07021_fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	240	1.00e-63
	1G5W	A Chain A, Solution Structure Of Human Heart-Type Fatty Acid Binding Protein	238	6.00e-63
	1HMR	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	6.00e-63
	1HMS	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	6.00e-63
	1HM1T	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	6.00e-63
	2HMB	Fatty Acid Binding Protein (Holo Form, Human Muscle) (M-Fabp)	238	6.00e-63
	1714345A	fatty acid-binding protein	237	1.00e-62
	AAB29294.1	heart fatty acid binding protein; hFABP	214	9.00e-56
	NM_007634	U(C-IR)		
	2.52			
	U:(C-D)			
	NP_031660.1	Mm.4008	AAB60342.1	cyclin F
	2.12		P41002	CG2F_HUMAN G2/mitotic-specific cyclin F
			AAH12349.1	cyclin F
			NP_001752.1	cyclin F; G2/mitotic-specific cyclin F; F-box only protein 1
			A55501	cyclin F
			CAA85308.1	cyclin F [Homo sapiens]
				1197
				0
				1206
				0
				1205
				0
				1205
				0
				1197
				0
				1197
				0



		AAC27076.1	ABC transporter MOAT-B	402	e-111
		AAC27077.1	ABC transporter MOAT-B isoform	353	2.00e-96
		U:(C-IR) 2.5			
AF363457	Mm.13083 2	U:(C-D) 2.33	NP_077015.1 caspase recruitment domain protein 14 isoform 1; CARD-containing	1257	0
AAK60137.1			CARE_HUMAN Caspase recruitment domain protein 14 (CARD-containing	1257	0
			Q9BXL6 MAGUK protein	1257	0
			AAG53403.1 AF322642_1 caspase recruitment domain protein 14	1257	0
			AAK54453.1 CARD-containing MAGUK 2 protein	1257	0
			AAH18142.1 Similar to caspase recruitment domain protein 14	953	0
			NP_438170.1 caspase recruitment domain protein 14 isoform 2; CARD-containing	407	e-113
			AAH01326.1 Unknown (protein for MGC:5551)	407	e-113
			Q9BXL7 CARB_HUMAN Caspase recruitment domain protein 11 (CARD-containing	202	3.00e-51
			MAGUK protein	202	3.00e-51
			AAG53402.1 AF322641_1 caspase recruitment domain protein 11	202	3.00e-51
			NP_115791.2 caspase recruitment domain family, member 11; card-maguk protein 1;	202	3.00e-51
			AAL34460.1 AF352576_1 CARD-containing MAGUK protein CARMAL	202	3.00e-51
			BAB84875.1 FLJ00120 protein	202	3.00e-51
		U:(C-IR) 2.49			
		U:(C-D) 2.42	urate anion exchanger 1 isoform a; organic anion transporter 4-like; urate transporter		
NM_009203		P_653186.2	1; solute carrier family 22 member 12	780	0
		AAK68156.1	AC044790_3 RST	780	0
		BAB96750.1	URAT1	780	0
		BAB68364.1	organic anion transpoter 4 like protein	688	0
		NP_060954.1	solute carrier family 22 member 11; organic anion transporter 4	502	e-142
		BAA953316.1	organic anion transporter 4	502	e-142
		AAK68155.1	AC044790_2 OAT4	502	e-142



NM_011356 NP_035486.1	U:(C-IR) Mm.3246	Q92765	FRZB_HUMAN Frizzled-related protein precursor (Frzb-1) (Frizzled) (Fritz)	595	e-169
	2.45	AAC51217.1	frizzled	595	e-169
		AAH2785.1	Unknown (protein for MGC:34598)	595	e-169
		NP_001454.1	frizzled-related protein; Fritz, Frzb-1; frizzled (Drosophila) homolog-related; fzfb; hfz	593	e-169
		AAC50736.1	Frzb precursor	593	e-169
		AAB51298.1	Fritz	593	e-169
		NP_003005.1	secreted frizzled-related protein 4; secreted frizzled-related protein 4	312	2.00e-84
		AAC04617.1	fprHE	312	2.00e-84
NM_053115 NP_444345.1	U:(C-IR) 2.42	NP_003491.1	acyl-Coenzyme A oxidase 2, branched chain; Peroxisomal branched chain acyl-CoA oxidase	1033	0
		Q99424	CAO2_HUMAN Acyl-coenzyme A oxidase 2, peroxisomal (Branched-chain acyl-CoA oxidase) (BRCACox) (Trihydroxyprostanoyl-CoA oxidase) (THCCox) (THCA-CoA oxidase)	1033	0
		CAA64489.1	branched chain acyl-CoA oxidase	1033	0
		CAB65596.1	peroxisomal branched chain acyl-CoA oxidase	1033	0
		AAB30019.2	peroxisomal acyl-coenzyme A oxidase	536	e-152
		Q15067	CAO1_HUMAN Acyl-coenzyme A oxidase 1, peroxisomal (Palmitoyl-CoA oxidase) (AOX)	535	e-152
		I38095	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal	534	e-151
		CAA50574.1	peroxisomal acyl-CoA oxidase	534	e-151
AAH08767.1		AAH08767	Similar to acyl-Coenzyme A oxidase 1, palmitoyl	532	e-151

		AAH10425.1	AAH10425 Unknown (protein for MGC:15225)	531	e-150
		AAA18395.1	peroxisomal fatty acyl-CoA oxidase	530	e-150
		NP_009223.1	acyl-Coenzyme A oxidase isoform b; acyl-coenzyme A oxidase 1	526	e-149
		A54942	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal splice form I	526	e-149
		AAA19113.1	acyl-CoA oxidase	526	e-149
		NP_004026.1	acyl-Coenzyme A oxidase isoform a; acyl-coenzyme A oxidase 1	523	e-148
		B54942	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal splice form II	523	e-148
		AAA19114.1	acyl-CoA oxidase	523	e-148
		NP_003492.1	acyl-Coenzyme A oxidase 3, pristanoyl	268	2.00e-71
		O15254	CAO3_HUMAN Acyl-coenzyme A oxidase 3, peroxisomal (Pristanoyl-CoA oxidase)	268	2.00e-71
		CAA72214.1	pristanoyl-CoA oxidase	268	2.00e-71
		NP_001731.1	calbindin 2 full length protein isoform; calbindin 2, (29kD, calretinin); calbindin D29K	371	e-102
		P22676	CLB2_HUMAN Calretinin (CR) (29 kDa calbindin)	371	e-102
		A60253	calretinin	371	e-102
		CAA39991.1	calretinin	371	e-102
		I709139B	calretinin	371	e-102
		AAH15484.1	AAH15484 calbindin 2, (29kD, calretinin)	371	e-102
		NP_004920.1	calbindin 1; calbindin 1, (28kD)	249	5.00e-66
		P05937	CABV_HUMAN Calbindin (Vitamin D-dependent calcium-binding protein, avian-type) (Calbindin D28) (D-28K)	249	5.00e-66
		S00234	calcium-binding protein, vitamin D-dependent	249	5.00e-66
		CAA29860.1	calbindin (AA 1-261)	249	5.00e-66
		AAC62230.1	27kDa calbindin	249	5.00e-66
		AAD08724.1	calbindin 1	249	5.00e-66
		AAH06478.1	AAH06478 calbindin 1, (28kD)	249	5.00e-66
		AAH20864.1	AAH20864 calbindin 1, (28kD)	249	5.00e-66

		1403296A	calbindin 27kD		249	5.00e-66
		1709139A	calbindin D28K		249	5.00e-66
		NP_009019.1	calbindin 2 isoform 22k; calbindin 2, (29kD, calretinin); calbindin D29K		199	1.00e-50
		NP_009018.1	calbindin 2 isoform 20k; calbindin 2, (29kD, calretinin); calbindin D29K		198	1.00e-50
NM_013612 NP_038640.1	Mm.2913 U:(C-IR) 2.38	XP_002585.4	similar to Natural resistance-associated macrophage protein 1 (NRAMP 1)		905	0
		P49279	NRM1_HUMAN Natural resistance-associated macrophage protein 1 (NRAMP 1)		905	0
		155679	integral membrane protein		905	0
		AAA57521.1	integral membrane protein		905	0
		BAA08908.1	Nramp		905	0
		AAG15405.1	natural resistance-associated macrophage protein 1		905	0
		BAA08907.1	Nramp		904	0
		JC4095	natural resistance-associated macrophage protein NRAMP 1		889	0
		NP_000569.1	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1; natural resistance-associated macrophage protein 1 (might include Leishmania); solute carrier family 11 (sodium/phosphate symporters), member 1		887	0
		CAA57541.1	NRAMP		887	0
		BAA07370.1	Nramp		818	0
		CAD38517.1	divalent metal transporter		649	0
		NP_000608.1	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2; natural resistance-associated macrophage protein 2		649	0
		BAA24933.1	NRAMP2		649	0
		AAC21460.1	natural resistance-associated macrophage protein 2		649	0
		AAC18078.1	NRAMP2 iron transporter		649	0
		AAH02592.1	AAH02592 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2		649	0
		P49281	NRM2_HUMAN Natural resistance-associated macrophage protein 2 (NRAMP 2) (Divalent metal transporter 1) (DMT1)		648	0

		AAC21459.1	natural resistance-associated macrophage protein 2 non-IRE form	648	0
		AAC21461.1	natural resistance-associated macrophage protein 2	648	0
		BAB93467.1	natural resistance-associated macrophage protein 2 non-IRE form	648	0
		BAA34374.1	natural resistance-associated macrophage protein 2	633	0
		IS7022	integral membrane protein	629	e-180
		AAA79219.1	integral membrane protein	629	e-180
NM_020503 NP_065249	Mm.1038 1 03	U:(C-IR) 2.38	NP_062545.1 taste receptor T2R1; taste receptor, family B, member 7; taste receptor, type 2, member 1	260	2.00e-69
			AAF43902.1 AF227129_1 candidate taste receptor T2R1	260	2.00e-69
NM_026091 NP_080367.1	Mm.2771 1	U:(C-IR) 2.36	BAB14854.1 unnamed protein product	323	4.00e-88
			CAC17545.1 dJ1009E24.3 (novel protein)	323	4.00e-88
			AAH12196.1 AAH12196 Unknown (protein for MGC:4349)	323	4.00e-88
			AAH24036.1 chromosome 20 open reading frame 27	323	4.00e-88
			NP_060344.1 chromosome 20 open reading frame 27	321	1.00e-87
			BAA91252.1 unnamed protein product	321	1.00e-87
NM_008123 NP_032149.1	Mm.56907 1	U:(C-IR) 2.35	P48165 CXA8_HUMAN Gap junction alpha-8 protein (Connexin 50) (Cx50) (Lens fiber protein MP70)	679	0
			AAF32309.1 AF217524_1 gap junction protein alpha 8	679	0
			NP_005258.1 gap junction protein, alpha 8, 50kDa (connexin 50); gap junction membrane channel protein alpha-8 (connexin 50); gap junction protein, alpha 8, 50kD (connexin 50)	673	0
			I39176 intrinsic membrane protein MP70	673	0
			AAA77062.1 gap junction membrane channel protein alpha-	673	0
			gap junction protein, alpha 3, 46kDa (connexin 46); gap junction protein, alpha 3, 46kD (connexin 46)	332	8.00e-91

CAC16957.1	bA26414.3 (novel connexin (gap junction protein))
Q9Y6H8	CXA3_HUMAN Gap junction alpha-3 protein (Connexin 46) (Cx46)
AAD42925.1	gap-junction protein, alpha 3
	gap junction protein, alpha 5, 40kDa (connexin 40); gap junction protein, alpha 5, 40kD (connexin 40)
P36382	CXA5_HUMAN Gap junction alpha-5 protein (Connexin 40) (Cx40)
	AAA91833.1 connexin 40
AAD37801.1	AF151979_1 connexin 40
	AAA60457.2 connexin40
AAH13313.1	AAH13313 gap junction protein, alpha 5, 40kD (connexin 40)8 connexin40
I38429	
AAK55516.1	AF271261_1 connexin 58
NP_110399.1	connexin 59; gap junction alpha 10
P57773	CXAA_HUMAN Gap junction alpha-10 protein (Connexin 59) (Cx59)
AAG09406.1	AF179597_1 connexin 59
NP_115991.1	connexin 62
AAK51676.1	AF296766_1 connexin 62
CAC93847.1	connexin62
AAD56533.1	AF180815_1 truncated connexin 37 polymorph
U:(C-IR) NP_036593.2 2.35	XP_036593.2 similar to annexin A8
NM_013473 NP_038501.2	Mm.3267
AAH04376.1	AAH04376 annexin A8
NP_001621.1	annexin VIII; Annexin VII
P13928	ANX8_HUMAN Annexin A8 (Annexin VIII) (Vascular anticoagulant-beta) (VAC-beta)
CAA34650.1	vascular anticoagulant-beta (AA 1 - 327)
LUHU8	annexin VIII

	AAB46383.1	annexin VIII	590	e-168
	XP_054475.4	similar to annexin A8	575	e-165
P09525	ANX4_HUMAN Annexin A4 (Annexin IV) (Lipocortin IV) (Endonexin I) (Chromobindin 4) (Protein II) (P32.5) (Placental anticoagulant protein II) (PAP-II) (PP4-X) (35-beta calcimedin) (Carbohydrate-binding protein P33/P41) (P33/41)		337	4.00e-92
NP_001144.1	annexin IV; annexin IV (placental anticoagulant protein II); placental anticoagulant protein II		337	4.00e-92
XP_031596.2	similar to annexin IV; annexin IV (placental anticoagulant protein II); placental anticoagulant protein II		337	4.00e-92
A42077	annexin IV		337	4.00e-92
AAA51740.1	annexin IV (placental anticoagulant protein II)		337	4.00e-92
BAA11227.1	annexin IV (carbohydrate-binding protein p33/41)		337	4.00e-92
AAH00182.1	AAH00182 annexin A4		337	4.00e-92
AAH11659.1	AAH11659 Similar to annexin A4		337	4.00e-92
AAC41689.1	protein PP4-X		337	4.00e-92
1ANW	A Chain A, Annexin V		328	2.00e-89
1ANW	B Chain B, Annexin V		328	2.00e-89
1ANX	A Chain A, Annexin V		328	2.00e-89
1ANX	B Chain B, Annexin V		328	2.00e-89
1ANX	C Chain C, Annexin V		328	2.00e-89
NP_001145.1	annexin V; endonexin II; anchorin CII; lipocortin V; placental anticoagulant protein I		328	2.00e-89
P08758	ANX5_HUMAN Annexin V (Lipocortin V) (Endonexin II) (Calphobindin I) (CBP-I) (Placental anticoagulant protein I) (PAP-I) (PP4) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha) (Anchorin CII)		328	2.00e-89
AQHUP	annexin V [validated]		328	2.00e-89
1AVH	A Chain A, Annexin V (Hexagonal Crystal Form)		328	2.00e-89
1AVH	B Chain B, Annexin V (Hexagonal Crystal Form)		328	2.00e-89

	IHAK	A Chain A, Crystal Structure Of Recombinant Human Placental Annexin V Complexed With K-201 As A Calcium Channel Activity Inhibitor	328	2.00e-89	
	IHAK	B Chain B, Crystal Structure Of Recombinant Human Placental Annexin V Complexed With K-201 As A Calcium Channel Activity Inhibitor	328	2.00e-89	
	IAVR	Annexin V (Rhombohedral Crystal Form)	328	2.00e-89	
	CAA30985.1	VAC protein (AA 1-320)	328	2.00e-89	
	AAA35570.1	anticoagulant precursor (5' end put.); putative	328	2.00e-89	
	AAA52386.1	endonexin II	328	2.00e-89	
	AAB55545.1	anticoagulant protein 4	328	2.00e-89	
	BAA00122.1	blood coagulation inhibitor	328	2.00e-89	
	AAA36166.1	lipocortin-V	328	2.00e-89	
	AAB40047.1	annexin V	328	2.00e-89	
	AAB60648.1	annexin V	328	2.00e-89	
	AAH01429.1	AAH01429 annexin A5	328	2.00e-89	
	AAH04993.1	AAH04993 annexin A5	328	2.00e-89	
	AAH12804.1	AAH12804 Similar to annexin A5	328	2.00e-89	
	AAH12822.1	AAH12822 Similar to annexin A5	328	2.00e-89	
	1512315A	calphobindin	328	2.00e-89	
	1313303A	coagulation inhibitor	328	2.00e-89	
NM_008075	U:(C-IR)	gamma-aminobutyric acid (GABA) receptor, rho 1 ; gamma-aminobutyric acid			
NP_032101.1	Mm_14116 2.33	NP_002033.1 (GABA) A receptor, rho-1	881	0	
		GAR1_HUMAN Gamma-aminobutyric-acid receptor rho-1 subunit precursor (GABA(A) receptor)	881	0	
		P24046			
		A38627	gamma-aminobutyric acid receptor A rho-1 chain precursor	881	0
		AAA52509.1	gamma-aminobutyric acid receptor type A rho-1 subunit	881	0
		P28476	GAR2_HUMAN Gamma-aminobutyric-acid receptor rho-2 subunit precursor (GABA(A) receptor)	654	0

		CAC07339.1	dJ131H7.1 (gamma-aminobutyric acid (GABA) receptor rho 2)	654	0
		NP_002034.1	gamma-aminobutyric acid (GABA) receptor, rho 2 precursor	652	0
	A38079		gamma-aminobutyric acid receptor rho-2 chain precursor	652	0
		AAA52510.1	gamma-aminobutyric acid	652	0
			similar to Gamma-aminobutyric-acid receptor rho-3 subunit precursor (GABA(A) receptor)	459	e-129
	XP_116036.2			315	2.00e-85
	NP_068712.1		gamma-aminobutyric acid (GABA) A receptor, beta 3, isoform 2 precursor	315	2.00e-85
	NP_000805.1		gamma-aminobutyric acid (GABA) A receptor, beta 3, isoform 1 precursor	315	2.00e-85
		P28472	GAB3_HUMAN Gamma-aminobutyric-acid receptor beta-3 subunit precursor (GABA(A) receptor)	315	2.00e-85
		A55275	gamma-aminobutyric acid A receptor beta 3 chain splice form 1	315	2.00e-85
		AAA52511.1	GABA-alpha receptor beta-3 subunit	315	2.00e-85
		AAH10641.1	gamma-aminobutyric acid (GABA) A receptor, beta 3	312	1.00e-84
		NP_000806.1	gamma-aminobutyric acid (GABA) A receptor, delta	305	2.00e-82
			GAD_HUMAN Gamma-aminobutyric-acid receptor delta subunit precursor (GABA(A) receptor)	305	2.00e-82
		AAB70007.1	GABA-A receptor delta subunit	305	2.00e-82
		AAH33801.1	gamma-aminobutyric acid (GABA) A receptor, delta	302	2.00e-81
		NP_000804.1	gamma-aminobutyric acid (GABA) A receptor, beta 2, isoform 2	302	2.00e-81
		P47870	GAB2_HUMAN Gamma-aminobutyric-acid receptor beta-2 subunit precursor (GABA(A) receptor)	302	2.00e-81
			gamma-aminobutyric acid A receptor beta 2 subunit; (GABA)A receptor beta 2 subunit	302	2.00e-81
		AAB29370.1		302	2.00e-81
		AAB33983.1	GABA receptor beta 2 subunit	302	2.00e-81
				268	2.00e-71
		NM_008009		268	2.00e-71
	NP_032035.1	Mm.46053 2.32	NP_005121.1 heparin-binding growth factor binding protein		
		A41178	heparin-binding growth factor-binding protein precursor		

		AAA58636.1	heparin binding protein	268	2.00e-71
		AAD39216.1	AF149412_1 HBP17 heparin-binding and FGF-binding protein	268	2.00e-71
		AAH03628.1	heparin-binding growth factor binding protein	268	2.00e-71
		AAH08910.1	heparin-binding growth factor binding protein	268	2.00e-71
NM_008352	U:(C-IR) 2.29		interleukin 12B precursor; natural killer cell stimulatory factor-2; interleukin 12B; cytotoxic lymphocyte maturation factor 2, p40; interleukin-12 beta chain; interleukin 12, p40; natural killer cell stimulatory factor, 40 kD subunit; IL23, subunit p40	431	e-120
NP_032378.1	U:(C-D) 2.24	NP_002178.2	IL2B_HUMAN Interleukin-12 beta chain precursor (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (NK cell stimulatory factor chain 2) (NKSF2)	431	e-120
	P29460		interleukin 12B precursor	431	e-120
	A38957		cytotoxic lymphocyte maturation factor 40 kDa subunit	431	e-120
	AAA35695.1		cytotoxic lymphocyte maturation factor 40 kDa subunit	431	e-120
	AAD55386.1	AF180563_1 interleukin 12, P40		431	e-120
	AAG32620.1	interleukin 12 p40 subunit		431	e-120
		AF512686_1 interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)		431	e-120
	AAM34792.1			429	e-120
	AAA59938.1	natural killer cell stimulatory factor		400	e-111
	1F42	A Chain A, The P40 DChain Of Human Interleukin-12		400	e-111
	1F45	A Chain A, Human Interleukin-12		234	5.00e-61
NM_019980	U:(C-IR) 2.28	BAB32547.1	small integral membrane protein of lysosome/late endosome		
NP_064364.1	Mm.2111 9			178	3.00e-56
		NP_004853.1	LPS-induced TNF-alpha factor		







		NP_003059.1	small 2; neural crest transcription factor SLUG; slug (chicken homolog), zinc finger protein	249	6.00e-66
	O43623	SLUG_HUMAN Zinc finger protein SLUG (Neural crest transcription factor Slug) (Snail homolog 2)		249	6.00e-66
	AAC31288.1	zinc finger protein slug		249	6.00e-66
	AAD55240.1	AF084243_1 zinc finger protein SLUG		249	6.00e-66
	AAH14890.1	AAH14890 slug (chicken homolog), zinc finger protein		249	6.00e-66
	AAH15895.1	AAH15895 slug (chicken homolog), zinc finger protein		249	6.00e-66
NM_021546	Mm.1437	U:(C-IR) 2.26	AAL01118.1 AF409141_1 NIP1	477	e-134
NP_067521.1	48				
		NP_112508.1	amyloid beta (A4) precursor protein-binding, family A, member 2 binding protein, isoform 1; synaptotagmin interacting protein STIP3; X11L-binding protein 51; amyloid beta (A4) precursor protein-binding, family A, member 2; synaptotagmin interacting protein 2; neuronal calcium-binding protein NECAB3	475	e-134
		AAG28415.1	AF193759_1 neuronal calcium binding protein NECAB3	475	e-134
		CAD37360.1	dJ63M2.4.1 (amyloid beta (A4) precursor protein-binding family A, member 2 protein, variant 1)	397	e-110
		NP_112509.1	amyloid beta (A4) precursor protein-binding, family A, member 2 binding protein, isoform 2; synaptotagmin interacting protein STIP3; X11L-binding protein 51; amyloid beta (A4) precursor protein-binding, family A, member 2; synaptotagmin interacting protein 2; neuronal calcium-binding protein NECAB3	358	2.00e-98
		BAB16413.1	X11L-binding protein 51	358	2.00e-98
		NP_071746.1	synaptotagmin interacting protein 1	254	3.00e-67
		BAC04568.1	unnamed protein product	254	3.00e-67
		AAG28412.1	AF193756_1 neuronal calcium binding protein NECAB1	196	7.00e-50
NM_025746	Mm.4614	U:(C-IR) 2.24	2208307A PNG gene	206	9.00e-53
NP_080022.1	2				

AK010751						
AAN60072.1	Mm.29522	U:(C-IR) 2.23	AAI23683.1	MARK4 serine/threonine protein kinase unnamed protein product	183	9.00e-51
		BAC11510.1			183	9.00e-51
		AAM55491.1	MAP/microtubule affinity-regulating kinase-like 1		183	9.00e-51
		BAC03375.1	microtubule affinity-regulating kinase-like1		183	9.00e-51
		BAB55238.1	unnamed protein product		183	9.00e-51
NM_028189	Mm.2885	U:(C-IR) 2.22	BAB21531.1	beta-1,3-N-acetylglucosaminyltransferase bGnT-3	508	e-144
NP_082465.1	6	U:(C-IR) 2.41	NP_055071.1	beta-1,3-N-acetylglucosaminyltransferase bGnT-3; type II membrane protein; transmembrane protein 3; core 1 extending beta-1,3-N-acetylglucosaminyltransferase; beta-1,3-galactosyltransferase; beta-1,3-galatase 8; beta3gal-T8; UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 8; beta-3-GX-T8	506	e-143
Q9Y2A9				B3G8_HUMAN Beta-1,3-galactosyltransferase 8 (Beta-1,3-GalTase 8) (Beta3Gal-T8) (b3Gal-T8) (UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 8) (UDP-Gal:beta-GlcNAc beta-1,3-galactosyltransferase 8) (Beta-3-Gx-T8) (Core 1 extending beta-1,3-N-acetylglucosaminyltransferase) (Core1-beta3GlcNAcT)	506	e-143
			BAA76497.1	type II membrane protein	506	e-143
			AAK00849.1	AF293973_1 core 1 extending beta-1,3-N-acetylglucosaminyltransferase	506	e-143
			CAC45044.1	beta-1,3-galactosyltransferase	506	e-143
			CAC82374.1	beta 1,6-GlcNAc transferase	458	e-128
			NP_619651.1	beta-1,3-N-acetylglucosaminyltransferase protein	332	1.00e-90
			BAB88882.1	beta-1,3-N-acetylglucosaminyltransferase 6	332	1.00e-90
			AAH235357.1	Unknown (protein for IMAGE:4907098)	298	3.00e-80
			NP_660279.1	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7; hypothetical gene supported by AK000770	266	1.00e-70

		AAM61770.1	AF502430_1 beta 1,3-N-acetylglucosaminyltransferase 7	2666	1.00e-70
		CAC45045.1	beta-1,3-galactosyltransferase	254	4.00e-67
		BAC04622.1	unnamed protein product	253	9.00e-67
		CAC82375.1	beta 1,3 galactosyltransferase	253	9.00e-67
		AAL37219.1	AF321825_1 beta-1,3-galactosyltransferase-related protein	253	9.00e-67
NM_008522	U:(C-IR)				
NP_032548.1	Mm.7612	2.22	AAA59479.1 neutrophil lactoferrin	1038	0
			P02788 TRFL_HUMAN Lactotransferrin precursor (Lactoferrin) [Contains: Lactoferrin A; Lactoferrin C]	1038	0
			TFHUIL lactotransferrin precursor	1038	0
			AAB60324.1 lactoferrin	1038	0
			AAH15822.1 lactotransferrin	1036	0
			AAH22347.1 lactotransferrin	1035	0
			CAA37116.1 precursor lactoferrin (709 AA)	1035	0
			AAA36159.1 lactoferrin	1035	0
			AAN11304.1 lactoferrin	1035	0
			AAA59511.1 lactoferrin	1035	0
			AAG48753.1 lactoferrin precursor	1034	0
			AAN63998.1 lactotransferrin precursor	1034	0
			AAH15823.1 lactotransferrin	1033	0
			NP_002334.1 lactotransferrin	1032	0
			CAA37914.1 precursor (AA -19 to 692)	1032	0
NM_009637	U:(C-IR)				
NP_033767.1	Mm.86453	2.22	XP_058567.1 similar to AE binding protein 2; AE-binding protein 2	562	e-160
			NP_694939.1 hypothetical protein MGCI17922	562	e-160
			AAH15624.1 AAH15624 Similar to AE-binding protein 2	562	e-160

NM_010198 NP_034328.1	Mm.5723 2.22	U:(C-IR) 2.22	AAH22220.1 Unknown (protein for MGC:17922)			562 e-160
			NP_004103.1 fibroblast growth factor 11; fibroblast growth factor homologous factor 3			444 e-125
			Q92914 FGFB_HUMAN Fibroblast growth factor-11 (FGF-11) (Fibroblast growth factor homologous factor 3) (FHF-3)			444 e-125
			AAB18915.1 fibroblast growth factor homologous factor 3			444 e-125
			AAL15439.1 fibroblast growth factor 11			444 e-125
			AAM11871.1 fibroblast growth factor 11			444 e-125
			AAH32502.1 fibroblast growth factor 11			444 e-125
			NP_004106.1 fibroblast growth factor 14; fibroblast growth factor homologous factor 4			273 1.00e-73
			Q92915 FGFE_HUMAN Fibroblast growth factor-14 (FGF-14) (Fibroblast growth factor homologous factor 4) (FHF-4)			273 1.00e-73
			AAB18916.1 fibroblast growth factor homologous factor 4			273 1.00e-73
			AAN16025.1 AE014303_1 FHF4			273 1.00e-73
			NP_066360.1 fibroblast growth factor 12 isoform 1; fibroblast growth factor homologous factor 1; myocyte-activating factor; fibroblast growth factor 12B; fibroblast growth factor FGF-12b			273 2.00e-73
			Q92912 FGFC_HUMAN Fibroblast growth factor-12 (FGF-12) (Fibroblast growth factor homologous factor 1) (FHF-1) (Myocyte-activating factor)			273 2.00e-73
			AAB18913.1 fibroblast growth factor homologous factor 1			273 2.00e-73
			CAA94239.1 fibroblast growth factor 11			261 5.00e-70
			NP_004105.1 fibroblast growth factor 13, isoform 1A; fibroblast growth factor homologous factor 2			246 2.00e-65
			Q92913 FGFD_HUMAN Fibroblast growth factor-13 (FGF-13) (Fibroblast growth factor homologous factor 2) (FHF-2)			246 2.00e-65
			AAB18914.1 fibroblast growth factor homologous factor 2			246 2.00e-65
			AAD16400.1 fibroblast growth factor 13 isoform 1A			246 2.00e-65
			AAH12347.1 AAH12347 Unknown (protein for MGC:20109)			246 2.00e-65
			AAH3340.1 fibroblast growth factor 13			246 2.00e-65

		NP_004104.3	fibroblast growth factor 12 isoform 2; fibroblast growth factor homologous factor 1; myocyte-activating factor; fibroblast growth factor 12B; fibroblast growth factor FGF-12b	223	2.00e-58
	JG0184		fibroblast growth factor - human	221	7.00e-58
	AAB18786.3		fibroblast growth factor	221	7.00e-58
	AAH22524.1	Unknown (protein for MGC:26659)		219	2.00e-57
	NP_378668.1	fibroblast growth factor 13 isoform 1B; fibroblast growth factor homologous factor 2		213	1.00e-55
	AAD16401.1	fibroblast growth factor 13 isoform 1B		213	1.00e-55
NM_007995	U:(C-IR) 2.21 U:(C-D) 2.45	NP_001994.2	ficolin 1 precursor; ficolin (collagen/fibrinogen domain-containing) 1	386	e-107
NP_032021.1	Mm.10510	O00602	FCN1 HUMAN Ficolin 1 precursor (Collagen/fibrinogen domain-containing protein 1) (Ficolin-A) (Ficolin A) (M-Ficolin)	386	e-107
		AAH20635.1	ficolin (collagen/fibrinogen domain-containing) 1	386	e-107
		BAA12120.1	ficolin	386	e-107
		S61517	ficolin-1 precursor	382	e-106
		AAB50706.1	ficolin	382	e-106
		NP_004099.1	ficolin 2 isoform a precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2 (fucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin	379	e-105
		Q15485	FCN2 HUMAN Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Ficolin-B) (Ficolin B) (Serum lectin p35) (EBP-37) (Hucolin) (L-Ficolin)	379	e-105
		BAA08352.1	serum lectin P35	379	e-105
		BAA09636.1	lectin P35	379	e-105
			ficolin 2 isoform b precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2		
		NP_056652.1	(fucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin	352	6.00e-97
			ficolin 3 precursor; ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen)	289	5.00e-78
		NP_003656.1			

	O75636	FCN3_HUMAN Ficolin 3 precursor (Collagen/fibrinogen domain-containing lectin 3 p35) (Hakata antigen)	289	5.00e-78
	3) (Collagen/fibrinogen domain-containing lectin 3 p35) (Hakata antigen)		289	5.00e-78
BAA32277.1	Hakata antigen		281	2.00e-75
AAH20731.1	Similar to ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen)		281	2.00e-75
BAC11429.1	unnamed protein product		236	7.00e-62
AAH32953.1	Unknown (protein for MGC:33476)		215	1.00e-55
XP_045044.2	similar to Microfibril-associated glycoprotein 4		215	1.00e-55
NP_002395.1	microfibrillar-associated protein 4; microfibril-associated glycoprotein 4		215	1.00e-55
P55083	MFA4_HUMAN Microfibril-associated glycoprotein 4 precursor		215	1.00e-55
AAB00968.1	microfibril-associated glycoprotein 4		215	1.00e-55
AK006553	U:(C-IR) 2.2 U:(C-D) 2.58 U:(IR-D) 2.72			
BAB24650.1	Mm.59283	NP_063839.1 hypothetical protein	398	e-110
NM_021370	Mm.8883	NP_689550.1 hypothetical protein FLJ32702	397	e-110
NP_067345.1	g	BAB71401.1 unnamed protein product	397	e-110
	2.19	NP_032835.1 similar to amiloride-sensitive sodium channel	776	0
CAB85607.1	amiloride-sensitive sodium channel		776	0
AAB48981.1	sodium channel 2		218	2.00e-56
NP_001086.2	amiloride-sensitive cation channel 2; neuronal isoform b; hBNaC2; Cation channel, amiloride-sensitive, neuronal, 2		218	2.00e-56
AAC62935.1	proton-gated cation channel subunit		213	5.00e-55
NP_064717.1	testis amiloride-sensitive cation channel 3, isoform b; testis sodium channel 1; proton-gated cation channel subunit; modulatory subunit of ASIC2a		211	3.00e-54
AAF19818.1	AF195025_1 acid sensing ion channel 3 splice variant c		211	3.00e-54

NP_004760.1	testis amiloride-sensitive cation channel 3, isoform a; testis sodium channel 1; proton-gated cation channel subunit; modulatory subunit of ASIC2a	211	3.00e-54						
AAC64188.1	proto-gated cation channel ASIC3	211	3.00e-54						
NP_064718.1	testis amiloride-sensitive cation channel subunit; modulatory subunit of ASIC2a	211	3.00e-54						
AAF19817.1	AF195024_1 acid sensing ion channel 3 splice variant b	211	3.00e-54						
NP_001085.2	neuronal amiloride-sensitive cation channel 1; degenerin	206	1.00e-52						
Q16515	BNA1_HUMAN Amiloride-sensitive brain sodium channel BNaC1 (Amiloride-sensitive cation channel neuronal 1) (BNC1) (Degenerin channel MDEG)	206	1.00e-52						
AAC50498.1	degenerin channel MDEG	206	1.00e-52						
AAB49182.1	sodium channel 1	206	1.00e-52						
AAC50432.1	sodium channel 1	206	1.00e-52						
2211325A	Na channel	206	1.00e-52						
JE0091	testis sodium channel 1	203	5.00e-52						
BAA25897.1	sodium channel	203	5.00e-52						
U(C-IR) NP_057453.1	claudin 18	424	e-118						
U(C-IR) 2.17									
NM_019815	Mm.3509								
NP_062789.1	0								
		P56856	CLD1_HUMAN Claudin-18	424	e-118				
		AAF26448.1	AF221069_1 Claudin-18	424	e-118				
		AAL15637.1	AF349452_1 claudin-18A2.1	399	e-110				
		U(C-IR) 2.17	retinoid binding protein 7; putative cellular retinol-binding protein CRBP IV	259	2.00e-69				
NM_022020	Mm.4602								
NP_071303.1	3	NP_071303.1	2.04	Q96R05	RET7_HUMAN Retinol-binding protein IV, cellular (CRBP-IV) (Retinoid binding protein 7)	259	2.00e-69		
				AAK85409.1	retinoid binding protein 7	259	2.00e-69		

		AAN61071.1	putative cellular retinol-binding protein CRBP IV	259	2.00e-69
		AAH33833.1	Similar to retinoid binding protein 7	212	3.00e-55
NM_007702		U:(C-IR) 2.16	NP_001270.1 cell death-inducing DFFA-like effector a	340	3.00e-93
NP_031728.1	Mm.449	O60543	CIDA_HUMAN Cell death activator CIDE-A (Cell death-inducing DFFA-like effector A)	340	3.00e-93
		AAC34987.1	cell death activator CIDE-A	340	3.00e-93
		AAH31896.1	Similar to cell death-inducing DFFA-like effector a	319	5.00e-87
NM_025639	Mm.2359	U:(C-IR) 2.16	NP_076958.1 hypothetical protein MGC861	293	2.00e-79
NP_079915.1	6		CAB77147.1 hypothetical protein	293	2.00e-79
			AAH00705.1 AAH00705 Unknown (protein for MGC:861)	293	2.00e-79
NM_025834	Mm.8079	U:(C-IR) 2.16	AAH07495.1 AAH07495 hypothetical protein MGC861	293	2.00e-79
NP_080110.1	8	NP_003882.1	protein Z, vitamin K-dependent plasma glycoprotein	560	e-159
		P22891	PRTZ_HUMAN Vitamin K-dependent protein Z precursor	560	e-159
		AAA36500.1	protein Z	560	e-159
		BAA85763.1	protein Z	560	e-159
		AAL27631.1	AF440358_1 protein Z, vitamin K-dependent plasma glycoprotein	560	e-159
		KXHUUZ	plasma protein Z precursor	550	e-156
		AAA36501.1	protein Z	550	e-156
		BAA85764.1	protein Z spliced variant	550	e-156
		AAA36499.1	protein Z	454	e-127
		AAA51984.1	coagulation factor X precursor	214	7.00e-55
		1205236A	coagulation factor X	214	7.00e-55
		AAA52490.1	factor X prepeptide	213	1.00e-54
		NP_000495.1	coagulation factor X precursor; Prothrombinase	213	1.00e-54

	P00742	FA10_HUMAN Coagulation factor X precursor (Stuart factor)	213	1.00e-54
	EXH1U	coagulation factor Xa (EC 3.4.21.6) precursor	213	1.00e-54
	AAA52421.1	coagulation factor X	213	1.00e-54
	AAA52764.1	coagulation factor X	213	1.00e-54
	AAM19347.1	AF503510_1 coagulation factor X	213	1.00e-54
	CAA21954.1	F9 (coagulation factor IX (plasma thromboplastic component, Christmas disease,haemophilia B))	201	6.00e-51
	NP_000124.1	coagulation factor IX; Coagulation factor IX (plasma thromboplastic component); Factor 9; Factor IX; Christmas factor	201	6.00e-51
	AAA52023.1	coagulation factor IX precursor	201	6.00e-51
	AAA52763.1	factor IX (Christmas factor) precursor	201	6.00e-51
	AAM96188.1	coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B)	201	6.00e-51
	P00740	FA9_HUMAN Coagulation factor IX precursor (Christmas factor)	201	6.00e-51
	KFHU	coagulation factor IXa (EC 3.4.21.22) precursor	201	6.00e-51
	AAB59620.1	factor IX	201	6.00e-51
	AAA56822.1	factor IX	201	6.00e-51
	AAA98726.1	factor IX	199	3.00e-50
U16162 AAC52197.1	U:(C-IR) Mm.2212 2.16	DAHUA1	procollagen-proline dioxygenase (EC 1.14.11.2) alpha chain precursor, splice form 1	1001 0
		AAA59069.1	alpha-subunit of prolyl 4-hydroxylase	1001 0
		NP_000908.1	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide 1; procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide 1	991 0
		AAA36534.1	prolyl 4-hydroxylase alpha subunit (EC 1.14.11.2)	991 0
	P13674	P4H1_HUMAN Prolyl 4-hydroxylase alpha-1 subunit precursor (4-PH alpha-1) (Procollagen-proline,2-oxoglutarate-4-dioxygenase alpha-1 subunit)	982 0	
	DAHUA2	procollagen-proline dioxygenase (EC 1.14.11.2) alpha chain precursor, splice form 2	982 0	

		AAA59068.1	alpha-subunit of prolly 4-hydroxylase	982	0
		AAH34998.1	Similar to procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I	982	0
		AAA36535.1	prolyl 4-hydroxylase alpha subunit (EC 1.14.11.2)	971	0
		NP_004190.1	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II; prolly 4-hydroxylase, alpha polypeptide, type 2, prolly 4-hydroxylase, alpha polypeptide, type II	679	0
		O15460	P4H2_HUMAN Prolyl 4-hydroxylase alpha-2 subunit precursor (4-PH alpha-2 (Procollagen-proline,2-oxoglutarate-4-dioxygenase alpha-2 subunit)	679	0
		AAB71339.1	prolyl 4-hydroxylase alpha (II) subunit	679	0
		CAC85689.1	Prolyl 4-hydroxylase alpha IIb subunit	679	0
		CAC85688.1	Prolyl 4-hydroxylase alpha IIa subunit	658	0
		AAH35813.1	Similar to procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II	658	0
	U:(C-IR) 2.15 Mm: 1028 U:(C-D) 2.04 NP_038771.1 3	NP_002603.1	pyruvate dehydrogenase kinase, isoenzyme 4	764	0
		Q16654	PDK4_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial precursor (Pyruvate dehydrogenase kinase isozyme 4)	764	0
		AAC50669.1	pyruvate dehydrogenase kinase isoform 4	764	0
		AAC50670.1	pyruvate dehydrogenase kinase isoform 4	764	0
		AAB67048.1	pyruvate dehydrogenase kinase isoform 4	764	0
		AAH40239.1	pyruvate dehydrogenase kinase, isoenzyme 4	764	0
		NP_002601.1	pyruvate dehydrogenase kinase, isoenzyme 1	562	e-159
		Q15118	PDK1_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial precursor (Pyruvate dehydrogenase kinase isozyme 1)	562	e-159
		I55465	[Pyruvate dehydrogenase (lipoamide)] kinase (EC 2.7.1.99) 1	562	e-159
		AAC42009.1	pyruvate dehydrogenase kinase	562	e-159

	AAH39158.1	Similar to pyruvate dehydrogenase kinase, isoenzyme 1	562	e-159
	2203383A	pyruvate dehydrogenase kinase:ISOTYPE=1	562	e-159
	NP_002602.2	pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
Q15119	PDK2_HUMAN	[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 2)	556	e-157
	AAH05811.1	AAH05811 pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
	AAH40478.1	pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
I70159		[Pyruvate dehydrogenase [lipoamide]] kinase (EC 2.7.1.99) 2	554	e-157
	AAC42010.1	pyruvate dehydrogenase kinase	554	e-157
	2203383B	pyruvate dehydrogenase kinase:ISOTYPE=2	554	e-157
	NP_005382.1	pyruvate dehydrogenase kinase, isoenzyme 3	527	e-149
Q15120	PDK3_HUMAN	[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 3)	527	e-149
I70160		[Pyruvate dehydrogenase [lipoamide]] kinase (EC 2.7.1.99) 3	527	e-149
	AAC42011.1	pyruvate dehydrogenase kinase	527	e-149
	AAH15948.1	AAH15948 pyruvate dehydrogenase kinase, isoenzyme 3	527	e-149
	2203383C	pyruvate dehydrogenase kinase:ISOTYPE=3	527	e-149
NM_025806	U:(C-IR) NP_079105.1	hypothetical protein FLJ22662	870	0
NP_080082.1	Mm.3311 2.15			
	BAB15442.1	unnamed protein product	870	0
	AAH00909.2	AAH00909 hypothetical protein FLJ22662	397	e-110
	XP_113725.2	similar to RIKEN cDNA 1300012G16	271	2.00e-72
	AAH30618.1	similar to RIKEN cDNA 1300012G16	271	2.00e-72
NM_008030	U:(C-IR) 2.14			
NP_032056.1	Mm.2900 2.22	U:(C-D) P31513	FMO3_HUMAN Dimethylaniline monooxygenase [N-oxide forming] 3 (Hepatic flavin-containing monooxygenase 3) (FMO 3) (Dimethylaniline oxidase 3) (FMO II)	847 0
	AAC51932.1		flavin containing monooxygenase 3	847 0

		dJ127D3.1 (Hepatic Flavin-containing Monooxygenase 3 (Dimethylamine Monoxygenase (N-Oxide forming) 3, EC1.14.13.8, Dimethylamine Oxidase 3, FMO II, FMO 3))	.	847	0
	AAH32016.1	flavin containing monooxygenase 3		847	0
	NP_008825.2	flavin containing monooxygenase 3; Flavin-containing monooxygenase-3		846	0
	S511130	dimethylamine monooxygenase (N-oxide-forming) (EC 1.14.13.8) 3		846	0
	CAA87632.1	flavin-containing monooxygenase 3 (FMO3)		846	0
	A38228	dimethylamine monoxygenase (N-oxide-forming) (EC 1.14.13.8), hepatic 2	795	0	
	AAA86784.1	flavoprotein	795	0	
	CAA15909.1	dJ127D3.2 (Flavin-containing Monooxygenase family protein)	770	0	
	Q99518	FMO2_HUMAN Dimethylamine monooxygenase [N-oxide forming] 2 (Pulmonary flavin-containing monooxygenase 2) (FMO 2) (Dimethylamine oxidase 2) (FMO 1B1)	610	e-174	
	NP_002012.1	flavin containing monooxygenase 1; Flavin-containing monooxygenase 1 (fetal liver)	580	e-165	
	Q01740	FMO1_HUMAN DIMETHYLANILINE MONOOXYGENASE [N-OXIDE FORMING] 1 (FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 1) (FMO 1) (DIMETHYLANILINE OXIDASE 1)	580	e-165	
	A40876	dimethylamine monooxygenase (N-oxide-forming) (EC 1.14.13.8), hepatic 1	580	e-165	
	AAA52457.1	flavin-containing monooxygenase	580	e-165	
	NP_001451.1	flavin containing monooxygenase 2; Flavin-containing monooxygenase 2 (adult liver)	561	e-159	
	CAA70462.1	flavin-containing monooxygenase 2	561	e-159	
	CAA15910.1	dJ127D3.3 (Flavin-containing Monooxygenase 2)	561	e-159	
	AAH05894.1	flavin containing monooxygenase 2	561	e-159	
	P49326	FMO5_HUMAN DIMETHYLANILINE MONOOXYGENASE [N-OXIDE FORMING] 5 (HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 5) (FMO 5) (DIMETHYLANILINE OXIDASE 5)	546	e-155	
	S71618	dimethylamine monooxygenase (N-oxide-forming) (EC 1.14.13.8) FMO5	546	e-155	
	AAA67849.1	flavin-containing monooxygenase 5	546	e-155	
	NP_001452.1	flavin containing monooxygenase 5	545	e-155	

		S51131	flavin-containing monooxygenase 5 (FMO5)	545	e-155
		CAA87633.1	flavin-containing monooxygenase 5 (FMO5)	545	e-155
NM_011012 NP_035142.1	U:(C-IR) Mm_2991 2.14	NP_000904.1	opiate receptor-like 1; kappa3-related opioid receptor	573	e-163
		P41146	OPRX_HUMAN Nociceptin receptor (Orphanin FQ receptor) (Kappa-type 3 opioid receptor) (KOR-3)	573	e-163
		S43087	orphan opioid receptor ORL1	573	e-163
		CAAS4386.1	ORL1	573	e-163
		AAA84913.1	orphan opioid receptor	573	e-163
		AAK11714.1	AF348323_1 nociceptin receptor	573	e-163
		AAH33433.1	opiate receptor-like 1	573	e-163
		AAL54890.1	AF126470_1 KOR-3D	558	e-159
		AAA96251.1	opioid receptor-like protein	509	e-144
		2201468A	opioid orphan receptor	509	e-144
		CAC17003.1	dJ1022E24.1 (opiate receptor-like protein 1 (OPRL1))	445	e-125
		CAC15482.1	dJ366F13.1 (opioid receptor mu 1)	296	4.00e-80
		P35372	OPRM_HUMAN Mu-type opioid receptor (MOR-1)	296	4.00e-80
		I56553	mu opiate receptor	296	4.00e-80
		AAA73958.1	opioid receptor	296	4.00e-80
		2108340A	mu opioid receptor	296	4.00e-80
		NP_000905.1	opioid receptor, mu 1	296	4.00e-80
		AAA20580.1	Mu opiate receptor	296	4.00e-80
		S65693	opioid receptor mu variant MOR1A	293	4.00e-79
		AAB60354.1	mu opioid receptor variant	293	4.00e-79
		AAN87342.1	DRG kappa 1 splice variant KOR 1A	285	8.00e-77
		P41143	OPRD_HUMAN Delta-type opioid receptor (DOR-1)	285	1.00e-76
		AAA83426.1	delta opiate receptor	285	1.00e-76

		CAA15671.1	dJ212P9.1		285	1.00e-76
NM_015750 NP_056565.1	Mm.4567 NP_056565.1_0	U:(C-IR) 2.14	NP_005374.1	staldase 2; cytosolic sialidase; N-acetyl-alpha-neuramidase 2	539	e-153
			Q9Y3R4	NER2_HUMAN Sialidase 2 (Cytosolic sialidase) (N-acetyl-alpha-neuramidase 2)	539	e-153
			CAB41449.1	neuraminidase; sialidase	539	e-153
			NP_006647.2	sialidase 3; neuramidase 3; ganglioside sialidase; N-acetyl-alpha-neuramidase 3	267	4.00e-71
			CAB96131.1	Nuramidase	267	4.00e-71
			Q9UQ49	NER3_HUMAN Sialidase 3 (Membrane sialidase) (Ganglioside sialidase) (N-acetyl-alpha-neuramidase 3)	264	3.00e-70
			BAA82611.1	ganglioside sialidase	264	3.00e-70
			CAC81904.1	staldase	231	2.00e-60
			NP_542779.2	staldase	231	3.00e-60
NM_031389 NP_113566.1	Mm.8479 NP_113566.1_2	U:(C-IR) 2.14	XP_085972.4	similar to PYRIN-containing APAF1-like protein 4; PAAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	758	0
			NP_604393.1	PYRIN-containing APAF1-like protein 4; PAAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	758	0
			Q96MN2	NAL4_HUMAN NACHT-, LRR- and PYD-containing protein 4 (PAAAD and NACHT-containing protein 2) (PYRIN-containing APAF1-like protein 4) (Ribonuclease inhibitor 2)	758	0
			AAL35293.1	AF442488_1_NALP4	758	0
			AAL68396.1	PAAAD and NACHT-containing protein 2	758	0
			AAL87104.1	AF479747_1_PYRIN-containing APAF1-like protein 4	758	0
			BAB71254.1	unnamed protein product	758	0
			AAL88672.1	AF482706_1_ribonuclease inhibitor 2	749	0
			XP_062261.4	similar to PYRIN-containing APAF1-like Protein 7	495	e-139
			NP_659444.1	PYRIN-containing APAF1-like protein 6	427	e-119
			PS9045	PYA6_HUMAN PYRIN-containing APAF1-like protein 6	427	e-119
			AAM14632.1	PYRIN-containing APAF1-like protein 6	427	e-119

		AAH34730.1	PYRIN-containing APAF1-like protein 6	427	e-119
		AAH16443.1	AAH16443 Unknown (protein for IMAGE:3448931)	391	e-108
		AAL78632.1	AF468522_1 NALP3 long isoform	379	e-104
		NP_004886.2	cold autoinflammatory syndrome 1; chromosome 1 open reading frame 7; angiotensin/vasopressin receptor AI/AVP-like; cryopyrin; PYRIN-containing APAF1-like protein 1	378	e-104
		Q96P20	CIS1_HUMAN Cold autoinflammatory syndrome 1 protein (Cryopyrin) (NACHT-, LRR-and PYD-containing protein 3)(PYRIN-containing APAF1-like protein 1) (Angiotensin/vasopressin receptor AI/AVP-like)	378	e-104
		AAL33908.1	AF410477_1 cryopyrin	378	e-104
		AAL12497.1	cryopyrin	378	e-104
		AAL65136.1	AF420469_1 PYRIN-containing APAF1-like protein 1	378	e-104
		XP_064988.5	similar to PYRIN-containing APAF1-like protein 4; PAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	367	e-101
NM_025621 NP_079897.1	Mm.1442 2.11	U:(C-IR) NP_088993.1	similar to RIKEN cDNA 2310050C09	229	5.00e-60
NM_011377 NP_035507.1	Mm.4775 2.09	U:(C-IR) NP_005060.1	single-minded (Drosophila) homolog 2 long isoform; human transcription factor SIM2, homolog of the Drosophila single-minded gene SIM1	939	0
		Q14190	SIM2_HUMAN Single-minded homolog 2	939	0
		AAB62396.1	transcription factor SIM2 long form	939	0
		BAA89433.1	single-minded 2 protein	939	0
		NP_033664.1	single-minded (Drosophila) homolog 2 short isoform; human transcription factor SIM2, homolog of the Drosophila single-minded gene SIM1	849	0
		AAB62397.1	transcription factor SIM2 short form	849	0
		CAA05055.1	human SIM2	729	0
		NP_005059.2	single-minded (Drosophila) homolog 1; Single-minded, drosophila, homolog of, 1	634	0
		P81133	SIM1_HUMAN Single-minded homolog 1	629	e-180
		AAB62395.1	hSIM1	629	e-180

		A58520	single-minded gene 2 protein	462	e-129
		BAA12919.1	Sim	461	e-129
		NP_071406.1	basic-helix-loop-helix-PAS protein	295	3.00e-79
		AAG35180.1	AF164438_1 basic-helix-loop-helix-PAS protein	295	3.00e-79
		BAB21221.1	NPASS3 (MOP6)	295	5.00e-79
		BAC53756.1	NPASS3	295	5.00e-79
AF319951 AAL37178.1	Mm.35253 2.08	U:(C-IR) AAM73657.1	solute carrier family 12 member 8	1011	0
		AAK94307.1	solute carrier family 12 member 8	766	0
		AAH20506.1	hypothetical protein FLJ23188	370	e-102
			solute carrier family 12 (potassium/chloride transporters), member 8; solute carrier family 12 (sodium/potassium/chloride transporters), member 8	369	e-101
		NP_078904.1	unnamed protein product	369	e-101
		BAB15571.1	solute carrier family 12 (sodium/potassium/chloride transporters), member 2; Solute carrier family 12 (sodium/potassium/chloride transporters)	229	2.00e-59
		NP_001037.1		229	2.00e-59
		P55011	S122_HUMAN Solute carrier family 12 member 2 (Bumetanide-sensitive Na-K-Cl cotransporter)	229	2.00e-59
		A57187	bumetanide-sensitive Na-K-Cl cotransporter	229	2.00e-59
		AAC50561.1	bumetanide-sensitive Na-K-Cl cotransporter	229	2.00e-59
		AAH33003.1	Similar to solute carrier family 12 (sodium/potassium/chloride	229	2.00e-59
		NP_000329.1	sodium potassium chloride cotransporter 2; Solute carrier family 12	223	1.00e-57
		Q13621	S121_HUMAN Solute carrier family 12 member 1 (Bumetanide-sensitive Na-K-Cl cotransporter)	223	1.00e-57
		AAB07364.1	S123_HUMAN Solute carrier family 12 member 3 (Thiazide-sensitive sodium-chloride	223	1.00e-57
		P55017		201	4.00e-51
			solute carrier family 12 (sodium/chloride transporters), member 3; Solute carrier family 12 (sodium/potassium/chloride transporters),	201	4.00e-51
		NP_000330.1		201	4.00e-51
		AAC50355.1	thiazide-sensitive Na-Cl	201	4.00e-51
		G01202	NaCl electroneutral Thiazide-sensitive cotransporter	201	5.00e-51

NM_008074			CAA62613.1	NaCl electroneutral Thiazide-sensitive cotransporter	201	5.00e-51
NP_032100.1	Mm.1345	U:(C-IR) 2.08	NP_150092.1	gamma-aminobutyric acid (GABA) A receptor, gamma 3	841	0
			AAB30369.1	GABAA receptor gamma 3 subunit	841	0
			Q99928	GAC3_HUMAN Gamma-aminobutyric-acid receptor gamma-3 subunit precursor	838	0
			AAF99698.1	GABAA receptor gamma 3 subunit (GABA(A) receptor)	838	0
			AAF63215.1	GABAA receptor gamma 3 subunit	836	0
			AAD50273.1	gamma-aminobutyric acid A receptor gamma 2	588	e-167
			NP_000807.1	gamma-aminobutyric acid A receptor, gamma 2 precursor	584	e-166
			P18507	GAC2_HUMAN Gamma-aminobutyric-acid receptor gamma-2 subunit precursor	584	e-166
			S03905	gamma-aminobutyric acid/benzodiazepine receptor gamma-2 chain precursor	584	e-166
			CAA32437.1	GABA-A receptor gamma 2 subunit	584	e-166
			1506443A	GABAa receptor gamma2	584	e-166
			AAH31087.1	similar to GAMMA-AMINOBUTYRIC-ACID RECEPTOR GAMMA-1 SUBUNIT PRECURSOR (GABA(A) RECEPTOR)	576	e-164
				similar to Gamma-aminobutyric-acid receptor gamma-1 subunit precursor (GABA(A) receptor) [Homo sapiens]	576	e-164
			NP_004952.1	gamma-aminobutyric acid (GABA) A receptor, epsilon, isoform 1 precursor	378	e-104
			AAB49284.1	GABA-A receptor epsilon subunit	378	e-104
			P78334	GAE_HUMAN Gamma-aminobutyric-acid receptor epsilon subunit precursor (GABA(A) receptor)	378	e-104
			CAA70904.1	GABA receptor epsilon subunit	378	e-104
			AAB91645.1	GABA-A receptor epsilon subunit	378	e-104
			CAA70903.1	GABRE	374	e-103
NM_010899	Mm.1168	U:(C-IR) 2.08	Q13469	NFC2_HUMAN Nuclear factor of activated T-cells, cytoplasmic 2 (T cell transcription factor NFAT1) (NFAT pre-existing subunit)(NF-ATp)	1522	0
NP_035029.1	02					

		AAC50887.1	transcription factor NFAT1 isoform C	1522	0
		NP_036472.1	nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2; nuclear factor of activated T-cells, cytoplasmic 2	1487	0
	G02326		transcription factor NFAT1 isoform B - human	1487	0
		AAC50886.1	transcription factor NFAT1 isoform B	1487	0
		CAC00528.1	dJ994O24.1 (nuclear factor of activated T-cells, cytoplasmic 2 (isoforms B and C))	835	0
		CAB54871.1	dJ1009H6.1.2 (nuclear factor of activated T-cells, cytoplasmic 2, isoform C)	649	0
		CAC00529.1	dJ1009H6.1.1 (nuclear factor of activated T-cells, cytoplasmic 2, isoform B)	615	e-175
1A02			N Chain N, Structure Of The Dna Binding Domains Of Nfat, Fos And Jun Bound To Dna	567	e-161
		AAD00451.1	transcription factor	551	e-156
	O95644		NFC1_HUMAN Nuclear factor of activated T-cells, cytoplasmic 1 (NFAT transcription complex cytosolic component) (NF-ATc1) (NF-ATc)	550	e-156
		AAC50869.1	nuclear factor of activated T cells	523	e-148
		NP_006153.2	nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1; nuclear factor of activated T-cells, cytoplasmic 1	521	e-147
		AAD00450.1	transcription factor	521	e-147
	U:(C-IRR)	NP_037504.1	cysteine knot superfamily 1, BMP antagonist 1; gremlin	311	2.00e-84
	2.07				
NM_011824	Mm.3046				
NP_035954.1	U:(C-D)				
	5				
		AAC39725.1	gremlin	311	2.00e-84
		BAA84462.1	gremlin homologue	311	2.00e-84
		AAF06677.1	gremlin	311	2.00e-84
		AAG23891.1	AF154054_1 DRM	311	2.00e-84
		BAC04620.1	unnamed protein product	254	3.00e-67
		BAC04643.1	unnamed protein product	253	8.00e-67

AF193796 AAL09298.1_2	Mm.20706 2.07	U:(C-IR)					
		XP_006804.2	similar to Homeobox protein Hox-C13 (Hox-3G)				
		NP_059106.2	homeo box C13; homeobox protein Hox-C13; homeo box 3G	505	e-142		
		P31276	HXCD_HUMAN Homeobox protein Hox-C13 (Hox-3G	505	e-142		
		AAF73439.1	HOXC13	505	e-142		
		AAH02754.1	homeo box C13	505	e-142		
		AAF67760.1	homeoprotein C13	504	e-142		
		BAB14786.1	unnamed protein product	280	7.00e-75		
		P31271	HXAD_HUMAN Homeobox protein Hox-A13	218	4.00e-56		
		AAC50993.1	transcription factor HOXA13	218	4.00e-56		
			homeobox protein A13; homeobox protein HOXA13; homeo box 1J; transcription factor HOXA13	218	4.00e-56		
		NP_000514.1	homeo box D13; homeo box 4I; homeobox protein Hox-D13	216	2.00e-55		
		P35453	HXDD_HUMAN Homeobox protein Hox-D13 (Hox-4I)	216	2.00e-55		
		AAC51635.1	HOXD13	216	2.00e-55		
		BAA93352.1	homeobox transcription factor	216	2.00e-55		
NM_008152							
NP_032178.1	Mm.2840 2.07	U:(C-IR)					
		XP_007392.1	similar to G protein-coupled receptor 65; T-cell death-associated gene 8	527	e-149		
		AAH35633.1	similar to G protein-coupled receptor	527	e-149		
		NP_003599.1	G protein-coupled receptor 65; T-cell death-associated gene 8	521	e-147		
		AAC31794.1	T cell-death associated protein	521	e-147		
		S68207	G protein-coupled receptor 6C.1	196	8.00e-50		
		AAA79061.1	G protein-coupled receptor	196	8.00e-50		
		2124311B	G protein-coupled receptor	196	8.00e-50		
		NP_005273.1	G protein-coupled receptor 4	196	8.00e-50		
		XP_009140.1	similar to Probable G protein-coupled receptor GPR4 (GPR19)	196	8.00e-50		

		P46093	GPR4_HUMAN Probable G protein-coupled receptor GPR4 (GPR19)	196	8.00e-50
		A57641	G protein-coupled receptor 4	196	8.00e-50
		AAA98457.1	G protein-coupled receptor	196	8.00e-50
		1S3033	G protein-coupled receptor	196	8.00e-50
		AAA63180.1	G protein-coupled receptor	196	8.00e-50
NM_008324	U:(C-IR) 2.07	NP_002155.1	indoleamine-pyrrole 2,3 dioxygenase; Indoleamine 2,3-dioxygenase; indole 2,3-dioxygenase	499	e-141
NP_032350.1	Mm.392	P14902	I23O_HUMAN Indoleamine 2,3-dioxygenase (IDO) (Indoleamine-pyrrole 2,3-dioxygenase)	499	e-141
		PC1161	indoleamine-pyrrole 2,3-dioxygenase (EC 1.13.11.42)	499	e-141
		CAA35663.1	indoleamine 2,3-dioxygenase	499	e-141
		AAA36081.1	indoleamine 2,3-dioxygenase (IDO) (EC 1.13.11.17)	499	e-141
		AAH27882.1	indoleamine-pyrrole 2,3 dioxygenase	499	e-141
		XP_095645.4	similar to indoleamine 2,3-dioxygenase	313	4.00e-85
NM_009827	U:(C-IR) 2.07	NP_000721.1	cholecystokinin A receptor	693	0
NP_033957.1	Mm.3521	P32238	CCKR_HUMAN Cholecystokinin type A receptor (CCK-A receptor) (CCK-AR)	693	0
		JN0692	cholecystokinin type A receptor	693	0
		AAA35659.1	cholecystokinin A receptor	693	0
		AAA02819.1	cholecystokinin A receptor	693	0
		AAA91123.1	cholecystokinin type A receptor	693	0
		BAA90879.1	cholecystokinin type-A receptor	693	0
		2118221A	cholecystokinin A receptor	679	0
		P32239	GASR_HUMAN Gastrin/cholecystokinin type B receptor (CCK-B receptor) (CCK-BR)	350	8.00e-96
		A47430	gastrin/cholecystokinin receptor B, short splice form	350	8.00e-96

		AAA35660.1	cholecystokinin receptor		350	8.00e-96
		AAA35657.1	cholecystokinin-B/gastrin receptor		350	8.00e-96
		AAC37528.1	gastrin receptor		350	8.00e-96
		BAA02264.1	cholecystokinin receptor		350	8.00e-96
		AAH00740.1	AAH00740 cholecystokinin B receptor		350	8.00e-96
		AAA91831.1	cholecystokinin B receptor		348	2.00e-95
		AAB30766.2	cholecystokinin B receptor		348	2.00e-95
		BAA04759.1	cholecystokinin-B receptor/gastrin receptor		348	4.00e-95
		AAC27510.1	gastrin/cholecystokinin brain receptor		345	3.00e-94
		AAK38351.1	CCK-B/gastrin receptor variant		243	1.00e-63
		AAN32829.	AF441129_1 cholecystokinin-C receptor		243	1.00e-63
		NP_000722.2	cholecystokinin B receptor		241	5.00e-63
		AAF67174.1	AF239668_1 CCK-B/gastrin receptor		241	5.00e-63
NM_013920	Mm.4198	U:(C-IR)	JC6095	hepatocyte nuclear factor 4 gamma chain	749	0
NP_038948.1	5	2.07				
		2208436B	hepatocyte nuclear factor 4		749	0
		NP_004124.2	hepatocyte nuclear factor 4, gamma		739	0
		CAA89990.2	hepatocyte nuclear factor 4 gamma (HNF4gamma)		739	0
		Q14541	HNF4G_HUMAN Hepatocyte nuclear factor 4 gamma (HNF4-gamma)		738	0
		AAF00110.1	hepatocyte nuclear factor 4 gamma		738	0
		CAA61133.1	Hepatocyte nuclear factor 4A		582	e-166
		AAB48082.1	hepatocyte nuclear factor 4-alpha		579	e-165
		NP_000448.2	hepatocyte nuclear factor 4, alpha; transcription factor-14; hepatic nuclear factor 4, alpha		579	e-165
		JC6096	hepatocyte nuclear factor 4 alpha2 chain		579	e-165
		CAA89989.1	hepatocyte nuclear factor 4 alpha (HNF4alpha4)		579	e-165
		2208436A	hepatocyte nuclear factor 4:ISOTYPE=alpha		579	e-165

		CAC01303.1	dJ1013A22.1 (hepatocyte nuclear factor 4, alpha)	578	e-165
	P41235	HN4A_HUMAN Hepatocyte nuclear factor 4-alpha (HNF-4-alpha) (Transcription factor HNF-4) (Transcription factor 14)		578	e-165
	CAA54248.1	hepatocyte nuclear factor 4		576	e-164
	JC4937	hepatocyte nuclear factor 4, splice form B		575	e-164
	CAA61134.1	Hepatocyte nuclear factor 4B		575	e-164
NM_020028 NP_064412.1	Mm.2325 U:(C-IR) 2.07	NP_004711.2	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor; lysophosphatidic acid receptor EDG4; LPA receptor EDG4	470	e-132
		Q9HBW0	EDG4_HUMAN Lysophosphatidic acid receptor Edg-4 (LPA receptor 2) (LPA receptor 2)	470	e-132
		AAB61528.1	R33799_1	470	e-132
		AAF43409.1	AF233092_1 Lysophosphatidic acid G protein-coupled receptor 4	470	e-132
		AAH23695.1	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4	470	e-132
		AAG28521.1	AF197929_1 Lysophosphatidic acid receptor EDG4	468	e-131
		AAC27728.1	G protein-coupled receptor Edg-4	463	e-130
		NP_001392.2	lysophosphatidic acid receptor EDG2; ventricular zone gene 1; LPA receptor EDG2	255	2.00e-67
		NP_476500.1	lysophosphatidic acid receptor EDG2; ventricular zone gene 1; LPA receptor EDG2	255	2.00e-67
		Q92633	EDG2_HUMAN Lysophosphatidic acid receptor Edg-2 (LPA receptor 1) (LPA-1)	255	2.00e-67
		CAA70686.1	G protein-coupled receptor Edg-2	255	2.00e-67
		AAC00530.1	Edg-2 receptor	255	2.00e-67
		AAH30615.1	Unknown (protein for MGC:33156)	255	2.00e-67
		AAH36034.1	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2	255	2.00e-67
		JCS293	lysophosphatidic acid receptor	255	2.00e-67
		AAC51139.1	lysophosphatidic acid receptor homolog	255	2.00e-67
		CAA70687.1	G protein-coupled receptor Edg-2	255	2.00e-67
		NP_036284.1	endothelial cell differentiation gene 7; calcium-mobilizing lysophosphatidic acid receptor LP-A3; LPA receptor EDG7	225	3.00e-58
		Q9UBY5	EDG7_HUMAN Lysophosphatidic acid receptor Edg-7 (LPA receptor 3) (LPA-3)	225	3.00e-58

		AAD56311.1	AF127138_1 lysophosphatidic acid G protein-coupled receptor	225	3.00e-58
		AAF00530.1	AF186380_1 calcium-mobilizing lysophosphatidic acid receptor LP-A3/Edg-7	225	3.00e-58
		AAF91291.1	G-protein coupled receptor EDG-7	222	2.00e-57
AK015988	U:(C-IR)				
XP_129281.1	Mm.40665	2.06	NP_079065.1 hypothetical protein FLJ22529	137	5.00e-89
			BAB15385.1 unnamed protein product	137	5.00e-89
NM_009565	U:(C-IR)				
NP_033591.1	Mm.17068	2.05	AAH12070.1 Similar to kruppel-related zinc finger protein hcKrox	593	e-170
		2.13	NP_056956.1 kruppel-related zinc finger protein hcKrox	592	e-170
			AAC51847.1 kruppel-related zinc finger protein hcKrox	592	e-170
			XP_113971.1 similar to HIV-1 inducer of short transcripts binding protein	206	9.00e-53
			NP_056982.1 HIV-1 inducer of short transcripts binding protein	205	3.00e-52
			AACT2973.1 HIV-1 inducer of short transcripts binding protein	205	3.00e-52
NM_008158	U:(C-IR)				
NP_032184.1	Mm.35009	2.05	NP_061844.1 G protein-coupled receptor 27; super conserved receptor expressed in brain 1	453	e-127
			Q9NS67 GP27_HUMAN Probable G protein-coupled receptor GPR27 (Super conserved receptor expressed in brain 1)	453	e-127
			JC7287 G-protein coupled receptor, SREB1	453	e-127
			BAA96645.1 SREB1	453	e-127
			AAH30577.1 similar to G protein-coupled receptor 85	249	5.00e-66
			NP_061843.1 G protein-coupled receptor 85; super conserved receptor expressed in brain 2	248	2.00e-65
			Q9NPD1 GP85_HUMAN Probable G protein-coupled receptor GPR85 (Super conserved receptor expressed in brain 2) (PKrCx1)	248	2.00e-65
			T47131 G-protein coupled receptor, SREB2	248	2.00e-65
			CAB82307.1 hypothetical protein	248	2.00e-65

		BAA96646.1	SREB2		248	2.00e-65
		AAF79956.1	AF250237_1 orphan G protein-coupled receptor 85		248	2.00e-65
		BAC05911.1	seven transmembrane helix receptor		248	2.00e-65
		NP_061842.1	super conserved receptor expressed in brain 3		233	3.00e-61
		Q9NS66	SRB3_HUMAN Super conserved receptor expressed in brain 3		233	3.00e-61
		JCT789	G-protein coupled receptor, SREB3		233	3.00e-61
		BAA96647.1	SREB3		233	3.00e-61
		AAH09861.1	AAH09861 super conserved receptor expressed in brain 3		233	3.00e-61
NM_019513 NP_062386.1	Mm.1170 15	U:C-IRR 2.05	NP_009151.1	carbonic anhydrase VB, mitochondrial precursor; carbonic dehydratase	605	e-173
			Q9Y2D0	CASB_HUMAN Carbonic anhydrase VB, mitochondrial precursor (Carbonate dehydratase VB) (CA-VB)	605	e-173
			BAA76671.1	carbonic anhydrase VB	605	e-173
			AAH28142.1	carbonic anhydrase VB, mitochondrial	605	e-173
			NP_001730.1	carbonic anhydrase VA, mitochondrial precursor; carbonic anhydrase V, mitochondrial; carbonic dehydratase	384	e-106
			P35218	CAHS_HUMAN Carbonic anhydrase VA, mitochondrial precursor (Carbonate dehydratase VA) (CA-VA)	384	e-106
			CRHUU5	carbonate dehydratase (EC 4.2.1.1) V precursor [validated]	384	e-106
			AAA02890.1	carbonic anhydrase V	384	e-106
			AAB47048.1	carbonic anhydrase V; CA V	384	e-106
			AAC99806.1	carbonic anhydrase V	384	e-106
			IUGD	Human Carbonic Anhydrase II[hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Ser (A65S)	286	4.00e-77
			IUGG	Human Carbonic Anhydrase II[hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Ser (A65S) - Orthorhombic Form	286	4.00e-77
			IUGF	Human Carbonic Anhydrase II [hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Thr (A65T)	285	9.00e-77

		1G52	A Chain A, Carbonic Anhydrase II Complexed With 4-(Aminosulfonyl)-N-[(2,3-Difluorophenyl)methyl]-Benzamide	285	9.00e-77
	1G54	A Chain A, Carbonic Anhydrase II Complexed With 4-(Aminosulfonyl)-N-[(2,3,4,5,6-Pentafluorophenyl)methyl]-Benzamide	285	9.00e-77	
1I8Z		A Chain A, Carbonic Anhydrase II Complexed With Al-6629 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide	285	9.00e-77	
	1IF4	A Chain A, Carbonic Anhydrase II Complexed With 4-Fluorobenesulfonamide	285	9.00e-77	
	1G53	A Chain A, Carbonic Anhydrase II Complexed With 4-(Aminosulfonyl)-N-[(2,6-Difluorophenyl)methyl]-Benzamide	285	9.00e-77	
	1IF8	A Chain A, Carbonic Anhydrase II Complexed With (S)-N-(3-Indol-1-Y1-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide	285	9.00e-77	
	1IF7	A Chain A, Carbonic Anhydrase II Complexed With (R)-N-(3-Indol-1-Y1-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide	285	9.00e-77	
1I90		A Chain A, Carbonic Anhydrase II Complexed With Al-8520 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 4-Amino-3,4-Dihydro-2-(3-Methoxypropyl)-, 1,1-Dioxide, $\oplus$	285	9.00e-77	
	1I91	A Chain A, Carbonic Anhydrase II Complexed With Al-6619 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide	285	9.00e-77	
	1IF5	A Chain A, Carbonic Anhydrase II Complexed With 2,6-Difluorobenesulfonamide	285	9.00e-77	
	1IF9	A Chain A, Carbonic Anhydrase II Complexed With N-[2-(1h-Indol-5-Y)-Butyl]-4-Sulfamoyl-Benzamide	285	9.00e-77	
	1G1D	A Chain A, Carbonic Anhydrase II Complexed With 4-(Aminosulfonyl)-N-[(2-Fluorophenyl)methyl]-Benzamide	285	9.00e-77	
	1IF6	A Chain A, Carbonic Anhydrase II Complexed With 3,5-Difluorobenesulfonamide	285	9.00e-77	
	1AM6	Carbonic Anhydrase II Inhibitor: Acetohydroxamate	285	9.00e-77	
	1F2W	A Chain A, The Mechanism Of Cyanamide Hydration Catalyzed By Carbonic Anhydrase II Revealed By Cryogenic X-Ray Diffraction	285	9.00e-77	
	1OKM	Carbonic Anhydrase II Complex With The 10km Inhibitor 4-Sulfonamide-[1-(4-Aminobutane)]benzamide	285	9.00e-77	

	1BN1	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1BN4	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1BN3	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1BNN	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1BNV	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1BNM	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1CIL	Carbonic Anhydrase II (E.C.4.2.1.1) Complexed With The Inhibitor EtS	285	9.00e-77
	2CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) Complex With Thiocyanate Ion	285	9.00e-77
	3CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) Complex With 3-Mercuri-4-Aminobenzenesulfonamide (AMS).	285	9.00e-77
	1CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1)	285	9.00e-77
	1BNT	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1BNU	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1A42	Human Carbonic Anhydrase II Complexed With Brinzolamide	285	9.00e-77
	1BNW	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1BNQ	Carbonic Anhydrase II Inhibitor	285	9.00e-77
	1OKN	Carbonic Anhydrase II Complex With The 1okn Inhibitor 4-Sulfonamide-[1-(4-N-(5-Fluorescein Thiourea)butane)]	285	9.00e-77
	1OKL	Carbonic Anhydrase II Complex With The 1okl Inhibitor 5-Dimethylamino-Naphthalene-1-Sulfonamide	285	9.00e-77
	1CRA	Carbonic Anhydrase II (E.C.4.2.1.1) Complex With 1,2,4-Triazole	285	9.00e-77
	1CAO	Carbonic Anhydrase II (E.C.4.2.1.1) Complex With Hydrogen Sulfide	285	9.00e-77
	2CBA	Carbonic Anhydrase II (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, Ph 7.8)	285	9.00e-77
	2CBD	Carbonic Anhydrase II (E.C.4.2.1.1) (2.4 M Ammonium Sulfate, 0.3 M Sodium Bisulfite, Ph 7.3)	285	9.00e-77
	2CBB	Carbonic Anhydrase II (E.C.4.2.1.1) (80 Mm Sodium Citrate, 2.4 M Ammonium Sulfate, Ph 6.0)	285	9.00e-77

	1RAY	Carbonic Anhydrase II (E.C.4.2.1.1) Complex With Azide	285	9.00e-77
	1RZB	Carbonic Anhydrase II (E.C.4.2.1.1) With Zinc Replaced By By Cobalt(Ii) At Ph 6.0	285	9.00e-77
2CBE	Carbonic Anhydrase II (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, 2mm Dipeptidomimetic, Ph 7.8)		285	9.00e-77
2CBC	Carbonic Anhydrase II (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, 0.2 Formate, Ph 7.6)		285	9.00e-77
1CAH	Carbonic Anhydrase II (E.C.4.2.1.1) (Native Zinc Replaced By Cobalt) Complex With Bicarbonate		285	9.00e-77
1RZC	Carbonic Anhydrase II (E.C.4.2.1.1) With Zinc Replaced By Copper(Ii)		285	9.00e-77
1BCD	Carbonic Anhydrase II (E.C.4.2.1.1) Complex With Trifluoromethane Sulphonamide		285	9.00e-77
1RAZ	Carbonic Anhydrase II (E.C.4.2.1.1) Complex With Bromide		285	9.00e-77
1RZA	Carbonic Anhydrase II (E.C.4.2.1.1) With Zinc Replaced By Cobalt(Ii)		285	9.00e-77
1RZD	Carbonic Anhydrase II (E.C.4.2.1.1) With Zinc Replaced By Manganese(Ii)		285	9.00e-77
1RZE	Carbonic Anhydrase II (E.C.4.2.1.1) With Zinc Replaced By Nickel(Ii)		285	9.00e-77
1CAY	Carbonic Anhydrase II (E.C.4.2.1.1) Complex With Acetate		285	9.00e-77
5CAC	Carbonic Anhydrase Form C (E.C.4.2.1.1) Complex With Hydrogen Sulfite		285	9.00e-77
4CAC	Carbonic Anhydrase Form C (E.C.4.2.1.1) (Ph 6)		285	9.00e-77
1BV3	A Chain A, Human Carbonic Anhydrase Ii Complexed With Urea		285	9.00e-77
1AVN	Human Carbonic Anhydrase Ii Complexed With The Histamine Activator		285	9.00e-77
1LZV	A Chain A, Site-Specific Mutant (Tyr7 Replaced With His) Of Human Carbonic Anhydrase Ii		285	9.00e-77
	NP_000058.1 carbonic anhydrase II; carbonate dehydratase II; carbonic dehydratase; carbonic anhydrase B		285	9.00e-77
P00918	CAH2_HUMAN Carbonic anhydrase II (Carbonate dehydratase II) (CA-II) (Carbonic anhydrase C)		285	9.00e-77
CRHU2	carbonate dehydratase (EC 4.2.1.1) II [validated]		285	9.00e-77
1EOU	A Chain A, Crystal Structure Of Human Carbonic Anhydrase Ii Complexed With An Anticonvulsant Sugar Sulfamate		285	9.00e-77

		1CNX	Mol_id: 1; Molecule: Carbonic Anhydrase II; Chain: Null; Synonym: Carbonate Dehydratase, Hca II; Ec: 4.2.1.1; Heterogen: Benzenesulfonamide	285	9.00e-77
		1CNW	Mol_id: 1; Molecule: Carbonic Anhydrase II; Chain: Null; Synonym: Carbonate Dehydratase, Hca II; Ec: 4.2.1.1; Heterogen: Ethylaminocarbonylbenzenesulfonamide	285	9.00e-77
		1CNY	Mol_id: 1; Molecule: Carbonic Anhydrase II; Chain: Null; Synonym: Carbonate Dehydratase, Hca II; Ec: 4.2.1.1; Heterogen: Aminocarbonylbenzenesulfonamide	285	9.00e-77
		4CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1)	285	9.00e-77
		1CA3	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) (pH 5.7)	285	9.00e-77
		1HCA	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) (pH 6.5)	285	9.00e-77
		CAA63426.1	carbonic anhydrase II (AA 1-260)	285	9.00e-77
		AAA51908.1	carbonic anhydrase II	285	9.00e-77
		AAA51909.1	carbonic anhydrase II	285	9.00e-77
		AAA51911.1	carbonic anhydrase II	285	9.00e-77
		IUGB	Human Carbonic Anhydrase II[HcaII] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Gly (A65g)	285	1.00e-76
		1LG5	A Chain A, Crystal Structure Analysis Of The Hca Ii Mutant T199p In Complex With Beta-Mercaptoethanol	285	1.00e-76
		1LG6	A Chain A, Crystal Structure Analysis Of Hca Ii Mutant T199p In Complex With Thiocyanate	285	1.00e-76
		1LGD	A Chain A, Crystal Structure Analysis Of Hca Ii Mutant T199p In Complex With Bicarbonate	285	1.00e-76
NM_008890	U:(C-IR)	NP_002677.1	phenylethanolamine N-methyltransferase	462	e-130
NP_032916.1	Mm.570302.04	P11086	PNMT_HUMAN Phenylethanolamine N-methyltransferase (PNMTase) (Noradrenaline N-methyltransferase)	462	e-130
		A28171	phenylethanolamine N-methyltransferase (EC 2.1.1.28)	462	e-130
		1HNN	B Chain B, Crystal Structure Of Human Pnmt Complexed With Slt&f 29661 And Adohcy(Sah)	462	e-130

		1HNN	A Chain A, Crystal Structure Of Human Pnmt Complexed With Sk&f 29661 And Adohcy(Sah)	462	e-130
	AAA60130.1	phenylethanolamine N-methyltransferase		462	e-130
	CAA36944.1	phenylethanolamine n-methyltransferase		462	e-130
	AAH37246.1	phenylethanolamine N-methyltransferase		462	e-130
	AAA60131.1	phenylethanolamine N-methyltransferase		461	e-130
NM_008985	U:(C-IR) 2.04	NP_002837.1	protein tyrosine phosphatase, receptor type, N precursor; islet cell antigen 2; islet cell antigen 512; islet cell autoantigen 3; protein tyrosine phosphatase-like N precursor	1389	0
NP_033011.1	Mm2902	Q16849	PTPN_HUMAN Protein-tyrosine phosphatase-like N precursor (R-PTP-N) (PTP IA-2)(Islet cell antigen 512) (ICA 512) (Islet cell autoantigen 3)	1389	0
		AAA90974.1	tyrosine phosphatase	1389	0
		CAA44688.2	Islet Cell Antigen 512	972	0
		AAH07713.1	AAH07713 protein tyrosine phosphatase, receptor type, N	972	0
		137577	islet cell antigen 512	850	0
			protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 2 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase	607	e-173
		NP_570857.1			
		AAB68603.1	protein tyrosine phosphatase receptor pi	607	e-173
			protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 1 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase	607	e-173
		NP_002838.1			
		Q92932	PTPX_HUMAN Protein-tyrosine phosphatase X precursor (R-PTP-X) (Islet cell autoantigen related protein) (ICAAR) (IAR) (Phogrin)	607	e-173
		JC5062	phogrin precursor	607	e-173
		AAC50742.1	phogri	607	e-173
		JCS263	transmembrane tyrosine phosphatase-like protein, ICAAR	607	e-173
		CAA69880.	Islet Cell Autoantigen Related	607	e-173
		AAB67600.1	IAR/receptor-like protein-tyrosine phosphatase precursor	607	e-173

		BAA20841.2	KIAA0387	607	e-173
		NP_570858.1	protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 3 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase	579	e-164
		AAH34040.1	protein tyrosine phosphatase, receptor type, N polypeptide 2	579	e-164
NM_054049 NP_473390.1	U:(C-IR) 2.03 Mm.46333 U:(C-IR) 2.46	AAK74066.1	odd-skipped-related 2A protein	481	e-152
		BAC11035.1	unnamed protein product		
		AAH16936.1	AAH16936 odd-skipped-related 2A protein	484	e-152
		NP_443727.1	odd-skipped-related 2A protein	509	e-144
		AAK74067.1	odd-skipped-related 2B protein	507	e-143
		XP_059439.2	similar to odd-skipped related 1 (Drosophila); odd-skipped related gene; odz (odd Oz/ten-m) homolog (Drosophila) related 1	347	2.00e-95
		NP_660303.1	similar to odd-skipped related 1 (Drosophila); odd-skipped related gene; odz (odd Oz/ten-m) homolog (Drosophila) related 1	347	2.00e-95
		AAH25712.1	Similar to odd-skipped related 1 (Drosophila)	347	2.00e-95
		BAB92079.1	zinc finger transcription factor	347	2.00e-95
		BAC11079.1	unnamed protein product	347	2.00e-95
NM_007924	U:(C-IR) 2.03	NP_006523.1	ELL gene (11-19 lysine-rich leukemia gene)	880	0
NP_031950.1	Mm.1552	P55199	ELL_HUMAN RNA polymerase II elongation factor ELL (Eleven-nineteen lysine-rich leukemia protein)	880	0
		I38880	eleven-nineteen lysine-rich leukemia gene (ELL) protein	880	0
		AAA57120.1	ELL	880	0
		AAB34056.1	MEN chimeric transcription factor	803	0
		NP_036213.1	ELL-related RNA polymerase II, elongation factor	371	e-102

		O00472	ELL2_HUMAN RNA polymerase II elongation factor ELL2	371	e-102
		AAC51232.1	RNA polymerase II elongation factor ELL2	371	e-102
		AAH28412.1	ELL-RELATED RNA POLYMERASE II, ELONGATION FACTOR	371	e-102
NM_008521					
NP_032547.1	Mm.4088	U:(C-IR) 2.03	AAH29498.1 leukotriene C4 synthase	204	5.00e-53
		JC5398	leukotriene C4 synthase (EC 6.-.-.)	204	7.00e-53
		NP_665874.1	leukotriene C4 synthase isoform 1	204	7.00e-53
		Q16873	LC4S_HUMAN Leukotriene C4 synthase (Leukotriene-C(4) synthase) (LTC4 synthase)	204	7.00e-53
		I38595	leukotriene-C4 synthase (EC 2.5.1.37)	204	7.00e-53
		AAA20467.1	leukotriene C4 synthase	204	7.00e-53
		AAA50555.1	leukotriene-C4 synthase	204	7.00e-53
		AAC50476.1	leukotriene C4 synthase	204	7.00e-53
		AAB06723.1	leukotriene C4 synthase	204	7.00e-53
NM_010780		U:(C-IR) NP_001827.1	chymase 1, mast cell proprotein; chymase, mast cell; chymase, heart; mast cell	345	9.00e-95
NP_034910.1	Mm.1252	2.03	protease I		
		P23946	MCT1_HUMAN Chymase precursor (Mast cell protease I)	345	9.00e-95
		KYHUCM	chymase (EC 3.4.21.39) precursor [validated]	345	9.00e-95
		AAA52019.1	chymase	345	9.00e-95
		AAA52020.1	mast cell chymase	345	9.00e-95
		AAA52021.1	chymase	345	9.00e-95
		1KLT	Crystal Structure Of Pmsf-Treated Human Chymase At 1.9 Angstroms Resolution	333	2.00e-91
		AAB26828.1	chymase	333	2.00e-91
		1914144A	chymase	333	2.00e-91
		1PJP	A Chain A, The 2.2 A Crystal Structure Of Human Chymase In Complex With Succinyl-Ala-Ala-Pro-Phe-Chloromethylketone	331	1.00e-90

NM_021470 NP_067445.1	Mm.8735 2	U:(C-IR) 2.03	NP_112198.1	ring finger protein 32	522	e-148
		CAB66808.1	hypothetical protein		522	e-148
		AAG50281.1	AF325690_1 FKSG33		522	e-148
		AAM18664.1	AF441222_1 ring finger protein RNF32		522	e-148
		AAD43189.1	AC005534_2 supported by human ESTs AA412402 (NID:g2070990) NH44021 (NID:g1182549), mouse EST AA065933 (NID:g1562789), and gencan		445	e-125
		AAH15416.1	AAH15416 Similar to hypothetical protein DKFZp434C135		319	4.00e-87
		AAH28120.1	Similar to ring finger protein 32		310	2.00e-84
NM_007513 NP_031539.1	Mm.5255 NP_03036.1	U:(C-IR) 2.02	NP_003036.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 1; ecotropic retroviral receptor; Solute carrier family 7 (cationic amino acid transporter, y+ system); amino acid transporter, cationic 1	990	0
			CTR1_HUMAN	High-affinity cationic amino acid transporter-1 (CAT-1) (CAT1) (System Y+ basic amino acid transporter) (Ecotropic retroviral leukemia receptor homolog) (ERR) (Ecotropic retrovirus receptor homolog)	990	0
		P30825			990	0
		CAA41869.1	retroviral receptor		990	0
		AAC27721.1	cationic amino acid transporter		990	0
		S29685	retroviral receptor		988	0
		CAA40560.1	RECIL		988	0
		P52569	CTR2_HUMAN	Low-affinity cationic amino acid transporter-2 (CAT-2) (CAT2)	654	0
		BAA06271.1	cationic amino acid transporter 2		654	0
			solute carrier family 7 (cationic amino acid transporter, y+ system), member 2; Solute carrier family 7 (cationic amino acid transporter, y+ system); amino acid transporter, cationic 2		648	0
		NP_003037.1			648	0
		AAB62810.1	hCAT-2A		648	0
		NP_116192.2	solute carrier family 7 (cationic amino acid transporter, y+ system), member 3		640	0
		AAL37184.1	cationic amino acid transporter		640	0
		BAC11353.1	unnamed protein product		640	0
		AAH33816.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 3		639	0

		BAC11253.1	unnamed protein product	637	0
		BAB55118.1	unnamed protein product	421	e-117
		XP_0366892.1	similar to Cationic amino acid transporter-4 (CAT-4) (CAT4)	411	e-114
		AAH08814.1	Unknown (protein for MGC:10733)	411	e-114
		NP_004164.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 4	393	e-109
O43246		CTRA4_HUMAN	Cationic amino acid transporter-4 (CAT-4) (CAT4)	393	e-109
		CAA04263.1	cationic amino acid transporter 3	393	e-109
NM_007962		U:(C-IR) Mm.33240 2.02			
NP_031988.1		NP_005788.1	epithelial V-like antigen 1 precursor	330	3.00e-90
		NP_658911.1	epithelial V-like antigen 1 precursor	330	3.00e-90
		O60487	EVA1_HUMAN Epithelial V-like antigen 1 precursor	330	3.00e-90
		AAC39762.1	epithelial V-like antigen precursor	330	3.00e-90
		AAF87240.1	AF275945_1 epithelial V-like antigen 1	330	3.00e-90
		AAG23183.1	AF304447_1 epithelial V-like antigen 1	330	3.00e-90
		AAH17774.1	epithelial V-like antigen 1	330	3.00e-90
NM_010393	Mm.1960	U:(C-IR) P30461 2.02	1B05_HUMAN HLA class I histocompatibility antigen, B-13 B*1301 alpha chain precursor (B13.1)	420	e-117
NP_034523.1	32	154442	MHC class I histocompatibility antigen HLA-B13 precursor	420	e-117
		AAA52657.1	MHC HLA-B13 precursor	420	e-117
		AAA50660.1	MHC HLA-B13 chain	420	e-117
		BAA08822.1	HLA-B*1302 antigen	420	e-117
		CAC17136.1	MHC class I antigen	420	e-117
		CAC17137.1	MHC class I antigen	418	e-117
		A45850	MHC class I histocompatibility antigen HLA-B13.1	418	e-117
		AAA59627.1	HLA-B13 protein	418	e-117
		BAA08821.1	HLA-B*1301 antigen	418	e-117

		AAA59618.1	glycosylation aa 86, alpha domain 1 aa 1-24, alpha domain 2 aa 25-114, alpha domain 3 aa 207-298	418	e-117
		CAC29063.1	MHC class I antigen	418	e-117
		AAA73509.1	MHC class I lymphocyte antigen	416	e-116
		AAD00010.1	HLA-B38	416	e-116
		AAB06829.1	MHC antigen	415	e-116
		AAA98506.1	MHC class I antigen HLA-B precursor	414	e-116
	184488		lymphocyte antigen	413	e-115
	AAC31793.1		HLA class I antigen HLA-B	412	e-115
	P30476	1B32_HUMAN	HLA class I histocompatibility antigen, B-39 B*3902 alpha chain precursor (B39.2)	412	e-115
	168850		MHC class I histocompatibility antigen precursor	412	e-115
	AAA52659.1		lymphocyte antigen	412	e-115
	AAA87396.1		MHC class I antigen	412	e-115
U:(C-IR) Mm:1976 X99104	NP_084656.1 2.02 95	GLI-Kruppel family member GLI2 isoform beta; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein	1821 0	1821 0	
	BAA25666.1	hGLI2		1821 0	
	NP_084655.1	GLI-Kruppel family member GLI2 isoform alpha; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein		1810 0	
	P10070	GLI2_HUMAN Zinc finger protein GLI2 (Tax helper protein)		1810 0	
	BAA25665.1	hGLI2		1810 0	
	NP_005261.1	GLI-Kruppel family member GLI2 isoform delta; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein		1263 0	
	BAA25668.1	hGLI2		1263 0	

		NP_084657.1	GLI-Kruppel family member GLI2 isoform gamma; oncogene GLI2; tax helper protein; tax-responsive element-25-bp sequence binding protein; zinc finger protein GLI2	1252	0
		BAA255667.1	hGLI2	1252	0
		NP_001159.2	GLI-Kruppel family member GLI3; oncogene GLI3; DNA-binding protein; zinc finger protein GLI3	1043	0
		CAB59315.1	GLI3 protein	1043	0
		P10071	GLI3_HUMAN Zinc finger protein GLI3	1004	0
		A35927	190K DNA-binding protein GLI3	1004	0
		AAAAS2264.1	DNA-binding protein	1004	0
		BAA03568.1	Tax helper protein 1	730	0
		BAA03569.1	Tax helper protein 2	719	0
		NP_005260.1	glioma-associated oncogene homolog	445	e-124
		P08151	GLI1_HUMAN Zinc finger protein GLI1 (Glioma-associated oncogene) (Oncogene GLI1)	445	e-124
		TVHUGL	transforming protein gli	445	e-124
		CAA30297.1	GLI protein (AA 1-1106)	445	e-124
		AAH13000.1	AAH13000 Similar to glioma-associated oncogene homolog (zinc finger protein)	445	e-124
		AAM13391.1	GLI1	445	e-124
		U:(C-IR) 2.01			
		Mm.2540 U:(C-D) 2.34			
		NP_056008.1	activity-regulated cytoskeleton-associated protein	763	0
		AAF07185.1	AF193421_1 ARC	763	0
		AAG33705.1	AF248637_1 activity-regulated cytoskeleton-associated protein	763	0
		AAH12321.1	AAH12321 Similar to activity-regulated cytoskeleton-associated protein	763	0

NM_020043 NP_064427	Mm.1437 4.1	U:(C-IR) 2.01	NP_066013.1	DDM36	2055	0
		U:(C-D) 2.17			2055	0
		BAB85306.1	hDDM36		1539	0
		BAB13454.1	KIAA1628 protein		260	2.00e-68
		AAC51287.1	neogenin		260	2.00e-68
		NP_002490.1	neogenin homolog 1 (chicken); neogenin (chicken) homolog 1		260	2.00e-68
		Q92859	NEO1_HUMAN Neogenin precursor		260	2.00e-68
		AAB17263.1	neogenin		260	2.00e-68
		NP_005206.1	deleted in colorectal carcinoma		226	2.00e-58
		P43146	DCC_HUMAN Tumor suppressor protein DCC precursor (Colorectal cancer suppressor)		226	2.00e-58
		A54100	tumor suppressor protein DCC precursor		226	2.00e-58
		CAA53735.1	turnour suppressor		226	2.00e-58
		AAA35751.1	colorectal tumor suppressor (put); putative		216	3.00e-55
		U:(C-IR) 2.01	Q9UP79	ATTS8_HUMAN ADAMTS-8 precursor (A disintegrin and metalloprotease with thrombospondin motifs 8) (ADAM-TS 8) (ADAM-TS8) (METH-2) (METH-8)	1404	0
		Mm.1005 NP_038934.1	U:(C-D) 2.16	AAD48081.1 AF060153_1 METH2 protein	1404	0
				NP_008968.2 a disintegrin and metalloprotease with thrombospondin motifs-8	1403	0
				NP_008919.2 a disintegrin and metalloprotease with thrombospondin motifs-1 preproprotein; human metalloproteinase with thrombospondin type 1 motifs	799	0
				AAF23772.1 AF207664_1 matrix metalloprotease	799	0
				BAA95502.1 metalloprotease with thrombospondin type 1 motifs	799	0
				AAD48080.1 AF060152_1 METH1 protein	798	0
				Q9UH8 ATTS1_HUMAN ADAMTS-1 precursor (A disintegrin and metalloprotease with thrombospondin motifs 1) (ADAM-TS 1) (ADAM-TS1) (METH-1)	798	0

		AAF15317.1	AF170084_1 metalloproteinase with thrombospondin type 1 motifs ADAMTS1	798	0
		BAA92584.1	KIAA1346 protein	798	0
		AAH36515.1	Unknown (protein for MGC:32979)	795	0
		NP_620686.1	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 15 preproprotein	733	0
		CAC86014.1	metalloproteinase disintegrin 15 with thrombospondin domains	733	0
NM_013866 NP_038894.1	Mm.1409 9	U:(C-IR) 2.01	XP_028643.4 similar to DKFZP586G1122 protein	543	e-154
			NP_056296.1 DKFZP586G1122 protein	543	e-154
		AAL08625.1	AF304052_1 hematopoietic zinc finger protein	543	e-154
		AAH29752.1	DKFZP586G1122 protein	543	e-154
		T17248	hypothetical protein DKFZp586G1122.1	426	e-119
		CAB55938.1	hypothetical protein	426	e-119
		BAB14910.1	unnamed protein product	321	3.00e-87
		NP_078973.1	hypothetical protein FLJ22419	279	1.00e-74
		BAB15350.1	unnamed protein product	279	1.00e-74
		AAH07212.1	AAH07212 hypothetical protein FLJ22419	279	1.00e-74
		BAC04870.1	unnamed protein product	266	1.00e-70
		NP_689733.1	hypothetical protein FLJ25270	263	1.00e-69
		BAB71629.1	unnamed protein product	263	1.00e-69
		XP_087103.1	similar to zinc finger protein 385, hematopoietic zinc finger	262	1.00e-69
		AAH38422.1	hypothetical protein FLJ25270	262	1.00e-69
NM_019762 NP_062736.1	Mm.2960 3	U:(C-IR) 2.01	NP_009114.1 plakophilin 3	1271	0
		Q9Y446	PKP3_HUMAN Plakophilin 3	1271	0
			CAB44310.1 plakophilin 3	1271	0
			AAF23050.1 AF053719_1 plakophilin-3 protein	1271	0

		AAH00081.1	AAH00081 plakophilin 3		1271	0
		CAA6265.1	plakophilin 2a		243	9.00e-64
		AAB97957.1	arm-repeat protein NPRAp/neurojungin		237	6.00e-62
		AAD00453.1	GT24		237	8.00e-62
		NP_001323.1	catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein); catenin (cadherin-associated protein), delta 2		237	8.00e-62
		BAA36163.1	neural plakophilin-related arm-repeat protein (NPRAp)		237	8.00e-62
		Q9UQB3	CTD2_HUMAN Catenin delta-2 (Delta-catenin) (Neural plakophilin-related ARM-repeat protein) (NPRAp) (Neurojungin) (GT24)		232	3.00e-60
		AAC63103.1	delta-catenin		232	3.00e-60
		S60712	band 6-protein		228	4.00e-59
		CAA55881.1	band 6-protein		228	4.00e-59
		NP_000290.1	plakophilin 1; Plakophilin 1		225	2.00e-58
		CAA84426.1	plakophilin		225	2.00e-58
		CAA98022.1	plakophilin 1		225	2.00e-58
		NP_004563.1	plakophilin 2		222	2.00e-57
		Q99959	PKP2_HUMAN Plakophilin 2		222	2.00e-57
		CAA66264.1	plakophilin 2b		222	2.00e-57
		NP_003619.1	plakophilin 4		222	3.00e-57
		Q99569	PKP4_HUMAN Plakophilin 4		222	3.00e-57
		CAAS7478.1	p0071 protein		222	3.00e-57
		U:(C-IR) Mm.1425 NP_082365.1 2	NP_000763.1 cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase		766	0
			AAB59356.1 cytochrome		766	0
			P33260 CPCI_HUMAN Cytochrome P450 2C18 (CYP2C18) (P450-6B/29C)		764	0
			A61269 cytochrome P450 2C18		764	0
			AAA02630.1 cytochrome P-4502C18		764	0

	AAB23864.2	cytochrome P-450	736	0
	NP_000762.2	cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	736	0
	P11712	CPC9_HUMAN Cytochrome P450 2C9 (CYP2C9) (P450 PB-1) (P450 MP-4)	736	0
	B38462	S-mephenytoin 4-hydroxylase (P-450MP)	736	0
	1313295A	cytochrome P450	736	0
	BAA00123.1	cytochrome P-450	736	0
	P11713	CPCA_HUMAN Cytochrome P450 2C10 (CYP2C10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) (P-450MP)	729	0
	D28951	cytochrome P450 2C10	729	0
	AAA52157.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	729	0
	AAA52158.1	cytochrome P450 S-mephenytoin 4-hydroxylase	729	0
	1506290A	cytochrome P450	728	0
	NP_000760.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	726	0
	P33261	CPCJ_HUMAN Cytochrome P450 2C19 (CYP2C19) (P450-11A) (Mephenytoin 4-hydroxylase) (CYP2C17) (P450-254C)	726	0
	AAB52426.1	cytochrome	726	0
	F38462	S-mephenytoin 4'-hydroxylase (EC 1.14.14.-) cytochrome P450 2C19	722	0
	U:(C-IR) 13.11	CAA11218.1 36 kDa phosphothreonine protein	231	2.00e-60
	NM_010689 NP_034819.1	Mm.1028 U:(C-D) 2.17	AAC39636.1 LAT	231 2.00e-60
			AAH11563.1 AAH11563 Similar to linker for activation of T cells	231 2.00e-60

			NP_055202.1	linker for activation of T cells	215	1.00e-55
		O43561	LAT	HUMAN Linker for activation of T cells (36 kDa phospho-tyrosine adaptor protein) (pp36) (p36-38)	215	1.00e-55
		AAC39637.1	LAT		215	1.00e-55
NM_017370 NP_059066.1	Mm.2673 U.(C-D) 6.81	CAA25926.1	haptoglobin		599	e-171
		P00737	HPT1	HUMAN Haptoglobin-1 precursor	598	e-171
		HPHUI	haptoglobin precursor, allele 1 [validated]		598	e-171
		AAA52684.1	preprohaptoglobin		598	e-171
		CAA25267.1	haptoglobin alpha 1S		598	e-171
		AAC27432.1	haptoglobin		597	e-170
		NP_066275.2	haptoglobin-related protein; Haptoglobin-related locus		569	e-162
		P00739	HPT2	HUMAN Haptoglobin-related protein precursor	569	e-162
		HPHUR	haptoglobin-related protein precursor		569	e-162
		AAA88079.1	haptoglobin-related protein		569	e-162
		AAA88081.1	haptoglobin-related protein		569	e-162
		CAA25927.1	haptoglobin		568	e-162
		AAC27433.1	haptoglobin-related protein precursor		565	e-161
		CAA61501.1	haptoglobin-related protein		565	e-161
		AAA52687.1	haptoglobin precursor		559	e-159
		NP_005134.1	haptoglobin		559	e-159
		P00738	HPT2	HUMAN Haptoglobin-2 precursor	559	e-159
		HPHUU2	haptoglobin precursor, allele 2		559	e-159
		CAA25137.1	haptoglobin precursor		559	e-159
		AAA88078.1	haptoglobin		559	e-159
		AAA88080.1	haptoglobin		559	e-159
		AAA52685.1	preprohaptoglobin		559	e-159

		1006264A	haptoglobin Hp2	508	e-144
NM_007424	U:(C-D) 4.11 U:(IR-D) 3.08	NP_031450.1	aggre can 1 isoform 2 precursor; Aggre can-1 (chondroitin sulfate proteoglycan-1, large aggregating proteoglycan, antigen identifies by monoclonal antibody A0122); chondroitin sulfate proteoglycan 1, large aggregating proteoglycan	1795	0
Mm.2759	NP_037359.1				
		NP_001126.1	aggre can 1 isoform 1 precursor; Aggre can-1 (chondroitin sulfate proteoglycan-1, large aggregating proteoglycan, antigen identifies by monoclonal antibody A0122); chondroitin sulfate proteoglycan 1, large aggregating proteoglycan	1794	0
		AAA62824.1	large aggregating cartilage proteoglycan core protein	1794	0
		A39086	aggre can precursor, cartilage long splice form	1792	0
			Similar to aggre can 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal antibody A0122)	1253	0
		AAH36445.1		823	0
		CAA35463.1	cartilage specific proteoglycan (600 AA)	573	e-162
		AAA35726.1	proteoglycan core protein		
		AAH10571.1	chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
		AAG23134.1	AF228710_1 chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
		AAG23135.1	AF229053_1 chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
NM_009008	U:(C-D) 2.85	NP_033034.1	ras-related C3 botulinum toxin substrate 2; Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP-binding protein Rac2); rho family, small GTP binding protein Rac2	390	e-108
Mm.1972	NP_002863.1		RAC2 HUMAN Ras-related C3 botulinum toxin substrate 2 (p21-Rac2) (Small G protein) (GX)	390	e-108
	P15153			390	e-108
	B34386		GTP-binding protein rac2	390	e-108
	IDS6		A Chain A, Crystal Structure Of A Rac-Rhogdi Complex	390	e-108
	AAA36538.1		ras-related C3 botulinum toxin substrate	390	e-108
	AAB22207.1		rac1 p21=small GTP-binding protein [human, HL60, Peptide, 192 aa]	390	e-108
	CAB45265.1		dJ151B14.2 (ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2))	390	e-108

		AAH01485.1 protein Rac2)	AAH01485 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)	390	e-108
	AAM21112.1	AF498965_1 small GTP binding protein RAC2		390	e-108
		ras-related C3 botulinum toxin substrate 1 isoform Rac1; rho family, small GTP binding protein Rac1		367	e-101
	NP_008839.2				
	P15154	RAC1_HUMAN Ras-related C3 botulinum toxin substrate 1 (p21-Rac1) (Ras-like protein 1C25)		367	e-101
	TVHUC1	GTP-binding protein rac1		367	e-101
	1I4D	D Chain D, Crystal Structure Analysis Of Rac1-Gdp Complexed With Arfaptin (P21)		367	e-101
	1I4L	D Chain D, Crystal Structure Analysis Of Rac1-Gdp In Complex With Arfaptin (P41)		367	e-101
	AAA36537.1	ras-related C3 botulinum toxin substrate		367	e-101
	AAB22206.1	rac1 p21=small GTP-binding protein [human, HL60, Peptide, 192 aa]		367	e-101
	CAB53579.5	Rac1 protein		367	e-101
	AAM21111.1	AF498964_1 small GTP binding protein RAC1		367	e-101
		AAH04247 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)		367	e-101
	AAH04247.1			367	e-101
	AAA35941.1	small G protein		366	e-101
	AAA35544.1	ras-like protein		366	e-101
	1I4T	D Chain D, Crystal Structure Analysis Of Rac1-Gnppp In Complex With Arfaptin		365	e-100
	1.00e+96	A Chain A, Structure Of The RacP67PHOX COMPLEX		363	e-100
	1HH4	A Chain A, Rac1-Rhodni Complex Involved In NADPH Oxidase Activation		362	e-100
	1HH4	B Chain B, Rac1-Rhodni Complex Involved In NADPH Oxidase Activation		362	e-100
		ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3; rho family, small GTP binding protein Rac3)		358	1.00e-98
	NP_005043.1				
	O14658	RAC3_HUMAN Ras-related C3 botulinum toxin substrate 3 (p21-Rac3)		358	1.00e-98
	AAC51667.1	Rac3		358	1.00e-98
		AAH15197 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)		358	1.00e-98
	AAH15197.1				

		AAH09605.1	AAH09605 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)	358	1.00e-98
		AAM21113.1	AF498966_1 small GTP binding protein RAC3	358	1.00e-98
		NP_061485.1	ras-related C3 botulinum toxin substrate 1 isoform Rac1b; rho family, small GTP binding protein Rac1	356	5.00e-98
		CAA10732.1	small GTPase rac1b	356	5.00e-98
		AAD30547.1	AF136373_1 ras-related C3 botulinum toxin substrate isoform	356	5.00e-98
		CAA10733.6	Rac1b protein	356	5.00e-98
AK013740	U:(C-D)				
BAB28979.1	Mm.27579	2.82	NP_068747.1 hypothetical protein FLJ22649 similar to signal peptidase SPCC22/23	298	1.00e-80
			BAB15437.1 unnamed protein product	298	1.00e-80
			Q9H0S7 SP22_HUMAN Microsomal signal peptidase 23 kDa subunit (SPase 22 kDa subunit)	295	9.00e-80
			CAB66595.1 hypothetical protein	295	9.00e-80
X00496 CAA25191.1	U:(C-D) Mm.7043	2.81	NP_004346.1 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); CD74 antigen (invariant polypeptide of major histocompatibility class II antigen-associated)	226	4.00e-59
			CAA25192.1 putative p33	226	4.00e-59
			AAA36033.1 cell surface glycoprotein	226	4.00e-59
			AAH18726.1 AAH18726 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	226	4.00e-59
			HLHUG class II histocompatibility antigen-associated gamma chain	226	4.00e-59
			CAA25193.1 putative p33	226	4.00e-59
			AAA36304.1 class II antigen gamma chain	226	4.00e-59
			CAA27047.1 gamma chain	225	9.00e-59
		P04233	HG2A_HUMAN HLA class II histocompatibility antigen, gamma chain (HLA-DR antigens associated invariant chain) (Ia antigen-associated invariant chain) (II) (p33) (CD74 antigen)	207	1.00e-53

NM_015737 NP_056552.1	Mm.5699 1	U:(C-D) 2.72 U:(IR-D) 2.1	AAH36390.1 4 (GalNAc-T4)	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4)	1078 0
			NP_003765.1	polypeptide N-acetylgalactosaminyltransferase 4; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4; GalNAc transferase 4; UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase 4; protein-UDP acetylgalactosaminyltransferase 4	1073 0
			CAA68875.1 CAC80100.2	UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase UDP-GalNAc-transferase 12	1073 0
			NP_078918.2	hypothetical protein FLJ12121; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12(GalNAc-T12)	624 e-178
			BAC07181.1	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12	622 e-178
			NP_004473.1	polypeptide N-acetylgalactosaminyltransferase 3; protein-UDP acetylgalactosaminyltransferase	462 e-130
			CAA63371.1 AAH35822.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6)	462 e-130
			BAC11118.1	unnamed protein product	461 e-129
			NP_009141.1	polypeptide N-acetylgalactosaminyltransferase 6; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6; protein-UDP acetylgalactosaminyltransferase 6; GalNAc transferase 6	459 e-129
			CAA69876.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase	459 e-129
			BAB67811.1	KIAA1918 protein	417 e-116
			NP_065207.2	polypeptide N-acetylgalactosaminyltransferase 1; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1; GalNAc-T1; GalNAc transferase 1; protein-UDP acetylgalactosaminyltransferase 1; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 1	416 e-116

		Q10472	PAGT_HUMAN Polypeptide N-acetylgalactosaminyltransferase (Protein-UDP acetylgalactosaminyltransferase) (UDP-GalNAc:polypeptide, N-acetylgalactosaminyltransferase) (GalNAc-T1)	416	e-116
		JC4223	polypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.41)	416	e-116
		CAA59380.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyl transferase	416	e-116
NM_018866 NP_061354.1	Mm.1011 NP_061354.16	U:(C-D) 2.65			
NM_008458					
NP_032484.1	Mm.14191	U:(C-D) 2.59	CAA48671.1 alpha1-antichymotrypsin	494	e-139
			XP_028322.1 similar to Alpha-1-antichymotrypsin precursor (ACT)	490	e-138
		P01011	AACT_HUMAN Alpha-1-antichymotrypsin precursor (ACT)	490	e-138
			serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	490	e-138
		AAH10530.1	Unknown (protein for MGC:18102)	490	e-138
			serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	489	e-138
		AAH34554.1	alpha1-antichymotrypsin precursor	478	e-134
		AAD08810.1	alpha1-antichymotrypsin precursor	476	e-134
		TTHUC	alpha1-antichymotrypsin precursor	470	e-132
		AAA51560.1	A Chain A, Alpha 1-Antichymotrypsin Serpin In The Delta Conformation (Partial Loop Insertion)	460	e-129
		1QMN	chymotrypsin inhibitor	441	e-123
		1313184C	NP_001076.1 alpha-1-antichymotrypsin; precursor; alpha-1-antichymotrypsin	439	e-123
			AAA51543.1 alpha-1-antichymotrypsin	439	e-123
		2ACH	A Chain A, Alpha 1 Antichymotrypsin	434	e-121
NM_010382 NP_034512.1	Mm.2256 NP_034512.14	U:(C-D) 2.59	AAH07920.1 AAH07920 Unknown (protein for MGC:14111)	390	e-108

	AAL40069.1	L76133_1 lymphocyte antigen	390	e-108
	AAH08403.1	AAH08403 Similar to major histocompatibility complex, class II, DR beta 5	387	e-107
	CAC08827.1	MHC class II antigen	386	e-107
IS4448		MHC class II histocompatibility antigen DR beta 1 chain precursor	386	e-107
	AAA59713.1	precursor	386	e-107
	CAC08823.1	MHC class II antigen	386	e-107
P20039		HB2L_HUMAN HLA class II histocompatibility antigen, DR-5 beta chain precursor	385	e-107
	A25324	class II histocompatibility antigen HLA-DR-5 beta chain precursor	385	e-107
	AAA36274.1	MHC HLA DR5 cell surface glycoprotein beta chain precursor	385	e-107
	CAC08826.2	MHC class II antigen	385	e-107
P13760		HB2H_HUMAN HLA class II histocompatibility antigen, DR-4 beta chain precursor (DRB1*0401)	385	e-107
	A29310	MHC class II histocompatibility antigen HLA-DR beta 1 chain DR4 precursor	385	e-107
	CAC19360.1	dI863G3.2 (major histocompatibility complex, class II, DR beta 1)	385	e-107
	CAB75359.1	human leucocyte antigen DRB1	385	e-107
P01912		HB2B_HUMAN HLA class II histocompatibility antigen, DR-1 beta chain precursor (Clone P2-beta-3)	385	e-107
		pir  HLHU3D MHC class II histocompatibility antigen HLA-DR beta 1 chain DR17 precursor	385	e-107
	CAA25295.1	precursor	385	e-107
	CAB06490.1	dJ93N13.3 (major histocompatibility complex, class II, DR beta 1 (clone P2-beta-3))	385	e-107
AK012581				
XP_126675.1	U:(C-D) Mm.21687 2.55	AAK67634.1 hypothetical protein SB143	240	2.00e-63
		NP_085053.1 hypothetical protein MGCI0986	240	2.00e-63
		AAH04400.1 Unknown (protein for MGC:10986)	240	2.00e-63

			BAC03855.1	unnamed protein product	240	2.00e-63
NM_027209 NP_0814851.7	Mm.2948 2.47	U:(C-D)	NP_690591.1	membrane-spanning 4-domains, subfamily A, member 6A isoform 1; CD20-like precursor; membrane-spanning 4-domains, subfamily A, member 6; four-span transmembrane protein 3; MS4A6A-polymorph; four-span transmembrane protein 3.1; HAIRB-iso	233	5.00e-61
			AAG41780.1	AF212240_1 CDA01	233	5.00e-61
			AAK37417.1	AF237908_1 MS4A6A protein	233	5.00e-61
			AAK37994.1	AF286866_1 MS4A6A-polymorph	233	5.00e-61
			AAH22854.1	membrane-spanning 4-domains, subfamily A, member 6A	232	8.00e-61
			AAL56222.1	AF350502_1 four-span transmembrane protein 3.1	229	5.00e-60
			AAG4626.1	AF253977_1 HAIRB-iso	222	1.00e-57
			NP_071744.2	membrane-spanning 4-domains, subfamily A, member 6A isoform 2; CD20-like precursor; membrane-spanning 4-domains, subfamily A, member 6; four-span transmembrane protein 3; MS4A6A-polymorph; four-span transmembrane protein 3.1; HAIRB-iso	208	1.00e-53
NM_011116 NP_035246.1	Mm.6483 2.45	U:(C-D)	AAL07357.1	AF354930_1 MS4A6A	208	1.00e-53
			AAG27920.1	AF142409_1 CD20-like precursor	207	2.00e-53
			AAL56223.1	AF350503_1 four-span transmembrane protein 3.2	207	4.00e-53
			AAH36327.1	Similar to phospholipase D3	890	0
			AAH00553.1	AAH00553 similar to vaccinia virus HindIII K4L ORF	818	0
			NP_036400.1	similar to vaccinia virus HindIII K4L ORF	816	0
			AAB16799.1	HUJ-K4	816	0
			NP_620145.1	hypothetical protein BC015003	385	e-106
			AAH15603.1	AAH15603 Unknown (protein for MGC:23565)	385	e-106
			NP_689879.1	hypothetical protein FLJ40773	275	2.00e-73
			BAC05230.1	unnamed protein product	275	2.00e-73
			BAC03722.1	unnamed protein product	223	9.00e-58

NM_013487 NP_038515.1	Mm.4527 2.39	U:(C-D) NP_000723.1	CD3D antigen, delta polypeptide (TIT3 complex)	228	5.00e-60
		P04234	CD3D_HUMAN T-cell surface glycoprotein CD3 delta chain precursor (T-cell receptor T3 delta chain)	228	5.00e-60
		RWHUD1	T-cell surface glycoprotein CD3 delta chain precursor	228	5.00e-60
		CAA25683.1	20K T3 glycoprotein precursor	228	5.00e-60
		AAA51792.1	T3 antigen delta-chain	228	5.00e-60
		CAA2573.1	T3 delta protein	228	5.00e-60
		1101394A	protein delta T3,glyco	222	2.00e-58
AK004773 XP_125911.2	Mm.32580 2.27	U:(C-D) NP_055686.1	KIAA0710 gene product	1150	0
		BAA31685.1	KIAA0710 protein	1150	0
		AAH24043.1	KIAA0710 gene product	1141	0
NM_007804 NP_031830.1	Mm.5116 2.26	U:(C-D) O14529	CUT2_HUMAN Homeobox protein Cux-2 (Cut-like 2)	1950	0
		BAA22962.2	The human homolog of mouse Cux-2	1950	0
		XP_027045.6	similar to Homeobox protein Cux-2 (Cut-like 2)	1949	0
		P39880	CUT1_HUMAN CCAAT displacement protein (CDP) (Cut-like 1)	892	0
		AAB26579.1	CCAAT displacement protein, CDP [human, Peptide, 1505 aa]	892	0
			cut-like 1, CCAAT displacement protein; cut like 1, CCAAT displacement protein	283	2.00e-75
		NP_001904.1 (Drosophila)		283	2.00e-75
		AAA35654.1	alternatively spliced	283	2.00e-75
		AAH25422.1	cut-like 1, CCAAT displacement protein (Drosophila)	283	2.00e-75
		AAG59620.1	AF271236_1 transcription factor CUX2	238	8.00e-62
NM_026384 NP_080660.1	Mm.1801 89	U:(C-D) CAD38961.1	hypothetical protein	761	0
			NP_115953.2 diacylglycerol O-acyltransferase homolog 2; GS1999full	751	0

		AAH15234.1	AAH15234 Unknown (protein for MGC:17861)	751	0
		AAK84176.2	AF384161_1 diacylglycerol acyltransferase 2	751	0
	BAB40641.2	product is unknown		751	0
	CAD13492.1	bA351K23.5 (novel protein)		340	2.00e-93
	NP_477513.1	diacylglycerol O-acyltransferase 2 like 1; diacylglycerol acyltransferase 2-like		331	1.00e-90
	AAK84178.1	AF384163_1 diacylglycerol acyltransferase 2-like protein		331	1.00e-90
	AAD4832.1	AC004876_5 similar to predicted proteins AAB54240 (PID:g2088822) and S67138 (PID:g2132925)		295	1.00e-79
	XP_088691.1	similar to bA351K23.5 (novel protein)		251	1.00e-66
	XP_088683.1	similar to bA351K23.5 (novel protein)		219	5.00e-57
	XP_093119.2	similar to bA351K23.5 (novel protein)		215	1.00e-55
	NP_079374.1	hypothetical protein FLJ22644		206	5.00e-53
	BAB15436.1	unnamed protein product		206	5.00e-53
AK004809	U:(C-D)				
BAB23580.1	Mm.28152 2.25	AAN41656.1	ezrin-binding protein PACE-1	1081	0
		CAB55300.1	hypothetical protein	956	0
		CAB52564.2	dJ9P20.1 (novel gene)	956	0
		AAN23123.1	ezrin-binding partner PACE-1	956	0
		NP_065156.4	ezrin-binding partner PACE-1	954	0
		AAH14662.1	Similar to hypothetical protein LOC57147	954	0
NM_009151	U:(C-D)				
NP_033177.1	Mm.22173 2.25	XP_006867.4	similar to P-selectin glycoprotein ligand 1 precursor (PSGL-1) (Selectin P ligand) (CD162 antigen)	286	5.00e-77
		Q14242	SEPL_HUMAN P-selectin glycoprotein ligand 1 precursor (PSGL-1) (Selectin P ligand) (CD162 antigen)	286	5.00e-77
		A57468	P-selectin glycoprotein ligand PSGL-1 precursor, long splice form	286	5.00e-77
		AAA74577.1	P-selectin glycoprotein ligand	286	5.00e-77

			NP_002997.1	selectin P ligand	284	2.00e-76
			AAAC50061.1	ligand for P-selectin	284	2.00e-76
			AAH29782.1	selectin P ligand	284	2.00e-76
			BAC05283.1	unnamed protein product	258	2.00e-68
NM_030255 NP_084531.1	Mm.8970 NP_084531.1	U:(C-D) 2.24	NP_660341.2	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F; similar to Phorbolin 3 (APOBEC1-like)	200	7.00e-51
AK009960	XP_133997.2	Mm.28248 2.23	U:(C-D) 2.23	KIAA1543 protein XP_048362.1 similar to KIAA1543 protein	388	e-108
			CAD38783.1	hypothetical protein	388	e-108
			AAL55764.1	AF289580_1 unknown	320	1.00e-87
			XP_036589.2	similar to KIAA1078 protein	237	2.00e-62
			AAH11385.1	Unknown (protein for IMAGE:3870900)	237	2.00e-62
			BAA83030.2	KIAA1078 protein	237	2.00e-62
			T14744	hypothetical protein DKFZp586F0424.1	236	3.00e-62
			CAB53664.1	hypothetical protein	236	3.00e-62
			AAH12778.1	Unknown (protein for IMAGE:3939659)	227	1.00e-59
			CAD39184.1	hypothetical protein	227	1.00e-59
NM_024249 NP_077211.2	Mm.3310 64	U:(C-D) 2.23	NP_612637.1	hypothetical protein MGC15523	689	0
			AAH14642.1	AAH14642 Similar to RIKEN cDNA 1810073N04 gene	689	0
			BAC04027.1	unnamed protein product	275	1.00e-73
NM_030562 NP_085039.1	Mm.1832 64	U:(C-D) 2.21	BAA96008.1	KIAA1484 protein	701	0
			XP_046088.1	similar to hypothetical protein MGC7599; clone MGC:7599	670	0
			XP_085176.1	similar to hypothetical protein MGC2656	484	e-136

		NP_689660.1	hypothetical protein FLL30803	484	e-136
		BAB70910.1	unnamed protein product	484	e-136
		BAA86560.1	KIAA1246 protein	466	e-131
		XP_166372.1	similar to hypothetical protein MGC2656	466	e-131
		NP_078785.1	hypothetical protein MGC2656	446	e-125
		AAH03578.1	AAH03578 Unknown (protein for MGC:2656)	446	e-125
		AAH25310.1	Similar to KIAA1484 protein	431	e-120
		NP_076941.2	hypothetical protein MGC3103	424	e-118
		AAH15581.2	similar to hypothetical protein MGC3103	424	e-118
		AAH14678.1	AAH14678 Unknown (protein for IMAGE:3860672)	274	2.00e-73
NM_033614 NP_291092.1	Mm.1969 2.15	JC4520	3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) alpha' chain	1489	0
		CAA64079.1	cone cGMP phosphodiesterase	1489	0
		2207224A	cGMP phosphodiesterase	1489	0
		P51160	CNRC_HUMAN Cone cGMP-specific 3',5'-cyclic phosphodiesterase alpha'-subunit	1484	0
		AAA92886.1	cone photoreceptor cGMP-phosphodiesterase alpha' subunit	1484	0
		NP_006195.2	phosphodiesterase 6C, cGMP-specific, cone, alpha prime	1478	0
		AAA96392.1	phosphodiesterase A' subunit	1478	0
		NP_000274.1	phosphodiesterase 6B, cGMP-specific, rod, beta	1092	0
		P35913	CNRB_HUMAN Rod cGMP-specific 3',5'-cyclic phosphodiesterase beta-subunit (GMP-PDE beta)	1092	0
		A42828	3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) beta chain	1092	0
		AAB22690.1	rod cGMP phosphodiesterase beta-subunit; PDDB	1092	0
		CAA46932.1	3',5'-cyclic-nucleotide phosphodiesterase	1092	0
		AAH00249.1	AAH00249 phosphodiesterase 6B, cGMP-specific, rod, beta (congenital stationary night blindness 3, autosomal dominant)	1089	0
		CAA44569.1	cGMP phosphodiesterase beta subunit	1085	0

		B34611	3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) alpha chain	1075	0
		NP_000431.1	phosphodiesterase 6A, alpha subunit	1074	0
	P16499	CNR4_HUMAN	Rod cGMP-specific 3',5'-cyclic phosphodiesterase alpha-subunit (GMP-PDE alpha) (PDE V-B1)	1074	0
	AAB69155.1	cGMP phosphodiesterase		1074	0
	CAA62215.1	Rod cGMP phosphodiesterase		893	0
	NP_058649.2	phosphodiesterase 11A; cyclic nucleotide phosphodiesterase 11A1		409	e-113
	BAB16371.1	phosphodiesterase 11A		409	e-113
	BAB62712.1	phosphodiesterase 11A4		409	e-113
NM_007441	U:(C-D)				
NP_031467.1	Mm.10112	2.14	NP_006483.1 aristless-like homeobox 3	516	e-146
			ALX3_HUMAN Homeobox protein aristless-like 3 (Proline-rich transcription factor O95076 ALX3)	516	e-146
			AAD01418.1 homeobox protein	516	e-146
NM_017394	Mm.3556	U:(C-D)	NP_062823.1 solute carrier family 7, member 10; asc-type amino acid transporter 1	904	0
NP_059090.1	7	2.14	Q9NS82 AAA1_HUMAN Asc-type amino acid transporter 1 (Asc-1)	904	0
			BAB03213.1 asc-type amino acid transporter 1	904	0
			AAK9960.1 AF340165_1 amino acid transporter	904	0
			CAC81900.1 ASC1 protein	904	0
			AAH35627.1 similar to solute carrier family 7	904	0
			Q9UHHS LAT2_HUMAN Large neutral amino acids transporter small subunit 2 (L-type amino acid transporter 2) (hLAT2)	669	0
			AAF20381.1 AF171669_1 glycoprotein-associated amino acid transporter LAT2	669	0
			BAB21519.1 L-type amino acid transporter 2	669	0
			NP_036376.1 solute carrier family 7 (cationic amino acid transporter, y <sup>+</sup> system), member 8	666	0
			CAB40137.1 SLC7A8 protein	666	0

		AAF05695.1	AFI35828_1 L amino acid transporter-2; LAT-2	534	e-151	
		NP_003477.2	solute carrier family 7 (cationic amino acid transporter, y <sup>+</sup> system), member 5; Membrane protein E16; Solute carrier family 7, member 5; 4F2 light chain	436	e-122	
Q01650	LAT1_HUMAN	Large neutral amino acids transporter small subunit 1 (L-type amino acid transporter 1) (4F2 light chain) (4F2 LC) (4F2LC) (CD98 light chain) (Integral membrane protein E16) (hLAT1)		436	e-122	
	JG0165	LAT1 protein		436	e-122	
	BAA33851.1	CD98 light chain		436	e-122	
	AAD20464.1	L-type amino acid transporter subunit LAT1		436	e-122	
	BAA84648.1	L-type amino acid transporter 1		436	e-122	
	AAC61479.1	amino acid transporter E16		436	e-122	
	AAH39692.1	Similar to solute carrier family 7 (cationic amino acid transporter, y <sup>+</sup> system), member 5		436	e-122	
	BAA75746.1	4F2 light chain		434	e-121	
	BAB70708.1	sodium-independent neutral amino acid transporter LAT1		434	e-121	
	NP_003974.1	solute carrier family 7 (cationic amino acid transporter, y <sup>+</sup> system), member 6		431	e-120	
	BAA13376.1	Similar to <i>Schistosoma mansoni</i> amino acid permease (125068).		431	e-120	
	AAH28216.1	solute carrier family 7 (cationic amino acid transporter, y <sup>+</sup> system), member 6		431	e-120	
AK018130	U:(C-D)					
BAB31085.1	Mm.5202	2.13	D59433	C. elegans protein Z37093 homolog [imported]	739	0
			BAA11212.1	similar to <i>C.elegans</i> protein (Z37093)	739	0
			AAC03237.1	D1013901	739	0
			XP_037574.1	similar to PTPL1-associated RhoGAP 1	739	0
			AAN04658.1	minor histocompatibility antigen HA-1	739	0
			AAH35564.1	Similar to PTPL1-associated RhoGAP 1	739	0
			NP_004806.1	PTPL1-associated RhoGAP 1	278	2.00e-74
			E59430	PTPL1-associated RhoGAP protein 1 [imported]	278	2.00e-74

		AAB81012.1	PTPL1-associated RhoGAP	278	2.00e-74
		NP_057657.1	Gem-interacting protein	265	2.00e-70
	D59435		Gem-interacting protein [imported]	265	2.00e-70
	AAF61330.1	AF132541_1	Gem-interacting protein	265	2.00e-70
AK014320					
BAB29271.1	Mm.30114	U:(C-D) 2.12	AAL14103.1 AF391100_1 alsin	1569	0
		BAB13389.2	KIAA1563 protein	1569	0
		NP_065970.1	alsin	1569	0
		BAB69014.1	long form	1569	0
		NP_667340.1	hypothetical protein LOC259173	244	5.00e-64
		BAC04237.1	unnamed protein product	244	5.00e-64
		BAB84944.1	FLJ001189 protein	244	9.00e-64
AK014599					
BAB29454.1	Mm.66017	U:(C-D) 2.12	AAD43186.1 AC006029_1 Similar to Sperm Surface Protein PH-20;Similar to P38568 (PID:585674)	749	0
		NP_036401.1	hyaluronoglucomannidase 4; hyaluronidase 4	749	0
		AAC98883.1	hyaluronidase 4	749	0
		NP_694859.1	sperm adhesion molecule 1 isoform 2; sperm surface protein PH-20; hyaluronoglucomannidase	385	e-106
		P38567	HYAP_HUMAN Hyaluronidase PH-20 precursor (Sperm surface protein PH-20) (Sperm adhesion molecule 1)	385	e-106
		CAA59086.1	sperm adhesion molecule gene SPAM1	385	e-106
		NP_003108.2	sperm adhesion molecule 1 isoform 1; sperm surface protein PH-20;	385	e-106
		AAH26163.1	sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding)	385	e-106
		AAC6607.2	PH-20	382	e-105
		S40465	sperm protein PH-20	382	e-105

		AAD24460.1	AF118821_1 hyaluronoglucosaminidase 1 isoform 2		337	9.00e-92
		AAD53277.1	AF173154_1 hyaluronoglucosaminidase 1 isoform 2		337	9.00e-92
		NP_009296.1	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase		336	1.00e-91
		NP_149349.2	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase		336	1.00e-91
		NP_695013.1	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase		336	1.00e-91
		AAD04190.1	hyaluronoglucosaminidase 1		336	1.00e-91
		AAD09137.2	putative tumor suppressor		336	1.00e-91
		AAH35695.1	hyaluronoglucosaminidase 1		336	1.00e-91
		JC5584	hyaluronoglucosaminidase (EC 3.2.1.35) 1 precursor		333	7.00e-91
NM_008969	U:(C-D)	NP_000953.2	prostaglandin-endoperoxide synthase 1, isoform 1 precursor; prostaglandin G/H synthase and cyclooxygenase; PGH synthase 1; PG synthetase; prostaglandin synthetase; cyclooxygenase-1; prostaglandin H2 synthetase 1		1043	0
NP_032995.1	Mm.2792	P23219	PGH1 HUMAN Prostaglandin G/H synthase 1 precursor (Cyclooxygenase -1) (COX-1) (Prostaglandin-endoperoxide synthase 1) (Prostaglandin H2 synthase 1) (PGH synthase 1) (PGHS-1) (PHS 1)		1043	0
		JH0259	prostaglandin-endoperoxide synthase (EC 1.14.99.1) 1 precursor		1043	0
		AAA03630.1	prostaglandin endoperoxide synthase		1043	0
		AAB21215.1	prostaglandin endoperoxide synthase; cyclooxygenase		1043	0
		AAB22217.1	prostaglandin G/H synthase; PGG/H/S		1043	0
		AAL33601.1	AF440204_1 prostaglandin-endoperoxide synthase 1		1043	0
		AAH29840.1	Unknown (protein for MGC:34214)		1043	0
		AAA36439.1	prostaglandin-endoperoxide synthase-1		1038	0
		NP_542158.1	prostaglandin-endoperoxide synthase 1, isoform 2 precursor; prostaglandin G/H synthase and cyclooxygenase; PGH synthase 1; PG synthetase; prostaglandin synthetase; cyclooxygenase-1; prostaglandin H2 synthetase 1		956	0
		AAB22216.1	prostaglandin G/H synthase; PGG/H/S		956	0

			NP_000954.1	prostaglandin-endoperoxide synthase 2 precursor; prostaglandin G/H synthase and cyclooxygenase; cyclooxygenase-2; endoperoxide synthase type II; prostaglandin H synthase type 2; prostaglandin synthase-2; PG synthetase	729	0
		P35354		PGH2_HUMAN Prostaglandin G/H synthase 2 precursor (Cyclooxygenase -2) (COX-2)(Prostaglandin-endoperoxide synthase 2) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II)	729	0
		AAA57317.1		cyclooxygenase-2	729	0
		BAA05698.1		prostaglandin endoperoxide synthase-2	729	0
		CAB41240.1		PTGS2 (prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase))	729	0
		AAH13734.1		AAH13734 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	729	0
		A46150		prostaglandin-endoperoxide synthase (EC 1.14.99.1) 2 precursor	729	0
		AAA58433.1		cyclooxygenase-2	729	0
		AAA35803.1		endoperoxide synthase type II	727	0
		AAN52932.1		cyclooxygenase 2b	380	e-105
NM_010225 NP_034355.1	U;(C-D) Mm.6260 2.11	NP_001443.1		forkhead box F2; forkhead (Drosophila)-like 6	521	e-147
		Q12947		FXF2_HUMAN Forkhead box protein F2 (Forkhead-related protein FKHL6) (Forkhead-related transcription factor 2) (FREAC-2) (Forkhead-related activator-2)	521	e-147
		T09474		forkhead protein FREAC-2	521	e-147
		AAC32226.1		forkhead protein FREAC-2	521	e-147
		AAD19875.1		forkhead transcription factor	521	e-147
		2208384B		transcription factor FREAC-2	508	e-143
		NP_001442.1		forkhead box F1; forkhead (Drosophila)-like 5; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1 [Homo sapiens]	251	3.00e-66
		Q12946		FXF1_HUMAN Forkhead box protein F1 (Forkhead-related protein FKHL5) (Forkhead-related transcription factor 1) (FREAC-1) (Forkhead-related activator-1)	251	3.00e-66

		AAC50399.1	FREAC-1	251	3.00e-66
		AAC61576.1	forkhead transcription factor	251	3.00e-66
		2208384A	transcription factor FREAC-1	251	3.00e-66
NM_028770	Mm.3338	U:(C-D) 2.1	XP_096612.2 similar to RIKEN cDNA 1200016G03	561	e-159
NP_083046.1	5				
		CAB76832.1	cytokeratin	270	6.00e-72
		NP_004684.1	cytokeratin type II	270	1.00e-71
		CAA76730.1	cytokeratin type II	270	1.00e-71
		AAH24292.1	keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types)	261	5.00e-69
		AAA36145.1	keratin K5	260	7.00e-69
		NP_000415.1	keratin 5; Keratin-5; 58 kda cytokeratin; keratin, type II cytoskeletal 5; cytokeratin 5	260	7.00e-69
		P13647	K2C5_HUMAN Keratin, type II cytoskeletal 5 (Cytokeratin 5) (K5) (CK 5) (58 kDa cytokeratin)	260	7.00e-69
		A29904	keratin 5, type II, epidermal	260	7.00e-69
		AAA36143.1	keratin type II	260	7.00e-69
		AAF97931.1	AF2274874_1 keratin 5	260	7.00e-69
		NP_002264.1	keratin 8; Keratin-8	259	1.00e-68
		CAA52882.1	Keratin 8	259	1.00e-68
		AAB18966.1	human cytokeratin 8	259	1.00e-68
		AAH00654.1	AAH00654 keratin 8	259	1.00e-68
		A34720	keratin 8, type II cytoskeletal	259	1.00e-68
		P05787	K2C8_HUMAN Keratin, type II cytoskeletal 8 (Cytokeratin 8) (K8) (CK 8)	259	1.00e-68
		AAA35763.1	cytokeratin 8	259	1.00e-68
NM_011671	Mm.1444	U:(C-D) 2.09	NP_003346.2 uncoupling protein 2	585	e-167
NP_035801.1	13		P55851 UCP2_HUMAN Mitochondrial uncoupling protein 2 (UCP 2) (UCPH)	585	e-167
			AAC51336.1 UCP2	585	e-167

	AAC39690.1	uncoupling protein 2	585	e-167
	AAD21151.1	uncoupling protein-2	585	e-167
	AAH11737.1	AAH11737 uncoupling protein 2 (mitochondrial, proton carrier)	585	e-167
	AAB53091.1	uncoupling protein homolog	583	e-166
	CAA11402.1	uncoupling protein 2	583	e-166
	AAB48411.1	uncoupling protein-2	583	e-166
	NP_003347.1	uncoupling protein 3, isoform UCP3L	451	e-127
	P55916	UCP3_HUMAN Mitochondrial uncoupling protein 3 (UCP 3)	451	e-127
	JC5522	uncoupling protein UCP3, mitochondrial	451	e-127
	AAC51367.1	UCP3	451	e-127
	AAC51369.1	uncoupling protein 3	451	e-127
	AAC51767.1	uncoupling protein-3	451	e-127
	AAG02284.1	AF050113_1 uncoupling protein-3	451	e-127
	AAC18822.1	uncoupling protein 3	445	e-125
	AAC51785.1	uncoupling protein 3	432	e-121
	NP_073714.1	uncoupling protein 3, isoform UCP3S	392	e-109
	AAC51356.1	UCP3S	392	e-109
	NP_068605.1	uncoupling protein 1; mitochondrial brown fat uncoupling protein	353	2.00e-97
	G01858	uncoupling protein 1, mitochondrial	353	2.00e-97
	AAA82271.1	uncoupling protein	353	2.00e-97
	P25874	UCP1_HUMAN Mitochondrial brown fat uncoupling protein 1 (UCP 1) (Thermogenin)	350	2.00e-96
	CAA36214.1	uncoupling protein	250	2.00e-96
	AAH08392.1	AAH08392 Similar to uncoupling protein 3 (mitochondrial, proton carrier)	206	5.00e-53
NM_011933 NP_036063.1	Mm.3576 U:(C-D) 2.09	NP_065715.1 peroxisomal 2,4-dienoyl-CoA reductase	466	e-131

		CAB92744.1	c359F1.1 (novel protein (ortholog of mouse and rat peroxisomal 2,4-dienoyl-coA reductase (PDCR, DCR-AKL)))	466	e-131
		CAC05664.1	peroxisomal 2,4-dienoyl-CoA reductase	466	e-131
		AAK61231.1	AE006463_11 2,4-dienoyl-Coenzyme A reductase 2 peroxisomal like	466	e-131
		AAH10740.1	AAH10740_24-dienoyl CoA reductase 2, peroxisomal	466	e-131
		AAH11968.1	AAH11968 Similar to 2,4-dienoyl CoA reductase 2, peroxisomal	370	e-102
NM_019424 NP_062297.1	Mm.1948 06	AAL50684.1 U:(C-D) 2.08	AF450133_1 Hermansky-Pudlak syndrome	1065	0
		NP_000186.1	Hermansky-Pudlak syndrome protein; Hermansky-Pudlak syndrome gene; Hermansky-Pudlak syndrome	1064	0
		Q92902	HPS1_HUMAN Hermansky-Pudlak syndrome 1 protein	1064	0
		AAB17869.1	Hermansky-Pudlak syndrome protein	1064	0
		AAB70662.1	Hermansky-Pudlak syndrome protein	998	0
		AAH00175.1	AAH00175 Hermansky-Pudlak syndrome	411	e-114
		AAC52074.1	alternative Hermansky-Pudlak syndrome associated protein	409	e-114
NM_008433 NP_032459.1	Mm.9911 NP_002241.1 2.06	U:(C-D) NP_002241.1	intermediate conductance calcium-activated potassium channel protein 1; putative erythrocyte intermediate conductance calcium-activated potassium Gardos channel	607	e-173
		O15554	KCN4_HUMAN Intermediate conductance calcium-activated potassium channel protein 4 (SK4) (IK1) (IKCa1) (Putative Gardos channel)	607	e-173
		AAB82739.1	calcium-activated potassium channel	607	e-173
		AAC36804.1	intermediate conductance calcium-activated potassium channel	607	e-173
		AAC23541.1	hIK1	607	e-173
		AAC51913.1	intermediate conductance calcium-activated potassium channel	607	e-173
		AAG26917.1	intermediate-conductance calcium-activated potassium channel 1	607	e-173
		AAH15337.1	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	607	e-173

		AAK81862.1	AF395661_1 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	606	e-173	
		AAL10706.1	small-conductance calcium-activated potassium channel SK3	286	5.00e-77	
		NP_002240.2	small conductance calcium-activated potassium channel protein 3 isoform a	285	1.00e-76	
		KCN3_HUMAN	Small conductance calcium-activated potassium channel protein 3 (SK3) (SKCa3)	285	1.00e-76	
		Q9UGI6	SK3 protein	285	1.00e-76	
		CAB61331.1				
		AAK15345.1	AF336797_1 small-conductance calcium-activated potassium channel	285	1.00e-76	
		T09172	probable calcium-activated potassium channel KCNN3	282	1.00e-75	
		AAC26099.1	calcium-activated potassium channel	282	1.00e-75	
		Q92952	KCN1_HUMAN Small conductance calcium-activated potassium channel protein 1 (SK1)	278	2.00e-75	
		AAB09562.1	small-conductance, calcium-activated potassium channel SK1	278	2.00e-75	
		AAD37507.1	small-conductance calcium-activated potassium channel 1	278	2.00e-75	
		NP_002239.2	small conductance calcium-activated potassium channel protein 1	278	2.00e-75	
		AAK84039.1	AF397175_1 small-conductance calcium-activated potassium channel	280	5.00e-75	
		Q9H2S1	KCN2_HUMAN Small conductance calcium-activated potassium channel protein 2 (SK2)	279	7.00e-75	
		AAG16728.1	AF239613_1 apamin-sensitive small-conductance Ca2+-activated potassium channel	279	7.00e-75	
		NP_067627.2	small conductance calcium-activated potassium channel protein 2 isoform a; apamin-sensitive small-conductance Ca2+-activated potassium channel	279	7.00e-75	
NM_013486	Mm.2284	U:(C-D) 2.06	RWHUC2	T-cell surface glycoprotein CD2 precursor	255	1.00e-67
NP_038514.1	2		AAA35571.1	T-cell surface antigen CD2 precursor	255	1.00e-67
			AAA53095.1	T11 surface antigen	255	1.00e-67
			CAC14840.1	dJ655N15.1 (CD2 antigen (p50), sheep red blood cell receptor)	255	1.00e-67
			AAA51946.1	CD2 surface antigen	255	1.00e-67
			NP_001758.1	CD2 antigen (p50), sheep red blood cell receptor; lymphocyte-function antigen-2	252	8.00e-67

		P06729	CD2_HUMAN T-cell surface antigen CD2 precursor (T-cell surface antigen T11/Leu-5) (LFA-2) (LFA-3 receptor) (Erythrocyte receptor) (Rosette receptor)	252	8.00e-67
		AAA51738.1	surface antigen CD2 precursor	252	8.00e-67
		CAA30721.1	T-cell surface antigen	252	8.00e-67
		AAH35583.1	CD2 antigen (p50), sheep red blood cell receptor	252	8.00e-67
NM_029796 NP_084072.1	Mm.1769 46	U:(C-D) 2.06	NP_443204.1 leucine-rich alpha-2-glycoprotein	330	3.00e-90
		P02750	A2GL_HUMAN Leucine-rich alpha-2-glycoprotein precursor (LRG)	330	3.00e-90
		AAK95527.1	AF403428_1 leucine-rich alpha-2-glycoprotein	330	3.00e-90
		NBHUA2	leucine-rich alpha-2-glycoprotein	329	6.00e-90
X71479 CAA50585.1	NULL	U:(C-D) 2.06	AAH34389.1 leucine-rich alpha-2-glycoprotein	327	2.00e-89
		CAA50586.1	cytochrome P450	268	2.00e-72
		NP_000769.1	cytochrome P450, subfamily IVA, polypeptide 11; fatty acid omega-hydroxylase; P450HL-omega; alkane-1 monooxygenase; lauric acid omega-hydroxylase	267	4.00e-72
		IS3015	fatty acid omega-hydroxylase (EC 1.14.15.-) cytochrome P450 4A11	267	4.00e-72
		AAB29502.1	fatty acid omega-hydroxylase; CYP4A11	267	4.00e-72
		I65981	fatty acid omega-hydroxylase (EC 1.14.15.-) cytochrome P450 4A11	267	4.00e-72
		AAB29503.1	fatty acid omega-hydroxylase; CYP4A11 <sup>v</sup>	267	4.00e-72
		Q02928	CP4Y_HUMAN Cytochrome P450 4A11 precursor (CYP4A11) (Fatty acid omega-hydroxylase) (P-450 HK omega) (Lauric acid omega-hydroxylase) (CYP4AII) (P450-HL-omega)	265	2.00e-71
		JX0331	laurate omega-hydroxylase (EC 1.14.15.3) cytochrome P450 4A11 (HL24)	265	2.00e-71
		AAA58436.1	cytochrome P450	265	2.00e-71
		BAA05491.1	fatty acids omega-hydroxylase (cytochrome P450HL omega)	265	2.00e-71
		1908216A	fatty acid omega-hydroxylase (cytochrome P450 4A)	265	2.00e-71
		BAA02864.1	fatty acid omega-hydroxylase	265	2.00e-71
		AAF76722.1	AF208532_1 fatty acid omega-hydroxylase CYP4A11	261	2.00e-70

		CAB72105.1	dJ18D14.4 (cytochrome P450, subfamily IVA, polypeptide 11)	253	6.00e-68
		AAH23102.1	Unknown (protein for MGC:40051)	202	1.00e-52
		BAC05226.1	unnamed protein product	202	1.00e-52
		BAC03751.1	unnamed protein product	202	1.00e-52
		O14753	OVO1_HUMAN Putative transcription factor Ovo-like 1 (hOvo1)	468	e-131
NM_019935 NP_0643191	Mm.3832 U:(IR-D) 2.05				
		NP_0643191_3			
		NP_004552.1	OVO-like 1 binding protein; putative transcription factor OVO-like 1; ovo (Drosophila) homolog-like 1	367	e-101
		AAB72084.1	OVO-like 1 binding protein	367	e-101
		NP_067043.1	zinc finger protein 339; ovo-like 2 (Drosophila)	275	3.00e-73
		BAB14002.1	unnamed protein product	275	3.00e-73
		Q9BRP0	Z339_HUMAN Zinc finger protein 339	271	2.00e-72
		AAH06148.1	AAH06148 putative zinc finger protein from EUROIMAGE 566589	271	2.00e-72
		CAB45151.1	hypothetical protein, similar to (AF134804) putative zinc finger transcription factor OVO1 [Mus musculus]	238	3.00e-62
NM_012006 NP_0361361	Mm.1978 U:(C-D) 2.05	XP_170752.1	similar to peroxisomal long-chain acyl-coA thioesterase; peroxisomal long-chain acyl-coA thioesterase ; putative protein	602	e-172
		P49753	PTE2_HUMAN Peroxisomal acyl-coenzyme A thioester hydrolase 2 (Peroxisomal long-chain acyl-coA thioesterase 2) (ZAP128)	600	e-171
		JC7367	second peroxisomal thioesterase	600	e-171
		AAF97985.1	peroxisomal long-chain acyl-coA thioesterase	600	e-171
		AAH04436.1	AAH04436 Unknown (protein for MGC:3983)	600	e-171
		AAH06500.1	AAH06500 Unknown (protein for MGC:2366)	600	e-171
		NP_006812.2	peroxisomal long-chain acyl-coA thioesterase; peroxisomal long-chain acyl-coA thioesterase ; putative protein	599	e-171
		AAH06335.1	AAH06335 peroxisomal long-chain acyl-coA thioesterase	599	e-171
		BAA91989.1	unnamed protein product	598	e-171

		NP_689544.1	hypothetical protein FLJ31235	494	e-139	
		BAC04313.1	unnamed protein product	494	e-139	
		AAC42007.1	ORF; putative	405	e-113	
		XP_090885.1	similar to Peroxisomal acyl-coenzyme A thioester hydrolase 2 (Peroxisomal long-chain acyl-CoA thioesterase 2) (ZAP128)	280	4.00e-75	
		NP_001692.1	bile acid Coenzyme A: amino acid N-acyltransferase; glycine N-choloyltransferase	265	2.00e-70	
		A53965	bile acid-CoA: amino acid N-acyltransferase	265	2.00e-70	
		AAC37550.1	bile acid CoA: Amino acid N-acyltransferase	265	2.00e-70	
		AAH09567.1	AAH09567 bile acid Coenzyme A: amino acid N-acyltransferase (glycine N-choloyltransferase)	265	2.00e-70	
AK004963		U:(C-D) Mm.186 2.04	NP_055419.1	Tax interaction protein 1	243	4.00e-64
BAB23703.1			AAB84248.2	Tax interaction protein 1	243	4.00e-64
			AAG44368.1	AF234997_1 glutaminase-interacting protein 3	243	4.00e-64
			AAK69111.1	AF277318_1 tax-interacting protein 1	243	4.00e-64
			AAH23980.1	Tax interaction protein 1	243	4.00e-64
			AAF43104.1	TIP1	228	2.00e-59
AK008849		U:(C-D) Mm.45435 2.04	NP_079119.2	duodenal cytochrome b; hypothetical protein FLJ23462	391	e-109
BAB25928.1			CAB66628.1	hypothetical protein	391	e-109
			BAB15661.1	unnamed protein product	386	e-107
				similar to data source:SPTR, source key:Q9H0Q8, evidence:ISS~homolog to		
			XP_166224.2	HYPOTHETICAL 31.6 KDA PROTEIN~putative	196	6.00e-50
			NP_705839.1	hypothetical protein MGCG20446	196	6.00e-50
			BAC11698.1	unnamed protein product	196	6.00e-50

NM_008532		U:(C-D)		TTD1_HUMAN Tumor-associated calcium signal transducer 1 precursor (Major gastrointestinal tumor-associated protein GA733-2) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Adenocarcinoma-associated antigen) (KSA) (KS 1/4 antigen) (Cell surface glycoprotein Trop-1)	446	e-125
NP_032558.1	Mm.4259	2.03	P16422	CAA32870.1 KSA preproantigen peptide	446	e-125
			CAA36151.1	adenocarcinoma-associated antigen precursor (KSA)	446	e-125
			AAA59543.1	KS1/4 antigen	446	e-125
				tumor-associated calcium signal transducer 1 precursor; membrane component, chromosome 4, surface marker (35kD glycoprotein); MK-1 antigen; antigen identified by monoclonal antibody AUA1	446	e-125
			NP_002345.1		446	e-125
			B48149	epithelial glycoprotein antigen GA733-2 precursor	446	e-125
			AAA35861.1	carcinoma-associated antigen GA733-2	446	e-125
			AAB00775.1	carcinoma-associated antigen GA733-2	446	e-125
			AAH14785.1	tumor-associated calcium signal transducer 1	446	e-125
			AAA35723.1	epithelial glycoprotein (EGP) precursor	444	e-124
			A48149	carcinoma-associated antigen GA733-1 precursor	265	2.00e-70
			CAA31781.1	GA733-1 protein (AA 1-323)	265	2.00e-70
			CAA54801.1	gp50/TROP-2	265	2.00e-70
			AAH09409.1	Unknown (protein for MGC:10655)	265	2.00e-70
				tumor-associated calcium signal transducer 2 precursor; membrane component, chromosome 1, surface marker 1 (40kD glycoprotein, identified by monoclonal antibody GA733); epithelial glycoprotein-1	263	6.00e-70
			CAA54799.1	gp50/Trop-2	263	6.00e-70
			P09758	TTD2_HUMAN Tumor-associated calcium signal transducer 2 precursor (Pancreatic carcinoma marker protein GA733-1) (Cell surface glycoprotein Trop-2)	262	1.00e-69
			AAA52505.1	GA733-1 protein precursor	262	1.00e-69
NM_009780		U:(C-D)				
NP_033910.1	Mm.16106	2.02	P01028	CO4 HUMAN Complement C4 precursor [Contains: C4A anaphylatoxin]	2587	0

		C4HU	complement C4A precursor [validated]	2586	0
		AAA51855.1	complement component C4A	2586	0
		NP_009224.1	complement component 4A preprotein; acidic C4; Rodgers form of C4; complement component 4S	2583	0
	CAB8302.	dJ34F7.4 (complement component 4A)		2582	0
		NP_00583.1	complement component 4B preprotein; Chido form of C4; basic C4; complement component 4F	2581	0
		AAB67980.1	complement component C4	2581	0
		AAB59537.1	complement component C4A	2563	0
		AAA99717.1	complement C4B precursor	2465	0
		NP_00055.1	complement component 3 precursor	624	e-178
	P01024	CO3_HUMAN Complement C3 precursor		624	e-178
		C3HU	complement C3 precursor [validated]	624	e-178
		AAA85332.1	complement component C3	624	e-178
		AAA59651.1	complement component C4B	573	e-163
		IHZF	A Chain A, C4adg Fragment Of Human Complement Factor C4a	544	e-154
NM_008874	U:(C-D)				
NP_032900.1	Mm.6888	2	NP_000923.1 phospholipase C, beta 3 (phosphatidylinositol-specific)	2015	0
			Q01970 PIP3_HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 3 (PLC-beta-3) (Phospholipase C-beta-3)	2015	0
			I38994 phospholipase C-beta-3	2015	0
			AAA77683.1 phospholipase C-beta-3	2015	0
			S52099 phospholipase C beta 3	1967	0
			CAA85776.1 phospholipase C beta 3	1967	0
			AAH32659.1 Similar to phospholipase C, beta 3	1824	0
			S27002 phospholipase C (EC 3.1.4.3), phosphatidylinositol specific	1663	0
			CAA78903.1 phospholipase C	1663	0

			phospholipase C, beta 1 (phosphoinositide-specific); phosphoinositide-specific phospholipase C-beta 1(phosphoinositide-specific)	NP_056007.1	1197	0
			PIB1 HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta (PLC-beta-1) (Phospholipase C-beta-1) (PLC-154)	Q9NQ66	1197	0
		CAB98142.1	phospholipase C-beta-1a	CAB98143.1	1197	0
		CAB98143.1	phospholipase C-beta-1b	AAFF86613.1	1192	0
		AAFF86613.1	phospholipase C beta 1	BAA25507.	1154	0
		BAA25507.	KIAA0581 protein	NP_004564.1	1047	0
		NP_004564.1	phospholipase C, beta 2	Q00722	934	0
		Q00722	PIB2 HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 2 (PLC-beta-2) (Phospholipase C-beta-2)	A43346	934	0
		A43346	1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase (EC 3.1.4.11) beta-2	AAA36453.1	934	0
		AAA36453.1	phospholipase C-beta-2	T46339	934	0
		T46339	hypothetical protein DKFZp434A0814.1	CAB70666.1	885	0
		CAB70666.1	hypothetical protein	NM_010129	885	0
	Mm.2082	U:(C-D) 2	epithelial membrane protein 3	NP_001416.1	250	1.00e-66
NP_034259.1	9			P54852	250	1.00e-66
			EMP3_HUMAN Epithelial membrane protein-3 (EMP-3) (YMP protein) (HNMMP-1) (Hematopoietic neural membrane protein)	AAC50920.1	250	1.00e-66
			YMP	AAC51730.1	250	1.00e-66
			hematopoietic neural membrane protein	AAH09718.1	250	1.00e-66
			AAH09718 epithelial membrane protein 3	JCS045	250	1.00e-66
			epithelial membrane protein 3	CAA64394.1	244	6.00e-65
			epithelial membrane protein-3	NP_004612.2	244	6.00e-65
NM_011644	Mm.8361	U:(C-D) 2	transient receptor potential cation channel, subfamily C, member 6; transient receptor potential channel 6	NP_035774.1	427	e-119
NP_035774.1	5		TRP6 HUMAN Short transient receptor potential channel 6 (TrpC6)	Q9Y210	427	e-119

	CAA06943.1	transient receptor potential protein		427	e-119
	AAC62289.2	transient receptor potential protein 6		427	e-119
	CAC01684.1	transient receptor potential channel 6		427	e-119
	NP_003296.1	transient receptor potential cation channel, subfamily C, member 3; transient receptor potential channel 3		421	e-117
	Q13507	TRP3_HUMAN Short transient receptor potential channel 3 (TrpC3) (Htrp-3) (Htrp3)		421	e-117
	CAA74083.1	transient receptor potential related channel 3 protein		421	e-117
	AAC51653.1	calcium influx channel		421	e-117
	NP_065122.1	putative capacitative calcium channel		411	e-114
	Q9HCX4	TRP7_HUMAN Short transient receptor potential channel 7 (TrpC7) (TRP7 protein)		441	e-114
	CAC03489.1	putative capacitative calcium channel		411	e-114
	CAD19069.1	short transient receptor potential channel 7		409	e-113
	AAF22928.1	AF063823_1 trp-related protein 4 truncated variant beta		369	e-101
	AAL24550.1	AF421359_1 transient receptor potential channel 4 beta splice variant		369	e-101
	AAL24551.1	AF421360_1 transient receptor potential channel 4 epsilon splice variant		369	e-101
	NP_057263.1	transient receptor potential 4; transient receptor potential channel 4		369	e-101
	Q9UBN4	TRP4_HUMAN Short transient receptor potential channel 4 (TrpC4) (trp-related protein 4) (hTrp-4) (hTrp4)		369	e-101
	AAD51736.1	AF175406_1 transient receptor potential 4		369	e-101
	AAF22927.1	AF063822_1 trp-related protein 4		369	e-101
	AAL24549.1	AF421358_1 transient receptor potential channel 4 alpha splice variant		369	e-101
	AAF22929.1	AF063824_1 trp-related protein 4 truncated variant delta		369	e-101
	NP_036603.1	transient receptor potential cation channel, subfamily C, member 5; transient receptor potential channel 5		359	2.00e-98
	Q9UL62	TRP5_HUMAN Short transient receptor potential channel 5 (TrpC5) (Htrp-5) (Htrp5)		359	2.00e-98
	AAF0002.1	AF054568_1 transient receptor potential calcium channel 5		359	2.00e-98
	CAC01686.1	transient receptor potential channel 6, variant delta377-431		333	1.00e-90



**Subtable 1C: Mixed Genes and Proteins**

Mouse Gene Protein	Unigene	Behavior	Human Proteins	Human Protein Name	Score (bits)	E-value
NM_011369	Mm.37801	U:(C-IR) 2.88 F:(IR-D) -2.63	NP_079021.2	likely ortholog of mouse Shc SH2-domain binding protein 1; hypothetical protein FLJ22009	1004 0	
NP_035499.1			AAH30699.1	Unknown (protein for MGC:26900)	1004 0	
			BAB71049.1	unnamed protein product	1003 0	
			XP_015700.2	similar to Shc SH2-domain binding protein 1	632 0	
			BAB15208.1	unnamed protein product	630 e-180	
			AAH00960.1	AAH00960 Unknown (protein for IMAGE:3451160)	615 e-176	
			AAG45336.1	GE36	230 8.00E-60	
			NP_1112195.1	chromosome 1 open reading frame 14; GE36 gene	228 2.00E-59	
			AAG66167.1	AF288398_1 C1orf14	228 2.00E-59	
			AAG66166.1	AF288397_1 C1orf14	204 6.00E-52	
NM_015810	Mm.859	U:(C-IR) 2.74 F:(IR-D) -3.23	Q9UHN1	DPG2_HUMAN DNA polymerase gamma subunit 2, mitochondrial precursor (Mitochondrial DNA polymerase accessory subunit (PolG-beta) (MtpolB) (DNA polymerase gamma accessory 55 kDa subunit) (p55))	712 0	
NP_056625.1			AAD50382.1	AF142992_1 DNA polymerase gamma accessory subunit	712 0	
			AAD55640.1	AF177201_1 mitochondrial DNA polymerase accessory subunit precursor	711 0	
			AAH09194.1	AAH09194 Unknown (protein for MGC:15231)	710 0	
			AAD56542.1	AF184344_1 DNA polymerase accessory subunit precursor	707 0	
			NP_009146.1	polymerase (DNA directed), gamma 2, accessory subunit; mitochondrial DNA polymerase, accessory subunit	600 e-171	
			AAC51321.1	mitochondrial DNA polymerase accessory subunit precursor	600 e-171	
NM_007659	Mm.4761	U:(C-IR) 2.72 F:(IR-D) -2.86	NP_001777.1	cell division cycle 2 protein, isoform 1; cell division control protein 2 homolog; cyclin-dependent kinase 1; p34 protein kinase; cell cycle controller CDC2	577 e-164	
NP_031685.1			P06493	CDC2_HUMAN Cell division control protein 2 homolog (p34 protein kinase)	577 e-164	

		(Cyclin-dependent kinase 1) (CDK1)		
	A29539	protein kinase (EC 2.7.1.37) cdc2	577	e-164
	CAA28963.1	CDC2 polypeptide (CDC2) (AA 1-297)	577	e-164
	CAA683376.1	CDC2 protein (AA 1-297)	577	e-164
	AAH14563.1	Similar to cell division cycle 2, G1 to S and G2 to M	577	e-164
	AAM34793.1	AF512554_1 cell division cycle 2, G1 to S and G2 to M	577	e-164
1306392A	gene CDC2	cell division cycle 2 protein, isoform 2; cell division control protein 2 homolog;	577	e-164
NP_203698.1		cyclin-dependent kinase 1; p34 protein kinase	409	e-114
	BAA26001.1	CDC2 delta T	409	e-114
	NP_001249.1	cyclin-dependent kinase 3	393	e-109
	Q00526	CDK3_HUMAN Cell division protein kinase 3	393	e-109
	S23382	protein kinase (EC 2.7.1.37) cdk	393	e-109
	CAA47001.1	serine/threonine protein kinase [Homo sapiens]	393	e-109
	CAA43807.1	cell division kinase. CDK2 homolog	390	e-108
	NP_001789.2	cyclin-dependent kinase 2, isoform 1; cdc2-related protein kinase; cell division kinase 2; p33 protein kinase	389	e-108
	P24941	CDK2_HUMAN Cell division protein kinase 2 (p33 protein kinase)	389	e-108
	A41227	protein kinase (EC 2.7.1.37) cdk2	389	e-108
1KE5		A Chain A, Cdk2 Complexed With N-Methyl-4-[(2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]amino}benzenesulfonamide	389	e-108
1KE6		A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With N-Methyl-4-[2-(7-Oxo-6,7-Dihydro-8h-[1,3]thiazolo[5,4-E]indol-8-Ylidene)hydrazino]phenyl]methanesulfonamide	389	e-108
1KE7		A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 3-[(2,2-Dioxido-1,3-Dihydro-2-Benzothien-5-Yl)amino]methylene}-5-(1,3-Oxazol-5-Yl)-1,3-Dihydro-2h-Indol-2-One	389	e-108
1KE8		A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 4-[(2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]amino}N-(1,3-Thiazol-2-Yl)benzenesulfonamide	389	e-108
1KE9		A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 3-[(4-((farno(Imato)methyl)amino)sulfonyl)anilino]methylene}-2- Oxo-2,3-Dihydro-1h-Indole	389	e-108
1FIN		A Chain A, Cyclin A - Cyclin-Dependent Kinase 2 Complex	389	e-108

		C Chain C, Cyclin A - Cyclin-Dependent Kinase 2 Complex	389 e-108
	1FIN	C Chain C, The Structure Of Cdk2CYCLIN A IN COMPLEX WITH AN OXINDOLE Inhibitor	389 e-108
	1FVV	A Chain A, The Structure Of Cdk2CYCLIN A IN COMPLEX WITH AN OXINDOLE Inhibitor	389 e-108
	1HCL	Human Cyclin-Dependent Kinase 2	389 e-108
	1HCK	Human Cyclin-Dependent Kinase 2	389 e-108
	1F5Q	A Chain A, Crystal Structure Of Murine Gamma Herpesvirus Cyclin Complexed To Human Cyclin Dependent Kinase 2	389 e-108
	1BUH	A Chain A, Crystal Structure Of The Human Cdk2 Kinase Complex With Cell Cycle-Regulatory Protein Ckshs1	389 e-108
	1JSV	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With 4-[6-Amino-4-Pyrimidinyl] Amino]benzenesulfonamide	389 e-108
	1JVP	P Chain P, Crystal Structure Of Human Cdk2 (Unphosphorylated) In Complex With Pkf049-365	389 e-108
	1D18	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	389 e-108
	1FVT	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With An Oxindole Inhibitor	389 e-108
	1CKP	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Purvalanol B	389 e-108
	1AQ1	Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Staurosporine	389 e-108
	1GIH	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Cdk4 Inhibitor	389 e-108
	1G5S	A Chain A, Crystal Structure Of Human Cyclin Dependent Kinase 2 (Cdk2) In Complex With The Inhibitor H717	389 e-108
	1DM2	A Chain A, Human Cyclin-Dependent Kinase 2 Complexed With The Inhibitor Hymenialdsine	389 e-108
	1F5Q	C Chain C, Crystal Structure Of Murine Gamma Herpesvirus Cyclin Complexed To Human Cyclin Dependent Kinase 2	389 e-108
	AAA35667.1	cdc2-related protein kinase	389 e-108
	AAH03065.1	cyclin-dependent kinase 2	389 e-108
	AAM34794.1	AF512553_1 cyclin-dependent kinase 2	389 e-108

	1717387A	cyclin A dependent p33 kinase:SUBUNIT=2	389 e-108
1E1X	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Nu6027	389 e-108	
1E1V	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Nu2058	389 e-108	
1B38	A Chain A, Human Cyclin-Dependent Kinase 2	389 e-108	
1B39	A Chain A, Human Cyclin-Dependent Kinase 2 Phosphorylated On Thr 160	389 e-108	
1E9H	C Chain C, Thr 160 Phosphorylated Cdk2 - Human Cyclin A3 Complex With The Inhibitor Indirubin-5-Sulphonate Bound	387 e-107	
1E9H	A Chain A, Thr 160 Phosphorylated Cdk2 - Human Cyclin A3 Complex With The Inhibitor Indirubin-5-Sulphonate Bound	387 e-107	
1H1P	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu2058	387 e-107	
1H1P	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu2058	387 e-107	
1H1Q	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6094	387 e-107	
1H1Q	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6094	387 e-107	
1H1R	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6086	387 e-107	
1H1R	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6086	387 e-107	
1H1S	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6102	387 e-107	
1H1S	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6102	387 e-107	
1GY3	A Chain A, Pdk2CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE Substrate	387 e-107	
1GY3	C Chain C, Pdk2CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE Substrate	387 e-107	
1QMZ	A Chain A, Phosphorylated Cdk2-Cyclin A-Substrate Peptide Complex	387 e-107	
1QMZ	C Chain C, Phosphorylated Cdk2-Cyclin A-Substrate Peptide Complex	387 e-107	
CAA43985.1	cdk2	387 e-107	

NM_007418	Mm.57205	U:(C-IR) 2.41 F:(IR-D) -2.1	P18825 C4)	A2AC_HUMAN Alpha-2C-adrenergic receptor (Alpha-2C adrenoceptor) (Subtype	636 0
NP_031444.1			AAG28076.1 AF280399 1 alpha 2C adrenergic receptor		636 0
			BAA02737.1 alpha2CII-adrenergic receptor		634 0
			AAG28077.1 AF280400 1 alpha 2C adrenergic receptor variant		634 0
			NP_000674.1 alpha-2C-adrenergic receptor; alpha2-AR-C4	601 e-171	
			A31237 alpha-2C-adrenergic receptor	601 e-171	
			AAA35513.1 kidney alpha-2-adrenergic receptor	601 e-171	
			AAC78723.1 alpha2-C4-adrenergic receptor	601 e-171	
			A34169 alpha-2A-adrenergic receptor	385 e-106	
			AAA51665.1 alpha-2 adrenergic receptor old gene name 'ADRA2R'	385 e-106	
			NP_000672.2 alpha-2A-adrenergic receptor; platelet type adrenoceptor, alpha-2A; alpha-2A adrenoceptor; alpha-2AAR subtype C10	384 e-106	
			P08913 A2AA_HUMAN Alpha-2A adrenergic receptor (Alpha-2A adrenoceptor) (Alpha-2AAR subtype C10)	384 e-106	
			AAF91441.1 AF281308 1 alpha 2A adrenergic receptor	384 e-106	
			AAG00447.2 adrenergic receptor alpha-2A	384 e-106	
			AAK26743.1 alpha-2A adrenergic receptor	384 e-106	
			AAK51162.1 alpha-2A adrenergic receptor	384 e-106	
			AAK01634.1 AF316894 1 alpha 2A adrenergic receptor	382 e-105	
			AAA51664.1 alpha-2-adrenergic receptor old gene name 'ADRA2R'	381 e-105	
			AAK01635.1 AF316895 1 alpha 2B adrenergic receptor	358 2E-98	
			P18089 A2AB_HUMAN Alpha-2B adrenergic receptor (Alpha-2B adrenoceptor) (Subtype C2)	355 2E-97	
			AAB62558.1 alpha2B-adrenergic receptor	355 2E-97	
			NP_000673.1 alpha-2B-adrenergic receptor; alpha-2-adrenergic receptor-like 1	258 4E-68	
			A37223 alpha-2B-adrenergic receptor	258 4E-68	
			AAA51666.1 alpha-2-adrenergic receptor (alpha-2 C2) old gene name 'ADRA2RL1'	258 4E-68	
NM_009608	Mm.686	U:(C-IR) 2.32 F:(C-D) -	NP_005150.1 actin, alpha, cardiac muscle precursor	764 0	
NP_033738.1					

	2.42 F:(IR-D) -5.6			
	XP_012405.3	similar to actin, alpha, cardiac		764 0
	P04270	ACTC HUMAN Actin, alpha cardiac		764 0
	ATHUC	actin, cardiac muscle		764 0
	AAB59619.1	alpha-cardiac actin		764 0
	AAH09978.1	AAH09978 actin, alpha, cardiac muscle		764 0
	NP_001091.1	alpha 1 actin precursor; alpha skeletal muscle actin		759 0
	XP_001869.1	similar to Chain B, The X-Ray Crystal Structure Of The Complex Between Rabbit Skeletal Muscle Actin And Latrunculin A At 2.85 Å Resolution		759 0
	P02568	ACTS HUMAN Actin, alpha skeletal muscle (Alpha-actin 1)		759 0
	ATHU	actin alpha 1, skeletal muscle		759 0
	AAB59376.1	alpha-actin		759 0
	AAA60296.1	alpha-skeletal actin precursor		759 0
	AAF02694.1	AFI182035_1 skeletal muscle alpha-actin precursor		759 0
	AAH12597.1	Similar to actin, alpha 1, skeletal muscle		759 0
	NP_001604.1	alpha 2 actin; alpha-cardiac actin		755 0
	P03996	ACTA HUMAN Actin, aortic smooth muscle (Alpha-actin 2)		755 0
	CAA32064.1	alpha-actin (AA 1-377)		755 0
	AAH17554.1	AAH17554 actin, alpha 2, smooth muscle, aorta		755 0
	ATHUSM	actin alpha 2, aortic smooth muscle		752 0
	AAA51577.1	alpha-actin		752 0
	NP_001606.1	actin, gamma 2 propeptide; actin, alpha-3		750 0
	P12718	ACTH HUMAN Actin, gamma-enteric smooth muscle (Alpha-actin 3)		750 0
	A40261	actin gamma, enteric smooth muscle		750 0
	CAA34814.1	gamma-actin (AA 1-376)		750 0
	BAA0546.1	enteric smooth muscle gamma-actin		750 0
	AAH12617.1	Similar to actin, gamma 2, smooth muscle, enteric		750 0
	JCS818	gamma-actin		723 0
	NP_001605.1	actin, gamma 1 propeptide; cytoskeletal gamma-actin; actin, cytoplasmic 2		723 0
	P02571	ACTG HUMAN Actin, cytoplasmic 2 (Gamma-actin)		723 0
	ATHUG	actin gamma 1		723 0

		CAA27723.1	gamma-actin		723 0
		AAA51579.1	gamma-actin		723 0
		AAH00292.1	actin, gamma 1		723 0
		AAH01920.1	actin, gamma 1		723 0
		AAH07442.1	actin, gamma 1		723 0
		AAH09848.1	actin, gamma 1		723 0
		AAH10999.1	Similar to actin, gamma 1		723 0
		AAH12050.1	Similar to actin, gamma 1		723 0
		AAH15005.1	actin, gamma 1		723 0
		AAH15695.1	actin, gamma 1		723 0
		AAH15779.1	actin, gamma 1		723 0
		AAH18774.1	actin, gamma 1		723 0
		NP_001092.1	beta actin; beta cytoskeletal actin		722 0
		P02570	ACTB_HUMAN Actin, cytoplasmic 1 (Beta-actin)		722 0
		ATHUB	actin beta		722 0
		CAA25099.1	beta-actin		722 0
		AAA51567.1	cytoplasmic beta actin		722 0
		AAH01301.1	actin, beta		722 0
		AAH02409.1	actin, beta		722 0
		AAH04251.1	actin, beta		722 0
		AAH09275.1	actin, beta		722 0
		AAH13380.1	actin, beta		722 0
		AAH14861.1	actin, beta		722 0
		AAH16045	actin, beta		720 0
		CAA45026.1	mutant beta-actin (beta'-actin)		718 0
AA510875	Mm.28984	U:(C-IR) 2.21 F:(IR-D) -2.64	NP_004640.1	chromosome 21 open reading frame 33; human HES1 protein, homolog to E.coli and zebrafish ES1 protein	243 9E-65
NP_613067.1			P30042	ES1_HUMAN ES1 protein homolog, mitochondrial precursor (Protein KNP-I)	243 9E-65
			JC4913	anti-sigma cross-reacting protein homolog I alpha precursor	243 9E-65
			BAA12984.1	KNP-Ia	243 9E-65

		AAC50938.1	GT335	243	9E-65
		AAC50937.1	similar to E. coli SCRPP27A and to zebrafish ES1	243	9E-65
		AAH02370.1	ES1 (zebrafish) protein, human homolog of	243	9E-65
		AAH02587.1	ES1 (zebrafish) protein, human homolog of	243	9E-65
		CAA68857.1	HES1	243	9E-65
		BAA9554.1	HES1 protein	243	9E-65
		BAA21138.1	KNP-I alpha protein	243	9E-65
NM_009349	Mm.299	F:(C-IR)-2.85	AAD04723.1	271	9E-73
NP_0333375.1		U:(IR-D) 3.02	O95050	INMT_HUMAN Indolethylamine N-methyltransferase (Aromatic alkylamine N-methyltransferase) (Indolamine N-methyltransferase)(Arylamine N-methyltransferase) (Amine N-methyltransferase)	
					267 2E-71
			AAF18304.1	AF128846_1 indolethylamine N-methyltransferase	267 2E-71
			AAF18306.1	AF128848_1 indolethylamine N-methyltransferase	267 2E-71
			NP_006765.3	indolethylamine N-methyltransferase; thioester S-methyltransferase-like	266 5E-71
			AAF18305.1	AF128847_1 indolethylamine N-methyltransferase	266 5E-71
			AAH33813.	Unknown (protein for IMAGE:5209218)	266 5E-71
			NP_006160.1	nicotinamide N-methyltransferase	239 6E-63
			P40261	NNMT_HUMAN Nicotinamide N-methyltransferase	239 6E-63
			A54060	nicotinamide N-methyltransferase (EC 2.1.1.1)	239 6E-63
			AAA19904.1	nicotinamide N-methyltransferase	239 6E-63
			AAA93158.1	nicotinamide N-methyltransferase	239 6E-63
			AAH00234.1	AAH00234 nicotinamide N-methyltransferase	239 6E-63
NM_019813	Mm.19016	F:(C-IR)-2.71	Q16643	DREB_HUMAN Drebrin (Developmentally regulated brain protein)	
NP_062787.1		U:(IR-D) 2.42	JN0809	drebrin E (clone gDbh13)	
			AAA16256.1	drebrin E2	760 0
					760 0

		BAA04480.1	drebrin E	760 0
		AAH00283.1	AAH00283 drebrin 1	760 0
		AAH07281.1	AAH07281 drebrin 1	760 0
		AAH07567.1	AAH07567 drebrin 1	760 0
		NP_004386.2	drebrin 1 isoform a; drebrin E; drebrin-1; drebrin E2	759 0
		T14763	hypothetical protein DKFZp434D064.1	704 0
		CAB53683.1	hypothetical protein	704 0
		NP_543157.1	drebrin 1 isoform b; drebrin E; drebrin-1; drebrin E2	703 0
NM_009185	Mm.3988	NP_003026.1	TAL1 (SCL) interrupting locus; SCL interrupting locus	1749 0
NP_033211.1	F:(C-IR)-2.64 U:(IR-D) 2.51			
		A41685	SIL protein	1749 0
		AAA60550.1	SIL	1749 0
		AAK51418.1	SIL protein	1749 0
		CAB72102.1	dJ18D14.1 (TAL1 (SCL) interrupting locus )	741 0
NM_009665	Mm.7880	NP_00171.1	S-adenosylmethionine decarboxylase 1	630 e-180
NP_0333795.1	F:(C-IR)-2.6 U:(IR-D) 3.96			
		NP_001625.1	S-adenosylmethionine decarboxylase 1 precursor	628 e-179
		P17707	DCAM_HUMAN S-adenosylmethionine decarboxylase proenzyme (AdoMetDC) (SamDC) [Contains: S-adenosylmethionine decarboxylase alpha chain; S-adenosylmethionine decarboxylase beta chain]	628 e-179
		DCHUDM	adenosylmethionine decarboxylase (EC 4.1.1.50) precursor	628 e-179
		AAA51716.1	S-adenosylmethionine decarboxylase proenzyme (EC 4.1.1.50) old gene name 'AMD'	628 e-179
		1JL0	B Chain B, Structure Of A Human S-Adenosylmethionine Decarboxylase Self-Processing Ester Intermediate And Mechanism Of Putrescine Stimulation Of Processing As Revealed By The H243a Mutant	623 e-178
		1JL0	A Chain A, Structure Of A Human S-Adenosylmethionine Decarboxylase Self-Processing Ester Intermediate And Mechanism Of Putrescine Stimulation Of Processing As Revealed By The H243a Mutant	623 e-178
		1JEN	A Chain A, Human S-Adenosylmethionine Decarboxylase	499 e-140

		I1JEN	C Chain C, Human S-Adenosylmethionine Decarboxylase	499 e-140
	II7C	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Complexed With Methylglyoxal Bis-(Guanylylhydrazone)	498 e-140	
	II72	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Covalently Bound S'-Deoxy-S-[n-Methyl-N-(2-Aminooxyethyl) Amino]adenosine	498 e-140	
	II79	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Covalently Bound S'-Deoxy-S-[3-Hydrazinopropyl)methylamino]adenosine	498 e-140	
	II7B	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Covalently Bound S-Adenosylmethionine Methylester	498 e-140	
	II7M	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently One-2'-Amidinohydrazone	474 e-133	
	II7M	C Chain C, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Complexed With 4-Amidinoindan-1-One-2'-Amidinohydrazone	474 e-133	
NM_026599 NP_080875.1	Mm_87428 F:(C-IR) -2.43 U:(IR-D) 2.5	BAB21840.1 KIAA1749 protein	201 2.00E-51	
		NP_116255.1 hypothetical protein FLJ14957	201 2.00E-51	
		BAB55415.1 unnamed protein product	201 2.00E-51	
NM_009519 NP_033545.1	Mm_22182 F:(C-IR) -2.4 U:(C-D) 2.09 U:(IR-D) 2.84	NP_004617.2 wingless-type MMTV integration site family, member 11 precursor	680 0	
		O96014 WNT11 HUMAN WNT-11 protein precursor	680 0	
		BAB72099.1  WNT11	680 0	
		CAA73223.1  WNT11	676 0	

		CAA74159.1	HWNT1		676 0
		BAC11683.1	unnamed protein product		362 1E-99
		BAC23080.1	WNT4		301 2E-81
		NP_110388.2	wingless-type MMTV integration site family, member 4 precursor; signaling protein WNT-4; WNT-4 protein precursor		301 2E-81
		P56705	WNT4 HUMAN WNT-4 protein precursor		301 2E-81
		AAK51699.1	AF316543_1 signaling protein WNT-4		301 2E-81
		AAG38658.1	WNT4 precursor		296 5E-80
		CAB52601.1	dJ224A6.2 (similar to Mouse Wnt-4 protein)		295 1E-79
		NP_116031.1	wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein precursor		262 1E-69
		NP_110402.2	wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein precursor		262 1E-69
		Q9H1J7	WN5B HUMAN WNT-5B protein precursor		262 1E-69
		AAH01749.1	AAH01749 Similar to wingless-related MMTV integration site 5B		262 1E-69
		BAB62039.1	WNT5B		262 1E-69
		NP_003383.1	wingless-type MMTV integration site family, member 5A precursor; proto-oncogene Wnt-5A precursor; WNT-5A protein precursor		261 3E-69
		P41221	WN5A HUMAN WNT-5A protein precursor		261 3E-69
		A48914	proto-oncogene Wnt-5A precursor		261 3E-69
		AAA16842.1	hWNNT5		261 3E-69
		AAG38659.1	WNT5b precursor		255 1E-67
AF294617	Mm.19669	F:(C-IR)-2.39	NP_004557.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	1030 0
AAG02118.1		U:(R-D) 2.05	XP_096349.2	similar to 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (6PF-2-K/Fru-2,6-P2ASE brain/placenta-type isozyme) (iPK-2)	
			Q16875	F263 HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (6PF-2-K/Fru-2,6-P2ASE brain/placenta-type isozyme) (iPK-2) [Includes: 6-phosphofructo-2-kinase ; Fructose-2,6-bisphosphatase ]	1030 0
			BAA08624.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase	1030 0
			AAD08818.1	ubiquitous 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	1030 0

	AAI40083.1	L77662_1 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase	1030 0
	AAH40482.1	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3	1030 0
	2208342A	fructose 6-phosphate 2-kinase/fructose 2,6-bisphosphatase	1030 0
	AAB99795.1	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase	1028 0
	JC4626	6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2, 6-bisphosphate 2-bisphosphatase (EC 3.1.3.46)	1028 0
	AAC62000.1	inducible 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	1005 0
	CAA06605.1	6-phosphofructo-2-kinase	699 0
O60825	F262_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (6PF-2-K/Fru-2,6-P2ASE heart-type isozyme) (PFK-2/FBPase-2) [Includes: 6-phosphofructo-2-kinase ; Fructose-2,6-bisphosphatase ]	697 0	
	NP_006203.1	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2; Fructose-2,6-bisphosphatase, cardiac isozyme	688 0
	CAA06606.1	6-phosphofructo-2-kinase	688 0
	BAB19681.1	6-phosphofructo-2-kinase heart isoform	680 0
	AAL99386.1	AF470623_1 PFK2/F26D Pase	680 0
	NP_004558.1	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4	670 0
Q16877	F264_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (6PF-2-K/Fru-2,6-P2ASE testis-type isozyme) [Includes: 6-phosphofructo-2-kinase ; Fructose-2,6-bisphosphatase ]	670 0	
	BAA18921.1	6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase	670 0
	AAD09427.1	testis 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	670 0
	AAH10269.1	AAH10269_6 phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4	670 0
	JCS871	6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2, 6-bisphosphate 2-bisphosphatase (EC 3.1.3.46)	669 0
NM_013927	Mm.10357 F:(C-IR)-2.33	NP_061971.2 cyclic nucleotide gated channel beta 3; cyclic nucleotide-gated channel, beta 3	910 0
NP_038955.1	5 U:(C-D) 3.63 U:(IR-D) 2.84	AAF86274.1 AF272900_1 cone photoreceptor cyclic nucleotide-gated channel beta subunit	910 0
		AAF80179.1 AF228520_1 cone photoreceptor cGMP-gated cation channel beta-subunit	773 0

		Q14028	CNG4 HUMAN Cyclic-nucleotide-gated cation channel 4 (CNG channel 4) (CNG-4)	609	e-173
		(CNG4)	(Cyclic nucleotide-gated cation channel modulatory subunit)		
		AAA65620.1	cyclic nucleotide-gated cation channel	609	e-173
		S32238	cGMP-gated cation channel 2, rod	609	e-173
		AAB32607.1	cGMP-gated cation channel subunit 2, cGMP-gated cation channel, subunit beta, hRCNC2 [human, retinal rod cells, Peptide, 909 aa]	609	e-173
		1912307A	cyclic nucleotide-gated cation channel	609	e-173
		AAB63387.1	cGMP-gated cation channel beta subunit	609	e-173
		NP_001288.1	cyclic nucleotide gated channel beta 1; cyclic nucleotide gated channel (photoreceptor), cGMP gated 3 (gamma)-like	609	e-173
		AAC04830.1	rod photoreceptor CNG-channel beta subunit	609	e-173
		AAA65619.1	cyclic nucleotide-gated cation channel	598	e-170
		S74179	cyclic nucleotide-gated channel protein	269	3.00E-71
		NP_001289.1	cyclic nucleotide gated channel alpha 3	269	3.00E-71
		Q16281	CNG3 HUMAN Cyclic-nucleotide-gated cation channel alpha 3 (CNG channel alpha 3) (CNG-3) (CNG3) (Cyclic nucleotide gated channel alpha 3) Cone photoreceptor cGMP-gated channel alpha subunit)	269	3.00E-71
		AAC17440.1	cone photoreceptor cGMP-gated channel alpha subunit	269	3.00E-71
		NP_000078.1	cyclic nucleotide gated channel alpha 1	268	6.00E-71
		A42161	cGMP-gated cation channel, rod photoreceptor	268	6.00E-71
		AAA52010.1	cGMP-gated cation channel protein	268	6.00E-71
NM_026302	Mm.78718	F:(C-IR) -2.21	NP_057305.1 dynactin 4 (p62); dynactin p62 subunit	886	0
NP_080578.1		U:(R-D) 2.61			
			XP_041993.1 similar to dynactin 4 (p62); dynactin p62 subunit	886	0
			AAF03896.1 AF195120 1 dynactin p62 subunit	886	0
			BAA91066.1 unnamed protein product	886	0
			AAH26323.1 dynactin 4 (p62)	883	0
			T47143 hypothetical protein DKFZp761J032.1	282	8.00E-76
			CAB82417.1 hypothetical protein	282	8.00E-76

NM_007755	Mm.22062	F:(C-IR)-2.2	NP_085097.2	cytoplasmic polyadenylation element binding protein; hypothetical protein FLJ13203	1039	0
NP_031781.1		U:(IR-D)2.11		similar to cytoplasmic polyadenylation element binding protein; cytoplasmic polyadenylation element-binding protein		
			AAK01239.1	AF329402_1 cytoplasmic polyadenylation element-binding protein long form	1039	0
			AAK01240.1	AF329403_1 cytoplasmic polyadenylation element-binding protein short form	898	0
			AAH35348.1	Similar to cytoplasmic polyadenylation element-binding protein	880	0
			BAB1496.1	unnamed protein product	878	0
			NP_055727.1	KIAA0940 protein	207	5E-53
			BAA76784.1	KIAA0940 protein	207	5E-53
			XP_047672.4	similar to RIKEN cDNA 4930447D24	207	6E-53
			BAB21764.1	KIAA1673 protein	207	6E-53
			AAH36899.1	Unknown (protein for MGC:46609)	207	6E-53
			AAH36444.1	Similar to KIAA0940 protein	203	9E-52
NM_008422	Mm.39092	F:(C-IR)-2.17	NP_004968.2	Shaw-related voltage-gated potassium channel protein 3; Kv3.3; voltage-gated potassium channel protein KV3.3	778	0
		U:(C-D)2.07				
		U:(IR-D)2.33				
			Q14003	KNC3_HUMAN Potassium voltage-gated channel subfamily C member 3 (Potassium channel Kv3.3) (KSHIII)	778	0
			AAC24118.1	Shaw type potassium channel Kv3.3	778	0
			NP_004967.1	Shaw-related voltage-gated potassium channel protein 1; voltage-gated potassium channel protein KV3.1; potassium voltage-gated channel subfamily C member 1	612	e-175
			P48347	KNC1_HUMAN Potassium voltage-gated channel subfamily C member 1 (Potassium channel Kv3.1) (Kv4) (NGK2)	612	e-175
			A46020	potassium channel KCNC1	612	e-175
			AAB25764.1	voltage-gated potassium channel; NGK2	612	e-175
			NP_004969.2	Shaw-related voltage-gated potassium channel protein 4 isoform a; voltage-gated potassium channel protein KV3.4	571	e-162

		CAC19684.1	dJ1003J2.3.2 (potassium voltage-gated channel, Shaw-related subfamily, member 4)	571 e-162
	Q03721	CIKG_HUMAN	Potassium voltage-gated channel subfamily C member 4 (Potassium channel Kv3.4) (KSHIII(C))	571 e-162
	AAA57263.1	potassium channel protein		571 e-162
	NP_720198.1	Shaw-related voltage-gated potassium channel protein 4 isoform b; voltage-gated potassium channel protein KV3.4		571 e-162
	CAC19683.1	dJ1003J2.3.1 (potassium voltage-gated channel, Shaw-related subfamily, member 4)		571 e-162
	NP_715624.1	Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2c		556 e-158
	BAC04407.1	unnamed protein product		556 e-158
	NP_631875.1	Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2b		556 e-158
	AAL27272.1	AF2688896 1 voltage gated potassium channel Kv3.2b		556 e-158
	AAM81577.1	potassium voltage-gated potassium channel subfamily C member 2		556 e-158
	NP_631874.1	Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2a		556 e-158
	AAL27273.1	AF2688897 1 voltage gated potassium channel Kv3.2a		556 e-158
NM_0111749	Mm.417	Q9UQR1	Z148_HUMAN Zinc finger protein 148 (Zinc finger DNA binding protein 89) (Transcription factor ZBP-89)	1460 0
NP_035879.1	F:(C-IR)-2.05 U:(IR-D) 2.34	AAC39926.1	zinc finger DNA binding protein 89 kDa	1460 0
		AAL99917.1	AF432210 1 CLL-associated antigen KW-10	1458 0
		NP_068799.1	zinc finger protein 148 (pHZ-52); zinc finger protein 148 (pHZ-52), BERP-1, ZBP-89	1455 0
		CAA15422.1	ZBP-89 protein	1455 0
		A54693	CACCC box-binding protein ht-beta	744 0
		AAA36664.1	CACCC box-binding protein	743 0
		AAH35591.1	Similar to zinc finger protein 148 (pHZ-52)	714 0
		AAB57692.1	zinc finger binding protein homolog	695 0
		CAB70967.1	zinc finger protein	371 e-102
		NP_036614.1	zinc finger protein 281; ZNP-99 transcription factor	371 e-102
		Q9Y2X9	Z281_HUMAN Zinc finger protein 281 (Zinc finger DNA binding protein 99) (Transcription factor ZBP-99) (GC-box-binding zinc finger protein 1)	371 e-102

		JC7089	zinc finger binding protein-99	371 e-102
		AAD21084.1	zinc finger DNA binding protein 99	371 e-102
		CAB70968.1	zinc finger protein	371 e-102
NM_030566 NP_085043.1	Mm.35467 F:(C-IR) -2.05 U:(C-D) 2.62 U:(IR-D) 2.1	NP_079092.1	Fos-related antigen	621 e-177
		BAB1594.1	unnamed protein product	621 e-177
NM_026334 NP_080610.1	Mm.46408 F:(C-IR) -2.04 U:(C-D) 2.14 U:(IR-D) 2.27	NP_004181.1	lipase, gastric	663 0
		P07098	LIPG_HUMAN Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL)	663 0
		S07145	triacylglycerol lipase (EC 3.1.1.3) precursor, gastric	663 0
		CAA29413.1	gastric lipase precursor	663 0
		CAA29414.1	gastric lipase precursor	657 0
		IHLG	A Chain A, Crystal Structure Of Human Gastric Lipase	635 0
		IHLG	B Chain B, Crystal Structure Of Human Gastric Lipase	635 0
		G01416	lysosomal acid lipase	474 e-133
		AAB60328.1	lysosomal acid lipase	474 e-133
		CAA83495.1	lysosomal acid lipase	474 e-133
		AAH12287.1	AAH12287 Similar to lipase A, lysosomal acid, cholesterol esterase (Wolman disease)	474 e-133
		S41408	lysosomal acid lipase (EC 3.1.1.-) / sterol esterase (EC 3.1.1.13) precursor	474 e-133
		CAA54026.1	lysosomal acid lipase; sterol esterase	474 e-133

		AAB60327.1	lysosomal acid lipase/cholesteryl ester hydrolase	474 e-133
		NP_000226.1	lipase A precursor; Lipase A, lysosomal acid, cholesterol esterase	474 e-133
P38571		LICH_HUMAN	Lysosomal acid lipase/cholesteryl ester hydrolase precursor (LAL) (Acid cholesteryl ester hydrolase) (Sterol esterase) (Lipase A) (Cholesteryl esterase)	474 e-133
		AAA52519.1	lysosomal acid lipase/cholesteryl esterase	474 e-133
		XP_089555.2	similar to bA304I5.1 (novel lipase)	433 e-121
		XP_061222.1	similar to Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL)	431 e-121
		CAC78754.1	bA304I5.1 (novel lipase)	428 e-119

**References**

1. Unger, R.H., Foster, D.W. (1998) Diabetes mellitus. In Williams Textbook of Endocrinology, J.D. Wilson, D.W. Foster, H.M. Kronenberg, and P.R. Larsen, eds. (Philadelphia, W.B. Saunders Company), pp. 973-1059.
- 5 2. Polonsky, K.S. (1995) The beta-cell in diabetes: from molecular genetics to clinical research. *Diabetes* 44:705-717
- 10 3. Velho, G., Froguel, P. (1997) Genetic determinants of non-insulin-dependent diabetes mellitus: strategies and recent results. *Diabete et Métabolisme* 23:7-17
4. Groop, L.C., Tuomi, T. (1997) Non-insulin-dependent diabetes mellitus-a collision between thrifty genes and an affluent society. *Ann. Med.* 29:37-53.
- 15 5. Reaven, G.M. (1988) Role of insulin resistance in human disease. *Diabetes* 37:1595-1607.
6. Clark, M.G., Rattigan, S., Clark, D.G. (1983) Obesity with insulin resistance: experimental insights. *Lancet* (ii) 1236-1240.
- 20 7. Kisseebah, A.H., Vydelingum, N., Murray, R., Evans, D.J., Hartz, A.J., Kakloff, R.K., Adams, P.W. (1982) Relation of body fat distribution to metabolic complications of obesity. *J Clin. Endo and Metab* 54(2):254-260.
8. Kisseebah, A.H. (1996) Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? *Diabetes Res Clin Pract* 30 (Suppl):25-30.
- 25 9. Friedman, J.M., Leibel, R. (1992) Tackling a weighty problem. *Cell* 69:217-220
10. Björntorp, P. (1991) Metabolic implications of body fat distribution. *Diabetes Care* 14:1132-1143.
- 30 11. Emery, E.M., Schmid, T.L., Kahn, H.S., Filozof, P.P. (1993) A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. *Am J Health Promot* 7:342-353.
- 35 12. Wickelgren, I. (1998) Obesity: how big a problem? *Science* 280:1365.

13. Surwit, R.S., Kuhn, C.M., Cochrane, C., McCubbin, J.A., Feinglos, M.N. (1988) Diet-induced type-II diabetes in C57BL/6J mice. *Diabetes* 37:1163-11672.
14. Surwit, R.S., Feinglos, M.N., Rodin, J., Sutherland, A., Petro, A.E., Opara, E.C., Kuhn, C.M., Rebuffe-Scrive, M. (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. *Metabolism* 44(5):645-651.
15. Ahren, B.E., Simonson, E., Scheurink, A.J.W., Mulder, H., Myerson, U., Sundler, F. (1997) Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. *Metabolism* 46(1):97-106.
16. Page, R., Morris, C., Williams, J., von Ruhland, C., Malik, A.N. (1997) Isolation of diabetes-associated kidney genes using differential display. *Biochem Biophys Res Commun* 232(1):49-53
17. Condorelli, G., Vigliotta, G., Iavarone, C., Caruso, M., Tocchetti, C.G., Andreozzi, F., Cafieri, A., Tecce, M.F., Formisano, P., Beguinot, L., Beguinot, F. (1998) PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. *Embo J* 17(14):3858-66
18. Peraldi, M.N., Berrou, J., Hagege, J., Rondeau, E., Sraer, J.D. (1998) Subtractive hybridization cloning: an efficient technique to detect overexpressed mRNAs in diabetic nephropathy. *Kidney Int* 53(4):926-31
19. Song, Y., Ailenberg, M., Silverman, M. (1998) Cloning of a novel gene in the human kidney homologous to rat munc13s: its potential role in diabetic nephropathy. *Kidney Int* 53(6):1689-95
20. Imagawa, M., Tsughiya, T., and Nishihara, T. (1999) Identification of inducible genes at the early stage of adipocyte differentiation of 3T3-L1 cells. *Biochem. Biophys. Res. Comm.* 254:299-305.
21. Nadler, S.T., Stoehr, J.P., Schueler, K.L., Tanimoto, G., Yandell, B.S., Attie, A.D. (2000) The expression of

adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 97:11371-11376

22. Lan H, Rabaglia ME, Stoehr JP, Nadler ST, Schueler KL, Zou F, Yandell BS, Attie AD. (2003) Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes 52:688-700.

CLAIMS

1. A method of protecting a human subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises administering to the subject a protective amount of an agent which is

(1) a polypeptide which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtables 1A and 1C,

or

(2) an expression vector encoding the polypeptide of (1) above and expressible in a human cell, under conditions conducive to expression of the polypeptide of (1);

where said agent protects said subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state.

2. A method of protecting a human subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state which comprises administering to the subject a protective amount of an agent which is

(1) an antagonist of a polypeptide, occurring in said subject, which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtable 1B and 1C, or

(2) an anti-sense vector which inhibits expression of said

polypeptide in said subject,

where said agent protects said subject from progression from  
a normoinsulinemic state to a hyperinsulinemic state, or  
5 from either to a type II diabetic state.

3. A method of screening for human subjects who are  
prone to progression from a normoinsulinemic state to a  
10 hyperinsulinemic state, or from either to a type II diabetic  
state, which comprises assaying tissue or body fluid samples  
from said subjects to determine the level of expression of a  
"favorable" human marker gene, said human marker gene  
encoding a human protein which is substantially structurally  
15 identical or conservatively identical in sequence to a  
reference protein which is selected from the group  
consisting of mouse and human proteins set forth in master  
table 1, subtables 1A and 1C,

and directly correlating the level of expression of said  
20 marker gene with the propensity to progression in said  
patient.

4. A method of screening for human subjects who have a  
propensity for progression from a normoinsulinemic state to  
25 a hyperinsulinemic state, or from either to a type II  
diabetic state, which comprises assaying tissue or body  
fluid samples from said subjects to determine the level of  
expression of an "unfavorable" human marker gene, said  
human marker gene encoding a human protein which is  
30 substantially structurally identical or conservatively  
identical in sequence to a reference protein which is  
selected from the group consisting of mouse and human  
proteins set forth in master table 1, subtable 1B and 1C,  
and inversely correlating the level of expression of said  
35 marker gene with the propensity to progression in said  
patient.

5. The method of claims 1 or 3 in which the reference

protein is of subtable 1A.

6. The method of claims 1 or 3 in which the reference protein is of subtable 1B.

5

7. The method of claim 3 or 4 in which the sample is a muscle tissue sample.

10 8. The method of any one of claims 1-7 in which the reference protein is a human protein.

9. The method of any one of claims 1-7 in which the reference protein is a mouse protein.

15 10. The method of any one of claims 3 or 4 in which the level of expression of the marker protein is ascertained by measuring the level of the corresponding messenger RNA.

20 11. The method of any one of claims 3 or 4 in which the level of expression is ascertained by measuring the level of a protein encoded by said marker gene.

25 12. The method of any one of claims 1-9 in which said polypeptide is at least 80% identical or at least highly conservatively identical to said reference protein.

13. The method of any one of claims 1-10 in which said polypeptide is at least 90% identical to said reference protein.

30 14. The method of any one of claims 1-11 in which said polypeptide is identical to said reference protein.

35 15. The method of any one of claims 1-14 in which the E-value cited for the reference protein in Master Table 1 is not more than e-6.

16. The method of claim 15 in which the E-value cited for the reference protein in Master Table 1 is less than e-10.

17. The method of claim 17 in which the E value calculated by BLASTN or BLASTX would be less than e-15, more preferably less than e-20, still more preferably less than e-40, even  
5 more preferably less than e-60, considerably more preferably less than e-80, and most preferably less than e-100.

18. The method of any of claims 2-17 in which the antagonist  
10 is an antibody, or an antigen-specific binding fragment of an antibody.

19. The method of any of claims 2-17 in which the antagonist is a peptide, peptoid, nucleic acid, or peptide nucleic acid oligomer.  
15

20. The method of any of claims 2-17 in which the antagonist is an organic molecule with a molecular weight of less than 500 daltons.

20 21. The method of claim 20 in which said organic molecule is identifiable as a molecule which binds said polypeptide by screening a combinatorial library.

25 22. The method of claim 1 or 2 in which the agent is delivered systemically.

23. The method of claim 1 or 2 in which the agent is selectively delivered to muscle tissue.  
30

**ABSTRACT OF THE DISCLOSURE**

Mouse genes differentially expressed in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic muscle by gene chip analysis have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against hyperinsulinemia or type 2 diabetes, or their sequelae.

10

C:\windows\Application Data\Corel\WordPerfect\9\Backup\wp{wp}.bk1